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Abstract 
 
Population ageing has received much attention as a contributing cause of spiralling healthcare 
expenditure. This study primarily aims to estimate the impact of population ageing on key 
diseases, and to develop a flexible modelling framework that can inform policy decisions.   
This research provides a proof-of-concept model where individual Discrete Event Simulation 
models for three diseases (heart disease, Alzheimer’s disease, and osteoporosis) were 
extended from existing published models to simulate the general UK population aged 45 years 
and older, and combined within a single model. Using external population projection data 
incorporating potential demographic changes, the methods for projecting future healthcare 
expenditures for the three diseases were demonstrated and the relative benefits of improving 
treatment of each of the diseases evaluated.  
Secondary outcomes include the development of a pragmatic literature search method which 
can be used for literature within diffuse topic areas, and a literature repository for future 
researchers to explore the existing literature on ageing and healthcare expenditure.  
Expenditure for the three diseases is projected to increase from £16 billion in 2012 to £28 
billion in 2037. A key finding from this work is that the estimates of costs, quality-adjusted life 
years (QALYs), and the projected expenditure for healthcare services can differ when multiple 
diseases are modelled in a single model compared with the summed results from single 
disease models. This implies that policy decisions on the allocation and planning of healthcare 
resources based on the results from individual disease models can be different from those 
based on linked models.  The novel approach of linking multiple disease models with 
correlations incorporated provides a new methodological option primarily for modellers who 
undertake research on comorbidities.  It also has potential for wider applications in informing 
decisions on commissioning of healthcare services and long-term priority setting across 
diseases and healthcare programmes, hence ultimately contributing to the improvement of 
population health. 
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CHAPTER 1   INTRODUCTION 
 
1.1. Background 
  
Population ageing is a dynamic process in which the proportion of older people in the 
population increases, resulting in a shift in the age structure of a population from younger to 
older groups. An older population typically includes people aged 60 – 65 years and over. In 
many developed regions, the age of 65 years is used to define an older person due to the 
statutory pension and retirement age, however, the United Nations (UN) often adopts 60+ 
years to refer to the older population. The World Health Organization (WHO) expects the 
number of people aged 60 years and older to increase from 900 million in 2015 up to 2 billion 
by 2050 (World Health Organization, 2015). The old-age dependency ratio, which is calculated 
as the number of persons aged 15 to 64 years divided by the number of persons aged 65 years 
or over, has been decreasing worldwide over the last five decades (from 12 in 1950 to 8 in 
2013). This is expected to continue to decline in the next 40 years and estimated to be 4 in 
2050 resulting in fewer people of working age. This can impose fiscal pressures on support 
systems for the older population including both public transfers from the government (such as 
healthcare and cash benefits) and private transfers (such as intergenerational support for care) 
of economic resources (United Nations, 2013).  
This demographic transition is occurring in both developing and developed parts of the world, 
and the population changes are mainly driven by a decline in mortality and fertility. The 
fertility rate has nearly halved between 1950-1955 and 2000-2005 from 5.0 children per 
woman to 2.7 globally (United Nations, 2001). According to the UN, fertility has been declining 
faster in less developed countries from 6.2 children per woman to 2.9 between 1950-1955 and 
2000-2005 (United Nations, 2001).  Furthermore, people are now expected to live longer due 
to a reduction in mortality rates at older ages. In all regions of the world, life expectancy at 
birth has increased by almost 20 years between 1950-1955 and 2000-2005. 
In the UK, life expectancy at birth was 78.1 years for men and 82.1 years for women in 2010. 
The Office for National Statistics (ONS) projects this to increase to 84.0 years for men and 87.3 
years for women in 2037 (Office for National Statistics, 2013c). Fertility rates have been falling 
as well from 2.45 children for women born in the mid-1930s to 1.84 children for women born 
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after 1990 (Rutherford, 2012). Long-term mortality and fertility assumptions by ONS project 
the population of the UK to gradually become older with the number of people aged 65 and 
over to increase by 23% from 10.3 million in 2010 to 12.7 million in 2018 (Rutherford, 2012). 
The number of people aged 80 years and above is projected to more than double from about 
2.5 million to 6 million by mid-2037 (Office for National Statistics, 2013c). 
The ageing population has received much attention as a contributing cause of spiralling 
healthcare expenditure. Healthcare expenditure is related to, but distinguished from, 
healthcare needs, demand, and service utilisation. Healthcare is ‘needed’ for anticipated 
improvements in health, and the need for healthcare is often measured at various levels by the 
perception of individuals or healthcare professionals, health status indicators such as blood 
pressure, and observed geographical variations such as comparison of infant mortality by 
regions. Need is an important determinant of demand (Gravelle et al., 2003). Demand is 
associated with the behaviour of the consumer, and thus, demand for healthcare is the 
healthcare that both patients and the national health system are willing and able to consume. 
Interplay between demand for, and supply of, healthcare will determine the utilisation of 
healthcare services. Demand will be partially reflected by the actual utilisation of the 
healthcare services. Through such utilisation, demands for healthcare are met, and healthcare 
expenditures are incurred. As older individuals tend to need more healthcare and related 
social care services than younger individuals due to a higher prevalence of both acute and 
chronic diseases, the anticipated changes in the age composition of the population are 
expected to significantly increase future expenditure on these services (European Commission 
Directorate-General for Economic and Financial Affairs, 2009).  
Hence, the impact of the projected demographic changes on future health and social care 
expenditure is a growing concern for many governments and health authorities across the 
world (European Commission Directorate-General for Economic and Financial Affairs, 2009). 
Overall health spending grew by nearly 5% annually in real terms in Organisation for Economic 
Co-operation and Development (OECD) countries over the period 2000-2009, and the total 
healthcare expenditure as percentage of gross domestic product (GDP) in the UK increased 
from 5.9% in 1981 to 9.6% in 2010 (OECD, 2012). In addition, total expenditure on long-term 
social care services in the UK is projected to increase from 1.49% of GDP in 2002 to 3.14% in 
2051; with the public expenditure element comprising 0.96% to 1.94% growth (Hancock et al., 
2007a). 
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However, demographic changes such as population ageing form only one of many factors that 
can influence healthcare expenditure. Rising healthcare expenditure may reflect changes in 
the level of need and/or demand, or changes in the pattern of healthcare utilisation. As 
economies get richer, consumption patterns tend to move towards services including 
healthcare services, instead of tangible goods such as cars and clothes. In addition, more 
healthcare needs may be met due to improvements made to access to, or provision of, 
healthcare services.   
A number of studies have suggested that ageing per se may not be the major driver of rising 
healthcare expenditure, but has at best a modest effect on both the per-capita and aggregate 
healthcare costs when adjusted for non-demographic variables associated with demand- and 
supply-side of a healthcare system (Gerdtham et al., 1993, Reinhardt, 2003, Seshamani and 
Gray, 2004c, Breyer and Felder, 2006, Christiansen et al., 2006, Werblow et al., 2007, Zweifel 
et al., 1999). Although the probability of death is positively correlated with the age of an 
individual (Payne et al., 2007) and per-capita healthcare expenditure increases with age 
(Meerding et al., 1998, Alemayehu and Warner, 2004), these studies found that healthcare 
costs are concentrated on the time period immediately preceding death, and the age effect on 
costs becomes much smaller when time to death of individuals is controlled for. This has been 
termed the ‘red herring’ argument (Zweifel et al., 1999). For example, Zweifel et al. (1999) 
showed that age itself was largely irrelevant as a determinant of healthcare expenditure in the 
last two years of life using data from two sickness funds in Switzerland. Due to the changing 
mortality patterns, estimates of future healthcare costs based solely on the age composition of 
the future population may differ from those based on the proximity of the population to death.  
A wide range of demand-side, supply-side, as well as regulatory (or institutional) factors 
influence healthcare expenditure.  Demand-side factors include demographic changes such as 
population ageing, the health status of a population, income, and the population’s health-
seeking behaviour (e.g. healthy lifestyles and the use of preventative health services) and their 
perceived needs (Christiansen et al., 2006, Astolfi et al., 2012, Schulz et al., 2004). Supply-side 
factors such as technological advances, changes in treatment practices, productivity, and price 
of healthcare services may explain changes in healthcare expenditure (Astolfi et al., 2012). 
Some studies suggest that the effect on healthcare expenditure of some factors that change at 
a relatively fast pace such as technological progress may outweigh that of population changes 
(Meara et al., 2004, Christiansen et al., 2006). These factors would in turn be associated with 
the capacity, facilities, resources and governance of the healthcare sector (Layte et al., 2009). 
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Regulatory factors including the economic context of the country, institutional characteristics 
of healthcare system and political framework conditions, such as political influence on 
decisions on healthcare policy, also play a role (Astolfi et al., 2012, Schulz et al., 2004). For 
example, Erixon and van der Marel (2011) argue that the way in which healthcare provision is 
organised is a strong determinant of expenditure increases as inflation in the healthcare sector 
is higher than that in the other sectors due to low productivity growth and the labour-intensive 
nature of healthcare.  
A number of studies have investigated the impact of age composition of the population, 
economic, and institutional factors, such as GDP of the country; patterns of care delivery; and 
ratio of public and private financing on health and social care expenditure (Seshamani and 
Gray, 2004b, Breyer and Felder, 2006, Christiansen et al., 2006, Werblow et al., 2007). Efforts 
have also been made across countries to estimate the likely impact of the challenges of an 
ageing population arising from both the demand for, and supply of, health and social care 
services (European Commission Directorate-General For Economic Financial Affairs, 2006, 
Department of Economic and Social Affairs Population Division, 2009, Congressional Budget 
Office, 2007).  
Studies have found that the health status of a population is an important determinant of the 
utilisation of healthcare services, and thus expenditure (Layte et al., 2009, Christiansen et al., 
2006, Astolfi et al., 2012, OECD, 2006, Westerhout and Pellikaan, 2005). There is some 
evidence that disability rates among the elderly have been falling, indicating improvements in 
health status (Manton et al., 1997, Parker and Thorslund, 2007, Cutler, 2001). Jacobzone et al. 
(2000) documented that the reduction in prevalence of disability rates was mainly found 
among the age groups 65 to 80 years in a sub-group of OECD countries.  
There are contrasting views on the relationship between mortality (increase in life expectancy) 
and morbidity (health status at the end of life). Fries (1980) argues that gains in life expectancy 
would mean an increased period of healthy life, thus a shrunken period of morbidity termed 
“compression of morbidity”. A counterargument proposed by Olshansky et al. (1991) is the 
theory of “expansion of morbidity” suggesting that increased longevity extends the time with 
diseases and disabilities. An alternative theory known as “dynamic equilibrium” assumes that 
gains in life expectancy lead to approximately the same increase in time of healthy life, and 
thus the period of end-of-life morbidity remains unchanged (Manton, 1982). Empirical 
evidence generally favours the compression of morbidity hypothesis. In many industrialised 
countries, the decline in age-specific disability outweighs the age-specific mortality decrease in 
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recent years, leading to the expansion of disability-free years of life (Jagger et al., 2005, 
Mathers et al., 2004, Payne et al., 2007, Crimmins, 2004). Although the prevalence of some 
chronic diseases such as diabetes, cancer, and arthritis has risen, recent evidence indicates 
that the severity of these diseases among older people is falling (Mathers et al., 2006, 
Crimmins, 2004, Payne et al., 2007).  
The recently observed downward trend in age-specific severity of chronic diseases and 
prevalence of disabilities may signal a reduction in healthcare demand, but linking the 
disability trend to a reduction in health expenditures is not straightforward because other 
factors and interactions between them will also have an impact. In a study by Jacobzone et al. 
(2000), the disability trends showed disparate results across countries, and it was noted that 
the economic impact of these trends is unclear and depends on the arrangements of 
institutional care services in the relevant countries, such as the level of subsidisation. 
The theories on trends in life expectancy, health status and healthcare expenditure and the 
relationships between them have significant implications for the modelling of health and 
healthcare. Failure to incorporate inter-relationships between the factors influencing 
healthcare expenditure may jeopardise the validity of the model results. It is important to have 
a model that incorporates as many relevant factors as practicable, and can answer policy 
questions regarding possible consequences/implications of changing demographic and non-
demographic factors in the coming decades. Based on the background provided in this section, 
the following sections will outline the research questions posed by the thesis and how they are 
addressed.   
 
1.2. Research questions and objectives 
 
 
This PhD aims to provide a model that can help answer research questions arising in relation to 
healthcare expenditure for an ageing population. The questions this PhD study tries to address 
will define the purpose of the model and inform the choice of modelling methodology, and are 
summarised below.   
 
27 
 
(1) What will happen to healthcare expenditure on key diseases if current trends continue? 
The main question that the model in this thesis will address is ‘what would happen if no action 
on healthcare services and health policy that may influence future healthcare costs is taken 
and the current trends in demographic changes and health status of the population continue?’ 
Some models forecasting overall health and healthcare expenditure have attempted to 
describe the current status of the system (European Commission European Foresight 
Monitoring Network, 2009, Astolfi et al., 2012). For instance, the US Congressional Budget 
Office (CBO) produces 75-year projections of total expenditures on various federal 
programmes such as Medicare and Medicaid (Congressional Budget Office, 2005, 
Congressional Budget Office, 2008, Congressional Budget Office, 2007). The models aid long 
term fiscal planning and the main part of their projections assume that no significant changes 
would be made in policy over the projection period.  
More detailed outcomes can be derived from the models describing the current healthcare 
system. In relation to identifying the viable policy options, the next question asked is ‘what 
would be the effect of the current trends on specific diseases?’ and ‘costs of which diseases 
will increase the most?’  The results could support exploring policy opportunities to constrain 
future spending on specific diseases. The models asking these questions could also be used to 
identify the major drivers of disease-level health expenditure growth (OECD, 2006). Projections 
based on the current trends in factors influencing demand for disease-specific healthcare 
services can be altered to reflect potential changes in those factors. 
 
(2) Will the estimation of future expenditure change if diseases are modelled simultaneously, 
rather than individually? 
The estimation of disease-level outcomes is typically performed using a model involving a 
single disease. However, due to some overlapping costs associated with co-morbidities, such 
as hospitalisation and care home use for multiple disease conditions, and possible correlations 
between diseases, such as the higher incidence of Alzheimer’s disease among people with 
cardiovascular conditions, the estimates from a single-disease model may differ from those 
from a model incorporating multiple diseases and relevant correlations between them. The 
next question to explore in relation to this is ‘will the estimation of future healthcare 
expenditure change if multiple diseases are modelled simultaneously, rather than individually?’ 
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(3) In which diseases, will investment, to reduce consequences of the disease, be most 
profitable?  
One may think of potential policies or interventions that can impact on some of the factors 
influencing expenditure such as the adoption of improved treatments and prevention 
programmes. An estimation of the current trends and status of the healthcare system naturally 
leads to questions such as ‘what would happen if some actions are taken’ and ‘in which 
diseases, will investment be most beneficial to reduce the health and economic consequences 
of the disease?’ This includes the assessment of possible consequences of potential 
interventions and policies on the healthcare sector. Policy decisions can make intended 
changes in the delivery of care and public healthcare costs. Also, models can help to assess the 
possible consequences of hypothetical unanticipated changes by conducting various ‘what-if’ 
scenario analyses.  For example, the US RAND’s Comprehensive Assessment of Reform Efforts 
(COMPARE) micro-simulation model was developed to project how individuals, households, 
and firms would respond to healthcare policy changes, and applied to evaluate the likely 
effects of a new law designed to expand health insurance coverage, the Patient Protection and 
Affordable Care Act (PPACA)(Eibner et al., 2010a). Such ex ante analyses tested various 
scenarios associated with policy designs and model assumptions on behavioural responses.  
 
In the process of undertaking this research, two other research questions were explored: 
(4) Can a framework be established to guide literature searching in diffuse topic areas? and; 
(5) Could a freely available repository containing relevant literature be set up for future 
researchers in order to save time? 
 
This study aims to estimate the impact of population ageing on disease-level healthcare 
expenditure and to develop a flexible modelling framework that can inform questions (1) – (3) 
incorporating a wider range of potential influences on healthcare expenditure. The outcomes 
of the model can assist the efficient planning of healthcare resources and the evaluation of 
potential interventions and policy changes. The methodology will enable simulation of future 
healthcare demand in a way which is flexible enough to explore the impact on demand of 
variations in the influencing factors incorporated in the model.  
29 
 
Health economics aims to achieve the optical allocation of limited healthcare resources for the 
efficient production of population health (Higgins and Green, 2011). In other words, efficiency 
is attained when society makes choices which maximise the health outcomes gained from the 
resources allocated to healthcare (Palmer and Torgerson, 1999). The efficient use of 
healthcare resources is defined as producing the maximum possible improvement in outcome 
obtained from a given set of resource inputs such as healthcare workforce, capital, and 
medical technology and equipment (‘technical efficiency’) and achieving the right mixture of 
healthcare programmes to maximise the health of society (‘allocative efficiency’) (Palmer and 
Torgerson, 1999). The method proposed in this PhD focusses on achieving allocative efficiency 
rather than technical efficiency, as it concerns the efficient allocation of healthcare resources 
between the diseases and health care conditions, rather than a technically efficient use of 
resource inputs. 
Economic evaluation techniques can be used to inform both technical and allocative efficiency 
in healthcare. Economic evaluation is defined as “the comparative analysis of alternative 
courses of action in terms of both their costs and consequences”, and aims to inform decisions 
on clinical practices, adoption of a technology and resource allocation (Drummond et al., 2005).  
Cost-utility analysis (CUA) is a type of economic evaluation in which interventions, which 
produce different consequences in terms of quantity and quality of life, are expressed in 
utilities and are compared in terms of incremental costs and quality-adjusted life years (QALYs), 
a measure which comprises both length and quality of life (Drummond et al., 2005). When 
QALYs are used, resource allocation decisions can be made by comparing competing 
interventions in terms of the incremental cost per QALY gained. Economic evaluation often 
requires decision analytic modelling as data and evidence needed for decision-making come 
from various sources. Decision analytic models provide a structured approach to synthesising 
the evidence of clinical and economic outcomes to produce detailed estimates of the 
consequences of different healthcare interventions that can inform decisions (Briggs et al., 
2006, Weinstein et al., 2003). 
This PhD provides a proof-of-concept model that can be used, modified, and expanded to 
incorporate other relevant factors and diseases. The model is an individual-level Discrete Event 
Simulation (DES) model linking multiple diseases. It records annual accrual of costs of 
preventing, treating, and managing selected diseases, which were used to estimate 
population-level costs. Existing disease-specific models that have been used for health 
technology assessment (HTA) were reviewed and replicated wherever possible in this model. 
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The model expands the existing HTA modelling frameworks to serve the aim of projecting 
healthcare expenditure for an ageing population using the methodology presented in this 
thesis.  Given the benefit of the individual- and disease-level modelling, it is anticipated that 
this thesis can help answer key policy questions, producing more detailed outcomes compared 
with the models that estimate aggregate healthcare expenditures. Hence, the outcomes of the 
model developed in this thesis are expected to allow healthcare expenditures to be attributed 
to disease conditions and demographic characteristics of age and gender, providing important 
information for health policy makers on the selected diseases. Such results can be used to 
assess current resource allocations in the healthcare system, and aid discussions concerning 
ageing populations and changing disease patterns. The model can also help analyse time 
trends, identify the drivers of healthcare spending, and provide an input into the future 
modelling of health care expenditures.  
 
1.3. Thesis structure 
 
The subsequent chapters of this thesis are structured to follow the process undertaken 
towards the development of a linked-disease model of selected diseases of the elderly.  Figure 
1.1 shows how the chapters in this thesis are related. 
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Figure 1.1. Structure of the thesis 
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In order to develop an understanding of existing methodologies and of the data requirements 
needed for the construction of a new model, a review of the previous research attempting to 
model the health and healthcare of the future population was undertaken. Chapter 2 presents 
the method of developing search strategies to identify pertinent research. Given the diffuse 
nature of the topic area and the substantial variation in the literature discussing issues 
relevant to population ageing and healthcare demands, designing pragmatic search strategies 
and subsequent categorisation of the information retrieved was essential. The searches made 
use of a core set of papers that were deemed representative of the diffuse literature set in 
order to reduce the number of overall papers identified. Chapter 3 describes the outcomes of 
the literature searches and review, including the results of categorising the information 
available from the extant literature; the development of a freely-accessible literature 
repository established to assist future researchers; and an overview of the models projecting 
future healthcare demand classified according to their methodology, which could inform the 
choice of the modelling methods for this thesis.  
Based on the review of the existing projection models, Chapter 4 designs the model 
constructed for this thesis. It describes the disease areas selected and the modelling 
methodology adopted. It also reports the general methods used to develop the individual 
disease models presented in subsequent chapters and outlines how the individual disease 
models were linked.   
Chapters 5, 6, and 7 describe the disease-level modelling for three selected diseases: heart 
disease, Alzheimer’s disease, and osteoporosis, and report the outcomes of the individual 
disease models, respectively.  The general UK population with and without history of any of 
the included health events was modelled for the purpose of estimating population-level 
healthcare expenditure. The model structure was developed to incorporate both prevalent 
and non-prevalent individuals to capture all future patient-related benefits and costs (Hoyle 
and Anderson, 2010). The results of projected annual costs of treating and managing the three 
diseases were also reported. Chapter 8 describes the correlations between the diseases that 
were incorporated in the model and the results from models where pairs of diseases were 
linked. Chapter 9 reports the results from the model where all included diseases were linked 
and correlated and examines the implications of these results for health technology 
assessment and the projection of future healthcare expenditure. Finally, Chapter 10 
summarises the findings of this PhD study and discusses the limitations and directions for 
future research.  
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CHAPTER 2    A METHODOLOGY FOR DEVELOPING 
PRAGMATIC SEARCH STRATEGIES: A CASE STUDY IN 
HEALTHCARE EXPENDITURE FOR OLDER POPULATIONS 
 
This chapter describes the search methods used to identify abstracts from the literature to 
screen when conducting a review of health and healthcare expenditure for an ageing 
population. Section 2.1 introduces some of the challenges in identifying relevant literature 
within a diffuse subject area. Section 2.2 describes the method proposed in this thesis to 
develop a pragmatic search strategy, and Section 2.3 shows how the method was 
implemented in five databases. Section 2.4 reports grey literature search methods. Section 2.5 
discusses limitations of the proposed approach.  
 
2.1. Background – Literature search 
 
Literature on the impact of ageing on healthcare expenditure is anticipated to be broad and 
diffuse given that it can involve a wide range of demographic, economic, and institutional 
factors (Gerdtham et al., 1993, Reinhardt, 2003, Seshamani and Gray, 2004c, Breyer and Felder, 
2006, Christiansen et al., 2006, Werblow et al., 2007). It is therefore difficult to conduct a 
systematic review – as defined by  Higgins and Green (Higgins and Green, 2011) – relevant to a 
broad research question.  
It is recognised that there are challenges in identifying relevant literature for reviews of diffuse 
topics in health and social sciences (Grayson and Gomersall, 2003, Matthews et al., 1999, 
Papaioannou et al., 2010). The issues associated with ageing and healthcare expenditure are 
widespread and multifaceted, both in terms of the sources chosen for the search and the 
methods of searching.  
Cross-disciplinary topics require the searching of multiple databases across multiple subject 
areas to maximise recall and maintain acceptable precision (defined as the proportion of 
relevant reports among those identified by a search) (Matthews et al., 1999, Taylor, 2009, 
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McFadden et al., 2012, Taylor et al., 2007). For example, in a review on student experiences of 
e-learning, Papaioannou et al. (2010) found that the 30 included studies identified from the 
database searching were derived from ten different sources. In a review of the health effects 
of social interventions on walking and cycling, only four of the 69 relevant studies found were 
from a “first-line” health database such as MEDLINE (McNally and Alborz, 2004). Searching 
multiple sources of literature has time and cost implications. Golder et al. (2008) also noted 
that the optimal number and combination of databases to search is unknown. 
Choosing search terms for reviews of diffuse topics can present difficulties both in the use of 
indexes and free text searching (Papaioannou et al., 2010). Indexing may be inconsistent, and 
may not be available in some databases. In addition, some free-text terms may be used in 
multiple contexts which increases the number of irrelevant references retrieved (Matthews et 
al., 1999).  Moreover, social science terminology is often “non-technical” and therefore 
overlaps “ordinary everyday language”  (Grayson and Gomersall, 2003) as language in the 
social sciences “varies according to the preferences of authors, schools of thought, cultures, 
and journals as well as with time and place” (Taylor, 2009). Furthermore, abstracts can lack 
detail or may be non-existent (McNally and Alborz, 2004, Taylor, 2009, Papaioannou et al., 
2010).In diffuse topic areas, database searches often cannot be restricted by study type such 
as randomised controlled trials (RCTs).This can greatly increase the number of references 
identified, demonstrating the need for efficient search strategies (Papaioannou et al., 2010).  
An iterative approach to constructing search strategies for diffuse topics is often 
recommended, whereby a scoping search is conducted and additional index and/or free-text 
terms are identified from the relevant references (Ogilvie et al., 2005).  This may also include 
contact with experts and/or checking of reference lists (Relevo and Balshem, 2011).  Long et al. 
(2002) describe the stages of this process as “scoping, refinement and confirmation”.  However, 
additional search methods are important. McNally and Alborz (2004) found unique potentially 
relevant references by supplementary methods such as snowballing and consultation with 
experts within a review on access to health care for people with learning disabilities. 
Snowballing is a literature searching technique that involves reference list checking or citation 
searching of a relevant source document (Booth et al., 2012, Webster and Watson, 2002, 
Hinde and Spackman, 2015). Golder et al. (2008) used these supplementary methods of 
reference checking in six databases (AgeLine, EMBASE, Health Management Information 
Consortium (HMIC), MEDLINE, PsycINFO, Social Sciences Citation Index) along with contacting 
authors to identify all included references in a review on the effectiveness of respite care.    
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Due to the diffuse topic area and the wide breadth of the literature discussing issues regarding 
population ageing, a comprehensive search was not considered feasible due to the potentially 
large number of hits identified, or the number needed to read (NNR).  Therefore, a ‘pragmatic’ 
search strategy, with the objective of being efficient, was developed at the planning stage of 
the review.  
This chapter describes the methods used to identify a pragmatic search strategy for conducting 
a literature review within a diffuse subject area of health and healthcare for an ageing 
population. The primary topics of papers intended to be retrieved were : i) studies estimating 
the future health and healthcare demand for an ageing population and ii) studies examining 
the effect of policies or interventions designed to tackle issues arising from population ageing 
on healthcare demand. Secondary topics included: trend analyses of healthcare spending; the 
determinants of healthcare spending; and the relationships between health and social care 
utilisation. The searches were limited to the literature written in English and those published 
before October/November 2011.  
The proposed approach is predicated on the belief that it is more efficient and pragmatic to 
refine search strategies so that the NNR which need to be sifted is greatly reduced compared 
with broad searches. This approach differs from standard search methods for systematic 
reviews that are used when specific target literature exists. A set of ‘seed’ papers from which 
subsequent searches would be expanded to retrieve the target literature were identified a 
priori by scoping searches and discussions with experts. It was deemed that an acceptable 
search strategy would need to be capable of identifying all of the seed papers. Search 
strategies that were acceptable and retrieved relatively few hits were considered pragmatic. 
The results of the pragmatic search strategy were sifted as normal with all relevant literature 
synthesised in the final review. The estimated efficiency improvement associated with the final 
search strategy was reported with respect to the precision of searches and total sifting time. 
The later part of this chapter also reported a different approach used to search grey literature. 
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2.2. Methods for developing pragmatic search strategies 
 
2.2.1. Steps in developing search strategies 
 
Figure 2.1 summarises the iterative approach used in this thesis to heuristically develop 
pragmatic search strategies. An initial set of papers that could be used as a seed to retrieve 
wider literature of interest were identified. The search strategy was broadened to identify all 
the seed papers and then refined to reduce the number of hits whilst maintaining 
identification of all seed papers.  The process of broadening and then refining the literature 
search was undertaken for all of the databases interrogated. The identified literature was 
sifted as normal.  
Each of the steps in Figure 2.1 is described in more detail in the following sections. 
 
Figure 2.1. Step-by-step approach to developing pragmatic search strategies 
 
37 
 
2.2.2. Step 1:  Selection of seed papers and establishing the initial 
search terms 
 
In Step 1, an initial set of papers deemed as key studies in the target literature were identified. 
These papers were intended to be used as the seeds for subsequent searches aimed at 
identifying the wider literature of interest and do not represent the totality of the evidence 
available. 
The search terms for the initial searches involved the main elements of the search question: 
ageing and healthcare demand (including healthcare needs and utilisation). The synonyms of 
the two elements were developed separately and all the terms in each category were 
combined with the Boolean operator ‘OR’. Then, the two sets of terms were combined using 
the Boolean operator AND within selected databases. Table 2.1 shows both free-text terms 
and MeSH headings that were likely to be relevant. The MeSH headings were selected as part 
of initial key terms as the Medline database was used for scoping searches. Adaptations were 
made to the included MeSH headings for searches in other sources such as EMBASE and 
Google Scholar.  
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Table 2.1. Search terms 
Ageing terms Healthcare demand terms 
MeSH headings 
Aging 
Aged 
"Aged, 80 and over" 
 Frail Elderly 
Health Services for the Aged 
Population Dynamics 
Adult, older 
Life Expectancy 
Longevity 
Health Expenditures 
Health Care Costs 
"Delivery of Health Care" 
"Health Services Needs and Demand" 
Health policy 
Long term care 
Hospitals 
"Cost of Illness" 
Hospitalizations 
Nursing homes 
Health Services Research 
Free text terms 
(“Population ag?ing”) 
(ag?ng.ab,ti.) 
(older.ab,ti.)  
(elder$.ab,ti)  
 (“Proximity to death”)  
 (health?care.ab,ti.) 
 
 
 
The method of identifying a set of seed papers was as follows.  The initial ad-hoc searches 
using the terms in Table 2.1 and recommendations from researchers experienced in policy 
analysis and systematic reviews identified relevant literature.  Related papers were then 
obtained via citation searching. The searches were supplemented by alternative methods of 
“snowballing” via reference list checking and using personal knowledge and/or contacts.  
Papers were considered for inclusion in the set of seed papers based on whether their 
inclusion: increased the range of relevant subject matters discussed; broadened the range of 
sources of papers; and raised the level of cross-reference within the seed papers set indicating 
their impact on the other research. In order to enhance the coverage of the seed papers, when 
a new strand of the literature was found within the seed papers, further literature was 
searched and examined for inclusion. The search was stopped when data saturation was 
deemed to be at an acceptable level, i.e. additional literature identified did not add to the 
existing set in terms of the subject, methodology or source of data (Booth, 2010). Subject 
headings assigned to these seed papers were also used to complement the initial search terms 
to establish a more comprehensive collection of terms. The above methods resulted in an 
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initial set of twelve seed peer-reviewed journal papers (Zweifel et al., 1999, Lloyd-Sherlock, 
2000, Spillman and Lubitz, 2000, Reinhardt, 2003, Schulz et al., 2004, Seshamani and Gray, 
2004a, Borger et al., 2006, Payne et al., 2007, Werblow et al., 2007, Hakkinen et al., 2008, 
Palangkaraya and Yong, 2009, Caley and Sidhu, 2011). 
The details of these papers including the rationale for inclusion are shown in Table 2.2 and are 
listed in chronological order. Hereafter, these twelve papers are referred to as the seed papers.  
 
40 
 
Table 2.2. The initial set of seed peer-reviewed journal papers 
Studies Source Summary Rationale for 
inclusion 
Zweifel et al. 
(1999) 
Medline keyword 
search using the 
term ‘proximity to 
death’ 
Claims that health care expenditure 
(HCE) may depend on remaining 
time to death rather than calendar 
age. Statistical analysis was 
conducted using HCE data of 
deceased Swiss individuals.  
An early study 
claiming ‘proximity 
to death’ rather 
than age itself is a 
determinant of 
HCE. 
Lloyd-Sherlock 
(2000) 
Pubmed search for 
review papers using 
the term 
‘population ageing 
and policy’. 
Highlights key issues arising from 
population ageing. Outlines patterns 
of ageing and their implications for 
policy in different settings. 
Policy related 
paper. 
Spillman and 
Lubitz (2000) 
Cited in ENEPRI 
2006 and Werblow 
et al. (2007). 
Estimates total national healthcare 
expenditures according to the age at 
death. Simulates expenditures using 
demographic projections of two 
cohorts: people turning 65 in 2000 
and those turning 65 in 2015. 
An early study on 
long-term care 
spending using 
Medicare data. 
Reinhardt (2003)  Citated in ENEPRI 
(2006). 
Argues that the impact of ageing on 
US healthcare demand will be small, 
as the ageing is too gradual to be 
ranked as a major cost driver.  
Summary of 
expenditure 
studies. US survey 
based simulation 
results. 
Schulz et al. 
(2004)  
Cited in ENEPRI 
(2006). 
Estimates the isolated ageing effect 
on utilisation (not expenditure) in 
hospital and LTC sectors using 
German data.  
‘Static ageing approach’ is used. Also 
estimates the share of potential 
informal carers to be required in the 
future. 
Supply-side 
projections of HCE 
are made. 
European datasets 
used. 
Seshamani and 
Gray (2004a) 
Cited in Werblow et 
al. (2007). 
Raises methodological concerns on 
the method used in the paper by 
Zweifel et al.(1999); Discusses 
appropriate methods for model-
based cost projections.  
Discusses 
methodological 
issues.  UK data. 
Borger et al. 
(2006)  
Google scholar 
using the term 
‘projection of 
healthcare 
demand’ 
Reports US Centres for Medicare and 
Medicaid Services (CMS) projection 
results. Makes projections of future 
private and public healthcare 
spending by sector (e.g. LTC). The 
main topic is not ageing. However, 
the effect of population ageing on 
LTC spending is mentioned. 
No age-related 
MeSH terms 
assigned. Searches 
to identify this may 
help expand the 
search to other 
relevant papers. 
Payne et al. 
(2007) 
Cited in a recent 
paper by Caley and 
Sidhu (2011)  
Reviews the ‘cost-of-dying’ studies 
comparing HCE for the deceased 
with HCE for survivors and the ‘time-
to-death’ studies modelling changes 
in expenditure as death approaches; 
Examines the relationships between 
age, mortality, and morbidity among 
the elderly and time trends of those 
relationships.  
A review of studies 
examining the 
relationship among 
HCE, age and 
death. A summary 
of methods used in 
existing models. 
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Werblow et al. 
(2007) 
Google search 
using the terms 
‘ageing and health 
care expenditure’ 
Estimates the effect of age on HCE 
using Swiss sickness fund data. 
Investigates whether ‘proximity to 
death’ rather than age per se is a 
significant determinant of all 
components of HCE. 
An estimate of the 
effect of age on 
HCE.   
Hakkinen et al. 
(2008) 
Pubmed search for 
articles ‘related to’ 
Werblow et al. 
2007. 
Tests the ‘proximity to death’ claim 
on different components of HCE 
using Finnish data. Also investigates 
the effect of income.  
A summary of 
relevant 
methodological 
issues. 
Palangkaraya 
and Yong (2009) 
Web of Science
SM
 
title search using 
the term ‘health 
care demand’. 
Suggests that population ageing may 
not be the main driver of health 
expenditure at the aggregate level. 
Evaluates the impact of ‘known’ 
factors using country-level OECD 
data.  
Different 
methodological 
approach deriving a 
demand function 
based on economic 
theory.  
Caley and Sidhu 
(2011) 
Medline search 
using the keywords 
‘aging’ and 
‘healthcare 
demand’ 
Compares three models for 
estimating future healthcare costs 
using i) current age-specific 
expenditure, ii) morbidity postponed 
to a later point in life, and iii) 
morbidity compression or expansion. 
Use of routinely 
available UK data. 
Recent paper. 
 
 
2.2.3. Step 2: Broadening search terms to increase the identification of 
seed papers  
 
The initial phase of the exploratory searches was aimed at identifying as many of the seed 
papers as possible. A search strategy would be deemed acceptable only if all the seed papers 
were identified. 
 The performance of a small number of key search terms in identifying the seed papers was 
tested with terms incrementally added in an attempt to identify all of the seed papers in the 
database. Using the terms previously specified in Step 1 (Section 2.2.2), various limits, 
subheadings, and focus/explode options were explored to identify pragmatic search strategies. 
The process of adding and/or broadening search terms was continued until all the seed papers 
within the database were found, or it became apparent that a supplementary search would be 
required to identify the missing papers as they were not identified despite broad searches and 
a large number of identified records.  
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2.2.4. Step 3: Refining search terms to reduce the number needed to 
read (NNR) 
 
Once all seed papers were identified, subsequent steps involved refining the search strategies 
to reduce NNR. The refinement of the search strategies (with specific search terms added 
and/or removed) was made iteratively until it was deemed no substantial reduction could be 
made in NNR unless it was at the expense of identifying a seed paper.  
It was possible that iteratively amending the search terms when attempting to increase 
precision resulted in a local (the best among the strategies tried), rather than global (the best 
possible) optimum. To counter this possible limitation, once an initial ‘optimal’ strategy was 
identified, a secondary search strand with different initial search terms was conducted (only 
within Medline and EMBASE) to determine if a fewer NNR whilst maintaining high coverage 
could be found.  
 
 
2.2.5. Step 4: Selecting and implementing the final search strategies 
 
The process of developing pragmatic search strategies was illustrated using five databases: 
Medline (1948 – November 2011); EMBASE (1980– November 2011); EconLit (1961 – October 
2011); Applied Social Sciences Index and Abstracts (ASSIA) (1987 – November 2011); and 
CINAHL (1982- November 2011). These were searched independently. EconLit, ASSIA, and 
CINAHL were also included as this group contained one of the seed papers (Palangkaraya and 
Yong, 2009) which was not available in either Medline or EMBASE. 
The final search strategy for each database was typically determined as the search that 
identified all the seed papers with the fewest hits. Where wider search strategies had potential 
to identify a different section of the literature and did not increase NNR excessively, these 
were retained at the discretion of the reviewer for comprehensiveness.  
The search results from individual databases were combined and then de-duplicated, and the 
combined results were sifted as standard.  This was done only for the final search strategies as 
the time required to do this for all interim search strategies would have been considerable. 
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2.2.6. Step 5: Sifting the literature as standard 
 
The literature identified from the final searches was sifted as in standard systematic literature 
reviews. The output of the sifting process is reported in Chapter 3 in detail. Summary statistics 
are provided in this chapter.  
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2.3. Implementation of the search method 
 
A detailed account of how the method described earlier was implemented is given for each of 
the databases considered in this section. The final search results obtained using this method 
are summarised at the end of this section.  All exploratory searches were conducted between 
the 21st November 2011 and the 13th December 2011. 
 
2.3.1. Implementing Steps 1-3: Selecting seed papers, and broadening 
and refining the search strategy 
 
MEDLINE searches 
 
A summary of all exploratory search results and the corresponding full search statements are 
given in Table 2.3 and Appendix 2.1, respectively. Table 2.3 shows which of the seed papers in 
Table 2.2 were identified from each search. One of the 12 seed papers (Palangkaraya and Yong, 
2009) was unavailable in Medline, but was included in the table for comparability with tables 
for other databases.  
The initial phase of the exploratory searches involved increasing coverage. A small number of 
search terms were first used to see whether they identify the seed papers (Searches 1-2). 
These narrow ‘focussed’ searches involved limiting part of search terms specified in Table 2.1 
to records where the term was the major concept of the study while including free-text terms 
related to ageing. As these ‘focussed’ searches failed to provide high coverage, searches were 
widened by using broader terms and adding more ageing- and healthcare-related terms to 
identify more of the seed papers (Searches 3-5). Additionally, some subject headings assigned 
to the seed papers regarding the utilisation of long-term and hospital care services were added 
to Search 5. As these improved the number of the seed papers identified, all search strategies 
following Search 5 used these terms. 
All of the initial searches failed to identify one of the seed papers by Borger et al. (2006). This 
was due to the main topic of the paper not being population ageing but the projection of 
future healthcare expenditure. A supplementary search (detailed later) was conducted to 
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further identify papers discussing future healthcare demand but not necessarily focussing on 
ageing issues. This supplementary search to identify the Borger et al. study (Borger et al., 2006) 
combined two MeSH terms – Health Expenditures/ AND Forecasting/ - and produced 613 
records (accessed on 01 December 2011). The final search strategy involved combining these 
results from the supplementary search with the main search output with the Boolean operator 
OR. 
The subsequent steps involved refining the search strategy to improve precision and thus, 
fewer NNR than the 22,771 identified by Search 5. Although this resulted in a lower coverage 
in some cases (Searches 6-7), there was generally a marked reduction in the NNR depending 
on the terms included and limiters/sub-headings applied (see Appendix 2.1). The exclusion of 
the ‘health policy’ term reduced the number retrieved while maintaining the high coverage of 
the seed papers. As the use of focussed terms in Search 10 may have caused relevant studies 
indexed differently from the seed papers to be missed, Search 11 used similar, but non-
focussed terms. However, Search 11 increased the NNR by more than 2000 with no increase in 
coverage. Search 10 identified all 10 papers contained in Medline with fewest number of 
records (n=4,188).  
In order to reduce the possibility of identifying a local optimum, an alternative attempt at 
improving precision was undertaken. Search 12 involved broadening ageing- and/or 
healthcare-related terms used in Search 4 – a strategy that achieved relatively high coverage 
with a moderate number of hits – by adding keywords identified in the literature from 
previous searches. Search 13 was based on Search 12 with added terms associated with 
increased life expectancy. Terms effective in identifying more papers in Searches 5-11 were 
added to Search 4 to yield Search 13. Finally, additional attempts were made to combine sets 
of good search strategies – Searches 10-11 and 12-13 – with varying levels of breadth of search 
terms (Searches 14-17). Whilst Searches 10-17 each detected all 11 available seed papers, 
Search 16 in combination with the 613 hits from the supplementary search was chosen as the 
final search strategy due to the fewest hits (n=4,407).  
 
 
 
46 
 
Table 2.3. MEDLINE search results (Access date: 01 Dec. 2011; Database: Ovid MEDLINE(R) 1948 to November Week 3 2011) 
No. Search details 
Seed papers 
Number of 
hits 
Number of 
seed papers 
identified 
(coverage) 
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Availability:  Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Max.= 11 
1 Narrow search using focussed ageing 
terms 
√ x x x x x x x √ √ NA √ 729 
4 
(36%) 
2 Narrow search with focussed HC
† 
terms 
√ x √ x x √ x √ √ √ NA √ 7578 
7 
(64%) 
3 Broad ageing and HC terms 
√ √ √ √ x √ x √ √ √ NA √ 29673 
9 
(82%) 
4 Broad title & abstract search for age 
terms & focussed HC terms 
√ √ √ √ x √ x √ √ √ NA √ 4442 
9 
(82%) 
5 Broad age & HC terms with long-term 
and hospital care terms added 
√ √ √ √ √ √ x √ √ √ NA √ 22771 
10 
(91%) 
6 As Search 5, but no Aged/ term 
√ √ x √ √ √ x √ √ √ NA √ 6408 
9 
(82%) 
7 As Search 5,but more specific HC terms, 
hence similar to Search 4  
√ √ x √ √ √ x √ √ √ NA √ 4361 
9 
(82%) 
8 As Search 7, but with ‘*Longevity’ added  
√ √ √ √ √ √ x √ √ √ NA √ 4391 
10 
(91%) 
9 As Search 8, but with *Aged/ or *Health 
Services for the Aged/ added  
√ √ √ √ √ √ x √ √ √ NA √ 5585 
10 
(91%) 
10 As Search 9, but no health policy term & 
with Life expectancy term added  
√ √ √ √ √ √ x √ √ √ NA √ 4188 
10 
(91%) 
11 As Search 9, but no health policy term 
with broader other HC terms added 
√ √ √ √ √ √ x √ √ √ NA √ 6445 
10 
(91%) 
12 As Search 4, but broader age & HC terms  
√ √ √ √ √ √ x √ √ √ NA √ 4804 
10 
(91%) 
13 As Search 12 but with ‘longevity & life 
expectancy’ added  
√ √ √ √ √ √ x √ √ √ NA √ 5330 
10 
(91%) 
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No. Search details 
Seed papers 
Number of 
hits 
Number of 
seed papers 
identified 
(coverage) 
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Availability:  Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Max.= 11 
14 Broad combination of Searches 11 and 
13 (HC terms from 11 & ageing terms 
from 13)  
√ √ √ √ √ √ x √ √ √ NA √ 8873 
10 
(91%) 
15 As Search 13, but with broader terms  
√ √ √ √ √ √ x √ √ √ NA √ 5770 
10 
(91%) 
16 Narrow combination of Searches 11 and 
13 (HC terms from 13 & ageing terms 
from 11)   
√ √ √ √ √ √ x √ √ √ NA √ 3860 
10 
(91%) 
17 As Search 16, but with broader age 
terms  √ √ √ √ √ √ x √ √ √ NA √ 5442 
10 
(91%) 
√: Included; X: Not included; NA: Not available in the database; HC: healthcare.  
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EMBASE searches 
 
The full strand of search results and the search statements for EMBASE are available in 
Appendix 2.1. Two of the seed papers (Palangkaraya and Yong, 2009, Caley and Sidhu, 2011) 
were not available in EMBASE. The initial broad search retrieved all but one of the included 
seed papers (Borger et al. (2006)) but produced greater than 20,000 hits (Search 1). It was 
judged that wider searches which could retrieve this paper would produce too many hits to be 
practical.  
Initial attempts to reduce NNR using a limited number of ageing- and healthcare-related terms 
found only slightly more than half of the seed papers.  Searches where the ‘health care cost’ 
term was focussed (Search 5) failed to detect the paper by Reinhardt (Reinhardt, 2003). Hence, 
subsequent search strategies were designed to incorporate the broader health care cost term. 
The most effective of those efforts was to remove the term ‘older’ from title and abstract 
searches (Search 11). This reduced NNR without a loss of coverage.  
As in the Medline searches, all of these searches missed the same paper - Borger et al. (Borger 
et al., 2006). A separate search combining the EMTREE terms *"health care cost"/ and 
forecasting/ using the ‘AND’ operator produced 566 records (accessed on 01 December 2011) 
identified the Borger et al. study. When the results from Search 11 were combined with this 
complementary search, the stand-alone results of 3,584 records increased to 4,112 records.  
The EMBASE search strategy that identified all available seed papers with the smallest number 
of results (Search 11 in conjunction with the supplementary search) was proposed for the final 
search.  
 
EconLit, ASSIA, and CINAHL databases 
 
As the projection of healthcare demand has significant economic and policy implications, the 
EconLit, ASSIA and CINAHL databases were also searched. Although these databases contained 
few of the seed papers, this search result was combined with results from other databases for 
greater inclusivity and identified one of the seed papers that the others did not (Palangkaraya 
and Yong, 2009).  
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The search results from, and relevant search strategies for, these databases can be found in 
Appendix 2.1, respectively. 
In EconLit, free text searching in the title, abstract and keyword fields was performed due to 
lack of subject indices equivalent to the MeSH terms. Although only five of the seed papers 
were available in the database, both broad and narrow free-text searches successfully 
identified all of those available. As this database excludes purely clinical papers, most of the 
retrieved documents appeared to be more relevant to the research topic compared with those 
from other databases. A simple search using ‘ageing or aging’ AND ‘healthcare or health care’ 
identified all five studies and the number of records was 159 (accessed on 21 November 2011). 
However, from the experience of further identifying papers by Schulz et al. (2004) and 
Spillman and Lubitz (2000) in Medline by adding the terms ‘long-term care’ and ‘longevity’, a 
search statement more comparable with the Medline searches was established (Search 4). This 
would allow a more comprehensive search including relevant papers that might have been 
missed in the simple search due to the small number of seed papers available in the database. 
The resulting Search 4 produced 542 records (accessed on 13 December 2011).  
In the ASSIA database, relevant subject headings similar to those used for Medline searches 
were identified using the ‘thesaurus’ function. The mapped ageing terms were then combined 
with the healthcare-related terms identified in the same manner. Varying the number of 
subject headings included in the two categories of terms did not materially alter the search 
results: both broad and narrow searches identified all five articles available in the database 
and produced very similar numbers of hits.  As with the EconLit search, a more comprehensive 
search strategy was chosen as the additional workload implication was not significant.  
The CINAHL database was searched using free-text and MeSH terms where possible. The 
comprehensive use of ageing and healthcare terms produced 1334 records, of which 752 
records were studies on humans written in English and 357 were non-Medline records. No 
more attempts were made to reduce NNR as the 752 records were not considered excessive.  
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2.3.2. Implementing Step 4: Selecting and implementing the final 
search strategies 
 
The iterative process of broadening and subsequently refining search strategies for each of the 
databases included resulted in 7745 hits after de-duplication within and across all databases. A 
summary of the final search results from the selected search strategies is provided in Table 2.4. 
All of the selected final search strategies had coverage of 100% at identifying the seed papers 
available within the database. The final search strategy used for MEDLINE is reported in Table 
2.5. Details of the final searches for other databases can be found in Appendix 2.2. 
Discrepancies in the numbers reported in Tables 2.3, Appendix 2.1 and Table 2.4 are due to the 
final searches being undertaken at a later date than the exploratory searches. Additionally, the 
application of the language and subject heading limits considerably reduced NNR.  
Duplicates were first removed within each of the databases and subsequently across all five 
databases (both using the automated function within reference managing software (Endnote 
X3, Thomson Reuters) and manually), resulting in the final number of retrieved records 
totalling 7745. It is noteworthy that only 12% (= 1063/8808) of hits were removed as these 
papers had already been identified in a separate database, implying that there was not a 
considerable overlap between databases due to the diffuse nature of the literature on this 
topic.  
 
Table 2.4. Final search results from peer-reviewed journal databases (Search date: 19 Jan 2012) 
Database Results Results after de-
duplication 
MEDLINE 3731 3713 
EMBASE 3052 3031 
EconLit 549 548 
ASSIA 757 757 
CINAHL 760 759 
Total for all 
databases 
8849 8808 
Total  
(after de-duplication across all 
databases) 
7745  
(1063 further removed 
from de-duplication across 
all databases) 
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Table 2.5. Final search strategy for MEDLINE 
MEDLINE <1946 to January Week 2 2012> (accessed on: 19 January 2012) 
1     "proximity to death".mp. (64) 
2     older.ab,ti. (200935) 
3     *Aging/ (101582) 
4     *Population Dynamics/ (7148) 
5     Life Expectancy/ (12347) 
6     *Longevity/ (6274) 
7     ag?ing.ab,ti. (105283) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (354785) 
9     Health Care Costs/ (22138) 
10     Hospitals/ut [Utilization] (2816) 
11     Long-Term Care/ut [Utilization] (323) 
12     *"Health Services Needs and Demand"/ (13692) 
13     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & Numerical 
Data, Supply & Distribution, Trends, Utilization] (30683) 
14     Health Expenditures/ec, lj, sn, sd, td [Economics, Legislation & Jurisprudence, Statistics & 
Numerical Data, Supply & Distribution, Trends] (5469) 
15     9 or 10 or 11 or 12 or 13 or 14 (71870) 
16     8 and 15 (3814) 
17     Health Expenditures/ (11889) 
18     Forecasting/ (64816) 
19     17 and 18 (603) 
20     16 or 19 (4353) 
21     limit 20 to (english language and humans) (3731) 
 
 
2.3.3. Implementing Step 5: Sifting the literature as standard 
 
Although more details will be available in Chapter 3, the sifting of the 7745 hits resulted in 891 
relevant papers at the title and abstract level. A significant improvement in precision was 
achieved compared with the broad search. If it is assumed that all 891 papers were identified 
within the broad Medline search (Search 5), the precision was improved from approximately 4% 
(891/22771) to 11.5% in the final search (891/7745). Moreover, this broad search did not 
identify Borger et al. (2006).  
The improvement was also made in terms of time: including the extra time taken for a single 
reviewer to identify the seed papers (2 weeks), and conduct the exploratory searches using 
Steps 1-4 (2 weeks) and supplementary searches (3 days), but excluding the time taken to 
develop the inclusion and categorisation criteria (2 weeks – see Chapter 3), the total sifting 
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time for the final search results of 7745 papers was approximately 3 months, assuming 22 
working days of 8 hours each month. This compares with 5.2 months, the estimated time that 
would have been taken to sift 22,771 papers identified from the Medline Search 5. This was 
calculated on the assumption that one reviewer sifts all papers and the sifting rate is 200 
papers per day for 22 working days per any calendar month. These values were established 
based on the reviewer’s experience acquired whilst sifting the results from the pragmatic 
search.  The estimated time saved was 2.2 months in the review for this thesis. However, this 
could vary by topic of the review, sifting methods, the number of papers identified from 
searches constructed with and without the pragmatic approach, and reviewers’ experience.   
It is noted that additional themes in the literature outside of those that were the focus of the 
seed papers were identified such as: models projecting future health and social care 
expenditure (146 papers); policies and interventions intended to tackle the issues of ageing 
population (251 papers); trends in healthcare expenditure (67 papers); and major disease 
areas for an ageing population (155 papers).  
 
 
2.4. Grey literature search 
 
Relevant literature is likely to be located in policy documents and within the grey literature 
arena as population ageing has significant implications for health and social policy, which is of 
interest to bodies such as national governments, international organisations and industry. 
Hence, web pages of such organisations and grey literature databases deemed to be relevant 
were hand-searched via free-text scanning of title and abstract or executive summary. 
Information on grey literature sources with the description of search fields targeted within 
each information source is available in Table 2.6. The focus of the search was on the 
identification of key up-to-date literature that might not be captured by the conventional 
literature searches.  
 
53 
 
Table 2.6. Grey literature sources 
Organisation/ 
Database 
Web link Website information Search fields Search methods 
Age UK -
Knowledge 
Hub 
http://www.age
uk.org.uk/profes
sional-resources-
home/knowledg
e-hub-evidence-
statistics/publica
tions/ 
 
The knowledge hub within 
the Age UK website 
provides access to the 
findings of UK and 
international research on 
older people.   
All publications 
with more focus 
on Evidence 
reviews (more 
in-depth reports 
providing 
evidence for 
decision making) 
Free text 
searching for 
‘healthcare’ and 
‘expenditure/co
st’. 
Centers for 
Medicare and 
Medicaid 
(CMS), US 
http://www.cms.
hhs.gov/home/rs
ds.asp 
The website provides 
access to selected reports 
from CMS research 
programmes conducted 
in-house or via research 
contracts. 
The Research, 
Statistics, Data & 
Systems section. 
Free text scan 
of titles of all 
research 
programmes.  
Comprehensiv
e Research 
Group in 
Operational 
Research, 
Management 
Science and 
Information 
Systems 
(CORMSIS) 
University of 
Southampton 
http://www.soto
n.ac.uk/maths/re
search/projects/
healthcare_mod
elling.page 
The CORMSIS Health Care 
webpage provides brief 
information on PhD 
projects being conducted 
on modelling healthcare.  
Health Care 
section within 
the CORMSIS 
website.  
Free text scan 
of all projects. 
Congressional 
Budget Office 
(CBO, US) 
http://www.cbo.
gov/publications
/bysubject.cfm?c
at=9 
 
The US CBO publishes 
budget reviews, economic 
outlook reports, and 
reports on various issues 
including education, 
environment, housing, 
government management, 
etc.   
All ‘health’ 
publications 
from 2005 were 
searched.  
Free text scan. 
Department of 
Health  
 
http://www.dh.g
ov.uk/en/Publica
tionsandstatistics
/index.htm 
 
The website is intended to 
enable NHS and social care 
professionals to find 
information about policy 
and to receive guidance 
and advice on best 
practice. 
All publications. Search using the 
terms ‘ageing 
healthcare 
demand 
expenditure’ 
while limiting 
records to ones 
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containing 
‘ageing’ within 
summary. 
Economic and 
Social 
Research 
Institute (ESRI, 
Ireland) 
http://www.esri.i
e/publications/se
arch_for_a_publi
cation/ 
http://www.esri.i
e/UserFiles/publi
cations/2009102
3164031/RS013.
pdf 
The ESRI produces 
research that contributes 
to understanding 
economic and social 
change in the new 
international context and 
that informs public 
policymaking and civil 
society in Ireland. 
All publications 
with focus on 
Working papers. 
Keyword search 
using the term 
‘ag(e)ing’. 
 
European 
Commission - 
Directorate 
General for 
Economic and 
Financial 
Affairs (DG 
ECFIN)  
 
http://ec.europa.
eu/economy_fin
ance/publication
s/index_en.htm 
http://ec.europa.
eu/economy_fin
ance/structural_r
eforms/ageing/in
dex_en.htm 
 
DG ECFIN aims to improve 
the economic wellbeing of 
the EU citizens. It 
produces reports on EU 
policies and relevant 
issues.  
i) Economic 
Publications 
section. (Types 
of reports 
searched: 
European 
Economy- 
Economic 
Papers,  
Occasional 
Papers, ECFIN 
Economic Briefs) 
ii) Ageing and 
Welfare state 
policies section. 
Free text scan 
of titles of all 
papers within 
the search 
fields. 
European 
Network of 
Economic 
Policy 
Research 
Institutes 
(ENEPRI) 
http://www.ene
pri.org/ 
 
The ENEPRI brings 
together 23 national 
economic policy research 
institutes from most of the 
EU countries. It provides 
information on various 
projects regarding 
demography, ageing, and 
health and social care. 
i) Research 
Reports section.  
ii) Webpage of 
the AHEAD 
project (Ageing, 
Health Status 
and 
Determinants of 
Health 
Expenditure). 
Free text scan 
of all Research 
reports titles.  
FUTURAGE 
PROJECT 
http://futurage.g
roup.shef.ac.uk/ 
 
FUTURAGE is a two-year 
project funded by the 
European Commission, 
under the Seventh 
Framework Programme, 
to create the definitive 
road map for ageing 
research in Europe for the 
Consultation 
reports (aimed 
to identify 
research 
priorities) 
Workshop 
Free text scan 
of all report 
titles & 
summary within 
the search 
fields.  
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next 10-15 years. reports 
Documents 
related to 
Healthy ageing 
theme. 
Health, 
Econometrics 
and Data 
Group (HEDG), 
University of 
York 
http://www.york
.ac.uk/res/herc/r
esearch/hedg/w
p.htm 
The aim of HEDG is to 
provide expertise in the 
development and 
application of quantitative 
research methods capable 
of informing health policy. 
It publishes journal articles 
and a number of working 
papers.  
Working papers.  
 
Free text scan 
of all titles and 
abstracts.  
Health 
Management 
Information 
Consortium 
(HMIC) 
database  
gateway.ovid.co
m/  
 
The HMIC database brings 
together the bibliographic 
database of two UK health 
and social care 
management 
organizations: the 
Department of Health's 
Library and Information 
Services (DH-Data) and 
King’s Fund Information 
and Library Service. 
HMIC (1979 to 
Jan. 2012) 
   
 
Search terms 
used in Medline 
search 16 were 
mapped to 
HMIC headings. 
(Search terms 
used include 
‘Ageing’, 
‘Population 
Dynamics’, 
‘health 
expenditure’, 
etc.) 
HM Treasury, 
UK 
 
http://archive.tr
easury.gov.uk/ 
 
Web page of the UK's 
economics and finance 
ministry. 
All sections of 
the HM Treasury 
main website 
and the archive. 
Title search in 
all sections. 
Advanced 
search for 
‘Documents’ 
using the terms 
‘ageing’ and 
‘healthcare’ 
House of 
Commons 
Health 
Committee 
 
http://www.parli
ament.uk/busine
ss/committees/c
ommittees-a-
z/commons-
select/health-
committee/ 
A web page within the UK 
Parliament website for 
Health Committee, one of 
the 19 Select Committees 
related to UK government 
departments. 
Reports, Special 
Reports, and 
Written 
Evidence 
sections (2005-
current). 
Free text scan 
of all reports in 
the search 
fields. 
National 
Bureau of 
Economic 
http://www.nber
.org/papers/ 
 
The NBER is a private, non-
profit, economic research 
organization. The website 
Working papers 
and other 
publications 
1. Working 
paper search 
using the terms 
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Research 
(NBER), US 
provides access to a large 
number of working 
papers, many of which are 
on fiscal policy, pension 
reform, and effect of 
insurance on healthcare 
utilisation. 
listed on the 
website.  
‘ageing 
health?care 
demand’. 
2. Full-text 
search using 
‘population 
aging health 
care demand 
utilization’. 
3. Title search 
using ‘aging’. 
NatCen Social 
Research, UK 
 
 
http://www.natc
en.ac.uk/our-
research/health-
and-
lifestyle/ageing 
British research centre for 
independent social 
research. 
All documents in 
the Health and 
Lifestyle - Ageing 
research section. 
Free text scan 
of all available 
reports. 
National End-
of-life care 
intelligence 
network 
(NEoLCIN) 
http://www.end
oflifecare-
intelligence.org.u
k/resources/publ
ications/default.
aspx 
The NEoLCIN, supported 
by the Department of 
Health’s National End of 
Life Care Programme, aims 
to improve the collection 
and analysis of 
information related to the 
quality, volume and costs 
of end of life care 
provided by the NHS, 
social services and the 
third sector. 
All End-of-life 
models. 
Free text scan.  
NHS Evidence 
& NICE 
 
http://www.evid
ence.nhs.uk 
NHS Evidence provides 
access to selected, 
quality health and social 
care evidence. It brings 
together hundreds of 
information sources 
including the Cochrane 
Library, NICE, Scottish 
NHS, Royal Colleges and 
HTA databases. 
Types of 
information 
searched: 
i) Systematic 
reviews, 
ii) Evidence 
Summaries, 
iii) Grey 
Literature, 
iv) Primary 
Research, 
v) Policy and 
Service 
Development, 
and vi) Health 
Technology 
Assessments. 
 
Search terms: 
“projection 
healthcare 
demand ageing 
population” and 
search filters for 
selected types 
of information 
were applied. 
More specified 
terms used due 
to the wide 
coverage of the 
database. 
Nuffield Trust http://www.nuffi
eldtrust.org.uk/p
An independent source of 
evidence-based research 
All publications 
(2000-current).  
Search terms: 
‘ageing’ term.  
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ublications/predi
cting-social-care-
costs-feasibility-
study 
 
and policy analysis for 
improving health care in 
the UK. The publications 
list covers research 
reports, conference 
proceedings, etc. 
Free text scan 
of lists of all 
publications 
since 2000 was 
scanned.  
Organisation 
for Economic 
Co-operation 
and 
Development 
(OECD) 
http://www.oec
d.org/publication
s/0,3353,en_264
9_201185_1_1_1
_1_1,00.html 
The website contains 
OECD publications 
including Outlooks, 
Country Surveys and 
statistics. It provides links 
to reports on a wide 
variety of topics including 
healthcare.   
OECD iLibrary.  Search terms: 
‘ageing/aging’ 
AND 
‘healthcare’.  
 
Oxford 
Institute of 
Population 
Ageing 
http://www.ag
eing.ox.ac.uk/p
ublications 
  
The Institute undertakes 
research into the 
implications of population 
change.  
All Working 
papers and 
articles 
published in a 
review journal, 
Ageing Horizons 
(2004-2010).  
Free text scan 
of all 
documents in 
the search 
fields. 
Personal 
Social Services 
Research Unit 
(PSSRU) 
http://www.pssr
u.ac.uk/search.ht
m 
 
The PSSRU has branches in 
three UK universities, 
carrying out independent 
research on social and 
health care services.  
Discussion 
papers.  
 
Search terms 
used: 
‘projection’, 
‘demand’, 
and/or ‘ageing’. 
RAND 
Corporation 
http://www.rand
.org/health/proje
cts/compare.htm
l  
http://www.rand
.org/labor/roybal
hp/projects/heal
th_status/fem.ht
ml 
A non-profit research 
institution that aims to 
improve policy and 
decision-making on health, 
education, national 
security, international 
affairs, law, business, etc. 
The website contains 
information on various 
specialised research 
centres and projects 
within RAND.   
1. General 
search of all 
publications. 
2. By research 
area: i) Health 
and Health Care, 
ii) Population & 
Aging 
3. By research 
group: i) RAND 
Roybal Center 
for Health Policy 
Simulation, ii) 
Comprehensive 
Assessment of 
Reform Efforts 
(COMPARE) 
project  
1. Search terms: 
“ag(e)ing”. 
 
2. Free text scan 
of ‘Reports’ 
titles under the 
two research 
areas i) and ii). 
Also, RAND 
Health 
Publications on 
Health Care 
Costs. 
 
3. Free text scan 
of all 
publications 
from the two 
research 
groups. 
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Society of 
Actuaries 
(SOA) 
http://www.soa.
org/files/pdf/agi
ng_curves.pdf 
 
The SOA website contains 
information of actuaries’ 
professional interest such 
as educational 
opportunities, and 
research outputs.   
Research 
Projects on 
Aging & Long 
Term Care. 
 
Free text scan 
of all reports 
available on the 
website. 
UK Network 
for Modelling 
& Simulation 
in Healthcare 
(MASHnet)  
http://mashnet.i
nfo/case-studies/ 
 
MASHnet brings together 
all parties engaged in 
healthcare modelling and 
simulation. The website 
introduces some case 
studies and provides web 
links to the relevant 
models.   
‘Case Studies’ 
section.  
Free text scan 
of all Case 
Studies.  
World Health 
Organisation 
(WHO) 
 
http://www.who
.int/publications/
en/ 
http://www.who
.int/topics/agein
g/en/ 
The website of WHO, the 
directing and co-
ordinating authority on 
international health within 
the United Nations’ 
system contains various 
publications including 
health guidelines and 
standards, and periodical 
reports such as World 
Health Report, World 
Health Statistics, etc.  
All publications.  
Publications 
categorised 
under the Health 
topic - Ageing  
 
i) Free-text 
search using 
‘impact/effect 
of ageing on 
healthcare 
demand’ 
ii) Title search 
using the terms 
‘ageing or 
aging’. 
 
 
The results from the grey literature search are reported in Table 2.7. Reported are the number 
of records retrieved by applying the search methods described in Table 2.6, and the number of 
documents identified as potentially relevant among those retrieved in cases where the search 
retrieved a large number of records or was not easily reproducible due to lack of a search 
function on the website.  
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Table 2.7. Search results for grey literature 
Organisation Search date Search Results – Number of 
papers identified 
Number of papers 
considered potentially 
relevant 
Age UK -
Knowledge Hub 
14/02/2012 158 results: Evidence Reviews 
search using ‘healthcare’. 
157 results: All publications 
search using ‘expenditure’.  
3 
Centers for 
Medicare and 
Medicaid (CMS), 
US 
13/02/2012 None identified.  0 
CORMSIS, 
University of 
Southampton 
08/02/2012 None identified.  0 
Congressional 
Budget Office 
(CBO, US) 
14/02/2012 17 results: potentially relevant 
presentations/reports/letters 
were identified from Health 
Publication lists.  
17 
Department of 
Health  
07/02/2012 12 results retrieved.  
 
4 
Economic and 
Social Research 
Institute (ESRI, 
Ireland) 
08/02/2012 15 results: Keyword search for 
‘ageing’.  
19 results: Working paper search 
using ‘ag(e)ing’. 
6 
European 
Commission - 
Directorate 
General for 
Economic and 
Financial Affairs 
(DG ECFIN)  
08/02/2012 4 results: Projection of healthcare 
expenditure report (2010) and 
Ageing reports 2006/2009/2012 
were identified.  
 
4 
European 
Network of 
Economic Policy 
Research 
Institutes 
(ENEPRI) 
31/01/2012 103 results: relevant Research 
Reports.  
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FUTURAGE 
PROJECT 
08/02/2012 None identified.  0 
Health, 
Econometrics 
and Data Group 
(HEDG), 
University of 
York 
08/02/2012  176 results: Working papers 
accessible on the web page.  
 
6 
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Health 
Management 
Information 
Consortium 
(HMIC) database  
16/02/2012 649 results: Search results (limited 
to records published since 2005).  
0 
HM Treasury, UK 
 
13/02/2012 3 results: 2 Derek Wanless’  
reports (interim and final) and 
responses to them, and  Public 
Expenditure Statistical Analyses.  
3 
House of 
Commons Health 
Committee 
 
14/02/2012 6 results: relevant reports 
identified. Integration of social 
and health care, workforce 
planning, etc.  
6 
National Bureau 
of Economic 
Research (NBER), 
US 
08/02/2012 Search 1. 45 results: Working 
paper search. 
Search 2. 185 results: ‘population 
aging health care demand 
utilization’. 
Search 3. 48 results: Title search 
using ‘aging’. 
14 
NatCen Social 
Research 
 
 
14/02/2012 23 results: Among 23 studies 
available under the ‘Ageing’ topic, 
reports on The English 
Longitudinal Study of Ageing 
(Waves 0-4) and the Health 
Survey for England (2004-2009) 
were found potentially relevant.  
2 
National End-of-
life care 
intelligence 
network 
(NEoLCIN) 
06/02/2012  3 results: End of life care 
modelling tools identified as 
potentially relevant. 
 
3 
NHS Evidence & 
NICE 
 
06/02/2012 402 results (overlapped with 
database searches):  
Systematic reviews (15), 
Evidence Summaries (13), 
Grey Literature (16), 
Primary Research (171), 
Policy and Service Development 
(129), Health Technology 
Assessments (58) 
0 
Nuffield Trust 08/02/2012 
 
162 results: Total number of 
publications since 2000.  
A search with ‘ageing’ term found 
no paper. 
5 
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Organisation for 
Economic Co-
operation and 
Development 
(OECD) 
09/11/2011 23 papers found relevant. 23 
Oxford Institute 
of Population 
Ageing 
14/02/2012 4 working papers and 6 journal 
articles were identified as 
potentially relevant.  
10 
Personal Social 
Services 
Research Unit 
(PSSRU) 
14/02/2012 347 discussion papers available.  
 
9 
RAND 
Corporation 
08/02/2012 1. 34 and 2071 results from search 
using “ageing” and “aging”, 
respectively 
- RAND Health (193), RAND 
Europe (22), and RAND Center for 
the Study of Aging (82).  
 
2. i) Health and Health Care: 896 
reports. ii) Population & Aging 
area: 395 reports. iii) RAND Health 
Publications on Health Care Costs: 
43 records. 
 
3. i) 5 Projects found ii) 2 full-
length reports identified.   
22  
(22 records were 
identified as 
potentially relevant 
from Searches 1-3). 
Society of 
Actuaries (SOA) 
08/02/2012 None identified.  0 
UK Network for 
Modelling & 
Simulation in 
Healthcare 
(MASHnet)  
14/02/2012  16 results: Total 16 case studies.  4 
World Health 
Organisation 
(WHO) 
14/02/2012 
 
284 results: Title search using 
“ageing or aging”. 
8 
Total number of 
papers 
 6,313 171  
(158 after de-
duplication and 
sifting) 
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A total of 158 papers after deleting duplications and sifting were identified as relevant from 
the grey literature. The inclusion was focussed on ‘recent’ studies discussing the modelling of 
health and social care demand or relevant policies – typically those published in or after the 
year 2000, unless considered to have direct relevance to the topic – on the assumption that 
the peer-reviewed literature searches of five databases would have already identified other 
categories of important studies.  
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2.5. Discussion 
 
The proposed method for developing a pragmatic search strategy to cover a broad topic with a 
range of themes and methodological approaches was implemented in five databases, and 
significantly reduced the NNR compared with the broad searches performed at the scoping 
search stage. The final search strategies selected achieved coverage of 100% and identified 
7745 records. This compared with over 29,000 hits in Medline (Search 3) using broad ageing 
and healthcare terms and over 21,000 hits in EMBASE (Search 1); searches that collectively 
identified only ten of the eleven seed papers included in these databases and which could not 
find the paper excluded from these databases.  
However, the suggested approach is not without limitations. Intrinsically, the ‘heuristic’ 
approach does not guarantee a ‘global’ optimum, but could identify a ‘local’ optimum. As 
subsequent searches are likely to be based on previous search terms, the final search strategy 
is potentially sensitive to the initial search terms. This could result in identifying a selected set 
of the literature as papers unlike the seed papers may not be retrieved by this approach. This 
was partly mitigated in this review by the use of alternative sets of search terms. 
Furthermore, the approach may be difficult to use for searching grey literature. The iterative 
approach may be applicable only to databases that support advanced search functions such as 
combinations or exclusions of search terms, and be easier to implement in databases using 
subject indexes. Unlike the established databases for peer-reviewed studies, sources of grey 
literature often employ diverse and non-standardised indexing mechanisms. As population 
ageing has significant implications for health and social policy, it is possible that relevant 
literature is located in policy documents and the grey literature arenas. However, no 
systematic method of searching grey literature was adopted in this chapter. 
Additionally, the method relies on the degree to which the seed papers cover all the key issues 
required in order to address the research question. If the papers omit some key areas 
altogether, then it is possible that entire sections of relevant literature would not be identified, 
and including further seed papers in the search retrospectively can lengthen the review 
process. Furthermore, it is not possible to know the comparative sensitivity of each 
exploratory search as the number of relevant papers within the search in addition to the initial 
seed papers is not known, which makes it difficult to compare the coverage of searches. 
However, the risks of this can be minimised if the researchers engaging in searches for such a 
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diffuse topic area: determine in advance the nature of the key issues within the broad area; 
undertake background work, such as scoping searches, consulting experts, and discussing the 
research question widely. This allows greater confidence in the selection of a limited number 
of seed papers. In this case study, efforts were made to ensure the papers covered a variety of 
relevant disciplines, perspectives and types of publications, to reduce the chances that the 
initial selection would rule out entire areas of literature. Additional themes were identified in 
the sifted papers. It is therefore possible that searches that identify all seed papers with a 
greater number of hits may identify one or more relevant papers not identified in the selected 
strategy.  
A conventional non-iterative subject search without using seed papers may identify papers not 
identified from the pragmatic search. Supplementary searches as used for MEDLINE and 
EMBASE databases were needed to identify one of the seed papers not identified in the 
pragmatic search (Borger et al., 2006). However, given the estimated time saved of 2.2 months, 
researchers should consider the trade-off between additional papers that may be identified 
from the conventional approach and the increased time to sift associated with the use of the 
conventional method. Although the saved time estimate is specific to this case study, it 
illustrates that the proposed approach provides a potential option for use in diffuse topic areas.  
When the pragmatic approach is chosen, it is recommended that reference lists from all 
included papers are checked and citation searching is undertaken for each seed paper 
identified in order to increase coverage. 
Although the generalisability of this approach to other diffuse topic areas is currently unproven, 
there appears no obvious reason why the proposed approach would not have the potential to 
deliver similar benefits in terms of identifying relevant literature, reducing the NNR and thus, 
reducing the time required to sift in other topic areas. Although the actual number of papers 
required in other topic areas may differ, this would be a matter of judgement in the early 
stages of exploratory searches and discussion with experts. 
Within the healthcare sector, there has been an increasing emphasis on evidence-informed 
policy. As policy decisions often relate to diffuse and complex questions, the corresponding 
literature review is likely to require a pragmatic search method to support robust decision-
making. Recent literature addressing good practice in search methodologies recommends the 
adoption of methods that balance precision and coverage i.e. identifying the best available on 
a given topic without producing an unmanageable volume of results (NICE, 2012); and also 
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suggests the use of iterative searching when pre-defined search strategies are not directly 
applicable (Marsh, 2010).   
This chapter showed that thoughtfully-designed search strategies can significantly reduce the 
NNR, whilst identifying a set of seed papers that were deemed to capture the important topics 
of the target literature. In the review for this thesis, all the seed papers were retrieved and the 
NNR was substantially reduced using iterative search strategies compared with broad searches. 
Furthermore, the broad searches did not identify all seed papers despite the considerable 
number of hits. 
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CHAPTER 3   OUTCOMES OF LITERATURE REVIEW 
 
3.1. Introduction – Literature Review 
 
 
In this chapter, the documents retrieved from the literature searches described in Chapter 2 
are reviewed to synthesise information available from previous research.  
Due to the diffuse subject area and the wide range of the literature potentially relevant to the 
modelling of health and social care demand, a systematic method and labelling system for 
categorising the identified literature was established. This chapter reports: i) the criteria for 
selecting studies to be included in the main review; ii) separate criteria for selecting 
supplementary studies to be kept for future reference; iii) the system of tagging/labelling used 
for studies selected in steps i) and ii); and iv) the results of applying i) – iii). In addition to the 
review of the general studies, a review of models for projection of health and social care 
expenditure which are the primary topic of the literature search is presented.  
This chapter also introduces a freely-accessible literature repository containing both the peer-
reviewed and grey literature identified in a review of population ageing and health and social 
care demand, in order to aid others undertaking reviews on related topics. It describes the 
literature that the repository contains, how it was developed, and how it can be used freely by 
others to help extract, summarise and categorise such broad-themed literature on population 
ageing and health and social care demand.  
It is expected to be useful for those wishing to undertake horizon scanning at the initial stage 
of their research. The papers in the repository have been classified under a set of tags showing 
the main theme of the papers.  For instance, if one wishes to explore existing research on a 
range of factors that may influence health and social care demand in the UK, a retrieval of 
relevant literature can be achieved by selecting a combination of the most relevant tags set 
within the repository – e.g. ‘factors influencing demand’ and ‘UK’ in this case.  
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Sections 3.2 and 3.3 cover the review methods including study selection criteria and 
categorisation; Section 3.4 describes the creation of the literature repository; and Section 3.5 
presents the results of the literature review of all studies included and categorised. The results 
of a review of models projecting future health and social care expenditure, which inform the 
methods of the models developed for this thesis, are covered in Section 3.6.  
 
3.2. Study selection: Methods to include studies 
 
3.2.1. Studies included in the main review 
 
Inclusion and exclusion criteria were developed separately for studies to be included in the 
main review and studies that are potentially relevant but not included in the review. All studies 
identified by the literature search were included to form a larger repository for future 
researchers, but only a proportion of these studies that were deemed directly relevant to 
modelling were included in the main review of the thesis.  In this review, the primary topics of 
the target papers included studies estimating the future health and healthcare demand for an 
ageing population and studies examining the effect of policies or interventions designed to 
tackle issues arising from population ageing on healthcare demand. Secondary topics included: 
trend analyses of healthcare spending; the determinants of healthcare spending; and the 
relationships between health and social care utilisation.  
The documents retrieved from the literature searches (n=7745) were sifted based on titles and 
abstracts in order to select studies relevant to the topic. Due to the broad range of topics 
contained in the identified literature, the decision process used to determine whether to 
include or exclude papers was turned into a formal algorithm (Figure 3.1). These study 
selection criteria were developed simultaneously with the categorisation of studies, as both 
involved a similar procedure.  Hence, Figure 3.1 also shows broad categories of papers. 
Categorisation was necessary in order to facilitate the development of organised selection 
algorithms, and quick retrieval and subsequent synthesis of the identified literature.  An initial 
categorisation of study type was conducted by examining randomly selected citations with a 
view to establishing broad selection criteria based on study types. The initial criteria were 
expanded to reflect types of information provided by papers or further types of studies that 
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arose while sifting.  The updated criteria were applied retrospectively to the citations sifted 
earlier for consistency when there were major changes to the selection criteria. 
From the initial selection of studies (approximately 300) used to identify broad categories of 
studies within the literature, studies were classified into two groups: studies informing 
methodology; and studies informing the parameters that may be required to model health and 
healthcare demand. Following this, the group of studies informing parameters was further 
divided into sub-categories according to the relevant component of the model. Amendments 
to the categorisation of papers were continued until it became apparent that it was unlikely 
that major changes were needed. 
Figure 3.1 was designed to include papers expected to help structure the model to be 
developed or studies discussing important evidence for modelling health and health services at 
the population level, and to exclude studies addressing ‘specific’ or ‘non-generalisable’ issues 
associated with ageing and healthcare demand (e.g. studies conducted on a population from a 
small locality) or providing information of limited applicability. Commentaries and editorials 
published before 2007 were included only when they discussed issues closely relevant to 
projection of demand, methodology, and factors influencing demand. General commentaries 
published after 2007 were more widely included (e.g. those describing any of the issues 
relevant to ageing and health and social care demand).  
It is noted that the criteria were not aimed to identify every study relevant to each category of 
information, but to identify all available ‘modelling’ studies directly relevant to the estimation 
of health and social care demand and to categorise the literature associated with these 
modelling studies to establish a set of key themes. Developing a set of tags used for more 
detailed categorisation is described in Section 3.3.
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Figure 3.1. Flow diagram of study selection criteria: Characteristics of included and excluded studies in the main review 
 
*Specific: of limited applicability due to very narrowly defined disease, population, care setting, geographical area or country, and thus unlikely to have significant impact 
on health or healthcare demand at a broader population level; **Considered for inclusion in the set of supplementary studies (see Section 3.2.2)
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3.2.2. Supplementary studies included in the repository  
 
 
The focus of the PhD thesis was not fully defined during the initial stage where there existed 
many potential research questions. As a variety of potentially relevant studies have been 
identified, it was deemed sensible to keep a subset of papers for future reference. Hence, in 
addition to the literature for the main review (i.e. papers directly relevant to the modelling of 
health and social care demand for an ageing population), the remaining identified literature 
was saved as supplementary set of literature for future reference. As these were thought to be 
relevant to future researchers, they were also included in the literature repository.  
These ‘supplementary’ studies were set aside, and could be retrieved if it were believed that 
the paper could contain relevant information for future modelling. Thus, a separate set of 
inclusion criteria for the supplementary studies was developed – also using an iterative 
approach – simultaneously with the criteria for selecting studies to be included in the main 
review. The types of supplementary studies are summarised in Table 3.1. 
In general, supplementary studies not included in the main review were those ‘broadly 
relevant’ to methodology and/or parameters required to model health and health/social care 
demand, but on a specific disease, population, care setting, geographical area or country, 
rather than directly related to modelling health/social care demand. The supplementary 
studies also involve general background/commentary articles on demand/utilisation, relevant 
policy and service delivery that may be used for general discussion rather than being 
incorporated into a model, papers discussing relevant issues specified in the main inclusion 
criteria but whose impact is anticipated to be limited. 
It is acknowledged that the categorisation between studies for the main review and 
supplementary studies could be subjective. For example, a certain policy adopted in a state of 
the US may be included in the main review if it can be generalisable to other localities, while a 
nation-wide US policy may not be included as it is specific to the US system.  
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Table 3.1. Criteria for supplementary studies that were not included in the main review 
Studies 
informing 
Types of supplementary studies 
Both 
Methodology & 
Parameters  
 
• Cost of illness that is prevalent among the elderly and studies on 
economic impact of a certain disease  
• Needs assessment for broad areas of care 
Methodology   
 
• Studies discussing relevant projection studies with no analyses of 
the authors’ own (e.g. review).  
• Methodologies that may be used for some parts of a model but 
not for the estimation of health or social care 
demand/expenditure. 
• Studies describing potentially relevant data sources, but not 
necessarily within an older population. 
 
Parameters 
 
Diseases  
• Disease-specific service utilisation; Papers discussing aspects of 
ageing relevant to health and social care 
• Transitions between states of major diseases 
• Cause of death/ place of death studies 
• Relevant clinical studies showing the relationship between major 
diseases of the elderly. 
• Primary research (RCTs) 
Policy & Intervention  
• Disease specific interventions/policy (e.g. treatment pathways for 
cancer); National policy and managerial issues arising from 
population ageing 
• Studies discussing implications of broadly relevant policies and 
interventions on health and social care (e.g. housing and de-
institutionalisation) 
• Technological progress in elderly care 
• Financing health and social care 
• Impact of health insurance coverage on utilisation/ Cost sharing 
studies/ Risk adjustment/assessment, capitation studies that 
describe factors influencing global healthcare expenditures. 
• Studies on certain US interventions e.g. issues related to 
managed care 
Planning & Capacity  
• Workforce flexibility/capacity in certain types of services for older 
people 
• Healthcare system efficiency 
Service delivery & Care settings  
• Links between health and social care for a certain type of service 
(e.g. integrated care design) 
• Issues specific to a care setting (e.g. residential care, home help, 
etc.) 
• Current status of the elderly care & service delivery system for a 
specific care type or disease 
• Determinants of (demand for) informal care provision 
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3.3. Categorisation of studies – Tagging system 
 
A system of tagging was established in which each item of identified literature was assigned 
one or more tags representing the information that the paper provided. The tags were: disease 
area; type of policy/intervention examined; factors that influence healthcare demand; and 
methodology used. Under the broad tags, sub-tags were created to describe detailed 
information. By using the same set of tags for both the studies to be included in the main 
review and those in the supplementary set, all information on a theme could be retrieved 
simultaneously. 
The tagging structure was expanded and updated using an iterative approach. An initial list of 
tagging terms was established based on the types of studies identified to create the initial 
selection criteria. Tags were then expanded to describe types of data provided by the study of 
interest and further types of studies identified while sifting. Also, new or more detailed tags 
were added if the existing tags did not provide appropriate descriptions of the information 
expected from the study although the tagging terms were kept as general as possible to keep 
the number of tags manageable.  
The list of tags developed is shown in Table 3.2. Due to the wide range of the studies retrieved, 
multiple tags were applied to individual records. For example, the combination of the tags 
‘Service utilisation’, ‘Disease – mental’, and ‘UK’ would indicate a study analysing the 
utilisation of mental health services by the UK population.  
A hierarchy in the tagging structure was expressed by the use of a hyphen, e.g. ‘Disease – 
cancer’ was used to indicate the ‘cancer’ category within the ‘Disease’ hierarchy.  
‘Disease’ tags and ‘Factors influencing demand’ tags were included to identify major disease 
areas related to population ageing and the determinants of healthcare demand or expenditure, 
respectively. Disease-related tags were assigned both for broad disease areas (e.g. mental 
diseases) and for specific disease (e.g. dementia). Also, tags covering a wide range of issues 
such as ‘Factors influencing demand’ were further sub-categorised to identify groups of 
determinants of healthcare demand or expenditure. The combination of the assigned tags may 
be used to retrieve papers relevant to a specific topic for the synthesis of the review findings 
and the narrower categories of studies. For example, a combination of ‘Trend analysis’, ‘Global 
healthcare demand’ and ‘US’ would locate studies on global healthcare demand trends in the 
US.  
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The same set of tags was applied to all citations whether they are included, excluded or 
included in the supplementary set. Some of the excluded items were given a tag describing 
reasons for exclusion. However, studies were classified differently depending on the 
anticipated significance of the evidence provided by the study. For example, a study on a 
national dementia prevention programme with a large participating population may be 
included in the main review while a similar intervention led by a local authority for a short 
period of time may be excluded.  
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Table 3.2. Final tagging structure 
I. METHODOLOGY 
Methodology 
Methodology
1
 
Projection 
Projection - healthcare demand 
Projection - Long Term Care 
Projection - retrospective 
Modelling - other 
 
Types of analysis 
 
Background 
General
2
 
Clinical 
Commentary  
Conference proceedings 
Primary Research (RCTs) 
Database
3
  
Review 
Time to death
4
  
Local study 
Letter 
Needs assessment 
International comparison  
Trend analysis 
Actuarial analysis 
Economic analysis 
Statistical analysis 
 
II. PARAMETERS 
Diseases and conditions 
 
Disease – mental  
Disease – behavioural  
Disease – dementia  
Disease – depression  
Disease – delirium 
Disease – neurodegenerative 
Disease – neurologic   
 
Disease – cancer 
Disease – colorectal 
Disease – liver 
Disease – pancreatic 
Disease – renal  
      
Disease – cardiovascular  
Disease – cerebrovascular  
Disease – hypertension 
Disease – stroke  
 
Disease – respiratory  
Disease – COPD  
 
Disease – diabetes 
Cost analysis 
Cost analysis  
Cost of illness
12
 
 
Policy 
Policy 
Financing 
Workforce and capacity
13
  
Insurance
14
  
Political 
 
 
Intervention 
Intervention 
Intervention - admin 
Intervention - care pathways 
Intervention - cost containment 
Intervention - effectiveness 
Intervention - integrated care 
Intervention - prevention 
Intervention – technology 
 
 
Relationships between 
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Disease – obesity  
 
Disease – disability  
Disease – falls
5
  
Disease – frailty 
Disease – incontinence  
Disease – urologic 
Disease – learning disabilities   
Disease – malnutrition  
 
Disease – musculoskeletal  
Disease – osteoarthritis  
Disease – osteoporosis  
Disease – arthritis  
Disease – pain  
Disease – sarcopenia 
 
Disease – pneumonia  
Disease – sensory (hearing, vision, etc.) 
Disease – oral  
Disease – multiple
6
  
 
Bio-demographics/Epidemiology of 
major diseases 
Population health status
7
 
Bio-demographics
8
   
 
 
Utilisation/Resource 
use/Needs/Demand 
 
Global healthcare demand
9
 
Service utilisation
10
 
Drug expenditure 
Factors influencing demand
11
 
 
 
parameters/Other Topics  
Demand and supply 
Delivery system 
Efficiency 
Relationship - health status and care setting 
Relationship - health status and demand 
Relationship - health status and disease 
Relationship - health status and risk factors 
Relationship - hospital and social care 
 
 
Care setting 
Community Care 
Institutionalisation 
Independent living 
Home care 
Hospital care 
Informal care 
Long Term Care 
Palliative care 
Primary care 
Social Care 
Self care 
Residential care 
End of life care  
 
Country/Location 
Asia 
Europe 
US 
UK 
AUS 
Canada 
1. General methodology; 2. Not only healthcare demand issues, but discusses more general issues 
including healthcare; 3. Includes self-reported data. Papers discussing data source and data usage;  
4. Describes/tests time to death as one of the ‘Factors influencing demand’;  
5. Includes accidents and injuries; 6. Indicates co-morbidity; 7. Specific or general health states of 
population of interest; 8. Includes mortality, life expectancy, fertility issues; Epidemiological studies; 
Population dynamics. Also, includes transition/disease progression issues; 9. To distinguish from 
demand for a certain type of healthcare, represent demand relevant to a whole sector of healthcare; 10. 
Utilisation of specific type of healthcare; 11. Broad tag for studies discussing factors determining 
demand (global healthcare demand, or long term care). Demand also includes demand, cost, 
expenditure, and utilisation. Anything that may affect the health and social care ‘expenditure’ or 
‘demand’ (not health status itself);  
12. Burden of illness studies; 13. Includes planning issues; 14. Includes cost-sharing issues 
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3.4. Forming a literature repository 
 
As part of the review output, a literature repository was established. Both studies included in 
the main review and those tagged as supplementary were included in the repository. The 
purpose of the repository is two-fold: first to ensure retrieval of papers on issues that may 
emerge as important to the models developed for this thesis; and second, given the 
considerable effort required to identify and classify the diffuse literature, the repository 
provides a useful resource for those researching the topic of ageing and healthcare.  The 
repository is thought to be particularly useful for those who are at an early stage of research 
regarding ageing and healthcare demand and wish to quickly retrieve relevant literature. 
Section 3.5.4 will describe the method of accessing and using the repository.  
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3.5. Results of the literature review 
 
 
3.5.1. Study selection 
 
The series of decisions shown in Figure 3.1 were followed to categorise the studies according 
to the type of information they provide. Studies informing ‘Methodology’ included i) studies 
estimating the future health and healthcare demand of an ageing population; ii) studies that 
are not directly on healthcare demand projection but whose methodology and underlying 
concepts may be applicable to other models; and iii) studies examining the effect of policies or 
interventions designed to tackle issues arising from population ageing on healthcare demand. 
Excluded were: studies addressing ‘specific’ or ‘non-generalisable’ issues associated with 
ageing and healthcare demand (e.g. studies conducted on a population from a small locality); 
and studies providing information of limited applicability.  
The group of studies informing parameters were divided into those informing parameters on 
certain diseases and those on global healthcare demand (Figure 3.1).  Both of these groups 
were further categorised into: studies on bio-demographics; policies and interventions; 
planning & capacity; service delivery & care setting based on the main theme of the paper; and 
commentaries or narratives providing background information. ‘Global healthcare demand’ 
included: studies informing factors determining global healthcare or long term care demand 
(‘Factors influencing demand’ category); studies projecting future healthcare or long term care 
demand, utilisation or expenditure (‘Projection’ category); studies on time trends of total 
health and/or long term care demand (‘Trend analysis’ category); and studies discussing 
proximity to death as one of the determinants of healthcare expenditure (‘Time to death’ 
category). The ‘time to death’ category was added as a separate topic as a number of studies 
discussing ‘Factors influencing demand’ focussed on this issue. 
Studies discussing issues identified as irrelevant, for example, those on private healthcare 
systems such as the US healthcare market and their associated policies; performance of a 
certain care setting; inequality and geographical variation; and political debate on healthcare 
policies were excluded.  The sub-categories used in Figure 3.1 are also defined in more detail. 
The ‘bio-demographics’ category under the ‘disease’ heading includes papers on demand for 
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services for major disease areas of the elderly and bio-demographic aspects of population 
ageing, and epidemiological studies of selected diseases. The ‘policies & interventions’ studies 
included those discussing policies or interventions that may impact on global health and social 
care demand from a whole population perspective, or may have a significant impact on the 
health and social care status of the elderly. ‘Planning & capacity’ included those discussing 
national workforce and capacity issues, or papers that help identify constraints (e.g. workforce 
availability) and factors permitting services for older people. A broader category was the 
‘Service delivery/Care settings’ which included studies informing relationships between health 
and social care utilisation, or discussing service delivery issues that may inform the structure of 
a model. Commentaries directly related to modelling healthcare demand or narratives 
providing background information formed another category. 
Applying the criteria also involved defining major disease areas relevant to population ageing. 
Only the diseases considered likely by the author to have significant impact on the health and 
healthcare demand of the elderly population were included. Therefore, acute diseases with a 
low possibility of hospitalisation and/or severe morbidity were not included. The iterative 
approach did not generate a complete set of relevant diseases. Instead, the importance of the 
newly identified disease was assessed by comparing it with those already included. The 
distribution of studies on different disease areas is reported in Section 3.5.2.  
 
 
3.5.2. Categorisation of the literature 
 
Categories of studies to be included in the main review 
 
891 studies were included in the main review. A broad categorisation was performed by the 
type of analysis and the information provided by the study.  
The full sifting and tagging of the literature identified a few ‘major’ types of studies that are 
related to modelling or methodology with a relatively high number of studies included. The 
distribution of papers across these types is summarised in Table 3.3. The major areas of the 
review among the identified types were the first five in Table 3.3: ‘Factors influencing demand’; 
‘Projection’; ‘Methodology’; ‘Trend analysis’; and ‘Time to death’ categories.  
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There were 146 ‘projection’ studies that could inform the models to be developed for this 
thesis, 65 of which were exclusively on health care sector including ‘hospital care’ and ‘primary 
care’ (see tags in Table 3.2 Final tagging structure), and 33 were on long term care and 
community care. The type of care described in the rest of the studies was either unclear based 
on titles and abstracts or both health and social care. ‘Projection’ studies could also include 
statistical analysis models for prediction and reviews of projection models.  
The distribution of studies across some of the most important categories of tags is presented 
in Figure 3.2. Some tags were more likely to be assigned together due to their relevance. For 
example, 55 out of the 112 ‘Methodology’ papers were also ‘Projection’ studies as 
‘Methodology’ could indicate projection methods, and of the 59 ‘Time to death’ studies, 41 
were also included in the ‘Factors influencing demand’ category. 
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Table 3.3. Sub-categorisation results of the studies screened to be included by type/topic of 
studies* 
 Description Number of 
papers 
Categories relating to modelling/methodology 
Factors influencing 
demand 
A broad category for studies discussing factors that may 
influence health or social care demand. 
 
Studies on factors influencing demand for the 
following selected types of care (with the highest 
numbers of studies included)**: 
o Global healthcare demand (78) 
o Long term care/Social care (50) 
o Hospital care (30) 
o End of life care (14)  
o Community/Home care (6) 
o Drug expenditure (5) 
330  
 
Projection  Studies estimating/projecting future healthcare or long 
term care demand; Studies on specific types of health 
and long term care, or on a specific population whose 
methods are considered potentially useful.  
146 
Methodology 
 
Studies that may inform methodology for future 
modelling; Also includes studies on countries whose 
healthcare systems significant differ from that of the UK 
112 
Trend analysis Studies discussing/estimating time trends of total 
health and/or long term care demand; Studies on 
demographic trends discussed in relation to future 
health or social care demand.  
67 
Time to death Studies discussing proximity to death (in terms of 
methodology or as one of the determinants of 
healthcare demand) 
60 
 
Other categories 
Policy/Intervention All studies discussing policies or interventions 
considered having potentially significant impact on 
health and social care demand; Includes commentaries 
discussing healthcare system reform; Majority were on 
251 
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‘global’ health or social care demand, but some were 
related to certain diseases or care settings. 
For selected types of care**, 
o Long term care (57) 
o Commentary (28) 
o Integrated care (26) 
Commentary Commentaries discussing issues related to health or 
social care demand and population dynamics; Also 
includes commentaries providing general background 
on relevant issues. 
70 
Workforce and capacity Studies discussing whether the current 
system/workforce can meet the growing demand from 
a national/wide population perspective; Also includes 
planning issues. 
35 
* Numbers in brackets ( ) denote the number of studies within the category; **Numbers for 
sub-categories do not add up to total as multiple, but not an exhaustive list of, relevant tags 
were assigned to each citation. 
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Figure 3.2. Distribution of studies included in the main review across some of the most 
important tags* 
 
*The relative size of the boxes and circles does not represent the proportion of studies 
included in that category.  
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Categories of supplementary studies 
 
In general, the supplementary studies (n=1214) that were not included in the main review 
were those ‘broadly relevant’ to methodology and/or parameters required to model health 
and health/social care demand, for specific diseases, populations, care settings, geographical 
areas or countries. These studies were not considered directly related to modelling 
health/social care demand.  The categories of the supplementary studies are available in Table 
3.4, and the distribution of supplementary studies across a few tags is shown in Figure 3.3.  
A large number of studies belonged to the ‘Intervention’, ‘Policy’ and/or ‘Service utilisation’ 
categories. The total number of studies assigned any combinations involving at least one of the 
three tags was 432. This is fewer than the summation of the individual categories (n=699) due 
to papers being assigned more than one of these categories. Studies on interventions were 
sub-divided by intervention type and by disease category. Not all citations were assigned a tag 
representing a specific disease or intervention type: those not assigned a disease tag may be 
cost analysis or service utilisation studies covering more general conditions; the tags for the 
type of intervention were assigned only when it was clear from the title and abstract. 
 
 
84 
 
Table 3.4. Sub-categorisation of the supplementary studies at title and abstract level* 
Category Description Number of papers 
Intervention Interventions for certain diseases/care 
settings/populations. 
 
By selected intervention type**: 
- Prevention (67) 
- Care pathways (30) 
- Cost containment (25) 
- Effectiveness study (12) 
- Integrated care design (20) 
- Use of new technology (31) 
300  
 
Policy Any studies evaluating, discussing, or suggesting 
policies; Also includes studies discussing health 
and social care reforms, resource allocation, or 
financing issues. 
224  
 
Service 
utilisation 
Studies on utilisation of health or social care for 
the treatment of a disease or within a specific 
care setting; Relevant to ‘Cost analysis’ category. 
175 
Commentary Commentaries potentially useful for theme-
setting. 
114 
Cost analysis Majority associated with the cost of treating a 
certain disease; Cost of treatment or 
interventions, etc.  
100 
Delivery system Studies describing delivery system for a certain 
kind of care (e.g. long term care, cancer 
treatment, etc.). 
100 
Cost of illness Burden of disease studies based on prevalence 
and incidence estimates for a whole population 
75 
Needs 
assessment 
Studies on assessment of needs of older people 
for a type of care (e.g. mental health care, 
residential care, etc.);  
67 
Methodology - 
other 
Methodologies that are not directly relevant to 
estimating health or long term care demand, 
but may be used for future modelling.  
61 
Informal care Studies discussing factors influencing provision 56 
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of informal care, or general issues related to 
informal care. 
Workforce and 
capacity 
Studies discussing whether the current 
system/workforce can meet the growing 
demand; Also includes planning issues; Only 
studies of narrower scope (e.g. on a certain care 
setting or a population) or broad commentaries 
were included in this category. 
54 
* Numbers in brackets ( ) denote the number of studies within the category; **Numbers for 
sub-categories do not add up to total as multiple, but not an exhaustive list of, relevant tags 
were assigned to each citation. 
 
 
Figure 3.3. Distribution of supplementary studies across some of the most important tags* 
 
*The relative size of the boxes and circles does not represent the proportion of studies 
included in that category.  
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Disease areas 
 
Of the 891 included papers, only a small proportion (n=155) were assigned a disease tag, 
which was expected as the aim was not to identify studies on a specific disease in the main 
review. Among the 1214 studies included in the supplementary group, 469 were given a 
disease tag. Table 3.5 shows the distribution of studies across selected disease areas. Broad 
terms were employed to include a wide range of diseases, but narrowly defined disease names 
could also be used where a large number of papers addressed such diseases. Although the 
number of studies on a particular disease does not represent the importance of the disease, it 
is likely to be indicative of the disease areas most discussed in the literature in the context of 
population ageing.  
Mental health diseases including dementia, functional disability, musculoskeletal diseases 
including osteoporosis and arthritis and cardiovascular diseases were the diseases most 
frequently identified.  
 
 
Table 3.5. Breakdown of studies by disease tag assigned*   
Studies included in the main review Supplementary studies 
 
Disability - functional (31) 
Dementia (18)/ Mental & Depression (25) 
Musculoskeletal (16) 
Cardiovascular (14) 
Diabetes (9) 
Obesity (9) 
Multiple (Co-morbidity) (12) 
Hypertension (4) 
Cancer (3) 
 
Dementia (67)/Mental & Depression (87) 
Musculoskeletal (56)  
Cardiovascular (49) 
Cancer (37) 
Falls & Injuries (35) 
Disability - functional (25) 
Multiple (co-morbidity) (25) 
Diabetes (18) 
COPD/Respiratory (11) 
Obesity (10) 
Stroke (9) 
Hypertension (5) 
*Numbers in brackets do not add up to total as not all papers were assigned a disease tag.
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3.5.3. Grey literature 
 
A total of 158 relevant articles were identified from the grey literature. The same study 
selection criteria and tagging scheme described previously were applied to the grey literature, 
although a smaller number of tags were used for the grey literature, and the selection was 
more focussed on the UK or European healthcare system. 
The categories and number of studies identified from the grey literature search are reported in 
Table 3.6. Among the 49 papers identified as projecting future demand for health and social 
care, 27 were related to global healthcare or hospital care, 26 to long term, social or 
residential care, and eight were projecting both. The remaining four articles were related to 
informal care (2), or the projection of bio-demographic trends (2). Fifteen out of the 30 papers 
considered to inform methodology were also assigned the ‘projection’ tag.  A large proportion 
of the papers discussed policy implications of population ageing, or evaluated existing or 
hypothetical policies (n=58). The issue of financing future health and social care appeared in 
seven of these 58 articles.  
 
 
Table 3.6. Categories of the included grey literature*  
Type of study Number of articles 
Studies discussing policies and interventions 58 
Projection studies** 49 
Studies discussing factors influencing health and social care demand 32 
Studies considered to inform modelling methodology 30 
Bio-demographics and population health status 25 
Trend analyses of health and social care expenditure 13 
*Numbers of articles do not add up to total as multiple tags could be assigned to each citation 
and the types of studies are not mutually exclusive; **Numbers reported here are the number 
of individual papers, rather than that of models used for their results. 
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3.5.4. Using the literature repository 
 
A total of 2263 papers (891 peer-reviewed and 158 grey-literature studies included in the main 
review, and 1214 supplementary studies) on the topic of population ageing and healthcare 
demand/utilisation were stored within a literature repository. All studies in the repository 
were classified under the tagging system described in Section 3.3.  
The repository is freely accessible for any future researchers. The complete file containing all 
citations can be downloaded in the form of an Endnote® library file (Thomson Reuters) at 
https://www.myendnoteweb.com/ (username and password available upon request to the 
author) and can be exported to other reference management software that supports the 
Endnote file format.  Searching the repository can provide an overview of relevant literature 
for those interested in any of the topics covered, especially if they do not wish to undertake a 
systematic search; it can provide an initial trawl for those wishing to develop their own 
systematic search on one of the topics covered; and it can complement a standard systematic 
search that may not be 100% sensitive.  
As the tags are not mutually exclusive, one may use a combination of tags to retrieve 
information of interest. Each citation has a ‘research notes’ field where the tags corresponding 
to the study were recorded (the ‘keywords’ field contains the keywords that the author(s) of 
the study specified when publishing their paper). Users can search references by typing the 
names of the tags representing the topic of interest in the search. The use of double quotes 
(“…”) would return references containing the exact tagging phrase in the quotation marks. Due 
to the limited search functionality within the web-based Endnote, users may export the 
records to other reference managing software and use an advanced search function to retrieve 
documents containing tags of interest in the ‘research notes’ field.     
The distribution of studies across some of the most important categories of tags is presented 
in Figure 3.4. Due to the large number of tags, this figure shows only a section of tags that 
made up a high proportion of the identified literature. Figure 3.5 provides an example of how 
combinations of tags could help retrieve relevant papers if one wishes to explore the 
population-level demographics and disease status associated with dementia and cognitive 
impairment.   
 
89 
 
Figure 3.4. Distribution of studies included in the data repository across some of the most important tags 
 
Numbers in brackets ( ): the number of papers included. 
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Figure 3.5. Illustration of how to retrieve literature from the repository  
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3.6. Review of methods for projection of health and long-term 
care demand 
 
 
3.6.1. Summary of models for projection of health and long-term care 
demand 
 
 
For the purpose of this review, ‘projection’ is considered to encompass forecasting. Projected 
results were assumed to be dependent  upon scenarios and assumptions representing the 
analysts’ beliefs which may or may not be realised, while ‘forecasting’ would involve obtaining 
the most likely estimate of the actual value or its trajectory. Studies projecting future health 
and/or long term care demand were identified from the literature search.   
Figure 3.6 summarises how these ‘projection’ studies have been identified from both the peer-
reviewed journals and the grey literature. Of 7745 papers identified, 146 papers were related 
to the projection of health and long term care demand at the title and abstract level.  The full-
text of these papers were retrieved and examined to identify those that are directly projecting 
health and/or social care demand or expenditure using a model-based approach. Based on the 
full-text, 77 modelling studies were identified, and a set of 49 projection papers identified from 
the grey literature were also included, increasing the total number of projection modelling 
studies to 126. A further 16 papers were added from the references of the articles already 
included, resulting in a final set of 142 projection papers as shown in Figure 3.6.  
Figure 3.7 shows the linkages between the 142 papers identified from both the published and 
grey literature, and the breakdown of the methods used in these studies. Three broad 
categories of models were identified: statistical/econometric models (30 papers), macro-
simulation (88 papers), and micro-simulation models (24 papers). Multiple papers were 
associated with individual models with the 142 papers relating to a total of 77 models: 11, 52, 
and 14 models for the three broad categories, respectively.  
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Figure 3.6. PRISMA diagram for studies on the projection of health and social care demand 
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Figure 3.7. Graphical representation of broad methodologies used for all projection models identified 
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Figure 3.7 was structured as follows: the smallest boxes represented individual papers, 
individual papers were grouped in a dotted box if they were either published by the same 
organisation (or authors) using the same method, or conducted as part of the same project, 
arrows were used when a paper made an explicit reference to another paper as a predecessor 
of their model, with the remainder of the papers were considered as stand-alone models. 
Stand-alone studies by definition cannot be linked to other studies, papers within the stand-
alone model boxes but were grouped if they used a similar method. The majority of the models 
(n=53) were stand-alone models that do not have links with other models. These results 
indicate the large number of models relating to the projection of health and long-term care 
demand.  
 
3.6.2. Methods used for projection of health and long-term care 
demand 
 
Models were classified into three groups – statistical/econometric models; macro-simulation 
models; and micro-simulation models – based on the type of the approach taken and the level 
of aggregation of the model. The statistical/econometric model is distinguished as it defines a 
statistical relationship between parameters and the projected demand/expenditure. The 
distinction between macro- and micro-simulation models is based on the level of aggregation 
of the model. Individual entities such as persons, families, and firms are followed in micro-
simulation models, whereas macro-simulation uses aggregate values for groups of those 
individual entities. The macro-simulation models are further divided into four categories: cell-
based; multi-state including Markov models; macro-economic models; and system dynamics. 
The following sections explain the main characteristics of the three groups of models with a 
description of a few selected studies that were considered to show representative 
characteristics of the method. Section 3.6.2.4 compares and contrasts the methods that were 
described in this section.  
 
3.6.2.1. Statistical/econometric models 
 
Statistical or econometric projection models refer to models which establish a statistical 
relationship between the total or per-capita cost and population characteristics, such as age, or 
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economic variables, such as GDP, in the form of mathematical equations: these equations can 
be either deterministic (where the entire set of variable states are uniquely determined by 
parameter values and initial conditions, so is the output of the model) or stochastic (where 
there is inherent randomness, thus the same set of parameters and initial conditions will yield 
different outputs). Typically, these models attempt to use standard statistical techniques to 
predict the future demand for health and social care and incorporate various socio-economic 
and health variables. Although macro- and micro-simulation models may also involve 
performing statistical estimations to obtain estimates to populate parameters within the 
model, models in this category are included only if they use a statistical approach for the main 
expenditure/demand projection. 
A total of 30 papers associated with 11 models were included in this category (Figure 3.7). A 
summary of all these models is given in Table 1 in Appendix 3.1. Out of the 11 models, there 
were three groups of linked papers: the ENEPRI/AHEAD project (Khoman and Weale, 2007); 
OECD econometric analyses (Gerdtham et al., 1993, Antioch et al., 1999); and the US CMS 
projections (Centers for Medicare and Medicaid Services, 2009), which was linked to be Wrobel 
et al. (2003).The remaining models were stand-alone.  
The majority of the studies (24 of 30 papers) used regression-based linear models. For 
example, the OECD econometric analyses (Gerdtham et al., 1993, Antioch et al., 1999) used 
regression approaches to develop coefficients that can be used to forecast public hospital 
expenditure for a cross-country comparison of total expenditure and its components.  A more 
complex use of different models could be found in the National Health Expenditures (NHE) 
projection studies published by the US Centers for Medicare and Medicaid Services (CMS) 
(Centers for Medicare and Medicaid Services, 2009, Heffler et al., 2003, Borger et al., 2006, 
Keehan et al., 2008). The CMS model combined projections for Medicare and Medicaid 
spending based on the Medical Insurance Trustees’ report (The US Department of the Treasury, 
2008) with projections for private health spending based on a multi-equation econometric 
model. The structure was a ‘top-down’ approach in which the growth in healthcare spending is 
primarily determined at the aggregate level based on historical trends and relationships in 
health spending. It also combined a number of exogenous projections made by various public 
and private organisations for different components of the model, e.g. the Medicare and 
Medicaid spending projections are given as exogenous variables for the projection of private 
spending. Recent updates made to the baseline projection model include the expansion of 
model to add new sub-models for spending by sponsor, or those who hold the ultimate 
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responsibility for financing such as employers and households, and changes made in response 
to the recent policy change such as the passage of the Patient Protection and Affordable Care 
Act of 2010 (Centers for Medicare and Medicaid Services, 2011). 
Most (6/7) of the ‘stand-alone’ models also adopted regression-based methods such as two-
part model. A two-part model first estimates the probability of service use, and the level of 
expenditure conditional on the service use in order to derive the expected healthcare 
expenditure. One study by Wang (2009) used a rather different approach. In its short-term 
econometric projections, it used an auto-regression model with one- or two-period lagged 
independent variables such as health expenditure and GDP growth rates. The use of stock 
returns was proposed as proxies for some factors likely to influence healthcare expenditure on 
the assumption that healthcare industry returns would contain some information on future 
expenditure growth.  
 
3.6.2.2. Macro-simulation models 
 
The macro-simulation method is defined as a projection method in which the unit of analysis is 
groups of people with similar characteristics and the projection outcomes for the total 
population are obtained by aggregating the group-level estimates (Comas-Herrera et al., 2003). 
Typically, the population is sub-divided according to socio-demographic characteristics such as 
age and gender. The actual disaggregation methods vary depending on the purpose and type of 
the model.  
In total, 88 papers used the macro-simulation method. These were associated with 52 models 
– 39 individual and 13 linked models.  Table 2 in Appendix 3.1 summarises all of these models. 
As in the previous section, this section also describes studies considered to be representative 
of the sub-groups of papers shown in Figure 3.7 as an example.  
The remainder of this section will describe four categories of the macro-simulation method: i) 
cell-based model; ii) multi-state & Markov type of models; iii) macro-economic model; and iv) 
System dynamics. The paper by Warshawsky (1994) was counted only once, although it was 
included in two of these categories. These broad categories were determined by the method 
used to project the future expenditure on or ‘demand’ for health and long term care services, 
irrespective of the methods used to project other components of the model. 
The largest proportion of the macro-modelling studies belonged to the cell-based model 
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category (75 papers (85%); 40 models (77%)). This method involves dividing the total 
population into demographic ‘cells’ by selected population characteristics that may influence 
the level of demand for health and social care services such as age, gender, health status, 
functional disability, and household composition. It assumes that the population can be broken 
down into homogeneous groups of people, often termed ‘cells’. Total expenditures are 
calculated by multiplying the projected number of people in each cell by the respective 
expected expenditure profiles and aggregating these group-level expenditures across all cells 
for each projection year. The numbers of people in the cells each year are usually obtained 
from external sources such as census and national population estimates. This allows inflows of 
people over time, as projected in the source data.  
Examples of country-specific models that adopted a cell-based macro-simulation approach are 
the UK long term care projection models developed by the Personal Social Services Research 
Unit (PSSRU) (see Figure 3.7)(Wittenberg et al., 2006, Wittenberg et al., 2008, Comas-Herrera 
et al., 2003, Comas-Herrera et al., 2001). This series of models have been modified and 
updated over time and aim to project long term care expenditure and associated social care 
staff required. Key projection outcomes were future numbers of disabled older people, future 
levels of long term care services and disability benefits, future public and private expenditure 
on long term care and future social care workforce requirement.  
The Wanless Social Care review published by the King’s Fund builds on this PSSRU model. The 
macro-simulation model was linked with a micro-simulation model also developed by PSSRU, 
or the CARESIM model (Malley et al., 2006, Wanless et al., 2006, Hancock et al., 2007b). 
Estimates of the proportion of care recipients eligible for local authority support under 
different charging regimes and the proportion of costs met by users are incorporated into the 
cell-based model.  
There were studies that used the cohort component method (Figure 3.7). It is in principle a 
type of population projection model in which different components of demographic changes – 
births, migration, and deaths – are estimated (Rice et al., 1983, Madsen et al., 2002, Serup-
Hansen et al., 2002, Polder et al., 2006). However, its expenditure projection was based on the 
same method as the cell-based method: each age group, or cohort, is followed through 
successive calendar years, and the number in each cohort is multiplied by the average 
expenditure to calculate the total costs.   
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Markov and multi-state approaches model a cohort of individuals which are grouped according 
to pre-defined states (Sonnenberg and Beck, 1993). However, they differ from the cell-based 
macro-simulation model as they used transition matrices to determine the number of people 
in each state, rather than these values being exogenously determined as in cell-based models.  
A Markov model simulates the movements of a cohort over a pre-specified number of time 
cycles. The numbers of people at each state are used to calculate the cost for each time cycle, 
and the per-cycle costs are aggregated across all modelled cycles to calculate a total cost.   
Multi-state models can be considered as a type of Markov model (Schoen, 1988). The term 
‘multi-state model’ was used separately from Markov models in this thesis in the sense that 
new inflows of people are allowed in the model to reflect the actual population changes (open 
model) as opposed to a closed model such as Markov models with the fixed number of initial 
entry. If the transition matrices differ according to the age band to which a cohort belongs, the 
new cohorts will make transitions at different rates to that for the existing population 
depending on the year that they entered the model.  
The implementation of the method may vary. Kildemoes et al. (2010) used a Markov model 
which started with a fixed cohort to project future drug utilisation per user and then applied 
population projection results to estimate population-wide treatment prevalence and 
expenditures. Unlike the Markov model, in the dynamic multi-state models used by Hare et al. 
(2009) and Boyle et al. (2010), model entry rate was determined by the population projections. 
In this sense, the multi-state life table method was considered as a type of multi-state 
approach (Lau et al., 2011, Feenstra et al., 2001, Struijs et al., 2005). The multi-state life-table 
method was also a population projection model as for models in the cell-based simulation 
category as it is a way of obtaining estimates of population characteristics such as mortality 
and expected life years spent without disabilities. However, the multi-state life-table method 
differs from the cohort component method where population sizes in different states are 
calculated by the sum of those in relevant components of the population as it follows 
transitions between states – associated to population projection – of successive birth cohorts 
and added new incident cases each modelled year.  The multi-state life-table method generally 
aims to estimate the prevalence of a certain condition or treatment, but can also be used to 
estimate total costs related to that condition or treatment.  
Macroeconomic models share the same general idea of the cell-based method, however, the 
macroeconomic approach differs in that it is based on a set of mathematical relationships 
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theoretically consistent in terms of the equilibrium of demand and supply of goods and 
services. The method may be considered as a variant of the multi-state model in which 
transition probabilities are 'implicitly' governed by some macroeconomic parameters such as 
unemployment in order to maintain global accounting consistency. A simple example of such 
macroeconomic consistency is the total number of residents in institutional settings not 
exceeding the total number of beds available in such care settings at any point in time. This 
type of consistency can be used to study linkages between demography, macro-economy, 
labour market, healthcare system, etc. Parameters for different modules are generally 
estimated by solving a series of mathematical equations via the partial equilibrium approach 
(Soede et al., 2004). 
Demographic projections or trends are inputs in the macro-economic model which attempts to 
describe the operation of the components of an economy or an economic system. The 
projections of aggregate economic activity and labour market outcomes for different 
population groups can be fed into models of relevant systems to obtain specific outcomes of 
interest. By solving the inter-related equations using econometric techniques, the total cost as 
percentage of GDP can be obtained. 
 
Although the macroeconomic model could potentially be included in the statistical model 
group as it is expressed in a set of mathematical relationships, it was considered as a type of 
macro-simulation method for this review as it is essentially based on the macro-level 
disaggregation of the population and the estimation method was not one of conventional 
statistical techniques but rather one based on economic theory.  The ‘semi-aggregate’ 
approach termed by Ferraresi and Monticone (2009) and the social security model by 
MacKellar et al. (2004) used the economic-demographic macro model built within a macro-
economic framework. The economic-demographic model was based on the 'demographic cells' 
and the projection is made by aggregating across the cells.  
 
System dynamics (SD) aims to enhance an understanding of the dynamic behaviour of complex 
systems. The model tracks changes in system states over time and updates the variables which 
represent the population of different states. The rate of change in each state may vary over 
time or as a function of the system state itself. SD does not incorporate individual-level 
modelling although individuals with a particular set of characteristics may still be considered 
dependent on the model specification. In this sense, the SD simulation model can be 
considered as a complex dynamic multi-state model and thus a macro-simulation model. 
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The numbers of people in each state are governed by rates of event and entry of new cohorts. 
The ‘flows’ of people caused by the events of falling ill or dying change the composition of 
‘stock’ variables such as the well, ill, or dead populations. The events are influenced by risk 
factors, with various types of relationships can be modelled using SD. Causal relationships 
between the health states may be included and the model can be run in continuous time. SD 
can also accommodate the non-linearity in the relationships between system states and 
parameters.  
Desai and colleagues (Desai et al., 2008) developed an SD model to model demand for older 
people’s services in the county of Hampshire in England and to test the effectiveness of 
different interventions for three age groups of service clients (65-74, 75-84, and 85+). The 
model used in Tuulonen et al. (2009) separately simulated the number of patients with four 
different eye diseases and the cost of treating them for the whole Finnish population divided 
into five age-groups.  
 
3.6.2.3. Micro-simulation models 
 
In micro-simulation models, the unit of analysis is individual entities such as individuals, 
families, or households. The micro-level modelling involved simulating and tracking the social 
and economic characteristics and behaviour of these individual units rather than measuring 
changes in aggregate values (Klevmarken and Lindgren, 2008), and often covers a wider 
economy rather than a healthcare system only. Micro-simulation is a broad term embracing 
diverse modelling techniques and various forms of model structures. It may also vary in terms 
of the method for micro-data generation. For instance, the rules and assumptions applied to a 
simulation model may be determined by applying separate statistical techniques to obtain 
estimates of model parameters, and multiple modules designed to address a specific section of 
a model may be linked to one another.  
The micro-simulation model category included 24 papers. A summary of all micro-simulation 
models reviewed in this thesis are given in Table 3 in Appendix 3.1. Characteristics of the micro-
simulation models studies will be exemplified below by describing some of the studies included 
in this category (see Figure 3.7).  
The Future Elderly Model (FEM) built by the RAND Corporation is a dynamic simulation model 
that aimed to project healthcare spending and estimate the effect of changes in health status 
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and disease treatments on the future expenditures. It consists of three separate models: a 
health status transition model, trend model for population ‘rejuvenation’, and healthcare 
expenditure model. The health status model predicts the health conditions and functional 
status of sample individuals over time (Goldman et al., 2004). The results of this model are 
used to model expenditures. Although the FEM does not model supply-side factors that may 
influence healthcare costs, it incorporates various factors related to disease prevalence and 
interactions between all health states, and attempts to investigate the implications of a 
number of potential healthcare scenarios.  
The Population Health Model (POHEM) is a micro-simulation model tracking diseases and risk 
factors (Houle et al., 1997). The simulation creates and ages a large representative sample of 
Canadian population. Each simulated person experiences various events, such as smoking 
initiation and cessation, weight loss and gain, and incidence and progression of certain 
diseases. Like the FEM, POHEM can be flexibly altered to investigate a range of ‘what if’ 
scenarios. Different versions of this model have been used to estimate healthcare costs for 
more targeted populations such as patients with cancer and diabetes.  
Projections based on micro-simulation methods may be made on more targeted outcomes 
depending on the objective of the model. In the micro-simulation model developed by Davis et 
al. (2010), the main outcomes were utilisation of general practice services and changes in 
practice patterns.  In addition, micro-simulation models could be linked with other types of 
models. The CARESIM micro-simulation model developed by PSSRU simulated how much each 
individual aged 65 years and over would have to pay towards the cost of social care in case 
they need such care. The outputs of CARESIM model were used in the PSSRU macro-simulation 
model to estimate the long term care expenditure by source of finance (Malley et al., 2006, 
Hancock et al., 2007b). PSSRU has also published a newer dynamic micro-simulation model 
(Forder and Fernández, 2012, Fernández and Forder, 2011) that was developed from the static 
micro-simulation model used for the Wanless review (Wanless et al., 2006). This was 
commissioned by the UK Department of Health and the Dilnot Commission secretariat as part 
of analytical support for the development of options for long term care funding system reform.   
 
3.6.2.4. Comparison of the methods 
 
The methods discussed in previous sections are summarised in Table 3.7. 
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Table 3.7. Summary of examples of all method categories 
Method name Simplified model for cost estimation  Differences 
1. Statistical/Econometric model 
Statistical/ 
Econometric 
model 
 
E[per capita cost] = a+ b*(Age band) a and b are 
estimated and 
used for total 
cost calculation.  
2. Macro-simulation model 
Cell-based model 
 
∑[(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 𝑐𝑜𝑠𝑡 𝑓𝑜𝑟 𝑖 𝑡ℎ  𝑐𝑒𝑙𝑙)
𝑖
× (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑖𝑛 𝑖 𝑡ℎ 𝑐𝑒𝑙𝑙)] 
The population is 
divided into 
demographic 
‘cells’, or groups, 
based on 
characteristics 
such as age and 
gender 
Markov model 
 
∑[(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 𝑐𝑜𝑠𝑡 𝑓𝑜𝑟 𝑠𝑡𝑎𝑡𝑒 𝑖 𝑖𝑛 𝑦𝑒𝑎𝑟 𝑡)
𝑖
× (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑖𝑛 𝑠𝑡𝑎𝑡𝑒 𝑖 𝑖𝑛 𝑦𝑒𝑎𝑟 𝑡)] 
Fixed cohorts; 
Movements 
between states 
governed by 
transition 
probabilities 
Multi-state model 
 
For year t,  
∑[(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 𝑐𝑜𝑠𝑡 𝑓𝑜𝑟 𝑠𝑡𝑎𝑡𝑒 𝑖)
𝑖
× (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑖𝑛 𝑠𝑡𝑎𝑡𝑒 𝑖)] 
Similar to Markov 
models, but 
based on 
population in- & 
out-flows, not on 
fixed cohort. 
Macro-economic 
model 
 
A series of equations:  
GDP = the number of working population * wage 
Total healthcare expenditure as percentage of GDP= (the 
number of the elderly people*per-capita cost) / GDP 
Change in total population= (change in the working 
population) + (change in the elderly population).   
The relationships 
between 
demographics 
and economic 
variables are built 
based on the 
macro-economic 
theory. 
System dynamics 
 
One possibility is:  
∑ [(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 𝑐𝑜𝑠𝑡 𝑓𝑜𝑟 𝑠𝑡𝑎𝑡𝑒 𝑖) ×𝑖
(𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑖𝑛 𝑠𝑡𝑎𝑡𝑒 𝑖)]  
Similar to multi-
state, but the 
rates of events 
and relationships 
between states 
can be built more 
flexibly. 
3. Micro-simulation model 
Micro-simulation 
model 
Cannot be summarised easily in an algebraic 
expression due to complexity and diversity of the 
method. 
The unit of 
analysis is 
individual entities 
such as 
individuals, 
families, or 
households. 
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Statistical or econometric projection models were models based on a statistical relationship 
between the total or per-capita cost and population characteristics. The use of 
statistical/econometric modelling method may be a convenient option; however, it may not be 
considered as a reliable option for the projection of healthcare demand, given the large 
number of interrelated factors affecting health care spending and the very complex network of 
reciprocal relationships between the factors and health spending (Przywara and European 
Commission, 2010). It may be more suitable for models that entail a small number of 
parameters and limited interaction between them. Therefore, the econometric analysis may be 
used to estimate part of inputs required in a larger model such as technological development 
and non-demographic determinants of expenditure, rather than as the main control of a 
projection model.  
Macro-simulation method assumes groups of people with similar characteristics as the unit of 
analysis and the projection outcomes for the total population are obtained by aggregating the 
group-level estimates.  
The models were divided into four groups: cell-based; multi-state including Markov models; 
macro-economic models; and system dynamics. The cell-based approach can produce different 
results depending on how these cells are defined.  This cohort-based method requires less 
computation efforts, and relatively less data, compared to individual-level models. Large 
multinational studies could be possible because of this relative convenience. However, it 
cannot reflect interactions between population changes with other economic factors as 
population projections are exogenously determined. It would also be difficult to investigate 
total uncertainty in the estimates due to the use of average utilisation rates, and the aggregate 
outcomes may be biased if the variables used to split the ‘cells’ do not successfully explain 
demand for care.    
Multi-state and Markov models track transitions between a set of health states or risk 
behaviours, and therefore changes in the size and composition of the population in each state 
are endogenously determined. As with other cohort-based methods, the multi-state and 
Markov models may be run at less computational cost. Depending on the model structure and 
assumptions adopted they can also take account of duration of stay in each state and co-
morbidity. In particular, multi-state models can account for population growth as they allow 
new entrants to the model. However, only a limited number of states may be modelled before 
the model becomes overly complex and it is difficult to incorporate individual behaviours 
regarding demographic changes and healthcare options. This type of method may be more 
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appropriate for the modelling of a specific disease in which a set of closely related states can 
be defined according to disease progression or pathways.  
 
Macro-economic models can provide a coherent framework for the demographic and 
economic interactions. Such a model specification may work well when modelling a system in 
which demand for health or long term care is met by consumer expenditures and largely driven 
by market forces of demand and supply. However, parameterisation based on macro-economic 
theory may be difficult in the healthcare area as the majority of European healthcare systems 
rely on state funding, and the relationships between economy, healthcare utilisation, and 
demographic changes may not always hold.  
 
In contrast, system dynamic models can account for interactions between modelled individuals 
and a large number of factors relevant to the target outcome including behavioural influences. 
As all three studies that used this method concentrated on regional or disease-specific services, 
this may suggest that the SD is appropriate for detailed modelling of a narrowly defined system 
but may not be practical for the modelling of a large-scale system.  
In summary, macro-simulation models comprised the highest proportion of the identified 
projection studies. They were based on relatively simple relationships between model 
components, and could be adopted for comparative analysis of projection results in different 
jurisdictions due to the relative ease of obtaining similar datasets. However, group-level 
modelling makes it difficult to take account of the heterogeneity of individuals and thus to 
assess the distributive impact of policy changes.  
Micro-simulation models can mimic the heterogeneity of the population and the complex 
relationships between model elements. Hence, they have been used to evaluate both the 
aggregate and distributional effects of individual factors influencing health expenditure. Also, 
given the richness of the outcomes that can be obtained through micro-simulation exercises 
and the ability to assess the potential impact of interventions before implementing them, this 
approach has been popular in forecasting the effect of alternative policy scenarios. For 
example, the effect of changes in tax systems can be examined by applying different tax rules 
to information about individuals, families or firms. However, micro-simulation often requires a 
wide range of datasets and greater modelling efforts, which make the model nearly infeasible 
in some cases. 
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The projection models in all of the three categories incorporated all or some common 
components: on the demand-side, demographic projections, population health status 
modelling, and quantity or intensity of health or long-term care utilisation; and on the supply 
side, unit costs of the health or social care services and care workforce required to meet the 
demand.  By defining relationships between these components across different time periods 
and combining them, the projections of future demand were made. Differences between the 
categories of methods previously described come from the methods used to define and 
estimate such relationships between the components. 
 
 
3.7. DISCUSSION 
 
This chapter reported the results of the literature review. The review identified 7745 relevant 
studies and a further set of 158 articles from the grey literature were also identified.  142 
papers identified from the retrieved literature described the models projecting future health 
and long-term care demand.  The aim of the chapter was to identify areas suitable for further 
research and to provide a resource for future researchers.   
This chapter also described a literature repository containing literature identified on the 
estimation of health and long term care demand for an ageing population.  The repository 
included studies that are broadly relevant to the topic of population ageing and health and 
long term care in order to assist future research with a different focus within the diffuse topic 
of ‘ageing’. 2,263 papers were included in the repository.   
There were limitations of the review conducted in this chapter. Sifting and categorisation was 
undertaken by one reviewer due to this study having been conducted as a PhD project. Hence, 
no cross-checking was involved. Categorisation structure was developed iteratively with 
subjective decisions made by the reviewer on the main theme of the paper. The tags used in 
the literature repository differ from the indexing terms adopted in databases such as Medline 
and EMBASE.  Furthermore, no systematic method of searching grey literature was adopted in 
this study. 
However, it is believed that the literature repository created covers the core themes within the 
literature around population ageing and demand for health and social care, which is a topic of 
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increasing interest to many researchers worldwide. It makes available a free and easily 
searchable resource which reflects the screening of 7,745 papers and the categorisation and 
inclusion of 2,263 papers.  Given the very broad and diffuse nature of the literature on this 
topic, the repository can be a valuable resource for researchers wishing to quickly identify 
papers relevant to specific topics in this area, and can therefore save considerable time and 
duplication of research effort. 
Also, three broad categories of the projection models – statistical/econometric, macro-
simulation, and micro-simulation models – were defined based on the methods used to 
estimate relationships between the components.  The review of projection models provides 
valuable information on the choice of a modelling method for this thesis, which is described in 
Chapter 4. 
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CHAPTER 4   DECIDING ON DECISION PROBLEMS 
ADDRESSED IN THIS THESIS – DISEASE AREAS AND 
MODELLING METHODS  
 
4.1. Overview of the modelling methods  
 
4.1.1. Rationale for the research 
 
A recently published UK Parliament report on ageing focussed on the implications of an ageing 
population with regards to individual life and public policy for the coming decade, and warned 
that ‘the NHS is facing a major increase in demand and cost consequent on ageing and will 
have to transform to deal with this’ (House of Lords, 2013). The increase in life expectancy will 
result in a larger number of the oldest-old people and the increasing prevalence of the long 
term conditions experienced by older people (House of Lords, 2013). Hence, the demand for 
health services to treat such conditions will change dramatically with the ageing of baby 
boomers, and those diseases are likely to be long term conditions that are costly to treat. 
Important questions to address include: ‘What are the key disease areas that will be most 
affected by population ageing?’; ‘How much will the demand for services to treat those 
diseases increase?’; and ‘which diseases would benefit most from prevention measures?’  
Hence, the main aims of the modelling undertaken within this research include: estimating the 
implications of key disease areas for the future healthcare demand; identifying/comparing 
potential interventions to reduce the demand; and projecting the future healthcare 
expenditure/demand for the ageing population.  
This thesis addresses the question of how much budgetary impact a selection of key diseases 
would make on healthcare resources. This differs from conventional health technology 
assessment (HTA) which relates to how to use resources more efficiently within a budget 
constraint.  Whilst the HTA compares decision options such as treatments or interventions 
from a micro-economic perspective for a person or a group of individuals in a specific 
population, this study estimates the budget impact of the diseases from a macro-economic 
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perspective at the total population level assuming the use of current (or assumed) treatments 
or interventions. In addition, estimates are provided of: relative gains of eradicating a disease; 
and relative gains of improved measures to reduce burden of disease.  
As discussed in Chapter 3, the majority of the existing published models estimating future 
health and social care expenditure were based on a macro approach of grouping the total 
population by characteristics that influence the utilisation of health services and attaching 
average cost to each of the groups.  It was considered that this type of model would not 
produce outcomes that are detailed enough to answer the proposed questions. It was 
considered that a better approach would be to target a selection of key disease areas that 
older people are more likely to develop and provide indicative values of their cost implications.  
The modelling approach proposed in this study is not intended to make precise forecasts of the 
exact level of future health expenditure across all diseases, as not all diseases were covered, 
and potential changes in healthcare were not considered in the base case. However, indicative 
results are presented and the modelling provides a proof-of-concept examination of the 
method of the linked disease-expenditure model.    
 
4.1.2. Chosen modelling approach 
 
In this research, a disease-based approach is used to focus on selected key diseases that are 
anticipated to significantly influence healthcare expenditure as the population ages. Models 
for the key diseases are initially constructed individually and then linked to incorporate 
interactions between the diseases and competing risks of events, which may be fatal. Within 
individual disease models, expenditure on services to treat or manage the disease is estimated. 
This allows an assessment and comparison of the fiscal importance of the selected diseases 
and the possible impact of hypothetical prevention and treatment interventions targeted at 
these diseases. By comparing the potential benefits of improving the treatments or reducing 
risk factors for the diseases, it is also possible to inform investment and resource allocation 
decisions. For example, it can provide information to answer questions such as ‘for which 
disease could the highest economic gains be made if the response rate of treatments related 
to the selected diseases increased by 10%?’   
Diseases were modelled at an individual patient level. Individual-level modelling captures 
variability and uncertainty around model outcomes, and produces more detailed simulation 
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results that make possible further analyses using the simulated outcomes. It also reduces the 
need for a very large number of health states that would be required if a cohort-based model 
was used, particularly when time since events and individual characteristics are important.  
The key outcomes of this study are summarised in Box 4.1. 
 
Box 4.1. Key population-level outcomes expected from the model 
1) Within the individual disease models, what is the total anticipated cost of each 
disease? 
2) In the combined model, what are the total cost of all the included diseases and total 
costs per disease? What proportion of the total all-disease cost can be attributed to 
each disease? 
3) In the combined model, how much savings can eradicating Disease A make, and how 
many QALYs or life years can it provide? How does that saving compare to the 
individual disease model results? By comparing the cost outcomes and savings 
estimated in the combined model and in the individual model, the value of linking the 
individual disease models can be estimated. 
4) Which disease would benefit most from an improved intervention? For example, how 
much money (QALYs or life years) can an additional 10% efficacy in drugs for treating 
Disease A save (give)?  
5) At a fixed cost-utility threshold, how much can we spend on an intervention? For 
example, how much could be charged for Drug T or a government programme with 
hypothetical efficacies to have a cost per QALY of £20,000? How can we best invest 
healthcare resources? 
 
 
 
4.1.3. Novelty of the chosen approach 
 
To the author’s knowledge, none of the models reviewed in this thesis (Chapters 2 and 3) have 
used such an approach. The vast majority of the demand projection models focussed on the 
‘care’ side of the demand rather than diseases. Often future health status was incorporated as 
one of the individual or population characteristics with estimates used for the probabilities of 
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contracting the disease, rather than explicitly modelling the diseases to simulate the future 
health status. For example, within the RAND Corporation’s COMPARE micro-simulation model 
(Eibner et al., 2010b), which was used to project the effect of health reforms on health 
insurance coverage and costs, and estimate impacts on businesses of different sizes, workers 
and their dependents, the courses of disease-related events were not modelled. In another 
model by RAND, the Future Elderly Model (FEM), disease onsets were modelled in a binary 
manner (i.e. with or without diseases), and their progression was not explicitly simulated 
(Goldman et al., 2004).  
There are other examples of models that adopted a disease-based approach, but differed from 
the approach used in this thesis in terms of the purpose of the model and the manner in which 
the model was constructed. The POHEM model from Statistics Canada was used to evaluate 
the health and healthcare system impacts of new prevention or treatment policies targeted to 
specific risk factors or to particular diseases (Houle et al., 1997). It has been modified to model 
certain chronic diseases individually (breast, lung and colorectal cancers, diabetes, acute 
myocardial infarction, and osteo-arthritis) (Kopec et al., 2010). However, the disease-specific 
versions of the model have not been linked to project the combined health expenditure. 
Another example is the model developed by the Australian Institute of Health and Welfare 
(AIHW) which provided projections of future health spending on a specific set of diseases 
(cardiovascular disease, road traffic injuries, dementia, musculoskeletal disorders, lung cancer 
and diabetes), incorporating different drivers of health expenditure for each disease. However, 
it used an aggregate cell-based approach for each disease modelled, and projections were 
made at only a few time points although it adopted a 30-year time horizon.  
The SIMPOP model (Jagger et al., 2011) has some similarities to the modelling approach in this 
thesis. It did not estimate healthcare expenditures, but simulated the impact of multiple 
diseases such as coronary heart disease (CHD), stroke, and dementia on disability states. The 
estimated disability states were then used in the PSSRU macro-simulation model in order to 
derive social care needs and expenditure. However, the objective of the model was to 
estimate the demand for social care services rather than healthcare, and the main outcome of 
the model was the disability status rather than states of specific diseases.  
 
There also have been models that focussed on a single disease incorporating demographic 
changes (Hoogendoorn et al., 2011). However, the main purpose of these models was not to 
estimate the effect of population ageing on healthcare demand and they did not attempt to 
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link multiple disease models. There were some cases where a set of diseases were modelled 
simultaneously as a risk factor for multiple diseases. They did not take the form of linking 
individually modelled disease models, but included a fairly crude level of disease modelling. 
For example, the Foresight micro-simulation model developed by the UK National Heart Forum 
estimated public health expenditures associated with diseases where obesity is a significant 
risk factor. Common disease pathways (recovery, continuance, and death) were applied to all 
the included diseases (diabetes, coronary heart disease, stroke, and colorectal and breast 
cancers). Then, the average NHS expenditure per patient for these diseases was applied to 
calculate the future burden of obesity-related diseases.  
The following sections provide an overview of the modelling process used within the thesis 
and sets out the common methods used for all individual disease models in detail.  
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4.2. Justification for disease selection 
 
 
As seen in the literature review in Chapter 3, no models projecting future healthcare 
expenditure based on multiple disease models were identified, leaving this an area for 
research. Diseases with significant cost implications for an ageing population were considered 
for inclusion in the model. Where it was difficult to make head-to-head comparisons between 
the costs, other criteria considered important for the future healthcare expenditure were also 
used. The criteria used for selecting the diseases are summarised in Box 4.2.  
 
Box 4.2. Criteria for selecting diseases to model 
o Diseases with major cost implications: High costs to the UK NHS and PSS* of 
treating/managing the diseases 
o Diseases of the elderly: Diseases with significant mortality and morbidity burden for 
older population and diseases whose incidence is expected to increase as population 
ages. 
o Whether there are sufficiently recent HTA reports undertaken for the disease in order 
that a peer-reviewed model could be replicated. 
o Establishing a balance between different disease areas in order to cover a spectrum of 
conditions. 
o Diseases of hard endpoints, rather than those being risk factors for other diseases 
themselves, such as diabetes and hypertension 
*Personal Social Services 
 
The major criterion for selecting the diseases to model was the current costs of the diseases to 
the UK NHS and Personal Social Services (PSS). Diseases expected to bear increasing 
importance for an ageing population, in that they become more prevalent as a population ages, 
were given a priority.  
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The presence of recently published (or in press) NIHR HTA reports was considered as it was 
deemed as evidence of the importance of the disease to major stakeholders such as decision-
makers in local government, policy-makers (including the National Institute for Health and 
Care Excellence (NICE)), health professionals, and the general public. Given the limited time 
scale of the PhD study, the use of the peer-reviewed existing models was considered a 
reasonable approach. 
A balance between different disease areas was also considered as one of the criteria. Including 
diseases from one or two areas of diseases whose mechanisms are similar may be misleading 
in estimating the broad impact of population ageing on healthcare expenditure and the 
interactions between diseases. Among diseases of significant economic, mortality and 
morbidity burdens, a spectrum of diseases that affect different parts of the body were 
included.  
Diseases with hard endpoints were preferred to those which were risk factors for other 
diseases such as diabetes and hypertension. It was believed that such diseases could be 
embedded in the chosen disease areas as a risk factor, and the consequences of the diseases 
could be represented in the models of other diseases.  
In order to identify a set of candidate diseases that could potentially be included in the model, 
non-systematic web searches were conducted for studies listing the most expensive diseases 
of the elderly using search terms such as ‘the most costly (expensive) diseases’, ‘diseases of 
the elderly’, ‘economic burden of diseases’, ‘NHS budget’ and combinations of these terms. 
Further searches were performed for reports from governmental agencies and international 
organisations such as the UK Department of Health, NHS evidence, Organisation for Economic 
Co-operation and Development (OECD), and World Health Organization (WHO). No single 
source of data was identified comparing the economic costs of major diseases of the elderly in 
the UK. US Data from MEPS-HC (Medical Expenditure Panel Survey- Health Care) reported the 
top five most costly conditions for the US non-institutionalised population aged 65 and older. 
The highest expenditures among the elderly were for care and treatment of heart conditions 
($48.4 billion). Treatment of cancer ranked second ($32.2 billion), followed by osteoarthritis 
and other non-traumatic joint disorders ($24.8 billion), hypertension ($23.8 billion), and 
trauma-related disorders ($20.5 billion) (Soni and Roemer, 2011).  
Given the lack of UK data, it was considered that the breakdown of the total NHS budget might 
indicate the relative importance of broad disease categories. The largest spending category in 
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the 2010/11 programme budgeting data was mental health problems, accounting for 11% of 
the overall programme budget. Expenditure on circulatory problems was the second largest 
spend (7.2%), followed by cancers and tumours (5.4%). These three areas have represented 
the top three spending categories since 2004/05. These values primarily represent the cost 
breakdown for the total population, rather than the older population.  
Although the adopted approaches and the purpose of the models differed, it was considered 
that the existing models could provide an indication of important diseases in the elderly. For 
example, the FEM model by RAND focussed on a few of the most prevalent diseases among 
the elderly: hypertension; diabetes; cancer (lung, breast, prostate, colon, uterine, throat, 
bladder, kidney, and brain); chronic obstructive pulmonary disease (COPD); acute myocardial 
infarction; coronary heart disease; and stroke – to assess the impact of chronic illnesses. 
Considering these disease lists, heart conditions, cancer, musculoskeletal diseases, mental 
health diseases, and respiratory diseases were chosen as candidate disease areas.  To compare 
the costs of each of the candidate diseases, recent burden of disease studies published 
between 2003 and 2013 for these diseases were identified via Web (Google) and Medline 
searches using combinations of terms relating to the disease name and cost or burden of 
illness. Further literature citing or cited by the studies from the simple searches was identified 
via snowballing of the literature. Background sections of NICE guidance were also inspected in 
search of relevant literature on the cost of diseases. The burden of disease studies were 
searched at a single disease level that can be modelled individually, rather than the broad 
categories of candidate disease areas.   
The identified studies estimating the costs of diseases of the elderly were based on different 
methods of calculation with different coverage of the cost items. Also, the searches were not 
conducted in a systematic manner. However, estimates from these studies might indicate the 
economic implications of the diseases that older people are more likely to develop.  
Table 4.1 summarises the estimates of healthcare costs including social care costs in the case 
of dementia for the candidate diseases whose costs were ranked high in recent UK studies. The 
most recent estimates representing costs to the UK NHS and PSS, excluding informal care costs 
and indirect costs from productivity loss and premature deaths, were chosen for comparison.  
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Table 4.1. Summary of UK cost estimates related to diseases of the elderly (direct costs only). 
Disease Estimated Cost Cost 
Year  
Cost inflated to 
20121 
Source 
Cardiovascular 
disease 
£14.4 billion 2006 £17.1 billion Allender et al. (2008) 
Dementia £10.5 billion 2010 £11.2 billion Fineberg et al. (2013) 
Osteoporosis £3.36 billion 2010 £3.57 billion Hernlund et al. (2013)  
Osteoarthritis £1 billion2 2010 £1 billion Estimated from Chen 
et al. (2012) 
COPD £1 billion 2011 £1 billion Department of Health 
(2011) 
Rheumatoid 
arthritis 
£560 million3 2008 £623 million National Audit Office 
(2009) 
Colorectal 
cancer 
£494 million3 
(€595 million) 
2009 £529 million Luengo-Fernandez et 
al. (2013) 
Breast Cancer £482 million4 
(€581 million)  
2009 £515.76 million Luengo-Fernandez et 
al. (2013) 
1. Costs were inflated using the Hospital and community health service (HCHS) pay and price inflation 
index; 2. UK direct costs only; sum of costs of non-steroidal anti-inflammatory drugs (NSAIDs), NSAIDs 
iatrogenic, proton pump inhibitors (PPIs), arthroscopy, and joint replacement surgeries; 3. NHS cost only; 
4. Using conversion rate of 0.83 £/€ (accessed on 11/11/2013).  
 
 
Cardiovascular diseases (CVD) were shown to be the most costly disease in the UK. A study by 
Allender et al. (2008) estimated that the cost of CVD to the UK healthcare system was £14.4 
billion in 2006. In addition, productivity losses accounted for £8 billion annually and the annual 
cost of informal care of people with CVD was also £8 billion. Another study showed a 
significant burden of cardiovascular diseases: the combined cost of CVD to the NHS and the UK 
economy is estimated to be £29.1 billion in 2004 (Luengo-Fernández et al., 2006).  
According to Fineberg et al. (2013), the annual cost of dementia on the health and social care 
system was estimated at £10.5 billion (£19 billion including indirect costs), more than the cost 
of cancer, coronary heart disease and stroke put together. Dementia imposes a significant 
economic burden not only on the health care system, but also on patients, on family and 
friends who provide unpaid care, and on the wider economy and society. Also, it affects a large 
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number of people, especially the older population. There are estimated to be about 820,000 
people living with dementia in the UK (Luengo-Fernandez et al., 2010). The incidence will rise 
as population ages (Matthews and Brayne, 2005), and the number of people with dementia is 
predicted to increase to 2 million by 2050 with the annual cost of care estimated to be nearly 
£60 billion (Lewis et al., 2014).  
Musculoskeletal conditions also represented a significant economic burden on the UK health 
and social care system with the annual cost estimated to be £5.7 billion in 1995/96 and 1.0 
million people affected each year, resulting in 11.6 million lost working days in 2004/05 
(Nicholson et al., 2006). However, studies comparing economic costs of different 
musculoskeletal diseases in the UK had not been identified.  The WHO’s Global Burden of 
Disease 2000 project selected osteoarthritis, rheumatoid arthritis, osteoporosis, and low back 
pain as the four major musculoskeletal conditions in terms of its disability burden (years of life 
with disability).   
A recent report by Hernlund et al. (2013) showed that the cost of osteoporosis-related incident 
fractures, excluding the costs of prevention and long term disability, amounted to nearly €4 
billion in 2010 (€3.98bn= £3.36bn when using conversion rate of 0.8413£/€). It also estimated 
that the cost of osteoporotic fractures represented 3% of the total healthcare spending in EU. 
A model based analysis by Burge et al. (2001) estimated the costs of osteoporosis-related 
fractures for the UK population aged 50-99 to be £1.8 billion in 2000 using a Markov model of 
the natural history of osteoporosis to predict fracture numbers.   
The total costs of rheumatoid arthritis (RA) in the UK, including indirect costs and work related 
disability, have been estimated at between £3.8 billion and £4.75 billion per year (Pugner et al., 
2000). Direct NHS cost for RA was estimated to be £560 million annually (National Audit Office, 
2009).  
There was a paucity of data on the economic cost of osteoarthritis (OA) in the UK (Parsons et 
al., 2011). The NHS Executive had calculated annual costs for OA at £320 million (Scott et al., 
1998). A recent study by Chen et al. (2012) estimated osteoarthritis-related costs in the UK by 
category of treatment. The annual cost of OA summed up to £1 billion across all treatment 
categories. However, it included the cost of joint replacement surgeries which can be caused 
by other conditions than OA.  
Respiratory disease is one of the most costly disease categories; the UK NHS care cost was 
about £3.0 billion in 2004 (British Thoracic Society, 2006). Among the respiratory conditions, 
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chronic obstructive pulmonary disease (COPD) involves significant costs from long-term 
medical management and disability-related care, costing the UK £1 billion a year (Department 
of Health, 2011). Over 27,000 people were estimated to have died from COPD in 2004 and 
more than 1 million bed days were related to COPD in England (British Thoracic Society, 2006). 
It is estimated that it is nearly ten times more costly to treat severe COPD than mild COPD, and 
some 2.7 million people are estimated to be living with the disease without knowing it 
(Department of Health, 2011). Hence, the prevention and early identification of the disease 
could deliver significant savings. 
Cancer was also a significant cost burden.  A recent report by Bupa (Bupa, 2011) estimated 
that the current cost of cancer diagnosis and treatment is £9.4billion in 2010, but will rise to 
£15.3 billion by 2021 – an increase of £5.9billion. It was stated that the increase in the overall 
cost of cancer diagnosis and treatment was, in part, the result of the UK’s ageing population, 
which is predicted to lead to a 20% growth in cancer rates by 2021.  
A study by Leal and Luengo-Fernandez (2012) suggested that the total cost of cancer is greater 
than £15 billion a year in the UK, including the healthcare costs, unpaid care costs by family 
and friends, and lost earnings due to absence from work and premature death: this total 
included £7.6 billion in economic costs, £5.6bn for health and £2.6bn for unpaid care.  
However, the diversity in the natural progression, diagnosis, treatment, and prognosis of 
cancers at different parts of the body makes it difficult to generalise all cancers in one model. 
Therefore, the costs of individual cancers were compared.  
Leal and Luengo-Fernandez (2012) reported that lung cancer was the most expensive, costing 
£2.4 billion a year, bowel cancer cost £1.6bn, breast cancer £1.5bn and prostate cancer £800 
million, including productivity loss. In a large European study by Luengo-Fernandez et al. 
(2013), breast cancer accounted for the highest healthcare costs in EU (€6.73 billion; 13% of all 
cancer-related health-care costs), followed by colorectal cancer (€5.57 billion; 11%), prostate 
cancer (€5.43 billion; 11%), and lung cancer (€4.23 billion; 8%). The healthcare cost in the UK 
was estimated to be €595 million for colorectal cancer, €581 million for breast cancer, €461 
million for lung cancer, and €413 million for prostate cancer in 2009.  
The set of selected diseases and the rationale for the selection are described in Section 4.2.1.  
 
118 
 
4.2.1. Selected diseases 
 
Based on the 2012 costs reported in Table 4.1, the burdens of the candidate diseases are 
compared in Figure 4.1. The diseases selected for modelling are shown in diagonal-lined area, 
with a rationale for their selection in the text below.  
 
Figure 4.1. Cost of illness (price inflated to 2012) 
 
 
 
The most expensive disease category was cardiovascular disease.  Heart conditions, such as 
coronary heart disease (CHD) and myocardial infarction (MI), and stroke were selected for 
modelling as they account for the largest proportion of mortality and prevalent cases in 
cardiovascular disease among older individuals (British Heart Foundation, 2014), and impose 
significant economic burden on the overall healthcare system (House of Lords, 2005).  
Dementia was selected for modelling considering its cost, the balance between the chosen 
diseases, and likely impact of population ageing. Amongst brain disorders, dementia was the 
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most expensive category of spending (Fineberg et al., 2013), and affects older people in 
particular, and is expected to be significantly affected by population ageing as the incidence is 
positively correlated with age. Only the most common form of dementia, Alzheimer’s disease 
(AD), was modelled in this thesis as the current NICE guidance and relevant model-based 
studies (including HTA reports) focussed on AD (see Chapter 6 for details). 
It was considered appropriate to include one or more musculoskeletal disorders due to the 
increase in prevalence and incidence with age. Amongst the musculoskeletal conditions, 
osteoporosis was deemed appropriate to include in the model due to its high cost.  OA was not 
selected as previous models have been built for OAs at different anatomical sites such as knees, 
hips, and joints of hands, which make it difficult to include given the aim of the thesis. 
Furthermore, the incidence of OA is difficult to estimate as the onset is not well-defined due to 
the discrepancy between the symptomatic OA and OA based on the radiological changes.  RA 
was considered for inclusion as it was anticipated to be increasingly costly and prevalent due 
to it mainly affecting people aged 65 years and older (Fejer and Ruhe, 2012). However, RA was 
not chosen for the modelling given that the cost of RA did not exceed that of OA and COPD.  
Cancer in collective terms is one of the major cost categories on the UK healthcare system. 
However, it was not selected for the modelling as individual cancers require a separate model 
and the top two costly cancers (breast cancer and colorectal cancer) were not shown to be as 
expensive as other diseases compared, incurring costs around £500 million, respectively. 
Examining the economic burden of illness on the NHS spending and the society and other 
aspects of the candidate diseases, the three most expensive diseases with significant mortality 
and disability burdens for the elderly  – heart disease (including stroke and MI), Alzheimer’s 
disease, and osteoporosis  – were selected for modelling (diagonal-lined areas in Figure 4.1).  
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4.3. Modelling methods 
 
This section reports modelling methods commonly adopted for models described in 
subsequent chapters. Section 4.4 describes general methods for linking individual disease 
models.  
 
4.3.1. Choice of modelling approach – Discrete event simulation 
  
Given the complexity of the model in conjunction with the set of diseases included in the 
model, individual-level modelling was considered appropriate. Cohort-based models, where a 
cohort of patients move between modelled states typically based on the mean transition 
probabilities, can be a simple and convenient option if patients can be adequately modelled 
through an aggregate model and the number of health states is manageable. However, an 
individual-level model provides a better option to incorporate heterogeneity among patients. 
While cohort models can account for different characteristics of individuals such as age, risk 
factors, and history of other diseases, the number of dimensions of the modelled states 
become exponentially large, which can cause problems in a model with a large number of 
defined health states.  
Although a Markov model can be constructed at the level of individual patients, Discrete Event 
Simulation (DES) models allow for greater flexibility in the times when events can occur.  In 
DES models, simulation time is advanced from time of one event to the next, whereas a state 
transition model with discrete time intervals, e.g. Markov model, updates the model states at 
fixed time points. Individual patient Markov models can also have difficulty in finding the 
appropriate length of time cycles. If time cycles are too short, computation time is increased 
due to the need to recalculate events for each cycle. If time cycles are too long, it may be 
inappropriate to assume only one event can occur in one cycle. DES models can save 
computation time by making these per-cycle calculations unnecessary, and there is not a 
possibility of multiple events occurring within a defined period.  
In DES, a ‘time to event’ approach is used, and thus transition probabilities for pre-specified 
equal-length cycles as in Markov models are not required. Hence, events can occur at any 
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point in time and repeatedly over time. Multiple events can occur within a short period of time, 
compared with Markov models allowing only one event to occur within one cycle.  
At entry and each event state in a DES model, the values of time to event are sampled for the 
next transition. The age of the individuals at entry and times to events are accumulated to 
calculate the total life years lived by the simulated patients. Using this approach, it is possible 
to apply varying event rates conditional on the time since the event and the patient’s time-
variant characteristics. For example, in the heart disease model, time to next event values 
were sampled from a distribution with a rate that differs between the first year and 
subsequent years after myocardial infarction (MI), and depending on the patient’s age band 
(age groups: group 1. < 55 years; group 2. 55-65 years; group 3. 65-75 years; group 4. 75-85 
years; group 5. >85 years). Rates of transitions were updated by repeatedly checking whether 
a sampled time-to-event value exceeds any of the future time points sectioning the first and 
subsequent years of an event, or the age bands. If a sampled value passed through the earliest 
sectioning point, a new time-to-event value was sampled using an updated rate associated 
with the time period after the cut-off point and added to the time to the cut-off point. To 
illustrate, if a time to next event value sampled based on the first year rate is greater than 1 
year, a new value is sampled from a distribution with the subsequent years event rate and the 
final time to event value is calculated as (1+the re-sampled value) years. If this individual was 
scheduled to move to the next age band in 3 years, and the re-sampled time to next event 
value was greater than 2 years, the event rate would change before the transition as 
scheduled by the sampled value. The 2-year cut-off is calculated as 3 years to a next age band 
minus 1 year at which the time to event value was re-sampled. In this instance, a new time to 
event is sampled again from a distribution associated with the new age band and the final time 
to next event becomes (3+the sampled value) years.  
As a result, an individual-level DES model was used as the main type of the disease models. 
Individual patients are simulated to move through different disease events according to the 
individual-specific event schedules sampled from appropriate time-to-event distributions. The 
use of DES allowed multiple health states and a number of patient characteristics to be 
incorporated with less computation time. For example, patients with a history of CVD events 
are associated with higher risks of having further CVD events and the times of such events 
could be recorded within the individual-level model to accurately model such relationships. 
The analysis was undertaken from the perspective of the UK NHS and PSS in line with the 
reference case preferred by the NICE (National Institute for Health and Care Excellence, 2013). 
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Estimates representing all direct health effects and the use of UK NHS and PSS resources were 
used. A lifetime horizon was used to fully assess the long term effect of potential preventative 
interventions. The model is built using the simulation software SIMUL8 (©SIMUL8 
Corporation).  
 
4.3.2. Modelling process 
 
For each disease included, a review of the existing models is undertaken. The aim of this mini-
review is to identify the most appropriate model structure, data sources, and the current 
recommended treatments, and to modify and expand this model, rather than attempting to 
develop a new conceptual model and populate it, given the time constraints of this study. 
Searches for the existing models were based on recently published HTA reports if available. If 
the HTA report included a recent systematic review of the existing models for economic 
evaluation of relevant health technologies from published literature and industry submissions, 
the models included in that review were also examined. Supplementary searches using 
keywords identified from the reviewed studies were undertaken to ensure that models 
published after the HTA report are also included. The NHS Economic Evaluation Database (EED) 
database was also searched.  
Based on the review of the existing models for each disease, the model that is considered most 
appropriate is replicated or adapted, when believed necessary. The results from the model are 
compared with those of the existing models to externally validate the model. The set of 
individual disease models that are developed in this manner are linked to each other in order 
to estimate the total impact of these diseases on healthcare expenditure. 
 
4.3.3. Model assumptions 
 
The key methodological assumptions that apply to the larger linked model and its components 
are summarised in Table 4.2.  
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Table 4.2.  General model assumptions 
Category  Assumption 
Time to event Where possible, parameters of time-to-event distributions are 
functions of patient history and other patient characteristics. 
Competing risks Only the event simulated to occur at the earliest time affects transitions 
between modelled events.  
Post-event states Once patients experience one of the modelled events, their disease 
history is recorded and the relevant costs and utility decrements are 
applied until death. 
Cost Where costs in the initial year differ from those in subsequent years, 
this is included in the model.  
Costs were additive following a series of multiple health events, i.e. the 
individual-specific cost is a combination of the current event cost and 
the (subsequent-year) costs associated with all events that the 
individual patient had previously experienced. 
When the patient experiences the same event multiple times, the same 
first-year and subsequent-year costs was applied only once (i.e. the cost 
is not multiplied by the number of times that the event occurred). 
Utility Multiplicative utilities are assumed. That is, if a patient experiences a 
series of health events over time, the utility multipliers relevant to all 
the current and previous events are applied.  
When the patient experiences the same event multiple times, the 
corresponding utility multiplier was applied only once.  
 
 
 
4.3.4. Model Population 
 
As a base-case, the general UK population with or without history of any of the modelled 
health events (that is, both the prevalent and non-prevalent cohorts) were considered. In 
order to estimate the ageing impact on healthcare demand, the UK population aged 45 and 
over, rather than only the elderly, were modelled. Hypothetical individuals were randomly 
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generated using the mid-2012 UK population estimates by age and gender published by the UK 
Office for National Statistics (ONS) (Office for National Statistics, 2013d).  
A modelled individual is assigned an age sampled from the age distribution for the UK 
population aged 45 and over. When constructing the age distribution, as data on the 
proportion of people aged 90 years and over were unavailable for each year of age, a constant 
mortality rate obtained from data on Deaths registered in England and Wales (Office for 
National Statistics, 2013a) was assumed for all people aged 90-99 years. Using this annual 
mortality rate, the proportion of people in the 90-99 age group at each year of age was 
estimated by assuming that the proportion of people aged (x+1) years decreases from that of 
people aged x years at the rate of the annual mortality, and scaling the proportions of people 
at each year of age 90-99 years to match their sum with the total proportion of people aged 
90-99 years.  Hence, the proportions of people aged 90-99 years tailed off at a constant rate.   
Following the sampling of age, the gender of the individual was sampled from separate sets of 
probability distributions for male and female populations estimated from the UK ONS 
Population estimates, which were conditional on the five-year age band to which the person 
belongs (Office for National Statistics, 2013d). The population aged 45 years and over entering 
in the base year of 2012 had an average age of 61.9 years. Among them, 52% were female.  
These individuals generated within the model were used as the common initial population for 
all disease models, and followed through the linked model.  Individuals were simulated to 
leave the model when they reach 100 years of age with a non-disease death scheduled to 
occur at the mid-point of the following year, if they had not been simulated to die before this 
time point. 
Demographic and/or socio-economic trends may be incorporated by varying model parameter 
values depending on the year in which the population enter the model. Demographic 
information such as the number of people in each age and gender group and prevalence of the 
included diseases on the future populations is obtained from the 2012-based population 
projections made by ONS (Office for National Statistics, 2013c). 
The following section describes the methods for estimating projected expenditures.  
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4.3.5. Population dynamics and annual cost projection 
 
One of the key outcomes in which it is assumed policy makers are interested in is the total cost 
on the healthcare system of a disease. In this thesis, total costs incurred for a calendar time 
period, such as annual projected costs for the next decade, were estimated. The estimated 
annual costs could be compared with the current budget for the disease, and validated against 
the actual expenditures in previous years.  
The model in this thesis followed the starting cohort representing the UK population aged 45 
years and older in the base year (2012), until death. As this population ages over time, the 
modelled population was rejuvenated every year with a new cohort of people aged 45 years 
entering the model. As the simulation model in this thesis recorded time from model entry 
rather than actual calendar time, no such mechanisms as yearly population rejuvenation were 
integrated in the model. Instead of the timed entry of new cohorts into the model, the model 
was run for the future cohorts of 45 year olds separately and the results for the base year 
population and future cohorts were combined. Year 0 denoted the base-year hereafter, and 
years 1, 2, and 3 referred to the first, second, and third year after the base-year (i.e. 2013, 
2014, and 2015) for convenience of describing the entry year of each cohort.  
The model estimated lifetime costs and (quality-adjusted) life years of the base year 
population and the new cohorts of 45 year olds entering the model each year. Hence, a crude 
summation of lifetime costs and QALYs across all cohorts would represent costs and QALYs 
accrued until deaths of all people who entered the model during the projection horizon, rather 
than those incurred for a specific time period.  This would provide results from a closed model, 
where individuals that entered the model in the beginning of modelled time are followed until 
the end of model time and no further entry of individuals is made over time. In this case, the 
time interval of interest is the entire time horizon of the model, not a specific calendar time 
period such as the year 2015 which is the focus of this thesis.  
In order to estimate the total annual cost of a disease, per-capita annual costs from the 
starting cohort representing the UK population in the base year and the following new cohorts 
of 45 year-olds with differing entry times are multiplied by the number of individuals in the 
relevant age and gender group. The stream of results are combined and discounted to the 
base year (2012) to calculate the total discounted costs. 
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For this calculation, the model time horizon was split into yearly periods since model initiation. 
Whenever the total lifetime cost was calculated, the costs of relevant years were also updated. 
For example, the costs accrued between years 2 and 5 were split according to the year in 
which the cost was incurred and saved in separate cost slots for years 2, 3, 4, and 5. These 
annual costs incurred by the base-year population and the yearly inflows of individuals were 
then scaled to the population level by multiplying them by the number of people in a relevant 
population in the UK, and combined to estimate the total population-level cost of a disease.   
Figure 4.2 is a simple representation of the methods for calculating the total annual costs for 
all populations related to different calendar years. Each rectangle represents the cost incurred 
in a year by a cohort that entered the model in one of the modelled years. The vertical 
summation of the rectangles gives the total cost for any relevant year.  For example, the total 
cost for the year 2015 is the sum of the following costs: 1) the cost incurred in 2015 by the 
base-year population; 2) the cost incurred in 2015 by a cohort that were 45 year old in the 
entry year 2013; 3) the cost incurred in 2015 by a cohort that were 45 year old in the entry 
year 2014; and 4) the cost incurred in 2015 by a cohort that were 45 year old in 2015. For ease 
of calculation, it was assumed that all populations entered the model in the beginning of a 
year.  
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Figure 4.2. Calculation of total annual costs 
 
 
Each rectangle in Figure 4.2 represents the total annual cost of a cohort that entered the 
model in a certain year. Algebraically, it is calculated as: 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑐𝑜ℎ𝑜𝑟𝑡 𝑖 𝑖𝑛 𝑦𝑒𝑎𝑟 𝑗 = [ 𝑃𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 𝑐𝑜𝑠𝑡𝑖𝑗] × [𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒𝑖𝑗] 
, where 𝑃𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 𝑐𝑜𝑠𝑡𝑖𝑗 denotes a per-capita cost for cohort i in year j and 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒𝑖𝑗 represents a multiplier used to scale the per-capita cost to the 
population level.  
The total projected cost for a calendar year j is the sum of these values across all cohorts 
relevant to the year j as below.  
𝑇𝑜𝑡𝑎𝑙 𝑎𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑓𝑜𝑟 𝑦𝑒𝑎𝑟 𝑗 = ∑[ 𝑃𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 𝑐𝑜𝑠𝑡𝑖𝑗 × 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒𝑖𝑗]
𝑖∈𝐼
 
, where 𝐼 denotes a set of all cohorts that have already entered the model by year j. 
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These calculations were similar to those used in the cell-based macro-simulation models 
described in Chapter 3.  In the cell-based models, an average cost per person in a ‘cell’ 
specified by a combination of pre-determined characteristics of the population such as age and 
gender was multiplied by the projected number of people in that cell with the cell-level costs 
summed across all cells that consist of the total population.  
Using the model outcomes, this calculation could be performed in two methods.  Method 1 is 
where the per-capita cost is a cost per person alive within the model each year. Hence, the 
per-capita cost is calculated as annual costs for the model population divided by the number of 
people who are alive within the model in year j, and 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒𝑖𝑗 is the number of 
people who are projected to be alive at year j by ONS. Costs per person alive would typically 
increase over time due to the ageing of the remaining population within the model. Time 
trends in mortality are reflected in both the ONS population projections and the per-capita 
costs as they account for the population size each year. Also, the use of annual ONS population 
projections allows their assumptions on birth rates, mortality rates, and migration to be 
incorporated in the cost projections.  
Method 2 is to use the cost per person who entered the model and the constant number of 
people from the ONS population projections over the projection period. The per-capita cost 
decreases over time as the costs incurred by the remaining individuals within the model are 
divided by a constant denominator – the total number of people simulated – for all projection 
years, whilst the number of people in the UK population from the ONS projections remains 
constant at the level of the population size in the year of the model initiation (e.g. 27 million 
people for the base-year population). Mortality trend is reflected in the per-capita costs 
obtained from the simulation model in this method.  If the modelled mortality perfectly 
replicates the mortality, migration, and fertility assumed in the ONS Population Projection 
(Office for National Statistics, 2013c), the results from Methods 1 and 2 should be the same. 
Method 2 was adopted for this thesis as it was simpler where the calculation was not based on 
‘cells’, but just two groups, i.e. ‘population aged 45 years and older at base year’ and ‘future 
45-year-olds’. Hence, the calculation would not replicate the method used in the cell-based 
projection models reviewed in Chapter 3.  
In summary, the population-level annual costs are calculated in three steps: 1) per-capita cost 
for each year estimated from the simulation model; 2) the size of the relevant population from 
the ONS population projections to scale up the per-capita costs from step 1; and 3) the 
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summation of the results across all populations related to the specific calendar year, to 
estimate the total population-level cost in the corresponding year.  
Per-capita results for the new incoming cohorts of 45-year-olds were obtained separately for 
males and females in order to reflect projected changes in the gender composition of future 
cohorts. The gender proportions reported in ONS mid-2012 Population Estimates (Office for 
National Statistics, 2013d) were applied to the sex specific results from the model to derive a 
weighted average of the population-level per-capita costs without increasing the number of 
simulation runs required.  Projected numbers of people aged 45 years at each year and the 
gender proportions are obtained from the 2012-based population projections (Office for 
National Statistics, 2013c) and reported in Table 4.3.  
The data provided the mid-year population projection, not at the beginning of the year. 
However, for simplicity, it was assumed that all populations enter the model in the beginning 
of a calendar year. The impact of the base year population on total annual costs would 
diminish due to the decrease in the proportion of the base-year population amongst all 
populations as more people aged 45 years enter the model over time, and those new cohorts 
generally stay longer in the model due to their younger age.  
 
Table 4.3. Projected numbers of people aged 45 years and gender proportions 
Year 
Total No. of 
people 
Male% Female% Year 
Total No. 
of 
people 
Male% Female% 
2013 924,106 49.27% 50.73% 2029 856,751 49.58% 50.42% 
2014 921,371 49.19% 50.81% 2030 880,455 49.92% 50.08% 
2015 896,609 49.18% 50.82% 2031 881,070 50.07% 49.93% 
2016 915,488 49.07% 50.93% 2032 877,732 49.68% 50.32% 
2017 884,136 49.36% 50.64% 2033 905,041 50.19% 49.81% 
2018 845,689 49.38% 50.62% 2034 907,723 50.63% 49.37% 
2019 808,204 49.31% 50.69% 2035 925,318 51.18% 48.82% 
2020 793,088 49.40% 50.60% 2036 948,039 51.16% 48.84% 
2021 777,446 49.42% 50.58% 2037 934,265 50.70% 49.30% 
2022 761,594 49.66% 50.34% Selected years 
2023 773,552 49.55% 50.45% 2041 891,329 51.62% 48.38% 
2024 829,705 49.54% 50.46% 2046 828,270 51.30% 48.70% 
2025 866,036 49.36% 50.64% 2051 889,025 51.35% 48.65% 
2026 866,160 49.31% 50.69% 2056 950,432 51.41% 48.59% 
2027 859,835 49.16% 50.84% 2061 956,886 51.43% 48.57% 
2028 861,633 49.33% 50.67% 2062 959,164 51.43% 48.57% 
Source: UK ONS (2013) Mid-2012 Population Estimates: United Kingdom 
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4.3.6. Non-disease deaths 
 
Data on mortality rates not associated with the diseases included in the model were obtained 
from the UK ONS interim life tables based on the data for the years 2009-2011 (Office for 
National Statistics, 2013b). Time to non-disease death was drawn from the time to death (TTD) 
distributions by age and gender estimated for each age up to 100 years and gender by 
calculating the proportion of people who survived each year, and were applied for all 
individuals aged 45-100 years.  
As the interim life tables include all-cause mortality, the deaths caused by the health events 
included in the model were subtracted from the number of survivors when estimating the TTD 
distributions. The mortality rates associated with diseases were obtained from the Mortality 
Statistics: Deaths registered in 2012 (Office for National Statistics, 2013a). For heart disease, 
death rates reported for heart disease (ICD-10 code I00-I52) and stroke (I64) were combined, 
and subtracted from the all-cause mortality rates as detailed in Chapter 5.  
Probability profiles, or discrete probability distributions, where the values of time to non-
disease death are attached to probabilities of the values being sampled were created for each 
age and gender. The distributions for age at death unadjusted for disease-related deaths are 
given in Figure 4.3. To illustrate, only the distributions for males and females at a few selected 
ages are shown. It is noted that the probability of death at the age of 100 years was higher as 
mortality rates for those aged over 100 years were combined due to the age limit of the model 
population.  
 
131 
 
Figure 4.3. Distributions of age at death for the UK population aged 45 years (unadjusted for 
disease-related deaths) 
a) 45 years male 
 
a’) 45 years female 
 
  
b) 65 years male 
 
b’) 65 years female 
 
  
c) 85 years male 
 
c’) 85 years female 
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4.3.7. Utilities 
 
Baseline utility values by age and gender in the UK general population were estimated from a 
statistical model in the study by Ara and Brazier (2010). Deterministic values were used in the 
base-case model (Table 4.4).   
 
Table 4.4. Baseline utility by age and gender  
Utility values 
Age Male Female Age Male Female Age Male Female 
45 0.893 0.872 65     0.815      0.794  85     0.710      0.689  
46 0.890 0.869 66     0.810      0.789  86     0.704      0.683  
47 0.887 0.865 67     0.806      0.784  87     0.698      0.677  
48 0.883 0.862 68     0.801      0.780  88     0.692      0.671  
49 0.880 0.858 69     0.796      0.775  89     0.686      0.665  
50 0.876 0.855 70     0.791      0.770  90     0.680      0.659  
51 0.873 0.851 71     0.786      0.765  91     0.674      0.652  
52 0.869 0.848 72     0.781      0.760  92     0.667      0.646  
53 0.865 0.844 73     0.776      0.755  93     0.661      0.640  
54 0.861 0.840 74     0.771      0.750  94     0.654      0.633  
55 0.857 0.836 75     0.766      0.745  95     0.648      0.627  
56 0.853 0.832 76     0.761      0.739  96     0.641      0.620  
57 0.849 0.828 77     0.755      0.734  97     0.635      0.613  
58 0.845 0.824 78     0.750      0.729  98     0.628      0.607  
59 0.841 0.820 79     0.744      0.723  99     0.621      0.600  
60    0.837     0.816  80     0.739      0.718  100     0.614      0.593  
61    0.833     0.812  81     0.733      0.712  101     0.607      0.586  
62    0.828     0.807  82     0.728      0.706     
63    0.824     0.803  83     0.722      0.701     
64    0.820     0.798  84     0.716      0.695     
Source: Ara and Brazier (2010) 
 
Events may occur at intervals longer than a year, with the age of the individuals change 
between events. For simplicity, the utility value corresponding to the age at the half point of 
such intervals was applied. For example, if the first event occurred at age 52 and the second at 
age 60, then the utility value related to the halfway in the interval, that is, age 56, was used for 
the calculation of QALYs accrued between the events.  
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4.3.8. Costs 
 
The cost estimates used in the existing models reviewed prior to modelling each disease were 
assumed to be correct. Typical data sources of medication and hospital costs included the 
British National Formulary (BNF) (Joint Formulary Committee, 2014) and Healthcare Resource 
Group (HRG) data (National Casemix Office, 2007). These costs were inflated to the 2012 price 
using the Hospital and Community Health Services (HCHS) pay and price inflation index (Curtis, 
2013). Although the indices were available up to the year 2012/2013, costs were inflated to 
2011/2012 as the data from which the model population was generated were based on mid-
2012 estimates. For drug costs, the 2014 price was obtained from the BNF (Joint Formulary 
Committee, 2014). Given that the drug price typically decreases or remains at the same level 
over time, the mismatch between the drug price year and other cost year was deemed 
acceptable.  
The costs of interventions and prevention policies to be evaluated within this study were 
obtained from other published studies examining such interventions or policies, and from 
sources such as the BNF. Future medical costs for ‘unrelated’ diseases other than the diseases 
incorporated in the model were not included. However, there has been controversy over what 
constitutes ‘related’ and ‘unrelated’ costs (Meltzer, 1997).  
 
4.3.9. Discounting 
 
As recommended by NICE (National Institute for Health and Care Excellence, 2013), an annual 
discounting rate of 3.5% was assumed for both costs and benefits as a base case.  It was used 
for one-off costs incurred at a specific point in time (discrete rate).  
In DES models, time cycles are not fixed and thus no assumption on the time point within 
cycles when a health state cost is incurred is made. Hence, a continuous discounting rate 
corresponding to the discrete rate was applied to any on-going costs (e.g. costs that are 
continuously incurred after an event) and QALYs that accrue over time. When the annual 
discount rate is 3.5%, the continuous discounting rate, 𝑟, is 0.0344 as 𝑒𝑟 = 1.035. Assuming 
the discount rate remains constant over time, the discounted outcome is calculated using the 
survival function of an Exponential distribution, 𝑆(𝑡) = 𝑒−𝑟𝑡, where time 𝑡 ≥ 0 and 𝑟 > 0. The 
total discounted cost or benefit accrued up to the time t1 is subtracted from the total 
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discounted value accrued up to t2, where t1 and t2 are event times and t1< t2, to calculate the 
cost or benefit accumulated between t1 and t2. Each of these total accrued values is equivalent 
to the integral of an exponential survival function with the failure rate being the discount rate. 
Algebraically, the discounted cost or benefit accrued between t1 and t2 is 𝐴 ∙
(𝑒−𝑟∙𝑡2−𝑒−𝑟∙𝑡1)
−𝑟
, 
where t1<t2, A is an undiscounted ongoing cost or benefit, and r is the continuous discount rate.  
 
4.4. General methods for linking individual disease models 
 
 
4.4.1. Modelling methods for linked model 
 
Individual disease models are linked in a single model with a common entry point for all 
simulated individuals. In the linked model, the competing risks across all individual disease 
models are compared and individuals are directed to move to the event corresponding to the 
earliest scheduled time to event.  
Individuals enter the combined model with the values of all patient characteristics relevant to 
the modelled diseases sampled at the entry point. These characteristics may be used for the 
sampling of times to next event and/or the calculation of costs and QALY accruals. They enter 
the model through the central routing point where the transition to the next event is executed. 
Once the patients move to the event and all relevant parameters are updated, they return to 
the central router to be routed out to a next event. This process is repeated until a patient is 
simulated to die. By recording the history of previous events the model can account for co-
morbidities, in terms of utility and influence on risks of future events.  
Figure 4.4 shows the linkages between individual disease models. Individuals may enter the 
model with one or more of the diseases (or without diseases) and move immediately to the 
central routing point and directed to the same or different diseases with the history of the 
previous disease event.  Conceptually, individuals initiate at the central routing point before 
moving to any disease or death event.   
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Figure 4.4. Model linkage 
 
 
 
Individuals in the linked model move between events via a central router. In the individual 
disease model, the transitions were made to the next event from the last event state, but in 
the linked model, individuals can move to the next event only through the central router (see 
Figure 4.5).  The central router directs simulated individuals to the event with the earliest 
event time across all diseases included. Before moving to the next event, the individual visits 
the central router where the disease-level times to next event are compared, and the patient 
routed accordingly.  The times to all further predicted events are then reduced by the time to 
the next event to account for the passing of time.  
 
Figure 4.5. Role of Central Router 
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Table 4.5 illustrates this time update and routing, following an individual from the model entry. 
Times to next event are updated at each event and the simulation time is shown alongside. For 
simplicity, the actual events (e.g. stroke and myocardial infarction) have not been documented.  
In this process, both the time and type of previous events are recorded. The most recent time-
to-event values within each disease model are kept for comparison of time to next event 
(TTNE) across diseases at the central router. These TTNE values are updated based on the 
previous event; if the previous event was from one disease, TTNEs for the other diseases are 
subtracted by the time spent for that previous event. For example, if the previous event was 
one of the heart disease events, the most recent TTNE value for Alzheimer’s disease events are 
updated by subtracting time passed since sampling of that value. By recording the history of 
previous events, the model accounts for co-morbidities.  
Then, any other time-related variables are recalculated in the central router after TTNE across 
all included diseases is determined. These variables include, for example, time left before the 
effect of treatments stopping, time left before the first year of any cardiac events or 
osteoporotic fractures, or any time periods that require time recording due different event 
rates, costs, or utility weights being applied.  
In this thesis, the heart disease and Alzheimer’s disease models were linked first, and 
osteoporosis was added to the two-disease model. The following chapters will report results 
from the two- and three-disease linked models.   
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Table 4.5. An illustration of time changes at the central router – How individuals move 
between events in the linked model 
Simulation 
time 
Location (Event 
where updates 
occur) 
Time to next disease event 
Time 0 Entry Time to next heart disease event: Sampled to be 2.5 years 
Time to next Alzheimer’s disease event: Sampled to be 12 
years  
Time to next osteoporosis event: Sampled to be 4.5 years 
Time 0 Central router  Time to next event: 2.5 years (heart disease event) 
Time 2.5 Heart disease 
event 
Next heart disease event: Sampled to be 6.8 years 
Time 2.5 Central router Next heart disease event: 6.8 years 
Next Alzheimer’s disease event: Updated to 9.5 (12-2.5) 
years 
Next osteoporosis event: Updated to 2 (4.5-2.5) years 
 Time to next event: 2 years (osteoporosis event) 
Time 4.5 Osteo event Next osteoporosis event: Sampled to be 7.3 years 
Time 4.5 Central router Next heart disease event: Updated to 4.8 (6.8-2) years 
Next Alzheimer’s disease event: Updated to 7.5 (9.5-2) years  
Next osteoporosis event: 7.3 years 
 Time to next event: 4.8 years (heart disease) 
Time 9.3 Heart disease 
event 
Next heart disease event: Sampled to be 8.2 years 
 
Time 9.3 Central router Next heart disease event: 8.2 years 
Next Alzheimer’s disease event: Updated to 2.7 (7.5-4.8) 
years  
Next osteoporosis event: Updated to 2.5 (7.3-4.8) years 
 Time to next event: 2.5 years (osteoporosis) 
  ⁞ 
The process continues until death 
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4.4.2. General methods for incorporating correlations between 
diseases 
 
 
At the common entry point, individuals are assigned the values of patient characteristics 
relevant to all modelled diseases such as age, gender, baseline cognitive function scores and 
presence of heart disease history.  At the model initiation, times to first event for all diseases 
included are sampled to be compared at the central router.  Once individuals move to an event 
state as directed at the central router, all relevant parameters are updated at the event state 
and return to the central router to be routed out to a next event, and this process is repeated.  
In the linked model, possible correlations between diseases in terms of incidence and/or 
prevalence rates are incorporated. Wherever possible, data on the incidence and prevalence 
of one disease with and without the other diseases will be obtained. For example, in the model 
linking AD and heart disease, the incidence of AD for the total population would be split into 
that for population with heart disease and for population without heart disease.  If the risks of 
developing the diseases are independent, the incidence (or prevalence) of the disease will be 
the same regardless of the presence of the others. However, if there are correlations, the 
presence of one disease may increase or decrease the probability of another. 
When a disease is assumed to progress based on time, the rate of this disease progression was 
applied for all events – not only those associated with the corresponding disease, but all other 
diseases. For example, cognitive function and functional capacity scores for AD patients 
decline over time. This time-based decline was applied in all heart disease, AD and 
osteoporosis related events.  In the same way, if the effect of a treatment differs according to 
the time lapsed after treatment initiation, the model adjusted for the treatment effect at all 
other disease events in order to reflect the treatment effect at all event times.  
Individuals with multiple diseases may have a higher risk of death. Co-morbidities were taken 
into account for disease-related death as competing risks; even when the individual is in an 
event associated with one disease, time to death related to the other prevalent diseases is 
compared in order to reflect the possible correlation.  This means that the disease-related 
mortality rate for individuals with multiple diseases is the maximum of mortality rates 
associated with the co-existing diseases. The combined disease-related death rates could be 
lower than the crude sum of death rates related to each of the diseases included. However, 
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this was not incorporated in the linked model due to lack of data encompassing the three 
diseases included.  
Death may not be related to any of the diseases explicitly modelled. Non-disease mortality 
rates in the linked model were defined as all-cause mortality minus death rates associated 
with the diseases included in the model.  
Costs incurred by those with co-existing conditions may be higher or lower than the crude sum 
of costs of all diseases that the individual has. The possible correlations between diseases with 
respect to the cost of treatment and management were explored, and included in the model 
wherever possible.  Where no data could be found, costs were assumed to be additive; if an 
individual has two or more diseases, the cost for each of the co-existing diseases was added to 
the total.  
Wherever possible, utility weights accounting for comorbidities were used. However, it was 
expected to be difficult to find appropriate data given that utility weights are typically reported 
for a single disease. In such cases, utility weights for QALY calculation were assumed to be 
multiplicative; a utility for one disease was multiplied by that for another disease that is 
present in the same individual. Hence, the effect of disease is reduced where there is already a 
prevalent disease.  
 
 
4.4.3. Modelling framework 
 
The modelling methods described in Sections 4.3 and 4.4 and the main steps involved in 
applying the modelling framework are summarised in Figure 4.6.  
Subsequent chapters are structured to reflect the steps described in this modelling framework. 
Chapters 5-7 describe individual disease models for HD, AD and osteoporosis, respectively. 
Chapter 8 details the literature identified on the correlations between the diseases and how 
the identified data were used. Chapter 9 reports results from the linked models and scenario 
analyses.  
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Figure 4.6. Modelling framework used in this thesis 
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CHAPTER 5 INDIVIDUAL DISEASE MODEL 1 – 
MODELLING HEART DISEASE 
 
5.1. Background  
 
Cardiovascular disease (CVD) is defined as a disease of the heart and blood vessels. The most 
common manifestation of CVD is coronary heart disease (CHD), also known as coronary artery 
disease and ischaemic heart disease. The prevalence of CVD increases with age and is higher 
among men (World Health Organization, 2012).   
Potentially important risk factors for CVD events include risk factors that cannot be modified 
such as age and sex, and modifiable risk factors such as high blood pressure, high blood 
cholesterol levels, obesity (or high body mass index or physical inactivity), and cigarette 
smoking (Frayn and Stanner, 2005). People with diabetes are also at an increased risk of CVD 
(American Heart Association, 2013).  
Although the definitions of prevention of CVD vary across studies, primary prevention 
generally refers to interventions that aim to prevent cardiovascular events in people who have 
no clinical evidence of CVD, whilst secondary prevention aims to prevent further CVD events in 
those for whom there is already manifested clinical evidence of CVD (NICE Technology 
Appraisal (TA) 94). For simplicity, CVD is referred to as heart disease hereafter. 
 
5.2. Review of existing heart disease models 
  
A rapid (non-systematic) review of recent heart disease models was undertaken. Searches for 
the existing models were based on recently published HTA reports if available. If the HTA 
report included a recent systematic review of models for economic evaluation of relevant 
health technologies, the models included in that review were also examined. Searches using 
keywords identified from the reviewed studies were undertaken to identify models published 
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after the HTA report. The NHS Economic Evaluation Database (NEED) database was also 
searched. The modelling methods, structure, and data sources of heart disease models 
published between 2009 and 2013 were identified and used to inform decisions on the model 
for this study.  
A total of 15 papers relating to 12 models were identified from this review. Table 5.1 
summarises the modelling methods used in the identified models.  
Among the twelve heart disease models, six models used UK sourced data, and were 
conducted from the perspective of the UK NHS and PSS. The majority of the identified models 
for heart disease employed an aggregate-level state-transition model (10 models). Seven of 
the reviewed models assessed the cost-effectiveness of statin treatments; all concluded that 
statins were considered cost-effective when applying a threshold value generally accepted in 
the relevant country. The models were divided into those including interventions for primary 
prevention of cardiovascular events, which aim to prevent CVD events in people who did not 
previously experience the events, and those for secondary prevention, whose aim is to prevent 
further CVD events in people who already experienced one or more CVD events (NICE, 2006). 
Four models assessed interventions for primary prevention, five for secondary prevention, and 
three models included both primary and secondary prevention interventions.  
Among the UK models, two models (Lindgren et al., 2009, Ward et al., 2006) included both 
primary and secondary prevention populations. The model by Ward et al. (2006) was 
considered appropriate to choose as the basis of the model in this thesis, as the current 
guidance recommended by the UK NICE was based on their model (as of December 2013), and 
it used data collated from a variety of sources unlike Lindgren et al. (2009) which was mainly 
based on a single clinical trial. Where applicable, sources of data and key assumptions 
reported in Ward et al. (2006) were considered as the main reference for the model in this 
thesis.  
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Table 5.1. Summary of the existing models included in the review  
Study Aim Model 
type 
Individual
/ Cohort-
level 
Countrie
s 
Target 
population 
Primary 
vs. 
Seconda
ry 
preventi
on 
Structure Health 
states 
Cycle 
length
/ Time 
horizo
n  
Notable 
assumptions 
Conclusion 
De Smedt 
et al. 
(2012) 
To quantify the 
clinical and 
cost-
effectiveness of 
optimizing 
secondary 
prevention 
individu
al-based 
state-
transitio
n model 
individual 
 
Belgium, 
Bulgaria, 
Croatia, 
Finland, 
France, 
Italy, 
Poland, 
and the 
UK 
 
EUROASPIRE III 
survey 
participants 
(i.e. patients 
aged 18-80 
years and 
admitted to a 
hospital for an 
acute coronary 
event or a 
cardiac 
procedure) 
Seconda
ry 
preventi
on 
All patients start in the 
CABG/ PTCA/ MI/ 
angina disease state. 
Every cycle, patients 
can suffer one of a 
coronary event, a 
stroke, or heart failure 
and move to the CHD 
state, CVD state, or CHF 
state, respectively. 
Once in one of these 
subsequent event 
states, patients enter a 
post-event state after 
one cycle 
Three 
disease 
states 
(CHD, 
CVD, 
CHF), two 
post-
event 
states 
(post-
CHD, 
post-
CVD), and 
a death 
state 
 
6-
month 
cycles;  
10 
year 
horizo
n. 
Patients suffering a 
MI will move to the 
CHD state. Patients 
suffering a stroke 
will move to the 
CVD state, patients 
suffering a heart 
failure will progress 
to the CHF state. 
Overall, optimizing 
secondary prevention 
based on the 2003 
joint European 
guidelines is cost-
effective compared 
with the current 
degree of 
cardiovascular 
prevention with an 
ICER of 
€12,484/QALY, when 
using a willingness to 
pay threshold of 
€30,000/QALY. 
Ohsfeldt 
et al. 
(2012) 
To examine the 
cost-
effectiveness of 
rosuvastatin for 
primary 
prevention of 
major CVD for 
various risk 
levels over a 
long-term 
horizon 
 
Monte 
Carlo 
simulati
on 
model 
 
Individual Sweden  
 
Patients with a 
10-year 
Framingham 
CVD risk >20 % 
were 
simulated in 
the model 
using the 
characteristics 
of the JUPITER 
clinical trial 
patients. 
 
Primary 
preventi
on 
Three health stages 
were included: 1) event 
free for the duration of 
the JUPITER trial, 2) 
event free beyond the 4 
years of the trial for 
those without a CVD 
event, and 3) post−CVD 
event stage for those 
who experience a non-
fatal CVD event. 
1) Initial 
CVD 
preventio
n during 
RCT 2) 
Initial CVD 
preventio
n – Post 
RCT and 
3) 
post−CVD 
event 
stage. 
1 year 
cycles; 
Lifeti
me 
horizo
n 
Initial and 
subsequent CVD 
events and death 
were estimated 
over the long term 
(20 years and 
lifetime of patients 
[to age 100 years] 
CVD events tracked 
in the model 
include: non-fatal 
MI; non-fatal 
stroke; unstable 
Considering the 
generally accepted 
threshold value in 
Sweden, treatment 
with rosuvastatin 10 
mg or 20 mg daily is 
cost-effective 
compared to relevant 
doses of simvastatin 
in the primary 
prevention of CVD for 
Swedish patients with 
high baseline CV risk 
(10-year Framingham 
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angina; CABG; 
PTCA; CVD death; 
non-CVD death; 
venous 
thromboembolism 
(VTE) death; and 
non-fatal VTE. 
CVD risk >20 %). 
Galper 
et al. 
(2012); 
Lazar et 
al.(2011) 
To assess the 
cost 
effectiveness of 
non-invasive 
stress testing to 
guide the use of 
aspirin and 
statins for 
primary 
prevention of 
coronary heart 
disease (using 
the US CHD 
Policy model). 
Markov 
model 
Cohort  US US men aged 
45 years in 
2011 and 
women aged 
55 years in 
2011 who had 
an 
intermediate 
risk (10%–20%) 
of developing a 
CHD event in 
the next 10 
years on the 
basis of the 
Adult 
Treatment 
Panel III (ATP 
III) guideline 
point system. 
Primary 
preventi
on 
Markov cohort model 
of CHD incidence, 
prevalence, mortality, 
and costs among 
people aged 35 to 84 
years in the US. The 
demographic-
epidemiological sub-
model predicts CHD 
incidence and non-CHD 
mortality among people 
without CHD, stratified 
by age, sex, blood 
pressure, smoking 
status, high-density 
lipoprotein cholesterol 
level, LDL cholesterol 
level, diabetes mellitus, 
and use of aspirin or 
statin therapy. 
CHD 
events, 
CHD 
death, 
and non-
CHD 
mortality.  
 
1 year 
cycle; 
Lifeti
me 
horizo
n 
As reliable evidence 
for effective 
primary prevention 
of acute myocardial 
infarction with 
aspirin exists only 
for men (relative 
risk of 0.77), only 
eligible male 
patients were 
prescribed aspirin; 
For the primary 
analysis, 
effectiveness and 
treatment 
adherence rates 
were assumed to be 
equivalent to those 
observed in clinical 
trials. 
 
Using a national-scale 
computer simulation 
model of CHD in US 
adults, we project 
that universal 
treatment of 
intermediate-risk 
women with statins 
and intermediate-risk 
men with statins plus 
aspirin, regardless of 
their LDL levels, 
would be a cost-
effective CHD primary 
prevention policy. 
Gillespie 
et al. 
(2012; 
2010) 
To examine the 
cost-
effectiveness of 
the Secondary 
Prevention of 
Heart disEase in 
geneRal 
practicE 
(SPHERE) 
Markov 
model 
Cohort Ireland Patients with 
CHD 
(documented 
MI, CABG, 
PTCA, or 
angina). 
Seconda
ry 
preventi
on 
Patients start the 
Markov simulation in 
the ‘CHD’ state.  In each 
cycle, individuals can 
experience a fatal event 
or a recurrent nonfatal 
CHD event (MI or 
angina) or survive the 
year without 
Disease 
progressio
n was 
modelled 
with three 
discrete 
health 
states: 
‘CHD’, 
1 year A series of 
published risk 
equations formed 
the basis for the 
transition 
probabilities in the 
model.  
In the case of stable 
angina SA and 
The SPHERE 
intervention 
dominated control. 
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intervention 
(tailored care 
plans where 
practices 
received 
training in 
prescribing and 
behaviour 
change, 
administrative 
support, etc.; 
and patients 
received 
motivational 
interviewing, 
target setting 
for lifestyle 
change, review 
visits). 
experiencing a 
recurrent CHD event. 
Individuals who 
experience a MI 
progress to the ‘Post-
MI’ state, a 1-year 
tunnel state, in which 
they are at an elevated 
risk relative to the 
general population for 
1 year. If they survive 
this year, they return to 
the ‘CHD’ state for the 
beginning of the next 
cycle. An individual who 
is predicted to 
experience a fatal event 
transitions to the ‘Dead’ 
state.  
‘Post-MI’ 
and 
‘Dead’. 
 
unstable angina UA, 
while the model 
includes differing 
rewards in terms of 
costs and utilities, it 
is assumed that 
there is no 
additional risk in 
the subsequent 
year, and the 
individual remains 
in the ‘CHD’ state. 
Earnsha
w et al. 
(2011) 
To examine the 
cost-
effectiveness of 
aspirin with or 
without a 
proton-pump 
inhibitor (PPI) 
to prevent 
gastrointestinal 
bleeding, while 
preventing CHD, 
in men with 
various risks of 
CHD and GI 
bleeding. 
Markov 
model 
Cohort US Men in the 
base-case 
analysis were 
assumed to be 
healthy, 
middle aged 
men with 
starting age of 
45 years, no 
history of CHD 
events, and 
10%, 10-year 
CHD risk.   
Primary 
preventi
on 
Men began treatment 
in the healthy state. 
During each cycle, men 
could remain in the 
healthy state; progress 
to initial, non-fatal 
cardiovascular events 
such as angina, MI, or 
stroke; have upper GI 
bleeding; or die.  
 
Angina, 
stroke, MI 
and GI 
bleeding 
1 
year; 
Lifeti
me 
horizo
n 
Men 
who had CVD 
events were 
assumed to stay in 
the sub-acute 
state for the 
remainder of that 
cycle and then 
entered a 
post-event health 
state during which 
they received 
optimal secondary 
preventive care. 
Men can progress 
from any health 
state to death 
Treatment with 
aspirin for CHD 
prevention is less 
costly and more 
effective than no 
treatment in men 
older than 45 years 
with greater than 10-
year, 10% CHD risks. 
Adding a PPI may only 
be cost-effective for 
selected men at 
increased risk for GI 
bleeding. 
Grosso To assess the 
cost-utility of 
Markov 
model 
Cohort UK Patients with 
hypertension 
Primary 
preventi
The entire cohort starts 
in the ‘Well’ state, and 
‘Well’, 
‘Coronary 
1 
year; 
10 year time 
horizon was used.  
Candesartan, the 
most widely 
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et al. 
(2011) 
adopting 
losartan or 
candesartan in 
the 
management of 
hypertension 
and heart 
failure 
 and high risk of 
heart failure. 
 
on can transition annually 
to the coronary heart 
disease and 
cerebrovascular disease 
states, or they can 
survive or die from 
either MI, stroke 
events, or other causes. 
A risk sub-model was 
then used to calculate 
the age- and sex-
related probabilities of 
stroke and CHD risk for 
each year in the model, 
based on Framingham 
risk equations. 
 
Heart 
Disease 
(CHD)’, 
‘Stroke’ 
and 
‘Death’ 
 
10 
year 
horizo
n 
prescribed 
angiotensin II 
receptor blocker 
(ARB), shows small 
difference in reducing 
blood  pressure  
when compared with 
losartan, and does 
not appear to be cost-
effective based on 
current and near 
future acquisition 
costs of losartan. No 
robust evidence 
supporting the 
superiority of 
candesartan over 
losartan was found in 
the treatment of 
heart failure. 
 
Soini et 
al. 
(2010) 
To evaluate the 
cost-
effectiveness of 
generic 
atorvastatin 20 
mg (A20), 
branded 
rosuvastatin 10 
mg (R10), 
generic 
simvastatin 40 
mg (S40) and 
the 
combination of 
generic S40 + 
branded 
ezetimibe 10 
Markov 
model 
Cohort Finland Patients not 
meeting the 
target goal of 
low-density 
lipoprotein 
cholesterol 
(LDL-C) with 
S40. Different 
populations 
were 
considered 
including 
patients with 
or without 
diabetes, with 
various serum 
cholesterol 
Seconda
ry 
preventi
on 
A probabilistic Markov 
model based on the 
recurrent CHD 
component of a 
broader model. 
Patients have an annual 
probability of 
experiencing a 
recurrent non-fatal 
event (MI or angina), a 
fatal event (CHD death 
and non-CHD death), or 
no CHD event.  
Recurrent 
non-fatal 
events 
(MI or 
angina), 
and fatal 
events 
(non-CHD 
death or 
CHD 
death) or 
no CHD 
event. 
1 year 
cycle; 
Lifeti
me 
horizo
n 
The risk of a fatal 
CHD event was 
predicted using 
Anderson’s 
individual event risk 
equations.   
The target 
population inputs 
for age, systolic BP 
and SC were 
assumed to be 
similar to values of 
high risk subjects 
who have CHD 
and/or DM (n=450) 
in the 
representative 
In the Finnish 
secondary prevention 
population that is not 
at goal on S40, 
switching generic S40 
to S40 þ EZ10 is more 
cost-effective than 
switching S40 to 
generic A20 or R10. 
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mg (S40 + EZ10) 
for the 
secondary 
prevention of 
coronary heart 
disease (CHD).  
profiles, and of 
either gender. 
 
population-level 
FINRISK 2002 study. 
 
Ara et 
al. 
(2009) 
To evaluate the 
cost-
effectiveness of 
high-dose 
statins 
(atorvastatin 80 
mg/day, 
rosuvastatin 40 
mg/day and 
simvastatin 80 
mg/day) versus 
simvastatin 40 
mg/day in 
individuals with 
acute coronary 
syndrome 
(ACS), whose 
symptoms 
include acute 
MI and angina. 
Markov 
model 
Cohort UK Individuals 
with acute 
coronary 
syndrome 
(ACS) who 
have 
experienced a 
recent ACS 
event. 
 
Seconda
ry 
preventi
on 
All individuals start in 
one of the three health 
states, unstable angina, 
non-fatal MI or 
revascularisation.  Age-
related transition 
probabilities were used 
to model the 
probabilities associated 
with the first year or 
subsequent year 
events. Individuals who 
did not experience an 
event in the current 
year moved to the 
corresponding ‘post’ 
health state, and 
subsequent year event 
rates were applied.   
Unstable 
angina, 
MI, 
revascular
isation, 
stroke, 
CVD 
mortality, 
and non-
CVD 
mortality. 
 
1 year 
cycle; 
Lifeti
me 
horizo
n 
Combined health 
states were 
included in which 
transitions rates to 
future events were 
assumed to be the 
maximum value 
associated with the 
events previously 
experienced. 
Individuals do not 
move to a health 
state with smaller 
costs and a greater 
quality of life.  
When using a 
threshold of £20,000 
per QALY, the 
probabilistic base-
case analysis showed 
that all the statin 
regimens compared 
(simvastatin 80 
mg/day, atorvastatin 
80 mg/day and 
rosuvastatin 40 
mg/day) would be 
considered cost-
effective compared 
with simvastatin 40 
mg/day in individuals 
with ACS. 
Taylor et 
al. 
(2009); 
Rosen et 
al. 
(2010)   
To examine the 
cost 
effectiveness of 
high-dose 
versus low-dose 
statin therapy in 
CHF patients. To 
assess the cost 
effectiveness of 
Atorvastatin 
80mg versus 
A10 in 
Markov 
model 
Cohort  US, UK, 
Spain, 
and 
Germany 
Patients with 
stable 
coronary heart 
disease 
Seconda
ry 
preventi
on 
Major CVD event status 
(stable CHF/CHD, one 
major event, various 
combinations of two 
major events), minor 
events and survival. 
Separate major event 
states include MI, 
stroke, CHF, 
revascularization, and 
resuscitated cardiac 
arrest, as well as all 
Major 
cardiovasc
ular 
events 
[MI, 
stroke, 
CHF, 
revascular
isation, 
resuscitat
ed cardiac 
arrest 
1 
year; 
Lifeti
me 
horizo
n 
Health states 
involving two major 
events allow for all 
possible 
combinations of 
events (excluding 
RCA). A second 
event is considered 
in the model only if 
it occurs within 1 
year of the first 
event. Patients in 
Intensive lipid-
lowering treatment 
with 80 mg 
atorvastatin appears 
to be a cost-effective 
use of health-care 
resources vs 
moderate statin 
treatment with 
atorvastatin 10 mg in 
secondary 
cardiovascular 
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secondary 
cardiovascular 
prevention 
possible combinations 
of two major events 
(excluding resuscitated 
cardiac arrest). Minor 
events include PAD, 
TIA, and angina. 
(RCA)],  
Minor 
cardiovasc
ular 
events 
[PAD, TIA, 
angina], 
and 
Death. 
major event states 
are subjected to the 
long-term utility 
and survival 
consequences of 
their specific 
cardiovascular 
event(s). Minor 
events result in only 
short-term cost and 
utility 
consequences. 
prevention. 
Bennett 
et al. 
2009 
To examine the 
cost-
effectiveness of 
various 
coronary heart 
disease (CHD) 
treatments 
(including 
medical and 
surgical 
treatments) 
Cell-
based 
policy 
model 
Cohort Ireland Men and 
women aged 
25 to 84 years 
in Ireland 
Primary 
and 
seconda
ry 
preventi
on 
The model utilises a 
very large Microsoft 
Excel spreadsheet to 
integrate data on: CHD 
patient numbers, 
uptake of specific 
medical and surgical 
treatments, 
effectiveness of specific 
treatments, and median 
survival in patients with 
and without CHD 
MI, 
revascular
isation, 
angina, 
and heart 
failure.  
NA Other information 
on the model is 
available on the 
IMPACT website 
(http://www.liv.ac.
uk/PublicHealth/sc/
bua/impact.html), 
as well as on 
http://www.ispor.o
rg/publications/valu
e/ViHsupplementar
y.asp. 
 
ICERs favoured simple 
medical treatments 
using aspirin, beta-
blockers, ACE 
inhibitors, 
spironolactone, and 
warfarin for MI, 
secondary 
prevention, angina, 
and heart failure 
(<€3000/LYG) and 
statins for secondary 
prevention 
(<€7000/LYG) 
Lindgren 
et al. 
(2009) 
To assess the 
cost 
effectiveness of 
four alternative 
treatment 
strategies in 
patients with 
hypertension 
and three or 
more 
cardiovascular 
risk factors in 
Markov 
model 
Cohort Sweden, 
and the 
UK.  
 
Men and 
women aged 
between 40 
and 79 years, 
with either 
untreated 
hypertension, 
or treated 
hypertension 
while not being 
treated with a 
statin or 
Primary 
and 
seconda
ry 
preventi
on. 
Patients in the event-
free state stand a risk of 
experiencing any of the 
three events (MI, 
revascularisation, and 
stroke) which in the 
case of strokes and MIs 
may or may not be 
fatal. Patients in the 
event states either die 
or remain within their 
current state for the 
Event 
free, MI, 
revascular
isation, 
stroke 
and death 
1 year 
cycles; 
Lifeti
me 
horizo
n 
The three event 
states (MI, 
revascularisation 
and stroke) were 
implemented as 
tunnel states to 
allow for 
differentiation of 
costs and lost utility 
over time. 
Applying the 
threshold values 
generally used in the 
UK and Sweden, a 
combination of 
amlodipine-based 
therapy and 
atorvastatin appears 
to be cost effective in 
patients with 
hypertension and 
three or more 
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the UK or 
Sweden. 
fibrate, and 
have a total 
cholesterol 
concentration 
of 6.5 mmol/L 
or lower. 
rest of the simulation. 
This means that only 
first events are 
explicitly incorporated 
in the model. 
additional risk factors 
Ward et 
al. 
(2006) 
To appraise the 
cost 
effectiveness of 
the use of 
statins for the 
management of 
patients at 
increased risk of 
death or other 
cardiovascular 
events from 
CHD and to 
advise on any 
patient groups 
for whom 
statins might be 
particularly 
appropriate. 
 
Markov 
model 
 
Cohort UK Patients at 
increased risk 
of death or 
other 
cardiovascular 
events from 
coronary heart 
disease 
Primary 
and 
seconda
ry 
preventi
on 
For the primary 
prevention analyses, all 
patients commence the 
evaluation in the event 
free health state. 
During each annual 
cycle of the model, a 
proportion of patients 
enter one of the 
qualifying event health 
states while the 
remainder remain in 
the event free state.  
For the secondary 
prevention analyses all 
patients commence in 
either post MI, post 
stable angina, post 
unstable angina, post 
TIA or post stroke 
health states.  
MI, stable 
angina, 
unstable 
angina, 
CHD 
death, 
TIA, 
stroke, 
CVD death 
or death 
through 
other 
causes 
1 year 
cycles; 
Lifeti
me 
horizo
n;  
The proportion of 
patients in each of 
the health states is 
governed by age 
dependent time-
variant transition 
matrices which 
describe the annual 
probability of 
moving to an 
alternative health 
state. 
 
Using a threshold of 
£20,000 per QALY, 
the results of the 
probabilistic 
sensitivity analysis 
show that statin 
therapy is cost 
effective for all 
patients with a 
history of coronary 
heart disease 
 
EUROASPIRE: European Action on Secondary and Primary Prevention by Intervention to Reduce Events; ICER: incremental cost-effectiveness ratio; CABG: coronary artery bypass graft; PTCA: 
percutaneous transluminal coronary angioplasty; CHD: coronary heart disease; CVD: cardiovascular disease; CHF: congestive heart failure; PAD: peripheral artery disease; TIA: transient 
ischemic attack; GI: gastrointestinal; 
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5.3. Model Overview and Structure 
 
5.3.1. The model structure and health events included 
 
An individual-level DES model was used to track the clinical pathways of patients at risk of 
cardiovascular disease: individual patients are simulated to move through different disease 
events according to the individual-specific event schedules sampled from appropriate time-to-
event distributions.  
Figure 5.1 depicts the structure of the DES model that was used for this analysis. The rest of 
this section describes how the health events have been selected and provides an overview of 
the model structure.  
 
Figure 5.1. The structure of the model 
 
MI: myocardial infarction; PAD: peripheral artery disease; Revasc: revascularisation 
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The model includes health events that were commonly used in other published heart disease 
models. The health states included in the existing models reviewed in Section 5.2 are 
summarised in Table 5.2. The major events included were MI, angina, and stroke; all models in 
the review included MI, whereas angina and stroke were also frequently included. More than 
half of the models (n=7) included revascularisation, such as coronary artery bypass graft (CABG) 
and percutaneous transluminal coronary angioplasty (PTCA), as one of the health states (Ara et 
al., 2009, Bennett et al., 2009, Ohsfeldt et al., 2012, Rosen et al., 2010, Taylor et al., 2009, 
Lazar et al., 2011, Galper et al., 2012, De Smedt et al., 2012, Lindgren et al., 2009). Although 
this is an intervention rather than a cardiac event, it was chosen to be an included event due 
to its significant cost and health implication.  
Although peripheral arterial disease (PAD) was included in only one model in the review, it was 
included in the model developed for this thesis. PAD, a deficit caused by ischaemia due to 
impaired blood flow to a limb, is a chronic disease, and was considered potentially related to 
high healthcare costs for the older population. Hirsch et al. (2008) estimated the mean 
Medicare expenditure for the treatment of PAD to be over $13,000 per person although this is 
based on the US data which may be considerably different from the UK cost. However, there is 
a paucity of UK-sourced evidence on the economic burden of PAD. One UK study by Hart and 
Guest (1995) estimated that critical limb ischaemia (CLI) —the most severe manifestation of 
PAD that can lead to major amputation or death if not treated promptly – costs the NHS more 
than £200 million annually.  
Although the HTA report by Ara et al. (2009) excluded PAD due to the paucity of trial data, it 
reported that PAD is also associated with high risks of MI, stroke, amputation, and death, as 
well as significant quality of life impairments. Also, the high prevalence implies significant NHS 
costs associated with PAD. The prevalence of PAD is estimated to be high among the elderly, 
and increase with age.  The worldwide prevalence was estimated to be nearly 10%, rising to 
15-20% in people aged 70 and over (Criqui et al., 1992). The Edinburgh Artery Study estimated 
that approximately 20% of people aged from 55 to 75 years have evidence of PAD in the legs 
(Fowkes et al., 1991), and around 4.5% of people in this age group within the UK were 
estimated to be affected by intermittent claudication (IC), the most common symptom of PAD 
(Squires et al., 2011, Norgren et al., 2007).  
Considering that PAD has not generally been included for the purpose of estimating the 
healthcare cost of the disease, the inclusion of this event into the heart disease model extends 
the coverage of major cardiovascular events beyond most current models.   
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Table 5.2. Health states included in the models identified in the review 
Study MI Angina Stroke Revasc
* 
TIA CHF Cardiac 
arrest 
PAD Death 
De Smedt 
et al. 
(2012) 
√ √ √ √ √ √ x x √ 
Ohsfeldt 
et al. 
(2012) 
√ √ √ √ x x x x √ 
Galper et 
al. (2012); 
Lazar et 
al.(2011) 
√ √ √ √ x x √ x √ 
Gillespie 
et al. 
(2012; 
2010) 
√ √ x x x x x x √ 
Earnshaw 
et al. 
(2011) 
√ √ √ x x x x x √ 
Grosso et 
al. (2011) 
√ x √ x x x x x √ 
Soini et al. 
(2010) 
√ √ x x x x x x √ 
Ara et al. 
(2009) 
√ √ √ √ x x x x √ 
Taylor et 
al. (2009); 
Rosen et 
al. (2010)   
√ √ √ √ √ √ √ √ √ 
Bennett 
et al. 
(2009) 
√ √ x √ x √ x x √ 
Lindgren 
et al. 
(2009) 
√ x √ √ x x x x √ 
Ward et 
al. (2006) 
√ √ √ x √ x x x √ 
Number 
of times 
included 
12 10 9 7 3 3 2 1 12 
MI: myocardial infarction; CHF: congestive heart failure; *Revasc=Revascularisation procedures include 
coronary artery bypass graft (CABG) and percutaneous transluminal coronary angioplasty (PTCA); VTE: 
venous thrombo-embolism;  
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Although a transient ischaemic attack (TIA) was included in some of the existing models (Taylor 
et al., 2009, NICE, 2006, De Smedt et al., 2012), it was excluded in this model as TIA was 
considered associated with relatively minor implications for costs and mortality, and relatively 
low event rates compared with the other events included in the model. 
Fatal events – cardiac death and non-cardiac death – are also included as absorbing events. 
Transitions to these events can be made from any other non-fatal health events. Although 
both events result in death, the separation was made due to different event rates applied from 
the other states. 
The final set of health events included were deaths from MI, stroke, angina, revascularisation, 
and PAD, and non-cardiac deaths. The modelled population progresses through the health 
events discussed above. The health events are divided into two temporal categories: first-year 
and subsequent years after the event. Individuals without a previous CVD event could remain 
in the event-free state, progress to initial, non-fatal cardiovascular events, or die (either from a 
cardiac or non-cardiac cause). People who had previously had one of the CVD events but do 
not experience a further event in the following year are assumed to enter the corresponding 
‘subsequent year’ event state during which the cost of treatments and health related quality of 
life (HRQoL) could differ from those in the first year after the event. No difference was made 
between the first year and subsequent years after PAD as there was no clinical evidence 
identified distinguishing the two periods (see Figure 5.1).  
Individuals’ history of heart disease events is recorded. People enter the model with a set of 
characteristics sampled from appropriate probability distributions. Upon the occurrence of 
each event, the values of times to next events are drawn from distributions whose parameters 
are conditional on individual disease history and risk factors. For example, individuals who 
survived both MI and stroke have a higher rate of stroke recurrence. It was assumed that 
patients could have a revascularisation surgery only in the first-year following a cardiac event, 
or after the model entry due to available data reporting only the first year probabilities (Ara et 
al., 2009). Other general methodological assumptions applied to the heart disease model are 
described in Section 4.1.  
Due to the difference in utility values for first and subsequent years after a cardiac event, an 
event called ‘utility cut-off point’ was added to the model. Due to the model using continuous 
time, it is possible for an individual to have multiple events within a 12-month period, and thus 
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to be affected by two or more first-year utility modifiers. The use of a utility cut-off point 
ensures that changes in HRQoL are handled appropriately.  
 
 
5.3.2. Modelled population 
 
The population in the base-case model consists of three groups of people: those not receiving 
any CVD interventions, those receiving an intervention for the primary prevention of CVD, and 
those receiving secondary prevention.  The base-case population was used for the assessment 
of cost-effectiveness outcomes unless otherwise stated. 
Individuals without history of any of the included health events commence at the event-free 
state (Figure 5.1). Among them, a proportion of people receive a preventative intervention 
before their first event (denoted a primary prevention population). Primary prevention is 
provided for people at an increased risk of cardiac events but without a prior CVD event.  Some 
individuals are assigned a history of one or more previous heart disease events on entry. These 
are subject to secondary prevention, where interventions are targeted at people who have 
experienced one or more prior CVD events.  
 
Primary prevention 
 
For primary prevention, statin therapy is currently recommended for adults in the UK whose 
10-year risk of developing CVD estimated using a risk calculator or by clinical assessment, is 
greater than 20% (NICE, 2006). Due to the lack of data on the UK prevalence of current statin 
use by age, the percentages of people whose the 10-year risk of developing CVD was higher 
than 20% in the general population were estimated from the Health Survey for England (HSE) 
1998 (Department of Health, 2005), and applied by age group and sex as in Ward et al. (2006). 
As the HSE study included the general population in both primary and secondary prevention, it 
is noted that the reported percentages of people with 10-year CVD risks greater than 20% may 
overestimate the proportions of people on primary prevention.  As the data were reported in 
the form of annual coronary heart disease (CHD) risks including MI and angina, but not PAD 
and stroke, the proportions of people at the annual CHD risk of greater than 2% reported in 
Ward et al. (2006) were taken as a proxy and shown in Table 5.3. Although it is noted that the 
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10-year risk converted from a 2% annual risk is less than 20% (18.3%), this was not thought to 
add significant inaccuracy and individuals at each age group were randomly assigned to the 
primary prevention group according to these proportions.  
 
Table 5.3. Percentage of the UK population who will be given statins for primary prevention 
 45-54 55-64 65-74 75-84 85+ 
Male 6% 27% 57% 76% 86% 
Female 1% 4% 11% 8% 2% 
 
 
As the people receiving statins for primary prevention are a high-risk population by definition 
(those whose 10-year CHD risk is greater than 20%), the base-case model assigned different 
baseline event rates to those who are on primary prevention and those who are not.    
However, there are some difficulties in assigning higher risks to the primary prevention 
population due to the lack of data on the baseline risk levels for those in the primary 
prevention.  Furthermore, the risk assessment used to determine the use of statin is based on 
a risk for multiple events, which means the 10-year risk of >20% should be split between the 
multiple events whilst maintaining the overall event rates across the primary prevention and 
no-statin populations.  
The base case model assigned different base rates for high-risk (primary prevention) and 
lower-risk (no-prevention) groups. The base-case assumes that the primary prevention group 
had the 10-year CHD risk of 20% which was used as a threshold in the risk assessment. The 20% 
risk was split between angina, sudden cardiac death, and MI according to the distribution of 
the age/sex specific incidence rates of these events on the pro rata basis. The incidence rates 
assumed were obtained from the Bromley Coronary Heart Disease Register (Sutcliffe et al., 
2003). For example, the ratio between the incident cases of angina, MI, and sudden cardiac 
death for females aged 35-44 years was 2:1:1. The 20% risk of angina, MI and sudden cardiac 
death were then split into 10%, 5%, and 5%, respectively. The baseline event rates calculated 
in this way were used for all transitions to MI, angina, and cardiac death (including sudden 
cardiac death) for the primary prevention population. The relative risks associated with the use 
of statins were applied to these baseline rates assumed. The estimated 10-year risk levels are 
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reported in Table 5.4. To the author’s knowledge (personal communication with two senior 
research fellows at the University of Sheffield – Robert Ara and Sue Ward), this calculation has 
not been undertaken previously. It is noted that the risk levels for those in the primary 
prevention group are maintained at 20% across all age groups, although the proportions of 
people receiving statins for primary prevention differed between age groups.  
Sudden cardiac death rate was added onto the baseline cardiac death rate for all age groups 
and time periods (first and subsequent years) as this was a part of the cardiac death category 
with the event rates for people aged 75 and over assumed to be the same as that for those 
aged 65-74 due to absence of data. Using the updated risks of cardiac death, the sampling 
procedure described in Section 4.1, where event rates are repeatedly updated conditional on 
the sampled time to event value, was applied.   
 
Table 5.4. 10-year risk estimated assuming 20% of CHD risk for primary prevention group. 
 Men Women 
Age 
group 
Angina MI Sudden 
cardiac 
death 
Total Angina MI Sudden 
cardiac 
death 
Total 
45-54 0.106 0.076 0.018 0.20 0.158 0.029 0.013 0.20 
55-64 0.122 0.052 0.026 0.20 0.152 0.034 0.014 0.20 
65+ 0.105 0.061 0.034 0.20 0.111 0.053 0.035 0.20 
 
 
The individual’s level of CHD risk changes over time and so does the probability of receiving 
statins for primary prevention. Individuals who did not receive the primary prevention 
intervention on model entry may have different event risks as they age, and be given the 
intervention before their first cardiac event. Hence, changes to the primary prevention status 
were made dynamically; if the age band an individual belongs to changes before the earliest 
time to next cardiac event, the use of primary prevention was re-assessed using the changed 
proportion of people with the 10-year CHD risk greater than 20%. Times to next event were re-
sampled using the changed event rates based on the new age band and the primary 
prevention status. Following the initiation of primary prevention, the time to cardiac events 
were re-sampled in order to take protective effects of statins in consideration.  
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As an illustration, take a 52-year-old individual not assigned for primary prevention at time 0. 
Time to the earliest cardiac event was sampled to be 4 years. As time before reaching the next 
55-64 age band (3 years) is shorter than this, the primary prevention status is reassessed at 
time 3, based on rates for those aged 55-64 years. If the individual is sampled to receive 
primary prevention at time 3, times to all cardiac events are sampled for a population on 
primary prevention aged 55-64 years. Say the sampled time to next cardiac event is 12 years. 
As time to next age band is now 10 years (from 55 to 65 years of age), the change in the age 
band occurs before the next cardiac event, and thus, time to next event is resampled at time 
13 (3+10 years) using rates for a population on primary prevention aged 65-74 years.  Final 
time to cardiac event is the accumulated time passed due to resampling plus time to next 
cardiac event sampled in the last loop without resampling. 
The change to the status of primary prevention could occur only at discrete times when the 
individuals’ age band changes. This was due to the source data reporting the proportions of 
people receiving statins rather than the rate of change to primary prevention. In order to split 
the time before the initiation of the primary prevention therapy and the time after, a separate 
event state was added to the model. Individuals whose primary prevention status was changed 
after model entry were sent to this event, and relevant costs were accrued from the time 
when the primary prevention therapy was initiated. 
However, as more individuals start receiving the primary prevention intervention when moving 
to a next age band and time to event is resampled, the proportions of individuals receiving the 
intervention at model entry reported in Table 5.3 could not be used for people who start 
receiving statins when the age band changes after the initial assignment of the primary 
prevention status on model entry. In order to maintain the percentage of people who receive 
the primary prevention intervention in each age band at the same level as the estimates 
reported in Table 5.3 over time, the proportions of people who are additionally assigned to 
receive primary prevention intervention after model entry were estimated to be the difference 
in the proportions reported in Table 5.3 between consecutive age bands (Table 5.5).  For 
females aged 75 years and over, the proportions of people whose status changes were 
estimated to be negative. However, it was assumed that individuals already receiving statins 
remain on the therapy without further individuals starting the therapy.  
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Table 5.5. Proportions of individuals who start receiving primary prevention when age band 
changes 
Age (years) 45-54 55-64 65-74 75-84 85+ 
Male - 22% 41% 44% 42% 
Female - 3% 7% 0%* 0%* 
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Secondary prevention 
 
On model entry, individuals who are assigned a history of one or more heart disease events 
receive statins for the secondary prevention of the cardiac events. Prevalence rates reported 
in the published literature were used to estimate the proportions of individuals with previous 
heart disease events (Table 5.6). For the prevalence of angina, MI and stroke by age and 
gender, the British Heart Foundation Statistics Database was used (Townsend et al., 2012). The 
published prevalence figures for angina were assumed to include both stable and unstable 
angina with the incidence ratio of unstable to stable angina was used to split the two, as 
reported in Ward et al. (2006). For PAD IC, the prevalence rate reported in Squires et al. (2011) 
was used; it reported two prevalence rates for populations aged 55 years and 74 years only, 
which were assumed for groups aged <70 and >=70 years, respectively. It was assumed that all 
individuals entering the model did not have a previous revascularisation or did not experience 
it within one year. Hence, all patients entered the model without a history of previous 
revascularisation.  Independence was assumed between the prevalence of these events.  
 
Table 5.6. Prevalence of diseases: Initial distribution of event histories for secondary 
prevention 
 MI Stroke Stable 
angina 
Unstable 
angina 
PAD IC 
Men      
45-54 years 0.021 0.012 0.018 0.006 0.02 
55-64 years 0.063 0.03 0.066 0.014 0.02 
65-74 years† 0.144 0.071 0.103 0.039 0.02 
75+     years‡ 0.166 0.131 0.159 0.068 0.07 
Women 
   
 
 
45-54 years 0.007 0.009 0.009 0.003 0.02 
55-64 years 0.016 0.023 0.026 0.006 0.02 
65-74 years† 0.033 0.042 0.060 0.023 0.02 
75+     years‡ 0.091 0.107 0.112 0.047 0.07 
No patients commence with a history of revascularisation; † 65-70 years for PAD; ‡ 70+ years for PAD. 
 
History of multiple diseases is accounted for by applying the event rates from the disease that 
is associated with the shortest average time to the event in question.  Therefore, the 
individuals are subject to the same event rate regardless of the order of the previous events.   
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The algorithms used to find the underlying event rates conditional on previous events or 
primary prevention status are given in Figures 5.2- 5.6. The rates from each event shown as the 
final step in the algorithms will be discussed in Section 5.4.1.  
It was assumed that previous revascularisation does not affect future event rates, apart from 
when the individual did not have any other events previously or the individual is currently at 
the revascularisation state (Figure 5.6).  As a constant rate of transition to PAD was assumed 
regardless of the state from which the individuals make transitions, no algorithms were 
needed to find the maximum risk of having PAD. At model initiation, it was assumed that all 
events had occurred more than 1 year previously and the rates associated with subsequent 
years were used.  
The algorithms were structured so that the highest risk of having the event was selected. The 
risks of having the event in question from all possible events that individuals could previously 
have had were compared. The maximum risk of the event were determined conditional on the 
type and timing (i.e. first or subsequent years) of previous events and the primary prevention 
status of an individual. For example, when an individual is at MI event, the first-year rates of 
the transition to stroke from MI and subsequent year rates from the other events were 
compared (Figure 5.4).  For ease of computation, figures in the third decimal point or lower in 
the event rate values were ignored when finding the maximum event rate. 
A different event rate was applied when the individual was at the MI event due to the high 
probability of having revascularisation within 1 year after MI (Figure 5.6). For the other event 
rates, the event rates derived from the National Audit of Percutaneous Coronary Intervention 
(PCI) covering 2012 data (National Institute for Cardiovascular Outcomes Research, 2013) and 
the total number of people aged 45 years and over in the UK (Office for National Statistics, 
2013c) were used to estimate the national average rates.  
The primary prevention population without history of previous events was given the initially 
assigned risks of MI, angina, and sudden cardiac death (Table 5.4) as they were the minimum 
event rates that could be selected. For comparison with the 10 year CHD risk of 20% and over 
for the primary prevention population, the 10-year risk of having MI or angina for men aged 70 
years in the secondary prevention group was around 70%, 34%, and 20% if they previously had 
MI, PAD, and stable angina, respectively. The corresponding level of risk for no-statin group 
was around 18%. It is noted that as the data sources often included people at increased risk of 
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cardiac events, the baseline event rates used for people not receiving statin treatments may 
be overestimated.  
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Figure 5.2. Algorithms determining the transition rate to MI  
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Figure 5.3. Algorithms determining the transition rate to MI at model initiation 
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Figure 5.4. Algorithms to find the transition rate to stroke 
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Figure 5.5. Algorithms to find the transition rate to angina 
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Figure 5.6. Algorithms to find the transition rate to revascularisation 
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Population for cost projections 
 
Future healthcare costs are projected including both the starting cohort representing the UK 
population in the base year and the new cohorts of 45 year-olds. All costs incurred by all 
relevant cohorts that are simulated to be alive in the model are combined and discounted to 
the base year (2012) to produce the total population-level cost projections.  The 2012-based 
principal projections of the number of 45 year olds in the UK by single year of age and sex were 
previously reported in Table 4.3 in Section 4.3.5. 
 
 
5.3.3. Default treatments assumed 
 
Statins were assumed to be used both for the secondary prevention of CVD events in patients 
with CHD (including angina or MI), PAD, or a history of stroke, and for primary prevention in 
patients who are at increased risk of coronary events.  
Different CVD treatments were assumed for the conditions included in the model (See Section 
5.4.2). Statin therapy is recommended for primary and secondary prevention: primary care 
and statin costs were assumed for both populations. For those having a revascularisation, it 
was assumed that 45% of the procedures were coronary bypass grafting surgery (CABG) and 55% 
percutaneous transluminal coronary angioplasty (PTCA) (Taylor et al., 2009). 
All patients with angina were assumed to be receiving sotalol treatments with a half of them 
receiving aspirins as well (Juul-Moller et al., 1992). Only the standard care assumed in Kearns 
et al. (2013) was used as the base-case treatment for people with PAD. No use of endovascular 
therapies such as PTCA was assumed for these patients.  
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5.4. Parameters & Data sources 
 
 
5.4.1. Event Rates  
 
 
This section describes the event rates used for the base-case model. The data sources were 
identified from the six UK-based studies included in the review in Section 5.2 (Ward et al., 
2006, Grosso et al., 2011, Taylor et al., 2009, De Smedt et al., 2012, Lindgren et al., 2009, Ara 
et al., 2009). The most appropriate parameter estimates reported for similar populations and 
contexts in the six studies and their sources of data were used for the model in this research. 
The baseline risks for individuals not receiving statin treatments were obtained. However, if 
data were identified from sources that did not specify the use of statins such as disease 
register, the baseline rates could include people receiving statins and those not on statins. UK-
sourced data were used wherever possible, and age-dependent time-variant rates of 
transitions between health events were preferred. Where the parameters reported in the 
modelling studies and the original sources differed due to the transformation of the reported 
values into the format that can be used in their model or the estimation of multiple age-
variant values from a single estimate reported for the whole study population, those used in 
the modelling studies were used for the ease of use.  
Baseline event rates used for the base-case model are summarised in Tables 5.7-5.12. The 
relative risks associated with statin use were applied to the baseline event rates to estimate 
time to events for patient groups receiving the treatment.  
As described in the previous section, all included disease states except PAD (MI, stroke, angina, 
and revascularisation) were split into two temporal categories – first year and subsequent 
years after the event – due to the difference in the rates for transitions to other events, costs, 
and/or utility weights between the first year of the event and thereafter.  
Various sources for cardiac death rates were used dependent on the ‘from’ state of the 
transition (See Table 5.2). The rate of transition to cardiac death varied with the age group and 
the temporal period (first year or subsequent years after the event), and time to cardiac death 
was sampled from an exponential distribution using the appropriate rate.  
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The event rates used in the model are summarised in the next sections by the origin of 
transitions, with each section followed by a summary table of the estimates (Tables 5.7-5.12). 
In addition, rates of transitions to fatal stroke and PAD were described in separate sections as 
they applied regardless of the origin of transitions.  
 
Transitions from Event-free state (at model initiation) 
 
Event rates differed depending on whether an individual is on primary or secondary 
prevention interventions, or is untreated. Rates of transitions from the event-free state are 
summarised in Table 5.7.  
For secondary prevention population with a history of one or more previous cardiac events, 
the underlying event rate was identified using the algorithms in Section 5.3 and time to next 
event was sampled from this exponential distribution. At model initiation, only the 
subsequent-year transition rates, not the higher first-year rates, were used, assuming that 
their latest previous event occurred earlier than one year before the model initiation 
(individuals were not experiencing any of the included cardiac events when they entered the 
model).  
Primary prevention population were assigned the 10-year CHD risks of 20% as reported in 
Table 5.4. For other events that were not included in the CHD risks (MI, angina, and sudden 
cardiac death), events rates for population receiving no preventative interventions were used.  
Initial events rates for those on neither primary nor secondary prevention interventions were 
obtained from published literature that reported rates of first-ever CVD events. Rates for 
transitions to initial non-fatal MI for male population were taken from the West Of Scotland 
Coronary Prevention Study (WOSCOPS) by converting the five year probability of MI reported 
for placebo group (7.8%) to an event rate (Shepherd et al., 1995). Although WOSCOPS typically 
included middle-aged males (mean age 55.1 and 55.3 years for the placebo and pravastatin 
arms, respectively, with the standard deviation of 5.5 years for both arms), it was preferred to 
the Framingham Heart Study as a number of studies suggested that the Framingham study 
may overestimate the MI rate (Hense et al., 2003, Marrugat et al., 2003). However, in order to 
estimate the rates of non-fatal MI in women, the combination of WOSCOPS and the 
Framingham heart study results was used by applying the ratio of MI rate for women to that 
for men from the Framingham heart study to the rate for men obtained from WOSCOPS study 
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(D’Agostino et al., 2008). MI was assumed to not be immediately fatal, but having an MI 
increased the risk of cardiac death as the data did not specify the cause of death. 
Initial rates for fatal and non-fatal stroke, angina, and cardiac death were derived from the 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) trial results (Lindgren et al., 2009) as their 
statistical analyses incorporated only the first ever events. The exponential regression 
equations were estimated using the trial results based on a simple set of covariates – age at 
event and sex. These equations were inserted in the model for the rates of transitions to 
stroke, revascularisation, and cardiac death. The equation for revascularisation rate was not 
used for people not receiving preventative interventions, as the trial involved high-risk people 
with hypertension and reported a disproportionately high number of revascularisation 
procedures in comparison with the number of revascularisation currently being performed in 
the UK. For those not receiving primary or secondary prevention, the national average rate of 
revascularisation was used. It was assumed that only primary prevention population – but not 
secondary, as they follow the underlying event rates algorithms – can receive the procedure. 
The proportion of stroke being fatal was estimated from the logistic regression results 
reported in the ASCOT study results.  Angina event rates were obtained from the ASCOT-LLA 
(Lipid Lowering Arm) data (Sever et al., 2003). This rate was assumed to be independent of the 
age and gender of the individuals as the data did not specify the number of events by age and 
gender. 
Due to paucity of data, transitions to PAD were estimated from the Edinburgh Artery Study 
data (Leng et al., 1996) on the incidence of ischaemic claudication (IC) among the general 
population. 
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Table 5.7. Baseline annual rates of transition from event-free state 
Baseline rates for individuals not receiving statin treatment 
From To Estimates Sources 
Event free MI Rate for men = 0.01624; Rate for 
women = 0.01123 
 
WOSCOPS 
(Shepherd et al. 
1995) and 
Framingham 
studies 
(D’Agostino et al. 
2008) 
 Stroke Exponential mean of Exp(9.218 + 
(-0.064)*age at event + (-
0.176)*gender) for time to event 
distribution 𝑇~𝐸𝑥𝑝(?̂?). Then, the 
prob of stroke being fatal applied. 
P(fatal stroke)=e^xb/[1+e^xb] 
where xb= -4.874 + 0.043*age – 
0.074*gender.   
ASCOT trial 
(Table 2. Lindgren 
et al. 2009) 
 Angina Rate = 0.0027 per patient-year.  
 
ASCOT-LLA data 
(Sever et al., 
2003)  
 Revascularisation For only primary and secondary 
prevention populations,  
Exponential mean of Exp(5.250 + 
(-0.013)*age at event + 
(0.479)*gender) for time to event 
distribution 𝑇~𝐸𝑥𝑝(?̂?).  
Otherwise, the national average 
rate of revascularisation was used.  
ASCOT trial 
(Lindgren et al., 
2009) 
 
National Audit of 
PCI (National 
Institute for 
Cardiovascular 
Outcomes 
Research, 2013) 
 PAD Rate= 0.021149= the incidence of 
PAD with intermittent 
claudication. 
 
Edinburgh Artery 
Study (Leng et al., 
1996) 
 CVD death For individuals not receiving any 
interventions,  
Males (females): 45-54 years 
0.000639 (0.000178); 55-64 years 
0.001711 (0.000573); 65-74 years 
0.004275 (0.001994); 75-84 years 
0.013182 (0.008621); 85 years and 
over 0.040947 (0.035576). 
 
For only primary and secondary 
prevention populations,  
Exponential mean of Exp(6.576 + 
(-0.035)*age at event + 
(0.437)*gender) for time to event 
distribution 𝑇~𝐸𝑥𝑝(?̂?). 
Mortality 
Statistics: Deaths 
registered in 
2012 (Office for 
National 
Statistics, 2013a) 
 
ASCOT trial 
(Lindgren et al., 
2009) 
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Transitions from MI 
 
Transition rates for patients in the MI state for progression to a second MI, stroke, and cardiac 
death were taken from the data used for the NICE technology assessment report (Ward et al., 
2006) (Table 5.8). The original data were derived from the Nottingham Heart Attack Register 
(NHAR). Annual probabilities reported in Ward et al. (2006) by age were converted to rates 
using an equation 𝑟 = −
1
𝑡
ln(1 − 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦) assuming a constant rate 𝑟 per time unit 𝑡 
(Fleurence and Hollenbeak, 2007). Data reported in Ara et al. (2009) were also based on the 
NHAR study, but were slightly different. However, the estimates reported in Ward et al. (2006) 
were used in the model as they covered wider age groups based on regression analyses. 
Time to next event values were sampled from a distribution with an appropriate rate by 
repeatedly checking whether a sampled time-to-event value passed any of the future time 
points sectioning the first and subsequent years after MI or the age bands (age groups: Group 
1 < 55 years; Group 2 55-65 years; Group 3. 65-75 years; Group 4. 75-85 years; Group 5. >85 
years) and updating the rate accordingly (for further explanation, see Section 4.1).  
Rates to angina and revascularisation from the MI event were estimated by converting the 
probabilities reported in individual trial results (Fox et al., 2005, Taylor et al., 2009) as Ward et 
al. (2006)’s model did not include these transitions. Both of the rates were assumed constant 
across all age groups as the data did not report age-dependent rates. It was assumed that the 
patient could receive revascularisation only within one year after MI as the data reported only 
the first year rate, i.e. if the sampled time to revascularisation was greater than 1 year, then it 
was assumed not to occur.  
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Table 5.8. Baseline annual rates of transitions from myocardial infarction 
Baseline rates for individuals not receiving statin treatment 
From To Estimate Sources 
MI  MI For age groups 1-5: First 
(subsequent) year(s) rates:  
0.13697 (0.01633),   
0.12239 (0.01806), 0.10747 
(0.01867), 0.09146 (0.0180), 
0.07375 (0.01613). 
 
NICE TA94 Table 
52 (NICE, 2006); 
Nottingham 
Heart Attack 
Register (NHAR). 
 
 
 Stroke For age groups 1-5: First 
(subsequent) year(s) rates:  
Group 1 (< 55): 0.00150 (0.0004),   
Group 2 (55-65): 0.00321 
(0.00100),  
Group 3 (65-75): 0.00682 
(0.00220),  
Group 4 (75-85): 0.01420 
(0.00471),  
Group 5 (> 85): 0.02819 (0.00914). 
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR);  
 
 
 Angina Exponential rate =  0.05975 
 
Ara et al. 2009. 
Table 8. (Fox et 
al. 2005) 
 Revascularisation First year rate = 0.504347 
 
TNT trial 
(Taylor et al., 
2009) 
 PAD Rate= 0.021149= the incidence of 
PAD with intermittent 
claudication. 
 
Edinburgh Artery 
Study (Leng et al. 
1996) 
 CVD death For age groups 1-5: First 
(subsequent) year(s) rates:  
Group 1 (< 55): 0.01755 (0.00541),   
Group 2 (55-65): 0.03387 
(0.00955), Group 3 (65-75): 
0.06465 (0.01603), Group 4 (75-
85): 0.12059 (0.02482), Group 5 (> 
85): 0.21791 (0.03615). 
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR). 
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Transitions from Stroke  
 
The baseline rates of transitions from stroke are summarised in Table 5.9. 
The same rates of having an MI after stroke were assumed for the first and subsequent year(s), 
as in Ward et al. (2006). Transition rates by age group were applied using the same technique 
of sampling and re-sampling the time to next event values whilst comparing the sample value 
with the time to next age band, as used for transitions from MI.  
Data for stroke recurrence rates (transitions from stroke to another stroke) were obtained 
from the South London Stroke Register (SLSR) (Mohan et al., 2009). Although data reported in 
Ward et al. (2006) and Ara et al. (2009) were also based on the same SLSR study, the source 
paper was used to differentiate the event rates by further patient characteristics. Baseline 
probabilities reported in the study were converted to 0-1, 1-5 and 5+ year rates of transitions, 
and hazard ratios reported for people with a history of previous MI and in different age groups 
(<65 years, 65-74 years, >75 years) were applied to the baseline rates.  
The rate of transition from stroke to angina was assumed to be the same as the rate of 
transition from the event-free state to angina. This was different from the rate used in Ward et 
al. (2006) where no transition to angina was assumed from the stroke state as it was 
considered unrealistic. A constant revascularisation rate taken from the UK average rate of 
revascularisation was used due to lack of age-specific data as for the transition from MI, 
assuming all revascularisation procedures were performed for people aged 45 and over.   
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Table 5.9. Baseline annual rates of transitions from Stroke 
Baseline rates for individuals not receiving statin treatment 
From To Estimate Sources 
Stroke  MI Rates by age group:  
Group 1 (< 55): 0.00160, 
Group 2 (55-65): 0.00310, 
Group 3 (65-75): 0.00552, 
Group 4 (75-85): 0.00803, 
Group 5 (> 85): 0.01045. 
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR). 
 Stroke 
(Stroke 
recurrence) 
Baseline rates for 0-1, 1-5, 5-10 
years for individuals aged <65: 
0-1 year rate= 0.06401 (mean = 
15.6237); 1-5 year rate= 0.02694; 
5-10 year rate= 0.01887. 
Then, probability of stroke being 
fatal= e^xb/[1+e^xb], where 
xb= -4.874 + 0.043*age – 
0.074*gender, was applied.  
Mohan et al. 
2009 – Stroke 
recurrence; 
ASCOT trial 
(Lindgren et al. 
2009)  
 
 Angina Rate = 0.0027 Assumed the 
same as the rate 
of transition 
from event free 
to angina state 
(NICE TA 94 
Table 52)  
 Revascularisation Rate= 0.01056 
 
TNT trial (Taylor 
et al. 2009) 
 PAD Rate= 0.021149= the incidence of 
PAD with intermittent 
claudication. 
 
Edinburgh Artery 
Study (Leng et al. 
1996) 
 CVD death For age groups 1-5: First 
(subsequent) year(s) rates:  
Group 1 (< 55): 0.00924 
(0.00421),   
Group 2 (55-65): 0.02245 
(0.00985),  
Group 3 (65-75): 0.05340 
(0.02102),  
Group 4 (75-85): 0.12466 
(0.04207),  
Group 5 (> 85): 0.27839 
(0.07796). 
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR). 
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Transitions to Fatal Stroke 
 
If the reported data did not explicitly state that the event probabilities were for non-fatal 
stroke only, then a proportion of the patients who experience a stroke was assumed to die due 
to the stroke. Thus, the transitions to stroke from event free, stroke, angina and 
revascularisation states included a subset of patients having a fatal event and subsequently 
moving to cardiac death state. The proportion of fatal stroke among all stroke events was 
estimated using the logistic regression equation reported in the ASCOT trial results (Lindgren 
et al., 2009) with an exception of transitions from revascularisation state where a 50% 
probability of stroke being fatal was assumed as in Ara et al. (2009).  
 
 
Transitions from Angina 
 
Rates of transitions from angina are given in Table 5.10. Individuals were assumed to have 
stable angina first and then progress to unstable angina, which requires more intense medical 
treatments. Once unstable angina was developed, it was assumed that patients cannot 
improve to stable angina.  
Different event rates from angina state were applied depending on whether the patient has 
stable angina or unstable angina. Data for the transitions from stable angina to other events 
were obtained from the Swedish Angina Pectoris Aspirin Trial (SAPAT) (Juul-Moller et al., 1992), 
as this was the only study that included a population without history of MI or unstable angina 
in a Medline search conducted by Ward et al. (2006). Constant event rates for transitions from 
stable angina to MI and stroke were assumed as the trial data did not report the event rates by 
patient characteristics. The proportion of angina patients who experienced a relevant event 
over the median follow-up of 50 months was converted to a constant rate in the model for this 
thesis. As the SAPAT study aggregated both non-fatal and fatal stroke, the logistic regression 
equation from the ASCOT trial was used to calculate the probability of a stroke being fatal 
based on the patient’s age and gender. The rates of progressing to unstable angina from stable 
angina were obtained from the study by Ward et al. (2006). The rate of transition to 
revascularisation was assumed the same as that from the event-free state.  
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Estimates for the rates of transitions from unstable angina were obtained from the NICE TA 
report (Ward et al. 2006) where the major sources of data were the NHAR (Gray and Hampton, 
1993) and the SLSR study (Addo et al., 2011, Mohan et al., 2009, Wolfe et al., 2002).  
178 
 
Table 5.10. Baseline annual rates of transitions from angina 
Baseline rates for individuals not receiving statin treatment 
From To Estimates Sources 
Angina MI 1) From Stable angina: Rate = 0.01520; 
2) Unstable angina 
5%, 4.9%, 4.7%, 4.3% from 1st year 
event. 
3.5%, 6.3%, 11.2%, 18.5% from 
subsequent yrs event for those aged 
<55, 55-65, 65-75, 75-85 yrs, 
respectively.  
Juul-Moller et al. 
(1992);  
Ara et al. (2009), 
Table 8; Gray and 
Hampton (1993) 
 Stroke 1) From Stable angina:  
Rate = 0.00791; Then, the prob of stroke 
being fatal applied, probability = 
e^xb/[1+e^xb], where xb= -4.874 + 
0.043*age – 0.074*gender.  
 
2) From Unstable angina: For age groups 
of <65, <75, <85, >85 years, 
[1st year rate] To non-fatal stroke: 0.2%, 
0.5%, 1%, 2%; To fatal stroke: 2.6%, 
4.3%, 7%, 10.3%;  
[subsequent yrs rate] To non-fatal 
stroke: 0.1%, 0.1%, 0.3%, 0.7%;  Fatal 
stroke: 0.4%, 0.5%, 0.6%, 0.7%. 
1) Juul-Moller et 
al. (1992); NICE 
(2006); Lindgren 
et al. (2009) 
 
2) Ara et al. 2009 
(HTA) Table 8.; 
Gray and 
Hampton (1993) 
 Angina 
(unstable) 
Annual probability from stable angina to 
unstable angina:  
Group 1 (< 55): 0.0013, 
Group 2 (55-65): 0.0029, 
Group 3 (65-75): 0.0060, 
Group 4 (75-85): 0.0091,  
Group 5 (> 85): 0.0122.  
NICE TA 94: Table 
52.  
 Revascularis
ation 
Rate=0.00269 Assumed the same 
as the minimum 
revascularisation 
rate from PAD 
state. (Leng et al. 
1996) 
 PAD Rate= 0.021149= the incidence of PAD 
with intermittent claudication. 
 
Edinburgh Artery 
Study (Leng et al. 
1996) 
 CVD death 1) If no history of angina=  
Group 1 (< 55): 0.009,  
Group 2 (55-65): 0.0035,  
Group 3 (65-75): 0.007,  
Group 4 (75-85): 0.007,  
Group 5 (> 85): 0.007.   
2) From unstable angina = (CHD and CVD 
death rates combined for 1st and 
subsequent years. 
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR). 
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Transitions from Revascularisation 
 
Sources of data on rates for all transitions from the revascularisation state to all non-fatal 
events and cardiac death were identified from Ara et al. (2009) (Table 5.11). Constant event 
rates were assumed, and the estimates were obtained from the RITA-2 and RITA-3 trial data 
(Henderson et al., 2003, Fox et al., 2005). The probability of stroke being fatal was taken to be 
50% as assumed in Ara et al. (2009). As the trial data reported only the first year probability of 
having another revascularisation operation after the first, it was assumed that a 
revascularisation procedure could be repeated only within one year (Taylor et al., 2009).  
 
Table 5.11. Baseline annual rates of transitions from revascularisation 
Individuals not receiving statin treatment 
From State To State Estimate Sources 
Revascularisation MI Rate= 0.03874 Fox et al. 
(2005); Ara et 
al. (2009) 
 Stroke Rate=0.002 with 50% of stroke 
being assumed to be fatal.  
Henderson et 
al. (2003); Ara 
et al. (2009) 
 Angina Rate = 0.032523 
 
Henderson et 
al. (2003); Ara 
et al. (2009) 
 Revascularisation First-year rate  of having a 2nd 
revascularisation= 0.14491 
TNT trial 
(Taylor et al. 
2009)  
 PAD Rate= 0.021149= the incidence 
of PAD with intermittent 
claudication. 
 
Edinburgh 
Artery Study 
(Leng et al. 
1996) 
 CVD death Rate = 0.005785 RITA-2 trial 
(Henderson et 
al., 2003) 
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Transitions from PAD 
 
Table 5.12 summarises the baseline rates of transitions from PAD used in the model for this 
thesis. A population of patients with IC, which is the most common symptom of PAD, and CLI, a 
more severe symptom, was considered for modelling. No distinction between the first and 
subsequent years after PAD was made as the main data source did not distinguish the two 
time periods with regards to the transitions to other cardiovascular events. 
PAD was modelled in a simplified manner. The model included only IC and CLI, and their drug 
treatment costs. Only one transition to PAD was allowed, and once patients experienced PAD, 
they were assumed to have it for the rest of their lives and could not have a second PAD event. 
Only symptomatic PAD which requires medical treatments was considered in the model.  
Transition rates from PAD to other non-fatal CVD events were obtained from the Edinburgh 
Artery Study (Leng et al., 1995, Leng et al., 1996). Event rates were converted from the 
proportion of people who experienced the event over the five year follow up, and constant 
rates over time were assumed as the data reported only the total numbers of events. The 
same age-specific cardiac mortality rate as that for people without history of CVD events was 
used due to lack of data, thus assuming no influence of PAD on mortality.  
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Table 5.12. Baseline rates of transitions from peripheral arterial disease 
Baseline rates for individuals not receiving statin treatment 
From To Estimate Sources 
PAD MI Rate = 0.01711 Edinburgh 
Artery Study 
(Leng et al. 
1996) 
 Stroke Rate= 0.01408  Edinburgh 
Artery Study 
(Leng et al. 
1996) 
 Angina Rate= 0.02019 Edinburgh 
Artery Study 
(Leng et al. 
1996) 
 Revascularisation  Rate=0.00269 Edinburgh 
Artery Study 
(Leng et al. 
1996) 
 PAD Rate=0 Assumed 
 CVD death Exponential mean of Exp(6.576 
+ (-0.035)*age at event + 
(0.437)*gender) for time to 
event distribution 𝑇~𝐸𝑥𝑝(?̂?). 
The same rate 
as the transition 
from event free 
to CVD death: 
ASCOT trial 
(Lindgren et al. 
2009) 
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Transitions to PAD 
 
New cases of PAD with IC in the Edinburgh Artery Study were used for the estimation of 
transition rates to PAD. The annual incidence of IC is difficult to measure as the methods for 
identifying IC do not always detect the presence or absence of PAD and a large proportion of 
people with IC are left undetected (Norgren et al., 2007). The incidence of symptomatic PAD in 
general population aged 55 and over was used for all transitions to PAD event from other 
disease states due to the lack of published evidence (Leng et al., 1996). Age dependent 
incidence was not included as it was not statistically significant in the Edinburgh Artery Study 
(Leng et al., 1996). However, there was some evidence of an increase with age in earlier 
longitudinal studies (Kannel and McGee, 1985, Widmer et al., 1985).   
Among patients with IC, approximately 20% progress to develop severe symptoms with CLI 
over a 5-year period and 1-2% undergo amputation over a lifetime (National Clinical Guideline 
Centre, 2012). In the model for this thesis, 20% of people with IC were randomly sampled to 
develop CLI at the time of developing PAD for simplicity.  
 
 
Effectiveness of statin treatments 
 
Statin treatments was assumed to reduce the risks of coronary events (MI, angina, and fatal 
CHD events) and stroke. As described in earlier sections, the model assumes that a proportion 
of individuals entering the model are receiving a statin treatment for primary and secondary 
prevention of CVD events. 
The relative risks (RRs) of events associated with statin use were applied to the baseline risks 
converted from the event rates reported in Tables 5.7-5.12 (transition rates), and are shown in 
Table 5.13.   
The estimates of RRs reported in the assessment report for NICE TA94 were used for MI, 
angina and cardiac death events (Ward et al., 2006). Ward et al. (2006) used the same RRs for 
primary and secondary prevention populations for the events included in this study as there 
was no significant difference in their meta-analyses between the effectiveness of statins in 
primary and secondary prevention. Although the base-case model in Ward et al. (2006) 
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assumed no impact of statin treatment on the probabilities of stroke, the RR estimates for 
simvastatin 40mg per day reported in the study by Ara et al. (2009) were used for all 
transitions to stroke in this study. Both Ward et al. (2006) and Ara et al. (2009) conducted 
meta-analyses of placebo-controlled studies to derive the RRs. These values incorporate the 
relationship between the reductions in LDL (low-density lipoproteins) cholesterol level and the 
risks of events to estimate the RRs associated with statin therapies at different doses.  
 
Table 5.13. Relative risks associated with statin use compared with placebo 
Transitions to Relative Risk Source 
MI 0.656 Ward et al. (2006) (NICE TA94) 
Non fatal stroke 0.754 Ara et al. (2009): Simvastatin 
40mg/day 
Fatal stroke (from Angina 
state) 
0.876 Ara et al. (2009): Simvastatin 
40mg/day 
Stable Angina (from event free 
state) 
0.59 Ward et al. (2006) (NICE TA94) 
To Fatal CHD event (CVD 
death) 
0.74 Ward et al. (2006) (NICE TA94) 
Non CVD death (from event 
free state) 
0.656 Ward et al. (2006) (NICE TA94) 
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Non-disease mortality 
 
Non-cardiac mortality rates used to construct distribution profiles for time to non-disease 
death were calculated by subtracting cardiac mortality rates from the all-cause death 
probability profiles presented in Section 4.3.6. Cardiac mortality rates were estimated by 
combining the rates reported for heart disease (ICD-10 code I00-I52) and stroke (I64) using 
data obtained from the Mortality Statistics: Deaths registered in 2012 (Office for National 
Statistics, 2013a). Cardiac mortality rates used to calculate the non-disease mortality are 
shown in Table 5.14. These were the same rates used for transitions to cardiac death from 
event-free state. 
Figure 5.7 shows distributions for time to non-cardiac death for a few selected age groups. As 
the cardiac death rates were constant across the 10-year age bands whilst the all-cause 
mortality rates were specified at every age 𝑥 between 45 and 100 years, the probability 
profiles created were not smooth, but had a few stepped decreases at the age cut off values.  
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Table 5.14. Cardiac death rates used to estimate non-cardiac mortality rates* 
 Age group 
Sex 45-54 55-64 65-74 75-84 85 and 
over 
Male 0.000639 0.001711 0.004275 0.013182 0.040947 
Female 0.000178 0.000573 0.001994 0.008621 0.035576 
*Adapted from Table 8 in Deaths registered in England and Wales, 2012 (Office for National 
Statistics, 2013a) 
 
 
Figure 5.7. Illustration of distributions for time to non-cardiac death 
Male aged 45 years Male aged 55 years 
  
Male 65 years Male 75 years 
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5.4.2. Costs 
 
The same cost estimates as used in the HTA report by Ara et al. (2009) and the NICE TA report 
(NICE TA94, 2006) were used (Table 5.15). Where the cost data were not available in these 
studies, individual clinical studies cited as the source of data in the existing models reviewed in 
Section 5.2 were searched. All cost estimates were inflated to the year 2011/2012 using the 
HCHS index (Curtis, 2013). 
Different costs for first year and subsequent years after the event occurrence were applied 
except for angina and PAD where the first year and subsequent year costs were assumed to be 
the same. The first year costs for MI, stroke, unstable angina, and revascularisation included 
hospitalisation costs. The cost of a revascularisation procedure was assumed to occur in the 
first year, and no on-going treatment costs were assigned.  
As described in Section 4.4.2, costs were additive – if the patient had already experienced MI 
prior to having a stroke, then both the subsequent-year cost of MI and stroke were incurred. If 
a current stroke patient had a previous stroke, then only the first year cost of the current 
stroke was added in order to avoid double counting.  
The cost of statin treatments was estimated using the method described in the Technology 
Assessment Report for NICE TA guidance by Ward et al. (2006).  All statins in current use were 
evaluated collectively: the weighted annual cost of statins based on the current prescribing 
patterns in the UK for a variety of statins was estimated using the number of prescriptions of 
each statin at each dose level reported in Ward et al. (2006) and the list price of different 
statins from BNF 2014 (Joint Formulary Committee, 2014). There was a mismatch between the 
drug price year (2014) and the base year for the model (2012) due to the unavailability of BNF 
data. Generic products of pravastatin and fluvastatin have become available since Ward et al. 
(2006) was published. Hence, the same ratio of branded to generic use of simvastatin was 
applied to pravastatin and fluvastatin when calculating the weighted annual cost of these 
statins. The annual cost of statin was estimated at £144.12, which was lower than £273 
reported in Ward et al. (2006) due to the availability of new generic drugs and the prices of 
other statins remaining approximately the same.  
For PAD, conservative estimates of costs were used. The monthly drug treatment costs for 
patients with IC and CLI reported in Kearns et al. (2013) were used to calculate the annual cost. 
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The costs of CLI and amputation were averaged assuming a proportion (2%) of patients with 
CLI will undergo an amputation surgery (National Clinical Guideline Centre, 2012).   
 
Table 5.15. Cost estimates used in the base-case model 
Event Data within 
source 
Price year Estimates  
(2011/2012 price) 
Original Source 
MI - 1st year £3,996 2007  £  4,519.10  Ara et al. (2009) 
estimated using 
British National 
Formulary (2008) 
MI - subsequent 
year 
£171 2004  £  214.89  NICE TA 94 (GP 
contacts + 
medication costs) 
Stroke - 1st year £8,066 2007  £ 9,121.88  Ward et al. (2006) 
Stroke - 
subsequent yr 
£2,266 2007  £ 2,562.63  Ward et al. (2006) 
Stable angina £171 2004  £ 214.89  NICE TA 94 (GP 
contacts + 
medication costs) 
Documented 
angina 
 £     587.07  2005  £ 713.94  Taylor et al. (2009) 
Revascularisation 
- 1st yr 
 £  5,857  2007  £ 6,623.71  Taylor et al. (2009); 
HRG 
PAD (IC) £180 2009-
2010 
£189.31 Kearns et al. (2013) 
PAD (CLI) £624 2009-
2010 
£656.29 Kearns et al. (2013) 
Statin treatment £144.12 2014 £144.12 British National 
Formulary (2014); 
Estimated using the 
method by Ward et 
al. (2006) 
 
 
5.4.3. Utilities 
 
Baseline utility values by age and gender were given in Chapter 4. 
The utility values associated with the health states included in the model were obtained from 
the NICE TA94 and the HTA report by Ara et al. (2009). Table 5.16 describes the original 
sources of these values. All the utilities were estimated using the EQ-5D, and were assumed to 
be multiplicative. Utility multiplier values were assumed to increase by 10% after the first year 
of the event as assumed in Ara et al. (2009). It was assumed that the history of 
188 
 
revascularisation procedure did not affect the utility level, and the utility decrement for stable 
angina was used for individuals with history of angina. As a base-case, deterministic values for 
utility multipliers were used. 
Alongside the current event, the history of the other health events was incorporated in the 
utility multiplier. For example, if a man aged 65 years who has just had a stroke has a history of 
MI, then the utility decrements for both stroke (first year multiplier for stroke: 0.629) and that 
for MI (subsequent-year multiplier: 0.836) were applied to the baseline utility (0.815: see Table 
4.3); the utility weight for this person is thus 0.429 (i.e. 0.815*0.629*0.836).  
When more than one cardiac event occurs within one year, the first-year periods of those 
events overlap. For the time periods overlapping, utility multipliers associated with the events 
were applied multiplicatively. For instance, if an individual experiences an MI at time=2.3 years 
and subsequently a stroke at time=2.7 years, then for time between 2.3 and 2.7 years, only the 
utility multiplier for the first year of MI would be applied (0.760) whilst for time between 2.7 
and 3.3 years, utility multipliers associated with both first-year MI and first-year stroke would 
be applied (0.760*0.629=0.478). In the same way, for time between 3.3 and 3.7 years, utilities 
associated with subsequent years of MI and first year of stroke are used (0.836*0.629=0.526) 
In the model for this thesis, whenever individuals reach these time points, they are directed to 
the ‘utility cut off point’ event in order to update variables related to utility multiplier.  
 
 
Table 5.16. Utility multipliers by health state  
State First year - 
Mean (S.E.) 
Subsequent years -  Original Sources 
MI 0.760 (0.018) 0.836 (10% 
increase)  
Goodacre et al. (2004) 
Stroke  0.629 (0.04) 0.692 (10% 
increase) 
Tengs and Lin (2003) 
(Stable) angina  0.808 0.889 (10% 
increase) 
Melsop et al. (2003) 
Unstable angina  0.77 0.847 (10% 
increase) 
Goodacre et al. (2004) 
Revascularisation 0.78 0.858 (10% 
increase) 
Serruys et al. (2001) 
PAD IC 0.70 0.70 Kearns et al. (2013) 
PAD CLI 0.35 0.35 Kearns et al. (2013) 
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5.5. Results  
 
5.5.1. Base-case results 
 
In order to identify the appropriate number of simulated individuals to ensure stable results, 
first-order uncertainty was examined. This uncertainty is associated with the random 
variability of stochastic outcomes between simulated observations, and can be decreased by 
increasing the number of simulated observations as it is not due to intrinsic uncertainty around 
parameters or the model structure.   
First-order uncertainty around the main outcomes – cost and QALY outcomes with a default 
treatment – are reported in Figure 5.8 (a)-(b) with incremental cost and QALYs shown in Figure 
5.8 (c)-(e), comparing results from the base-case model where individuals in the primary or 
secondary prevention received statins and the model where statin was not used.  Each figure 
includes error bars to show the standard error in the mean estimates of (incremental) cost and 
QALYs, and showed the mean and jackknife confidence interval for the cost per QALY gained 
(Figure 5.8 (e)). The jackknife approach was used to estimate a confidence interval for the 
mean cost per QALY with a reduced level of bias associated with the classical estimation of 
non-linear statistics (Iglehart, 1975, NICE Decision Support Unit, 2014). The results in Figure 5.8 
were reported only for the age 45 years and over population who entered the model in the 
base year of 2012. 
The cost and QALYs with statin treatments stabilised when the number of simulated 
individuals was greater than 20,000. Uncertainty around the incremental costs and QALYs, and 
the cost per QALY comparing the statin and no-statin scenarios significantly decreased after 
50,000 individual runs. The mean (discounted) cost per QALY gained with 200,000 simulated 
individuals was £1,927 and the 95% jackknife confidence interval was £1,582-£2,261. Based on 
the results in Figure 5.8 and given the short time spent on extra individual runs, the chosen 
number of individuals to be simulated was 200,000.   
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Figure 5.8. First order uncertainty in relation to the number of patients simulated 
a) Cost with statin treatment  
Undiscounted 
 
Discounted 
 
b) QALYs with statin treatment  
Undiscounted 
 
Discounted 
 
c) Incremental cost of statin therapy compared with no therapy (discounted) 
Undiscounted 
 
Discounted 
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d) Incremental QALYs of statin therapy compared with no therapy (discounted) 
Undiscounted 
 
Discounted 
 
e) Cost per QALY gained – statin therapy vs. no statin therapy (jack-knife C.I.) 
Undiscounted 
 
Discounted 
 
*The mean results and uncertainty with 100, 500, 1000, 5000, 10000, 20,000, 50,000, 70,000, 
90,000, 100,000, 150,000, and 200,000 simulated individuals were examined. 
 
 
Table 5.17 shows the lifetime costs and QALYs per person in the base-case model using 
200,000 simulated individuals. The base-case model population (UK population aged 45 years 
and older) consists of individuals receiving statins for the secondary prevention of CVD, those 
receiving statins for primary prevention, and those who are not given statins. The primary 
prevention population was assumed to have a 10-year CHD risk of 20% for all age groups as 
previously described, and secondary was dependent on patient characteristics.   
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The lifetime cost accrued by an individual in the base-case population was £8,091 (£14,224 
when undiscounted) with 9.249 (13.843 when undiscounted) QALYs gained.  Results for the 
future incoming cohorts of males and females aged 45 years showed higher costs and QALYs 
than the base-case population due to the increased life years lived.  
 
Table 5.17. Base-case population results (with the default statin therapy) 
With statin 
therapy 
Cost Discounted 
Cost 
QALYs Discounted 
QALYs 
Life years 
Base-case 
population 
£ 14,224 £ 8,091 13.843 9.249 21.319 
  Men aged 
45 years 
£ 21,138 £ 9,979 21.908 13.342 32.469 
  Women 
aged 45 
years 
£ 22,823 £ 9,972 23.155 13.667 35.453 
Based on n=200,000 simulated patients; 2012 prices 
 
 
Cost per QALY gained for the statin treatment compared to no statin treatment was £1,927 
(£1,754 per QALY using undiscounted values) (Table 5.18). This mean ICER was generally lower 
than those reported in other studies: In NICE TA94, the ICERs for the use of statin treatment in 
secondary prevention using discounted costs and QALY values ranged from £10,000 to £16,700 
per QALY gained. For primary prevention, the report estimated discounted cost per QALYs to 
range from £9,000 to £21,000 for males at aged 45 years and £14,000 to £30,000 for females. 
The ICERs increased to over £100,000 per QALY gained at aged 85. The study by Ara et al. 
(2009) compared different doses of statin treatment instead of statin treatments vs. no statin, 
and reported costs per QALY from £5,300 to £60,000 for various statin regimes and scenarios.  
However, it is noted that the cost per QALY estimates from the model for this thesis are not 
directly comparable with the results from the published studies mentioned above which 
focussed on specific patient populations as opposed to the general population (including those 
on primary and secondary prevention therapies modelled in this thesis).  More detailed results 
for primary and secondary prevention populations are reported in next sections. 
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Table 5.18. Base-case result per person based on n= 200,000 simulated individuals 
 Undiscounted Discounted 
 Statin therapy No statin Statin therapy No statin  
Cost £ 14,224 £ 13,197 £ 8,091 £ 7,569 
QALYs 13.843 13.257 9.249 8.978 
Incremental 
Cost 
£ 1,027  £ 522  
Incremental 
QALYs 
0.586  0.271  
ICER (£/QALY) £ 1,754  £ 1,927  
 
A likely cause of the lower ICERs in the model for this thesis is that the cost of statins was 
updated including generic drugs that recently became available. When using the cost 
estimated by inflating the 2004 drug cost reported in Ward et al. (2006) to 2012 price, the 
mean ICER was increased to £7,330 (£6,045 when using undiscounted values). Added event of 
PAD could also lower the ICERs.  
 
 
5.5.2. Results for secondary prevention population 
 
In order to compare the model with the existing models from published literature, the model 
was run separately for populations on the statin therapy for the secondary and primary 
prevention. In the base-case model, individuals could have multiple previous heart disease 
events at model entry through random allocation. However, when running the model only for 
secondary prevention population, individuals were assigned only one previous heart disease 
event on a pro rata basis according to the prevalence of the included disease events scaled to 
sum to 100% in order for all individuals to receive the secondary prevention therapy.  
Table 5.19 presents lifetime per-capita costs, QALYs, and life years lived for the secondary 
prevention population. The use of statins for the secondary prevention of heart disease events 
for all population aged 45 years and over produced a cost per QALY gained of £2,351. This is in 
line with the conclusion of the majority of existing studies that supported statins as a cost 
effective use of resources for secondary prevention of CVD (see Section 5.2). 
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Table 5.19. Costs and QALYs associated with the use of statin for secondary prevention of 
cardiac events 
Secondary 
prevention 
population 
Undiscounted Discounted 
 Statin therapy No statin Statin therapy No statin  
Cost £ 27,364 £ 25,394 £ 16,758 £ 15,735 
QALYs 12.055 11.150 8.051 7.615 
Incremental 
Cost 
£ 1,970  £ 1,023  
Incremental 
QALYs 
0.905  0.435  
ICER (£/QALY) £ 2,177  £ 2,351  
 
 
The results by age and gender based on 200,000 simulated secondary prevention patients are 
shown in Table 5.20. For comparison purposes, it also reports the cost-effectiveness results 
reported in Ward et al. (2006) (Table 5.20 (b)). This was taken from one of their scenario 
analyses which took into account the reduction in stroke risks and CVD death for comparison 
with the model results in this section, as their base-case considered the effect of statins within 
the scope of coronary heart disease only (Scenario 2 Table 81 in Ward et al. (2006)).  
The results in Table 5.20 a) showed that there was little difference between the cost-
effectiveness results in men and women, and it was more cost effective to commence treating 
patients at younger ages than older ages. 
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Table 5.20. Secondary prevention population results by age and gender: Comparative results 
(statin vs. no statin) n= 200,000 
a) Cost-effectiveness results for secondary prevention population by age and gender from the 
model for this thesis  
  Undiscounted Discounted 
Gender Age Incre. 
Cost 
(£) 
Incre. 
QALYs 
ICER 
(£/QALY) 
Incre. 
Cost 
(£) 
Incre. QALYs ICER 
(£/QALY) 
Male 45 £2,167 1.426 £1,520 £903 0.578 £1,562 
 55 £2,018 1.069 £1,887 £1,040 0.522 £1,993 
 65 £1,583 0.703 £2,252 £968 0.411 £2,354 
 75 £1,126 0.411 £2,741 £798 0.284 £2,815 
 85 £598 0.163 £3,672 £485 0.130 £3,735 
Female 45 £2,525 1.586 £1,592 £892 0.606 £1,471 
 55 £2,805 1.141 £2,458 £1,341 0.525 £2,557 
 65 £2,143 0.783 £2,738 £1,237 0.439 £2,820 
 75 £1,295 0.435 £2,974 £891 0.291 £3,063 
 85 £641 0.164 £3,923 £510 0.129 £3,960 
 
b) Comparative cost-effectiveness results by age and gender reported in Ward et al. (2006)* 
  Undiscounted Discounted 
Gender Age Incre. 
Cost (£) 
Incre. 
QALYs 
ICER 
(£/QALY) 
Incre. 
Cost 
(£) 
Incre. QALYs ICER 
(£/QALY) 
Male 45 £10,452 0.700 £13,600 £4,651 0.462 £9,200 
 55 £7,722 0.565 £12,500 £4,041 0.411 £9,000 
 65 £5,238 0.397 £11,800 £3,218 0.314 £9,100 
 75 £3,332 0.227 £13,000 £2,382 0.193 £10,900 
 85 £1,911 0.115 £14,500 £1,563 0.103 £13,100 
Female 45 £11,650 0.776 £13,800 £4,871 0.493 £9,100 
 55 £8,768 0.644 £12,400 £4,312 0.452 £8,600 
 65 £6,163 0.499 £11,200 £3,562 0.387 £8,400 
 75 £3,979 0.297 £11,900 £2,701 0.248 £9,600 
 85 £2,257 0.148 £13,200 £1,784 0.132 £11,700 
*Reported in thousands. Rounding errors could be included 
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5.5.3. Results for primary prevention population 
 
A proportion of individuals were assumed to receive the statin treatment at model entry for 
primary prevention of heart disease (Section 5.3.2). The results reported in this section were 
obtained from the model where all individuals were assumed to receive statins for the primary 
prevention.   
The statin therapy for the primary prevention of heart disease for the base-case population of 
people in the UK aged 45 years and over was cost-effective with the cost per QALY gained of 
£2,446 (Table 5.21). Compared with the cost-effectiveness results for the secondary 
prevention population, the use of statins for primary prevention was associated with higher 
incremental costs and QALYs leading to slightly higher ICER of £2,446 per QALY gained.  
   
Table 5.21. Costs and QALYs associated with the use of statin for primary prevention of cardiac 
events 
Primary 
prevention; All 
population 
Undiscounted Discounted 
 Statin therapy No statin Statin therapy No statin  
Cost £ 11,755 £ 9,968 £ 6,659 £ 5,518 
QALYs 14.341 13.384 9.516 9.050 
Incremental 
Cost 
£ 1,788  £ 1,141  
Incremental 
QALYs 
0.957  0.467  
ICER (£/QALY) £ 1,868  £ 2,446  
 
 
A summary of cost and effectiveness of statin therapy for primary prevention by age and 
gender compared with no statin use is given in Table 5.22. The results by age and gender also 
showed that using statins for primary prevention of heart disease events would be a cost-
effective use of resources with ICERs for all age and gender groups being lower than £3,000 
per QALY gained.  
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Table 5.22. Results for primary prevention population using statins by age and gender 
  Undiscounted Discounted 
Gender Age Incre. 
Cost 
(£) 
Incre. 
QALYs 
ICER 
(£/QALY) 
Incre. 
Cost 
(£) 
Incre. 
QALYs 
ICER 
(£/QALY) 
Male 45 £2,750 1.658 £1,659 £1,516 0.680 £2,228 
 55 £2,149 1.189 £1,808 £1,358 0.582 £2,331 
 65 £1,598 0.778 £2,052 £1,126 0.459 £2,453 
 75 £1,005 0.418 £2,404 £783 0.289 £2,707 
 85 £488 0.189 £2,577 £416 0.151 £2,755 
Female 45 £2,617 1.714 £1,527 £1,445 0.648 £2,229 
 55 £2,276 1.235 £1,843 £1,394 0.563 £2,475 
 65 £1,727 0.816 £2,116 £1,175 0.457 £2,570 
 75 £1,095 0.469 £2,332 £830 0.313 £2,654 
 85 £544 0.226 £2,410 £455 0.177 £2,570 
Incre.=Incremental 
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5.5.4. Population-level cost projections 
 
In order to project future annual costs for the population aged 45 years and older, costs 
accrued by the base year population of all individuals aged 45 and over in the base year were 
combined with costs incurred by incoming cohorts of people becoming 45 years old every year 
(see Section 4.3.5). Per-capita cohort costs from the base year population and the yearly 
incoming cohorts of 45 year-olds were multiplied by the projected number of individuals in the 
relevant age and gender group. The stream of cohort-level costs for each calendar year was 
combined to estimate total population-level costs.  The per-capita costs and QALYs for these 
incoming cohorts of males and females aged 45 years at model entry are reported in Table 
5.23.  
The population-level costs of heart disease incurred by this combined population for the 
period of 2012 – 2037 are summarised in Figure 5.9 and Table 5.24. This projection horizon 
was determined by the availability of the ONS population data, and it is acknowledged that the 
results will become more uncertain as the extrapolation period increases as it is anticipated 
that treatments will change. Figure 5.9 presents the per-capita cohort-level costs obtained 
from the model simulation results and the total population annual costs projected by 
combining the per-capita costs with the ONS estimates of the projected number of future 
populations (Principal Population Projections data)(Office for National Statistics, 2013c). The 
per-capita annual costs for the base-year population and the incoming cohorts of 45-year-olds 
(Figure 5.9 a) and b)) increase in the beginning of the projection horizon due to the population 
ageing to have overall higher incidence than the base year, and then decrease as individuals 
die over time. The undiscounted annual cost of heart disease for the base year 2012 was 
estimated to reach approximately £9.4 billion and increase to over £18.3 billion in 2037.   
 
Table 5.23. Per-capita results for male and female populations aged 45 years  
(with statin therapy available) Males aged 45 
years 
Females aged 45 
years only 
Cost £ 21,138 £ 22,823 
Cost (discounted) £ 9,979 £ 9,972 
QALYs 21.908 23.155 
QALYs (discounted) 13.342 13.667 
Life years lived 32.469 35.453 
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Figure 5.9. Projection of total population-level annual costs for the treatment of heart disease  
Per capita cohort annual costs 
a) Base year population 
 
 
b)An incoming cohort of 45 year olds 
 
 
 
 
Total population-level annual costs 
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Table 5.24. Projected annual costs: 2012 – 2037 
Year 
Total cost 
(£, millions) 
Total cost 
discounted to 
2012 
(£, millions) 
Year Total cost 
(£, millions) 
Total cost 
discounted to 
2012 
(£, millions) 
Base year 
(2012) 
 £               9,424  £               9,261     
2013  £               9,952   £               9,451  2026 £             15,451   £               9,383  
2014  £             10,472   £               9,609  2027 £             15,850   £               9,300  
2015  £             10,979   £               9,733  2028 £             16,239   £               9,206  
2016  £             11,421   £               9,783  2029 £             16,502   £               9,039  
2017  £             11,885   £               9,836  2030 £             16,649   £               8,811  
2018  £             12,500   £               9,995  2031 £             17,014   £               8,699  
2019  £             12,766   £               9,863  2032 £             17,196   £               8,495  
2020  £             13,160   £               9,824  2033 £             17,534   £               8,370  
2021  £             13,567   £               9,785  2034 £             17,794   £               8,206  
2022  £             13,985   £               9,745  2035 £             18,022   £               8,030  
2023  £             14,352   £               9,663  2036 £             18,202   £               7,836  
2024  £             14,677   £               9,547  2037 £             18,344   £               7,630  
2025  £             15,163   £               9,530  
Total   
(2012-
2037) 
£           379,100 £            238,631 
 
 
5.6. Discussion and Limitations 
 
 
The model in this chapter was based on the model by Ward et al. (2006) with an added event 
of PAD and updated parameter estimates after a review of existing heart disease models.  
Although the ICER values varied, the use of statins for both primary and secondary prevention 
of cardiac events was cost-effective in line with the results reported in the study by Ward et al. 
(2006) and the other existing studies.  
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In common with the existing models, the model developed for this thesis was not free from 
limitations. As the model was based on the existing models identified from the review of 
recent UK models, many of the limitations that exist in those models also apply to the model in 
this thesis. For simplicity, many individual characteristics that can affect the event probabilities 
such as cholesterol level, blood pressure, body mass index (BMI), diabetes status and smoking 
status are not reflected in the model. Instead, age and gender specific event rates reported in 
the studies reviewed in Section 5.2 were used. Although conducting systematic reviews or 
meta-analyses of recent studies for each parameter might have identified more accurate 
estimates, the data reported in the existing models were used given the time scale of this PhD. 
For the same reason, time-constant hazards were assumed for some event rates. Also, MI was 
assumed to not be immediately fatal as the data available did not specify the cause of death. 
Although it was modelled that having an MI subsequently increased the risk of cardiac death, 
this assumption could have cost and QALY implications.  
 
In addition, the sources of event rates data were based on different populations. For example, 
the WOSCOPS study recruited only males with hypercholesterolemia (Shepherd et al., 1995), 
while the ASCOT-LLA study was for hypertensive patients with low cholesterol level (Sever et 
al., 2003). Also, due to the possible discrepancy between people receiving primary and 
secondary prevention therapies within the general population and the population in studies 
from which event rates were obtained as trials often included individuals with specified CVD 
risk factors such as hypertension and diabetes, the event rates used in this thesis might be 
overestimates.  
Also, potential correlations between events included in the heart model were not explicitly 
modelled as instead, independent, random sampling was used in this model. This might lead to 
overestimation of the cost if a group of patients with one of the heart disease conditions has a 
higher probability of having another disease event which has common cost items such as 
monitoring visits to a clinic.  
The total annual costs were subject to a high level of uncertainty as the per-capita annual costs 
were multiplied by large numbers representing the total UK population aged 45 and over and 
the projected UK population aged 45 years.  A small change in base-year population per-capita 
costs could then result in a considerable difference in total annual costs.   
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CHAPTER 6   INDIVIDUAL DISEASE MODEL 2 – 
ALZHEIMER’S DISEASE 
 
6.1. Background 
 
 
Dementia is typically a disease of later life, which is defined by the Diagnostic and Statistical 
Manual of Mental Disorders-Fourth Edition (DSM-IV) as:  
A syndrome consisting of progressive impairment in memory and at least one other cognitive 
deficit (aphasia, apraxia, agnosia, or disturbance in executive function) in the absence of 
another explanatory central nervous system disorder, depression, or delirium (American 
Psychiatric Association, 2000).  
The overall prevalence of dementia standardised to the England and Wales population aged 65 
years and older was estimated to be 6.6% for 1991 (MRC CFAS, 1998). The incidence rates for 
dementia increase with age for both sexes rising from 6.9 (6.3) per 1000 person years for male 
(female) aged 65-69 years to 58.4 (71.7) for male (female) aged 85 years and over in England 
and Wales (Matthews and Brayne, 2005).  
A Dementia UK report (Alzheimer's Society, 2007) estimated that the annual costs of dementia 
in 2007 amounted to £17 billion. Since 2007 the total cost of dementia has continued to rise: 
the Dementia 2012 report (Alzheimer's Society, 2012) produced updated figures for 2012, and 
estimated the annual cost at £23 billion to the NHS, local authorities and families. It was 
further estimated that there are 800,000 people living with the condition, with an average cost 
of £29,746 per person with dementia.  The greatest proportion of direct costs of dementia 
care was associated with institutional support in care homes: Accommodation accounted for 
41% of the total cost. This was often provided at a crisis point, is always costly and often 
precipitated by a lack of effective support (Alzheimer's Society, 2012).  
Over a third of the total cost (36%) was due to informal care inputs by family members and 
other unpaid carers. Not included in this amount is the estimated £690 million in lost income 
for those carers who have to give up employment or cut back their work hours. This lost 
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employment was estimated to be a loss of £123 million in taxes paid to the Exchequer 
(Alzheimer's Society, 2012, Alzheimer's Society, 2009).   
The most common form of dementia is Alzheimer’s disease (AD), accounting for approximately 
62% of all dementia cases (72% when considering mixed dementia including AD) (Alzheimer's 
Society, 2007) which is additionally characterised by the presence of neurofibrillary tangles 
and amyloid plaques in the cerebral cortex, observed at post-mortem. 
The severity of AD is often defined by, among others, Mini Mental State Examination (MMSE) 
score. Three acetylcholinesterase inhibitors (AChEIs) – donepezil, rivastigmine and galantamine 
– have marketing authorisations in the UK and are recommended as options for managing mild 
to moderate AD (measured by the MMSE score 10–26) by NICE (NICE, 2011). Memantine 
hydrochloride has a UK marketing authorisation for the treatment of people with moderate-to-
severe AD (MMSE score of ≤20), and is recommended by NICE as an option for managing 
moderate AD for people who cannot take AChEIs due to intolerance or contraindication, and 
as an option for managing severe AD (MMSE<10) (NICE, 2011). As described in Chapter 4, the 
model developed for this thesis considers AD only rather than other forms of dementia. This is 
due to the existing model-based studies focussing on AD and the highest prevalence of AD 
among all types of dementia.  
 
6.2. Literature review of published model-based economic 
evaluations of Alzheimer’s disease 
 
A recently published Health Technology Assessment (HTA) report (Bond et al., 2012) included a 
systematic review of economic models for assessing the cost effectiveness of pharmacological 
interventions for Alzheimer’s disease, and was used as a basis of a review of recently published 
model-based cost-effectiveness analyses (after 2009). Economic evaluations not based on a 
modelling approach such as those using trial data directly without a model were excluded from 
consideration.  
The PenTAG (Peninsula Technology Assessment Group) model used in the most recent HTA 
report by Bond et al. (2012) was based on a previous HTA report by Loveman et al. (2006) 
which used a Markov-type disease progression model based on the Assessment of Health 
Economics in Alzheimer’s Disease (AHEAD) model (Caro et al., 2001). The Southampton Health 
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Technology Assessment Centre-AHEAD (SHTAC-AHEAD) model by Loveman et al. (2006) 
evaluated mild to moderately severe AD and employed a predictive risk equation from the 
AHEAD model to determine a monthly hazard for the progression of AD up to a point where 
full-time care (FTC) is required.  
The AHEAD model was originally built to assess the cost-effectiveness of galantamine and uses 
three possible health states: pre-FTC, FTC and death.  Risk equations to predict the likelihood 
of patients requiring FTC and dying were estimated using regression-based statistical models 
which were functions of patient characteristics including age, presence of psychotic symptoms, 
cognitive function, age at disease onset and duration of AD. Numerous applications have been 
made using the same AHEAD structure such as Suh (2009), Migliaccio-Walle et al. (2003), 
Green et al. (2005). 
Although the PenTAG model used a model structure similar to that of the AHEAD model, the 
AHEAD-based equations used in the SHTAC model were replaced with a statistical model 
estimating time to FTC developed from UK-sourced data. Taking into account the criticism that 
the SHTAC model had received and given the concerns in the literature over the use of 
cognitive function alone to model AD progression, a number of amendments including the 
incorporation of population baseline characteristics in the estimation of the disease 
progression, have been made to the SHTAC-AHEAD model in the PenTAG model.   
Earlier models included those based on data derived from the Consortium to Establish a 
Registry in Alzheimer’s Disease (CERAD) database, which holds data on 1145 dementia patients 
examined annually between 1986 and 1995. The CERAD-Clinical Dementia Rating (CERAD-CDR) 
model by Neumann et al. (1999) follows AD progression through stages of cognitive function 
and residential settings based on annual transition probabilities estimated from the CERAD 
data. Although the model used the CDR scale which incorporates functional ability, AD 
progression was effectively determined by cognitive function, as stated in Loveman et al. (2006) 
and Green et al. (2011). Furthermore, the use of annual cycles and dated US data sources may 
hinder the application of the CERAD-based models to the model for this thesis.  
More recent models by Getsios et al. (Getsios et al., 2010, Getsios et al., 2012) used a DES 
approach. However, Bond et al. (2012) stated that effectively a 3-month cycle was used as in a 
Markov model because patient characteristics were updated at fixed intervals. Thus although 
it was claimed that this was a DES approach, the model calculated two of the most important 
parameters in determining costs and effects (patient-care costs and utilities) using weighted 
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averages in the same manner as a cohort-based model. Hence, it included elements of both 
individual sampling and cohort modelling approaches. 
A model using a system dynamics approach called the National Dementia Strategy 
implementation simulator (The Whole Systems Partnership, 2011) was identified. However, it 
was mainly aimed at supporting local partners such as local health authorities and regional 
NHS Trusts in examining the impact of implementing a government intervention called the 
National Dementia Strategy. It was considered that the model would not fit the purpose of this 
thesis.  
Notably, Getsios et al. (2009) included a screening stage in the model. However, none of the 
studies mentioned above modelled the onset of Alzheimer’s disease as these studies modelled 
people already with Alzheimer’s disease, not the general population. In the model developed 
for this thesis, the AD onset and diagnosis were included to accommodate both prevalent and 
non-prevalent populations (see Section 6.3.1).   
 
6. 3. Methods of Alzheimer’s disease modelling 
 
6.3.1. Scope and structure of the model 
 
The model developed for this thesis aimed to simulate individuals with and without dementia 
and to estimate costs associated with prevalent and future occurrences of dementia.  AD was 
taken as the scope of the model in this study as the current NICE guidance and relevant HTA 
reports focussed on AD. The disease occurs mainly in older people, referred to as late-onset 
dementia, but it may also occur in people under 65 years, referred to as young-onset dementia. 
This model includes only the late-onset Alzheimer’s disease.   
A DES model was constructed based on the Markov model used in the HTA report by Bond et 
al. (2012): this model will be called the PenTAG model hereafter. Many of the existing AD 
models identified in the systematic review in Bond et al. (2012) were based on the AHEAD 
model by Caro et al. (2001). The PenTAG model (Bond et al., 2012) and the previous HTA 
model by the SHTAC (Loveman et al., 2006) which the current and previous NICE guidance was 
based on, respectively, also adopted a structure similar to the AHEAD model.  As the PenTAG 
model addressed some of the limitations identified within the SHTAC model, this was chosen 
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as the basis of the model in this thesis. Individual-level modelling used in the model for this 
thesis enabled heterogeneity in disease progression and other outcomes to be captured, and 
changes in multiple attributes on continuous scales to be tracked. Thus, it was not based on 
average effectiveness and costs, which was one of the criticisms of the AHEAD model 
(Loveman et al., 2006).  
A simulated population representative of the UK population aged 45 and over enters the 
model. Some already have AD when entering the model. Those who do not have AD may or 
may not develop AD before death. It is assumed that it takes some time for AD to be 
diagnosed as the development of symptoms is insidious.  After a diagnosis of AD, the model 
structure replicates the simple three-state model as in the PenTAG model (Bond et al., 2012). 
The model structure is shown in Figure 6.1. As the existing HTA models (Loveman et al., 2006, 
Bond et al., 2012) included only people with AD, the onset and diagnosis of AD were added to 
the structure of the PenTAG model in order to model a general population.  Given the purpose 
of the model in this thesis, it was considered that the benefit of a simpler model (excluding the 
care pathways) would outweigh the potential inaccuracy in the estimation of disease 
progression and intermediate health states, provided that the model is capable of estimating 
the total costs and QALYs of treating patients with AD.  
 
Figure 6.1. Structure of the Alzheimer’s disease model  
 
 
 
The model in this thesis assumed the progression of disease to a point where the patients 
require institutionalisation. The institutionalisation state was defined in Bond et al. (2012) as 
‘living in a residential home or a nursing home (not as short respite care) or in hospital on a 
long-term or permanent basis’. For people with diagnosed AD, the state before 
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institutionalisation was termed ‘pre-institutionalisation’. The ‘institutionalisation’ state was 
chosen as a health state as in the PenTAG model. Many of the models identified in the review 
conducted by Bond et al. (2012) used health states described solely by the level of cognitive 
function such as MMSE. However, the use of the endpoint ‘institutionalisation’ was deemed 
more appropriate as institutionalisation can be determined by multiple factors (e.g. cognitive 
and functional ability, socio-economic status), rather than just MMSE given the concerns in the 
literature over the use of cognition alone to model disease progression. The previous HTA 
report by Loveman et al. (2006) adopted this approach and the endpoint of FTC was used 
instead of health states determined solely by cognitive function. The PenTAG model removed 
the FTC state and replaced it with institutionalisation as it was deemed that pre-FTC and FTC 
states are too heterogeneous to apply single cost and utility values.  Also, the equations used 
for time to FTC were based on a US study whilst the PenTAG model used a UK dataset which 
reflected time to institutionalisation, rather than FTC.  
Hence, the transitions between events were based on both cognitive and functional factors, 
not only on cognition factors.  Time to institutionalisation and death for people with AD were 
sampled based on the age, MMSE score which measures cognitive function, and Barthel 
Activities of Daily Living (ADL) score which measures functional capacity of the individual (see 
Section 6.3.4.4). The proportion of people with AD in institutional care was dependent on the 
severity of AD.  It was assumed that if an individual becomes institutionalised, then they could 
not return to the pre-institutionalised state. It was assumed that no time passes when 
individuals move from diagnosis to the pre-institutionalisation event.  A treatment 
discontinuation event was also incorporated to reflect the assumptions used in the PenTAG 
model (Figure 6.1). Transitions to death could occur at any point in time and from any disease 
event. 
Amongst the three AChEIs – donepezil, galantamine and rivastigmine – and memantine that 
NICE currently recommends as options for the treatment of AD, donepezil and memantine 
were taken as default treatments: memantine was used for people with MMSE < 10 at 
diagnosis, and individuals with 10≤ MMSE ≤26 at diagnosis received donepezil. It was assumed 
that donepezil was discontinued as soon as an individual becomes institutionalised whilst 
memantine could still be used when institutionalised as it was licensed for moderate-to-severe 
AD.  
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6.3.2. Modelled population 
 
Both prevalent and non-prevalent cohorts are included in the model (see Chapter 4). The 
general UK population aged 45 years and over with or without AD entered the model with age 
and gender values randomly sampled from the UK mid-2012 population estimates published 
by the ONS (Office for National Statistics, 2013b). However, the PenTAG model included only 
patients who already have a diagnosed dementia as their population. Due to the discrepancy 
between the population modelled in the PenTAG model and the current study population, the 
data obtained from the PenTAG model were applied only to people who have experienced the 
diagnosis event. 
 
 
6.3.3. Model assumptions 
 
The key model assumptions are summarised in Box 6.1. Many of these were also used in the 
PenTAG model.  
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Box 6.1. Key model assumptions 
Assumptions 
 Patients cannot return to pre-institutionalisation from the institutionalisation state. 
 An infinite capacity of institutionalised care is assumed.  
 Both MMSE and ADL (cognitive and functional) are used to predict the time to 
institutionalisation.  
 Drug treatments delay time to institutionalisation, but do not directly affect life 
expectancy. 
 Costs associated with the pre-institutionalisation state were all assumed to fall on 
the NHS or PSS budget, while 28% of the post institutionalisation costs 
(accommodation costs) were assumed to be met by the patients or their families.  
 No costs of carers were incorporated in this model. The review on the costs 
associated with Alzheimer’s disease conducted by Bond et al. (2012) did not identify 
data on such costs.  
 When an AD diagnosis is made, all people with AD start a drug treatment.  
 A constant rate of treatment discontinuation was assumed. 
 Six months after treatment initiation, the effect of treatment stops. This was due to 
the longest follow-up to compare across different drugs and outcomes evaluated in 
the PenTAG model being 6 months.  Individuals receiving the treatment after the 6 
months will still incur the cost. However, the drug treatment stops affecting the rate 
of change in MMSE and ADL score after 6 months (see Section 6.3.6).  
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6.3.4. Modelled events & data sources 
 
 
6.3.4.1. Individual characteristics at model entry 
 
Individual characteristics associated with AD, such as the presence of the disease, MMSE score, 
ADL score, and Barthel ADL score, are assigned conditional on the age, gender, and previously 
sampled dementia-related variables in order to incorporate correlations between the variables.   
At model initiation, of those individuals who already have AD, there are three groups: 1) those 
who are undiagnosed; 2) those who are already diagnosed; and 3) those who are 
institutionalised.   
The prevalence of AD at the start of the simulation was set as in Table 6.1 (MRC CFAS, 1998). 
The MRC CFAS data were chosen as this was a large UK study and stratified by age. Those who 
were simulated to have AD at model entry moved to the Onset event at time zero, but not 
necessarily the diagnosis state (data in Table 6.1 were assumed to provide estimates of true 
prevalent cases, not diagnosed cases). As the prevalence was reported for all dementia, it was 
assumed that in each age group, 72% (62% AD only; 10% mixed dementia including AD) of 
people with dementia has AD (Alzheimer's Society, 2012).  As this model includes only the late-
onset AD, the prevalence of AD for people aged 65 years and under was set to zero.  
 
Table 6.1. Prevalence of dementia at model initiation 
 Alzheimer’s disease All types of dementia 
Age-group 
(years) Men Women Men Women 
<65 0* 0* 0* 0* 
65-69 0.01008 0.0108 0.014 0.015 
70-74 0.02232 0.01584 0.031 0.022 
75-79 0.04032 0.05112 0.056 0.071 
80-84 0.07344 0.10152 0.102 0.141 
85+ 0.14112 0.198 0.196 0.275 
*It was assumed that individuals aged <65 years did not have dementia in this model 
as the model focusses on late-onset AD.  
Source: (MRC CFAS, 1998) 
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The incidence of AD was required for sampling of time to the onset of AD. Table 6.2 shows the 
incidence estimates for all dementia in the UK. It was assumed that 72% of dementia onset 
was AD (Alzheimer's Society, 2012). 
 
Table 6.2. Incidence of dementia and Alzheimer’s disease 
 Total Dementia Alzheimer’s disease 
Age-group Men Women Men Women 
<65 0 0 0 0 
65-69 0.0069 0.0063 0.0050 0.0045 
70-74 0.0145 0.0061 0.0104 0.0044 
75-79 0.0142 0.0148 0.0102 0.0107 
80-84 0.0170 0.0312 0.0122 0.0225 
85+ 0.0584 0.0717 0.0420 0.0516 
(Matthews and Brayne, 2005, Alzheimer's Society, 2012)) 
 
Table 6.2 shows that the incidence rate of AD typically increases as a person ages. In order to 
account for this, the incidence rate was updated and time to AD onset was re-sampled every 
time the individual’s age was simulated to move to the next age group. This procedure was 
detailed in Section 4.3 Modelling Methods.  
Initial MMSE values were assigned to individuals entering the model conditional on the 
presence of AD.  As MMSE is used for diagnosis of all types of dementia, distributions of MMSE 
reported for dementia patients were also used for people with AD. Different discrete 
distributions of MMSE were estimated for groups of people with and without dementia using 
the results of MRC CFAS study (Huppert et al., 2005). The distribution reported for people with 
dementia reported in Huppert et al. (2005) was normalised so that the sum of the probabilities 
would become 1. Parametric distributions for discrete random variables could not be uniquely 
determined using all the summary statistics reported, and one parameter distributions, such as 
the Poisson distribution, did not give a good fit. Non-parametric probability profiles of MMSE 
for population without dementia were fitted by trial and error by age group and sex using 
summary statistics (mean, median, and 5th, 10th, 25th, 75th, 90th, and 95th percentiles) of 
normative MMSE values for people without dementia reported in Huppert et al. (2005). 
Median and other percentile values were first matched with the reported values using these 
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equal probability estimates, and then the mean of the distribution was matched by adjusting 
and smoothing the probabilities for adjacent MMSE values. Probability values were adjusted 
by 0.025 intervals for the ease of computation. When an interval between two consecutive 
percentile values reported are two or more MMSE scores apart, equal probabilities were 
assigned to the MMSE values in-between.  The distributions used in the model are shown in 
Figure 6.2. Higher probabilities were assigned to higher MMSE values because of the skewed 
nature of the distribution. Those aged 64 years and under were assigned the full MMSE value 
of 30; those without dementia could also have MMSE less than 26 (Huppert et al., 2005). 
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Figure 6.2. Initial MMSE distributions by age group and sex for the initial population without 
AD 
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Physical functions (measured by ADLs and Instrumental ADLs (IADLs) that measure functional 
ability required for independent living) are correlated with the cognitive functions measured 
by MMSE (Warren et al., 1989). The Alzheimer's Disease Cooperative Study Activities of Daily 
Living Inventory (ADCS-ADL) is one of the most widely used ADL scales for Alzheimer's disease. 
The ADCS-ADL Inventory is a 23-item assessment of ADLs that is scored from 0 (greatest 
impairment) to 78. It evaluates activities of daily living. Conditional on the MMSE score of the 
modelled individual, an ADCS-ADL score was sampled from a generalised beta distribution with 
lower and upper bounds of 0 and 78 using the mean of the patients in the London and South-
East Region Alzheimer’s Disease (LASER-AD) study (Livingston et al., 2006). Baseline ADCS-ADL 
scores for the LASER-AD participants (n=198) were used as shown in Table 6.3. Individuals with 
AD would generally have lower ADCS-ADL scores. However, as people without AD could have 
an MMSE score lower than 26, it is possible that some with AD have higher ADCS-ADL scores 
than some without AD.  
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Table 6.3. Baseline ADCS-ADL (Alzheimer’s Disease Cooperative Study – Activities of Daily 
Living) scores 
Disease status Mean  99% C.I. width 
Mild                            (MMSE >=20) 54.6 15.0 
Moderate                  (15<= MMSE < 19) 40.0 15.2 
Moderately severe  (10<=MMSE<15) 37.0 21.7 
Severe                        (MMSE < 10) 18.9 15.0 
 
 
The parameters of the Beta distributions were estimated using the method of matching 
moments. Standard deviation was estimated assuming that the reported 99% confidence 
interval covers +/-2.58 standard deviations as would be the case for a Normal distribution. 
However, as the standard deviation was based on the symmetric Normal distribution, when 
the actual beta distribution is skewed, the variance of the sampled ADL values using the 
parameters estimated from this method could be inaccurate.  
The deterministic mapping reported in Bond et al. (2012) was used to calculate the Barthel 
score. The Barthel score is an index that measures functional capacity. A study by 
Wolstenholme et al. (2002) used a UK dataset and reported that the MMSE and the Barthel 
ADL Index are significant predictors of both time to institutionalisation and cost of care. 
However, as none of the studies included in the review by Bond et al. (2012) used, or reported, 
this measure, the reported ADCS-ADL scores were mapped onto the Barthel scale. The 
assumed statistical relationship in Bond et al. (2012) between the ADCS-ADL index and Barthel 
ADL index is shown in Eq.6.1. 
𝐵𝑎𝑟𝑡ℎ𝑒𝑙 𝑠𝑐𝑜𝑟𝑒 = 0.534 × (𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿 𝑠𝑐𝑜𝑟𝑒) − 0.0036 × (𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿 𝑠𝑐𝑜𝑟𝑒)2   [Eq.6.1] 
 
The model in this thesis used the data on the proportion of patients who, at the start of the 
model, were in the institutionalised state from the LASER-AD study also used by the PenTAG 
model (Bond et al., 2012). This estimated that 10% of the mild to moderate AD cohort and 40% 
for the moderate to severe cohort would be institutionalised. It was assumed that 5.6% of 
people with MMSE >19, 27.1% of people with MMSE 15-19, and 59% people with MMSE < 15 
were in the institutionalisation state at time zero (Livingston et al., 2006).  
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6.3.4.2. Mortality 
 
Distributions for time to non-disease death were obtained using all-cause mortality data from 
the UK death statistics (Office for National Statistics, 2013a).  The presence of AD could affect 
the mortality rates by having a competing risk of death from the pre-institutionalisation and 
institutionalisation events. An equation used in the PenTAG model (Bond et al. 2012) was 
adopted to sample time to death for people with AD (see Section 6.3.4.4). The assumed time 
to death was the earliest between the time to death sampled from the UK all-cause death 
distributions and time to death estimated from the survival equation used in the PenTAG 
model.  
6.3.4.3. Onset & diagnosis of Alzheimer’s disease 
 
The onset and diagnosis of AD were modelled as separate events. Onset of AD did not mean 
the patient receives a drug treatment as the condition might not be diagnosed.  The PenTAG 
model estimated time to institutionalisation and death based on a patient’s age, MMSE, and 
Barthel score (equations provided in Section 6.3.4.4). The same equations were used in the 
model in this thesis using the values when a patient was diagnosed with AD.  
Not all people with dementia are diagnosed. The dementia diagnosis rate in England is 
estimated to be 48% (Alzheimer's Society, 2012). This was used as the proportion of people 
with AD who were diagnosed and were receiving a drug treatment at the start of the model 
time, and these people start the simulation at the Diagnosis event.  
All individuals who developed AD including those who entered the model with AD at the start 
of the model without a diagnosis were assigned a sampled value of time to diagnosis. Those 
who did not have AD at model initiation may develop dementia and get assigned a time to 
diagnosis at the ‘onset’ event.  The break-down of individuals with or without AD and with or 
without diagnosis at model initiation is shown in Table 6.4.  
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Table 6.4. Distribution of individuals at model initiation 
 No Alzheimer’s 
disease (AD) 
With diagnosed 
AD 
With AD but not 
diagnosed 
Total 
Age group Men Women Men Women Men Women Men Women 
<65 years 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 100% 100% 
65-69 years 98.99% 98.92% 0.48% 0.52% 0.52% 0.56% 100% 100% 
70-74 years 97.77% 98.42% 1.07% 0.76% 1.16% 0.82% 100% 100% 
75-79 years 95.97% 94.89% 1.94% 2.45% 2.10% 2.66% 100% 100% 
80-84 years 92.66% 89.85% 3.53% 4.87% 3.82% 5.28% 100% 100% 
85+ years 85.89% 80.20% 6.77% 9.50% 7.34% 10.30% 100% 100% 
 
 
Time taken to receive a diagnosis of AD since AD onset was provided in Table 6.5. Time to 
dementia diagnosis was assumed to equate to the time to diagnosis of AD. Data reported in 
Alzheimer's Society (2012) were rescaled excluding the ‘don’t know’ category.  
 
Table 6.5. Time to diagnosis of Alzheimer’s disease 
 Raw data before 
scaling 
Assumed proportion 
in each category 
Cumulative 
proportion 
< 12 months* 22% 24.44% 24.44% 
1-2 years 37% 41.11% 65.56% 
3-4 years 23% 25.56% 91.11% 
5-6 years 5% 5.56% 96.67% 
Over six years** 3% 3.33% 100% 
Don’t know 5% N/A N/A 
*A minimum time of 3 months was assumed. 
**A maximum of 10 years was assumed. 
Source: Alzheimer's Society (2012) 
 
Time to diagnosis since AD onset was estimated using a sample from a Uniform [0,1] 
distribution. The random number not only informed which time interval the value falls on, but 
also it determined the time value itself. For example, if the random number was 0.4, the time 
to diagnosis is between 1 and 2 years as 0.4 is between 0.2444 and 0.6556, and the value was 
set as 1.3784 years. This value was calculated using the proportion of the relevant year band 
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the random number was associated with. In the example, the following formula would be used:  
1+ [(0.4-0.2444)/(0.6556-0.2444)]=1.3784. The minimum time to diagnosis was arbitrarily 
assumed to be 3 months as it is believed unlikely that dementia is diagnosed immediately after 
the onset.  
Time taken to receive a diagnosis was calculated in this manner for both incident AD cases and 
those who already had AD but were undiagnosed at the start of the model. It is acknowledged 
that the use of the data in Table 6.5 for those with undiagnosed AD could overestimate the 
time to diagnosis, as their onset could be earlier than the start of the model.  
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6.3.4.4. Pre-Institutionalisation & Institutionalisation 
 
 
The institutionalisation state was defined as ‘living in a residential home or a nursing home 
(not as short respite care) or in hospital on a long-term or permanent basis’, as in the PenTAG 
model. For people with diagnosed AD, a state before institutionalisation was called ‘pre-
institutionalisation’.  
Time to institutionalisation from the pre-institutionalisation state was estimated using an 
equation from an exponential survival regression analysis conducted by Bond et al. (2012).  
For people who are not receiving a drug treatment, the time to institutionalisation was 
sampled from an exponential distribution with the rate parameter of: 
𝜆 = 1 exp (4.928 + 0.00409 × 𝑀𝑀𝑆𝐸 + 0.02139 × 𝐵𝑎𝑟𝑡ℎ𝑒𝑙 𝐴𝐷𝐿 − 0.05735 × 𝐴𝑔𝑒)⁄  
𝑤ℎ𝑒𝑟𝑒 𝑀𝑀𝑆𝐸, 𝐵𝑎𝑟𝑡ℎ𝑒𝑙 𝐴𝐷𝐿, 𝑎𝑛𝑑 𝐴𝑔𝑒 variables were the values at diagnosis. The effects of 
drug treatment on time to institutionalisation are detailed in Section 6.3.6. 
Time to all-cause death from the pre-institutionalisation and institutionalisation states was 
also sampled from an exponential distribution with the rate parameter of: 
𝜆 = 1 exp (4.322 + 0.00228 × 𝑀𝑀𝑆𝐸 + 0.04173 × 𝐵𝑎𝑟𝑡ℎ𝑒𝑙 𝐴𝐷𝐿 − 0.04875 × 𝐴𝑔𝑒)⁄  
using the variables at diagnosis (Bond et al., 2012). The above equation was used for both 
populations receiving and not receiving a drug treatment as it was assumed that the treatment 
does not directly affect all-cause mortality, but does so only by improving MMSE and ADL 
scores. 
At the institutionalisation event, time to death was updated subtracting the time spent before 
being institutionalised, i.e. (time to death – time to institutionalisation).  
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6.3.5. Disease progression  
 
In the model, an individual’s cognitive function (measured by MMSE), and functional status 
(measured by ADCS-ADL and Barthel ADL score) could be changed due to two reasons: the 
progression of the disease and drug treatment. Annual rates of decline in MMSE score over 
time due to disease progression were used to calculate a total change in MMSE over the time 
between events, based on an equation estimated from a piece-wise linear regression model 
conducted by Getsios et al. (2010) using CERAD data. Based on the changed MMSE value, 
ADCS-ADL and Barthel ADL scores were also updated.  These updated values were used for the 
sampling of time to next event and QALY calculation.  
Getsios et al. (2010) used an equation for the annual rate of change in the MMSE score since 
previous measurement as follows: 
𝑀𝑀𝑆𝐸 𝐶ℎ𝑎𝑛𝑔𝑒 = 5.4663 − 0.4299𝑃𝑀1 − 0.0042𝑃𝑀2 + 0.1415𝑃𝑀3 − 0.0791𝑃𝑟𝑒𝑣𝑅𝑎𝑡𝑒
+ 0.0747𝐴𝑔𝑒 + 𝛿𝑖  
𝑤ℎ𝑒𝑟𝑒 𝑃𝑀1 = min(𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸, 9) , 𝑃𝑀2 = max(0, min[𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸 − 9,9]) and 𝑃𝑀3 =
max (0, min[𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸 − 18, 12]). 𝑃𝑟𝑒𝑣𝑅𝑎𝑡𝑒 is the patient’s last known annual rate of 
decline, 𝐴𝑔𝑒 patients’ age at diagnosis, and 𝛿𝑖  a random intercept parameter.  
This equation provides a different slope for different ranges of MMSE score, and was 
reproduced in the model for this thesis for three ranges of MMSE score as follows:  
𝐼𝑓 𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸 ≤ 9,
𝑀𝑀𝑆𝐸 𝑐ℎ𝑎𝑛𝑔𝑒
= 5.4663 − 0.4299𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸 − 0.0791𝑃𝑟𝑒𝑣𝑅𝑎𝑡𝑒 + 0.0747𝐴𝑔𝑒 + 𝛿𝑖  
𝐼𝑓 9 < 𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸 ≤ 18,
𝑀𝑀𝑆𝐸 𝑐ℎ𝑎𝑛𝑔𝑒
= 1.6350 − 0.0042𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸 − 0.0791𝑃𝑟𝑒𝑣𝑅𝑎𝑡𝑒 + 0.0747𝐴𝑔𝑒 + 𝛿𝑖  
𝐼𝑓 18 < 𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸 ≤ 30,
𝑀𝑀𝑆𝐸 𝑐ℎ𝑎𝑛𝑔𝑒
= −0.9876 + 0.1415𝑃𝑟𝑒𝑣𝑀𝑀𝑆𝐸 − 0.0791𝑃𝑟𝑒𝑣𝑅𝑎𝑡𝑒 + 0.0747𝐴𝑔𝑒 + 𝛿𝑖  
If an updated MMSE score exceeded the maximum score of 30, then it was replaced with 30. 
Based on the updated MMSE value, the ADCS-ADL score was sampled, and conditional on the 
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ADCS-ADL score, the deterministic mapping for Barthel score was applied as in Section 6.3.4.1. 
It was assumed that the values were independent of values in previous years. Changes in 
MMSE values due to drug treatments are detailed in the next section.  
 
 
6.3.6. Effectiveness of drug treatment 
 
Different time-to-event equations from those shown in Section 6.3.4.4 were used for drug 
treated cohort (Bond et al., 2012). For individuals on drug treatment, the average time to 
institutionalisation increased by 0.1032 × ∆𝑀𝑀𝑆𝐸 + 0.0781 × ∆𝐵𝑎𝑟𝑡ℎ𝑒𝑙 for mild-to-
moderate patients (MMSE>15), and 0.0910 × ∆𝑀𝑀𝑆𝐸 + 0.1159 × ∆𝐵𝑎𝑟𝑡ℎ𝑒𝑙 for moderate-
to-severe patients, where ∆𝑀𝑀𝑆𝐸 and ∆𝐵𝑎𝑟𝑡ℎ𝑒𝑙 are the treatment effects on the MMSE and 
Barthel scores. This was added to the mean of the exponential distribution in Section 6.3.4.4, 
and time to institutionalisation was sampled from the distribution with the updated event rate. 
No treatment effect on survival (time to death) was assumed as in the PenTAG model (see 
Section 6.3.3). Hence, the effectiveness of the drug treatment is manifested by an average 
delay in time to institutionalisation, and consequent slower decline in cognitive function.   
After the adjustment for the mean treatment effect, the ADCS-ADL and Barthel values were 
bounded within the possible range of the score (ADCS-ADL between 0 and 78; Barthel between 
0 and 20).  
The effect of treatments was measured by change in MMSE and ADL scores (∆𝑀𝑀𝑆𝐸 and 
∆𝐵𝑎𝑟𝑡ℎ𝑒𝑙). The results from meta-analyses conducted by Bond et al. (2012) are reproduced in 
Table 6.6. Annual changes in MMSE and Barthel ADL scores were sampled from Normal 
distributions fitted using the mean and confidence interval reported in Table 6.6, and applied 
to the baseline estimate of MMSE and ADL scores.  
As the longest follow-up of the studies that were used to examine the effectiveness of drug 
treatment in Bond et al. (2012) was 6 months, it was assumed, as in Bond et al. (2012), that 
after 6 months, the MMSE and ADL scores of treated cohort declined at the same rate as those 
of untreated. To illustrate, Figure 6.3 shows the effect of drug treatment on the MMSE score. 
MMSE score declines at a slower rate for treated individuals compared with the untreated for 
the first 6 months after the treatment initiation, and the rate of decline for the treated is the 
same as that for the untreated after 6 months. Hence, a constant difference in MMSE score 
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between treated and untreated individuals was assumed from 6 months after treatment 
initiation, with all other things being equal. No bounce-back effect, where MMSE score goes 
back to the score which the individual would have had if he/she had not taken the drug from 
the beginning, was assumed as in Bond et al. (2012). It is noteworthy that although the same 
assumption as the PenTAG model was used due to the absence of data beyond 6 months, the 
6-month treatment effect may not reflect the actual increase in MMSE and ADL scores among 
those receiving drugs for AD.  
The treatment effect on MMSE and ADCS-ADL scores was assumed to last 6 months as 
reported in Bond et al. (2012) or until the treatment effect is sampled to discontinue, 
whichever is shorter. This was incorporated when sampling time to institutionalisation at the 
Pre-institutionalisation event.  
Time to institutionalisation was sampled using the parameter adjusted for the treatment. If the 
earliest time to next event was shorter than time before treatment effects stop, then MMSE 
and ADCS-ADL, and Barthel scores were considered to be over-adjusted. Hence, these scores 
were re-adjusted so they can reflect the changes up to the next event time.  
 
 
Table 6.6. Treatment effect at 6 months 
Drug 6-month 
change in: 
6-month 
estimate (95% 
CI) 
Distribution for 
annual change 
used in the model 
Source  
Donepezil 
10mg 
MMSE 1.24 (0.81,1.66) Normal (2.48, 
0.422) 
Meta analysis result in 
Bond et al. (2012) 
ADCS-ADL 2.02 (1.06, 3.28) Normal (4.04, 
1.122) 
Bond et al. (2012): 
Average of estimates 
from galantamine 
(24mg) and 
rivastigmine (<=12 mg) 
due to lack of data 
Memantine 
(15-20mg) 
MMSE 0.70 (0.02, 1.38) Normal (1.40, 
0.6942) 
Reisberg et al. (2003) 
ADCS-ADL 1.41 (0.04, 2.78) Normal (2.82, 1.42) Reisberg et al. (2003), 
van Dyck et al. (2007) 
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Figure 6.3. Illustration of treatment effect 
 
 
  
6.3.7. Treatment discontinuation 
 
At diagnosis, it was assumed that all individuals diagnosed with AD initiate a drug treatment. 
They may discontinue the treatment, but reasons for discontinuation were not modelled. 
Using data from Bond et al. (2012) and Getsios et al. (2012), 4% (annual rate of 0.4899) of the 
total population were assumed to discontinue the treatment each month, meaning that 
almost all individuals no longer receive the treatment after 2 years of treatment.  As with the 
6-month period of treatment effect, no bounce-back effect was assumed upon treatment 
discontinuation, with MMSE score declining at the same rate as that of untreated people. 
The same assumptions on treatment discontinuation as the PenTAG model (Bond et al. 2012) 
were used. In the PenTAG model, treatments with the any of the three cholinesterase 
inhibitors (donepezil, galantamine, and rivastigmine) were assumed to stop once patients 
become institutionalised. In the model for this thesis, donepezil treatment was stopped if their 
MMSE fell below 10 or they entered an institution, as the treatment was licensed for mild-to-
moderate AD. The model implicitly assumed that institutionalisation is equivalent to severe AD 
(MMSE <10): Bond et al. (2012) reported that the analysis of Wolstenholme et al. (2002) data 
suggested that entering institutionalisation is a good proxy for severe AD and also the current 
guidance recommends that patients be taken off those drugs at MMSE<10. No such 
assumption was made for memantaine, as the drug is licensed for moderate-to-severe AD. 
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Hence, unless treatment is discontinued, memantine was assumed to continue to be taken by 
patients until they die (NB almost all individuals discontinue within 2 years of treatment).  
 
 
6.3.8. Utility 
 
Baseline utilities for people without AD were based on their age and gender using the values 
estimated by Ara and Brazier (2010) as reported in Chapter 4. The utility value at the age 
halfway between events was used as in the heart disease model.  
If the person has AD, utility weights were based on the MMSE score. The EQ-5D values 
associated with MMSE score were reported in Jönsson et al. (2006) and were used as the base-
case estimates of utility weights for people with AD (Table 6.7). The weights were dependent 
only on the MMSE score regardless of age or gender. The paper by Jönsson et al. (2006) was 
chosen by Bond et al. (2012) as it reported the utility values across the whole MMSE score 
range and because the utilities reported in the paper were not particularly different from 
those in other literature identified. Bond et al. (2012) obtained the standard deviation (SD) of 
these utility weights by assuming SD as 1/√𝑁, and these values were used in the model for this 
thesis.   Institutionalised patients were assumed to have the utility weight used for people with 
MMSE <10 as in Bond et al. (2012).  
 
Table 6.7. Utility weights used for Alzheimer’s disease patients 
MMSE score Utility weights PenTAG estimates of SD* 
0-9 0.33 0.151 
10-14 0.49 0.107 
15-20 0.50 0.110 
21-25 0.49 0.200 
26-30 0.69 0.213 
Source: Jönsson et al. (2006); * SD= 1/√𝑁 was assumed in Bond et al. (2012) 
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6.3.9. Costs 
 
All individuals diagnosed with AD were assumed to incur costs (including those with MMSE 
>26). Three categories of costs were included in the model: 1) drug costs; 2) monthly costs of 
care (pre-institutionalised and institutionalised), and 3) six-monthly monitoring outpatients 
care for those on drug treatment. The same cost items as those included in the PenTAG model 
(Bond et al. 2012) were incorporated. The main sources of data for costs 2) and 3) in the model 
for this thesis were Unit Costs of Health and Social Care by Personal Social Services Research 
Unit (PSSRU)(Curtis, 2013), NHS Reference Costs (2008-2009), and BNF 67 (Joint Formulary 
Committee, 2014). Drug costs were taken from this BNF, and other costs were inflated to 2013 
prices using the inflation indices for Hospital and Community Health Services (HCHS) reported 
in the Unit Costs of Health and Social Care (Curtis, 2013).  
Individual-level costs of care were calculated by using the relationship between monthly cost 
and the time before the end of pre-institutionalisation provided in Bond et al. (2012). 
Equations for monthly costs were estimated from a linear mixed effects model based on the 
UK study by Wolstenholme et al. (2002). In the ‘Pre-institutionalisation’ event, patients with 
mild-to-moderate AD incurred the monthly healthcare costs of 2877 − 1122𝑡 + 194𝑡2 −
10.9𝑡3, and moderate-to-severe AD patients incurred 3363 − 1117𝑡 + 191𝑡2 − 10.7𝑡3, 
where t denoted years before the end of pre-institutionalisation (Bond et al., 2012). These 
equations reflect that the shorter the time before institutionalisation, the higher the monthly 
care cost. For all individuals at the pre-institutionalisation stage, these monthly costs were 
repeatedly calculated and summated until institutionalisation occurs by reducing t by one 
month at every calculation until 0 ≤ 𝑡 < 1/12.  All time units were expressed in years. 
For institutionalised individuals, the 2009 price of institutionalisation (£2,941) reported in 
Bond et al. (2012) was inflated to £3,184.43 (2013 price) using the 2012/13 inflation index of 
1.083. Only 72% of this monthly cost was included in the model as the HTA model assumed 
that the 28% of institutionalised costs were privately funded (the proportion is likely to 
increase in the near future due to social care funding cuts; see Chapter 10). The NHS/PSS 
funded cost was therefore £2292.79. The monthly cost of institutionalisation is accrued until 
the patient moves to the dead state.  
The costs of drugs used in the HTA report were updated using BNF 67 (Joint Formulary 
Committee, 2014).  The monthly cost of donepezil (10mg/day) was £128.25 (4.28 x 30). For 
226 
 
memantine (10-20mg/day), a weighted average of daily costs for 10 mg (20% x £1.23) and 
20mg (80% x £2.46) was calculated, which led to a daily cost of £2.22 and a monthly cost of 
£66.54. Drug costs were accumulated until moving to next event with discounting applied. The 
monthly costs were assumed to be incurred at the beginning of each monthly period.  
No cost associated with death was included in the model.  In the review conducted by Bond et 
al. (2012), no data on the NHS and PSS costs of carers of people with AD were identified. 
Similarly, no carer costs were included in the model.  
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6.4. Results 
 
6.6.1. First order uncertainty and comparison with existing model results 
 
As in Chapter 5, first-order uncertainty which can be decreased by increasing the number of 
simulated individuals was examined to identify the appropriate number of individuals to 
simulate. The mean results and uncertainty with varied number of simulated individuals 
ranging from 100 to 200,000 were examined (Figure 6.4). 
 
Figure 6.4. First order uncertainty in relation to the number of patients simulated (age 45+) 
a) Cost with drug treatment  
Undiscounted 
 
Discounted 
 
b) QALYs with drug treatment  
Undiscounted 
 
Discounted 
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c) Incremental cost of drug treatment compared with no therapy 
Undiscounted 
 
Discounted 
 
d) Incremental QALYs of drug therapy compared with no therapy 
Undiscounted 
 
Discounted 
 
e) Cost per QALY gained – drug therapy vs. no drug therapy (jack-knife C.I.) 
Undiscounted 
 
Discounted 
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f) Incremental net monetary benefit (NMB) of drug therapy  
Undiscounted 
 
Discounted 
 
 
 
The treatment was cost-saving compared with the no treatment option, and thus the drug 
treatment dominated no treatment option (i.e. costing less whilst producing more QALYs). 
However, the mean cost per QALY was not stable with an increasing number of modelled 
individuals as shown in Figure 6.4.  
This pattern may be caused by the large proportion of the model population that cannot 
develop AD by assumption – the prevalence of AD amongst people aged under 65 years was 
assumed to be 0% whereas the model runs were from a population aged 45 years and older. 
As the base-case model assumes drug treatment does not directly affect mortality, the 
incremental life years were zero, if random variability was successfully eliminated. For patients 
without AD the simulated utility would be identical for those receiving and not receiving 
treatment, rendering the cost per QALY in this group to approach infinity (i.e. ∆𝐶/∆𝐸 → ∞ as 
∆E approaches zero).  
In order to avoid the instability of cost per QALY due to the small values of incremental QALYs, 
the ratio-based measure was converted to incremental net monetary benefit (NMB) of the 
drug treatment using the willingness-to-pay threshold of £20,000 per QALY as shown in Figure 
6.4 f). Incremental NMB was defined as 𝜆 ∙ ∆𝐸 − ∆𝐶, where ∆𝐸 and ∆𝐶 are differences in 
effect and cost, respectively. Figure 6.4 f) shows that incremental NMB stabilises with the 
increasing number of simulated individuals.      
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In order to examine the level of uncertainty around cost per QALY gained, the model was run 
for a population simulated to have AD which would all be aged 65 years and over. Figure 6.5 
shows the first-order uncertainty results from this model run. When only those already with 
AD were included, this significantly reduced the standard error around the mean cost per QALY.   
When the population is restricted to people with AD aged 65 and over, incremental NMB 
stabilised with the lower number of simulated individuals than in Figure 6.4. Drug treatment 
was consistently cost-saving and the no treatment option was dominated for any number of 
simulated individuals over 10,000. Incremental NMB was around £1,000 with 50,000 and more 
simulated individuals.  
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Figure 6.5. First-order uncertainty only for population aged 65 and over with AD 
a) Cost with drug treatment (age 65+)  
Undiscounted 
 
Discounted 
 
b) QALYs with drug treatment (age 65+)  
Undiscounted 
 
Discounted 
 
c) Incremental cost of drug treatment compared with no therapy (age 65+) 
Undiscounted 
 
Discounted 
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d) Incremental QALYs of drug therapy compared with no therapy (Age 65+) 
Undiscounted 
 
Discounted 
 
e) Cost per QALY gained – drug therapy vs. no drug therapy (jack-knife C.I.) (age 65+) 
Undiscounted 
 
Discounted 
 
f) Incremental net monetary benefit (NMB) of drug therapy for population with AD aged 
65 and over 
Undiscounted  
 
Discounted 
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Although direct comparison could not be made due to differences in the default treatment 
assumptions, time horizon, and model population, for information the results for similar 
populations were compared to the results from Bond et al. (2012) in Table 6.8. The model 
results from population with AD aged 65 years and older were generally consistent with those 
from Bond et al. (2012). When compared with best supportive care (BSC), Bond et al. (2012) 
reported that donepezil saved £588 for 0.035 QALYs gained over 20 years horizon i.e. 
donepezil dominated BSC). On memantine, compared with BSC, 0.013 QALYs were gained for 
an extra cost of £405, leading to a cost per QALY of £32,100. In the model in this thesis, the 
donepezil treatment for mild to moderate AD and the memantine therapy for moderate to 
severe AD was cost-saving (£867) with 0.0029 QALYs gained compared with BSC (no treatment) 
(Table 6.8A).   As the population in the model by Bond et al. (2012) entered the model with 
diagnosed AD and no treatment costs were incurred without diagnosis, the costs from Bond et 
al. (2012) were higher compared with the results from the model in this thesis. When 
assuming an immediate diagnosis after the onset (Table 6.8B), the costs became closer to the 
level of cost reported in Bond et al. (2012). It is noteworthy that incremental QALYs from the 
model for this thesis were smaller than those from Bond et al. (2012) due to the difference in 
the assumed population between the models.  
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Table 6.8. Comparison of the model results with the results from Bond et al. (2012)  
 A. Results for those aged 65+ 
with AD from the model in this 
thesis 
B. Results for those aged 65+ with 
diagnosed AD from the model in 
this thesis 
C. Base-case deterministic results in Bond et al. (2012) 
 
 Treatment 
(Donepezil + 
Memantine) 
No treatment Treatment 
(Donepezil + 
Memantine) 
No treatment Treatment  
(Donepezil) 
No treatment 
(BSC) 
Treatment  
(Memantine) 
No treatment 
(BSC) 
TDC £ 59,592 £ 60,459 £ 68,220 £ 69,633 £69,624 £70,212 £78,528 £ 78,123 
TDQ 1.978 1.975 1.505 1.498 1.619 1.584 1.227 1.215 
Incremental 
cost of 
treatment 
Cost-saving of £867 
(undiscounted: cost saving of 
£1,006) 
Cost-saving of £1,413 
(undiscounted: cost saving of 
£1,579) 
Cost-saving of £588 £405 
Incremental 
QALYs of 
treatment 
0.0029 
(undiscounted: 0.0025)  
0.0071 
(undiscounted: 0.0072)  
0.035 0.013 
Based on N= 200,000 simulated individuals; TDC = total discounted cost; TDQ = total discounted QALYs.  
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Investigation into the simulated time to events for patients indicated that the random draws 
differed between individuals who received and did not receive intervention, even when the 
patient characteristics and parameters for distributions were the same. This was believed to be 
caused by the number of random draws in the intervention arm being greater than in the no 
treatment arm, and thus the random samples get misaligned for the same parameter between 
comparators. This could not be resolved within the time scale of the PhD, but it was 
considered it could be mitigated in terms of expectations of costs and QALYs by running a 
larger number of simulated individuals.  
 
 
6.6.2. Base-case results 
 
The base-case model results for the general population aged 45 years and older based on 
200,000 simulated individuals produced lifetime costs and QALYs as shown in Table 6.9. The 
drug treatment dominated no treatment with the (discounted) cost saving of £14 and 0.001 
QALY gain over a lifetime. Approximately, 24% individuals had AD at death. Average time to AD 
onset of the base year population who had AD at death was 19.8 years. The results for men 
and women aged 45 years at model initiation were also shown in Table 6.10.  
 
Table 6.9. Base-case model results based on n=200,000 - Lifetime per-capita costs and QALYs 
for the general population aged 45 years and over  
AD only model Treatment (donepezil 
and memantine) 
No treatment Incremental 
values 
Cost - Discounted £4,582 £4,596 Treatment 
saves £14 
QALYs - Discounted 10.642 10.641 0.001 QALYs 
Cost £8,845 £8,868 Treatment 
saves £23 
QALYs 16.548 16.545 0.003 QALYs 
Life years lived 21.653 21.650  
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Table 6.10. Base-case model results for men and women aged 45 years at model initiation 
(based on n=200,000 simulated individuals; with default treatment where applicable) 
MEN Discounted Undiscounted 
Cost £ 2,381 £ 7,888 
QALYs 15.916 27.828 
Life years lived  34.053 
WOMEN Discounted Undiscounted 
Cost  £ 2,655 £ 9,620 
QALYs 16.208 29.343 
Life years lived  37.130 
 
 
6.6.3. Annual cost projection results 
 
Total annual costs for the treatment and management of AD were projected to increase from 
£4.87 billion in the base year and peak in 2037 at £6.92 billion (Figure 6.6 and Table 6.11).  
 
Figure 6.6. Projected annual costs for the treatment and management of Alzheimer’s disease 
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Table 6.11. Projected annual costs for 2012-2037 for the treatment and management of 
Alzheimer’s disease 
Year 
Total cost 
(millions) 
Total cost 
discounted to 
2012 
(millions) 
Year 
Total cost 
(millions) 
Total cost 
discounted to 
2012 
(millions) 
2012 £               4,869 £               4,792 2025 £               5,747 £               3,613 
2013 £               4,593 £               4,363 2026 £               5,632 £               3,420 
2014 £               4,832 £               4,433 2027 £               5,795 £               3,400 
2015 £               5,024 £               4,454 2028 £               5,918 £               3,354 
2016 £               5,221 £               4,473 2029 £               5,969 £               3,269 
2017 £               5,225 £               4,324 2030 £               6,161 £               3,260 
2018 £               5,228 £               4,181 2031 £               6,265 £               3,204 
2019 £               5,306 £               4,100 2032 £               6,237 £               3,081 
2020 £               5,309 £               3,962 2033 £               6,282 £               2,998 
2021 £               5,434 £               3,919 2034 £               6,553 £               3,022 
2022 £               5,529 £               3,853 2035 £               6,542 £               2,915 
2023 £               5,610 £               3,777 2036 £               6,745 £               2,903 
2024 £               5,778 £               3,758 2037 £               6,923 £               2,879 
 
 
The undiscounted cost for the base year (£4.9 billion) was higher than the next year (£4.6 
billion), however the costs were projected to increase year-on-year thereafter. The difference 
between the year 1 and 2 costs was £275 million.  
Investigation into the causes of the lower cost in year 2 than year 1 revealed this was due to: 
assumptions regarding drug treatment and mortality for people aged 90 years and over. Firstly, 
it was assumed that all individuals with diagnosed AD at time zero receive treatment at the 
model initiation, although some discontinue the drug treatment (4% per month), and incurring 
less cost in the subsequent years. The effect of this assumption was explored by running the 
model assuming no drug treatment for both populations with and without AD. The base year 
and second year costs projected were £4.9 billion and £4.8 billion, respectively, and the 
difference between Year 1 and 2 was reduced to £102 million (Figure 6.7a). As the costs for 
drug treatment for both Year 1 and 2 were not counted, this reduction in the difference cannot 
fully explain the difference between Year 1 and 2 costs. However, it could be said that the drug 
treatment assumption had some effect on total annual cost.  
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Secondly, it was considered that the mortality assumed for people aged 90 years and over 
could cause the drop in the second year cost. Costs associated with the management of AD are 
correlated with the age distribution of the population due to the strong association of AD 
prevalence with age. Due to the assumption on the age composition of the model population, 
people aged 100+ were included in the 90+ age group in the model, forming a heavy tail on the 
distribution for the total population. In order to see the effect of this assumption on the model 
results, the annual costs for the population aged 90 years and over were estimated and shown 
in Figure 6.7b). The annual cost of population aged 90+ in the base year decreased rapidly as 
the population depletes quickly due to the high mortality rate in this age group. The 
distribution of people aged 90 and over was constructed assuming a constant annual mortality 
rate. The mortality rate was taken from Death Statistics UK (2012) for females aged 90 years 
and over as described in Section 4.3.4. The undiscounted cost for Year 1 was £823 million 
(£811 discounted) and that for Year 2 was £559 million (£531 discounted).  The difference 
between the first and second year undiscounted cost was approximately £264 million, which 
could explain the difference in the total annual costs.  
 
Figure 6.7. Reasons for the difference in Year 1 and Year 2 costs 
a) Annual costs with no drug treatment assumed b) Annual costs for people aged 90 years and 
older 
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6.5. Discussion 
 
The model in this chapter largely replicated the PenTAG model reported by Bond et al. (2012) 
with added events such as the onset and diagnosis of AD because the model was developed 
for the general population, not only for individuals already with AD. It also employed some 
data not used by Bond et al. (2012) and was constructed as a DES model.  
A significant proportion of estimates used in the PenTAG model were based on the individual 
level data reported in Wolstenholme et al. (2002), which were therefore used in the model in 
this thesis. Although the use of the UK data might ensure the generalisability of the data to the 
UK setting, the model was based on rather old data (1988-1999) collected on a small sample 
(92 patients with AD). The mean follow-up of the study by Wolstenholme et al. (2002) was 40 
months (range 1-132). Although it was not considered significantly short compared with other 
cohort studies, it was still questionable whether the estimates can be extrapolated to a 
lifetime horizon given the long-term nature of AD.  
One of the important assumptions used in the model as well as in the PenTAG model was that 
when individuals discontinue treatment, their MMSE and ADL scores decline at the same rate 
as individuals who did not receive treatment. As Bond et al. (2012) noted, no evidence 
informing what would happen after the discontinuation of treatment was found. If these 
scores were assumed to revert to the values which would have occurred without treatment, 
the cost-effectiveness results would be less favourable to the drug treatment.  
Furthermore, the trajectory of MMSE score was estimated based on the equation derived from 
a regression-based model in Getsios et al. (2010). This MMSE equation was estimated using 
US-based data from CERAD study.  It is unclear how representative the US CERAD cohort is of 
UK individuals with AD.   
The aforementioned limitations, nonetheless, are not existent only in the model for this thesis, 
but also in other models widely used.  As the majority of the relationships between 
parameters for individuals with diagnosed AD were set up in the same way as in the PenTAG 
model, the limitations would also apply to the PenTAG model.  
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CHAPTER 7   INDIVIDUAL DISEASE MODEL 3 – 
MODELLING OSTEOPOROSIS 
 
7.1. Background – Osteoporosis 
 
Osteoporosis is a skeletal disease characterised by low bone mass and structural deterioration 
of bone tissue that causes bone fragility and increases susceptibility to fractures (Consensus 
development conference, 1991). Bone mineral density (BMD) is an important – albeit not the 
only – predictor for osteoporotic fracture. Since an accurate measurement of BMD became 
possible, a definitive diagnosis of osteoporosis can be made based on BMD. BMD 
measurements can be taken at different sites such as hip, spine and femoral neck, and are 
typically reported as a T-score, the number of standard deviations (SDs) from the average BMD 
of healthy young women. The World Health Organization (WHO) defined osteoporosis as 
having a T-score of -2.5 SDs or less (Kanis, 2007). A precursor to osteoporosis, osteopenia was 
defined by a T-score of less than -1 but higher than -2.5 SDs.  
The risk of fracture steadily increases with age, especially for hip fracture whose incidence 
rises exponentially (Stevenson et al., 2005).  Hence, population ageing is expected to 
considerably affect the economic burden from osteoporotic fractures.  In England and Wales, 
for example, the cost of treating fractures was estimated in 2003 at £1.7 billion every year 
(Woolf and Akesson, 2003). A recent estimate in 2010 including fracture-related costs, cost of 
pharmacological fracture prevention and cost of long-term disability showed that the burden 
of osteoporosis in the UK amounts to €5.4 billion (approximately £3.9bn) (Hernlund et al., 
2013). This is likely to further increase in the future due to the increase in both the number 
and proportion of older population (Kanis and Johnell, 2005).  
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7.2. Review of existing osteoporosis models 
 
A recent systematic review of cost-effectiveness analysis models of interventions for screening 
and treating people with osteoporosis or osteopenia was identified (Müller et al., 2012). The 
review included studies in the Medline database published between January 2006 and 
November 2011. Müller et al. (2012) used a checklist developed by Philips et al. (2004) to 
assess the methodological quality of the included studies, and presented the number of 
positive and negative ratings across all dimensions of quality addressed in the checklist. In this 
thesis, only high-quality studies (n=6) with total points (i.e. the sum of positive (+1 point) and 
negative (-1 point) ratings based on Philips et al. (2004) checklist) being 12 or higher were 
reviewed.  
Among the high-quality studies, Schousboe et al. (2007) constructed a cohort-based Markov 
model to evaluate the cost-effectiveness of bone densitometry followed by oral 
bisphosphonate therapy to prevent fractures for those with osteoporosis, compared with 
neither bone densitometry nor follow-up drug treatment.  This study modelled osteoporosis in 
older men in contrast to the majority of the studies included in the review which reported 
results for women only, and showed bone densitometry followed by bisphosphonate therapy 
for those with osteoporosis may be cost-effective for men aged 65 years or older with a self-
reported prior clinical fracture and for men aged 80 to 85 years with no prior fracture. 
However, the study that provided source data was conducted in the US. Another cohort model 
that scored high in the assessment by Müller et al. (2012) was also a Markov model with a 1-
year cycle used to evaluate the cost-effectiveness of alendronate treatment in the UK setting 
(Kanis et al., 2008). This model had been extensively used to evaluate the cost-effectiveness of 
various drug treatments for osteoporosis and hormone replacement therapy in different 
settings (Borgstrom et al., 2006, Kanis et al., 2004b). 
A microsimulation model by Stevenson et al. (2007) achieved the highest rating in the 
methodological quality assessment. The report by Stevenson et al. (2007) was commissioned 
by the NIHR Health Technology Assessment (HTA) programme and the model was an updated 
version of Sheffield Health Economic Model for Osteoporosis (SHEMO), which has been 
previously reported (Stevenson et al., 2005). In the model by Stevenson et al. (2007), individual 
patients passed through the model one at a time. The individual-patient approach allowed the 
full patient history including previous fractures and current residential status to be recorded 
242 
 
and used to determine the level of even risks in the next time period. One-year time intervals 
were used in this model.  
In addition to the studies included in the Müller et al. (2012)’s review, other more recent HTA 
reports that were not available in the Medline database were searched within the NIHR 
Journals Library. The most recently published HTA report was a study by Stevenson et al. (2009) 
which was also based on the SHEMO model with updated parameter estimates and 
assumptions. It aimed to evaluate the clinical and cost-effectiveness of vitamin K in preventing 
fractures in postmenopausal women at high risk of fracture. Vitamin K therapy was compared 
with other licensed interventions such as bisphosphonates (alendronate and risedronate) and 
strontium ranelate. Due to As this model used recent data, has been applied extensively in the 
UK and the base model was assessed highly for methodological rigour in Müller et al. (2012), 
this model by Stevenson et al. (2009) was used as a basis of the model reported in this thesis.  
 
 
7.3. Methods for osteoporosis modelling 
 
 
7.3.1. Definition of osteoporosis used in the model 
 
As in Kanis and Gluer (2000), osteoporosis was defined as having a T-score, measured at 
femoral neck, of -2.5 SDs below the mean of the female reference group (both for men and 
women).  The same female reference group was chosen to define osteoporosis for both men 
and women as it has been shown that men and women have a similar fracture risk at a given 
level of absolute BMD measured (Langsetmo et al., 2010). Thus, men with a similar absolute 
BMD level would have a similar fracture risk to women.  
As Stevenson et al. (2009) focussed on female population only, all parameter values used in 
their model were for women only. Wherever possible, secondary data sources reported by 
Stevenson et al. (2009) were sought to find equivalent data for men. Otherwise, alternative 
data sources were used or assumptions were made given that a dominant number of 
osteoporosis studies analysed only a female population.  
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7.3.2. Structure of the model used in this thesis 
 
Stevenson et al. (2009) constructed a patient-based state-transition model with time slices of 1 
year, in Microsoft Excel (Microsoft Corporation). The HTA model included four main fracture 
types (hip, vertebral, wrist and proximal humerus fractures); nursing home entry from hip 
fracture event; breast cancer; and coronary heart disease; and non-fracture related death 
events.  
As in Stevenson et al. (2009), the main four fracture sites were assumed to include other 
relevant fractures. Hip fracture incorporated pelvis and other femoral fractures; proximal 
humerus fracture included tibia and fibula fracture; and wrist fracture included rib, sternum, 
clavicle and scapula fractures.  
Breast cancer, which was technically included in the model by Stevenson et al. (2009), was not 
incorporated in this model. This had been included in earlier versions of the SHEMO models in 
order to evaluate oestrogen and raloxifene treatments which could affect the risk of breast 
cancer. However, both of these treatments were not considered in the model by Stevenson et 
al. (2009). For the assessment of osteoporosis treatments (see Section 7.3.8), effect on the 
incremental cost and QALY outcomes due to the removal of breast cancer is expected to be 
minor.  
The model in this thesis was constructed on the platform of discrete event simulation (Figure 
7.1). As no fixed time cycles were assumed, all transition probabilities reported in Stevenson et 
al. (2009) were converted to event rates, which are the instantaneous likelihood of event 
occurring per unit of time, unlike probabilities defined over a fixed period of time. Events 
included in the model for this thesis were the four fractures (hip, vertebral, wrist and proximal 
humerus fractures) including nursing home entry from hip fracture; death following fracture; 
and non-fracture related death.  The initiation and discontinuation of a drug treatment were 
also included as qualifying events. It is noted that the model for this thesis included fractures 
occurring to both osteoporotic and non-osteoporotic populations, as in Stevenson et al. (2009). 
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Figure 7.1. Structure of the osteoporosis model 
 
 
As in the heart disease model in Chapter 5, the ‘utility cut off’ event was included in the model 
in order to reflect that costs and utilities for the first year and subsequent years after a 
fracture could be different. This event activates a transient utility state where a different utility 
value is applied when there is no actual disease event. When more than one fracture event 
occurs within a year, the cut-off time point dividing the first year and subsequent years for one 
fracture would be greater than the time to the next fracture, leading to an overlap of the first-
year periods. The logic was constructed so that the changes in utility respected both times of 
subsequent fractures and changes in utility after one year.  
The discount rates used for the model were 3.5% per annum for both costs and utilities in 
accordance with the NICE recommendation. A lifetime horizon was adopted whilst the time 
horizon of the model by Stevenson et al. (2009) was a 10-year period with the model results 
subsequently adjusted to account for treatment benefits beyond the initial 10 years.  
The UK general population aged 45 years and over was chosen for the base-case analysis as in 
the other disease models in Chapters 5 and 6. A summary of model assumptions is provided in 
Box 7.1 and is detailed in subsequent sections. 
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Box 7.1. Model assumptions 
 Costs and utilities for the first year and subsequent years after a fracture are different. 
 The Z-score of an individual is assumed to remain constant across time. 
 The difference in average T-score between men and women for all age groups is 
assumed to be constant. 
 The risk of having fracture following a previous fracture is assumed to be double that 
of a women without a previous fracture, as in Stevenson et al. (2009). 
 Drug treatment is initiated when women and men have an osteoporotic fracture.  
 The duration of the drug treatment was assumed to be 5 years. After the 
discontinuation of the 5-year treatment, the treatment would not be given to the 
same person again.  
 The efficacy of the drug treatment wanes over a 5-year period after treatment 
discontinuation in a linear fashion.  
 Nursing home stay is associated with lower utility. The same utility weight as that for 
institutionalised AD patients was used.  
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7.3.3. T-score, Z-score, and prevalence of osteoporosis at model entry 
 
 
Z-score is defined as the number of SDs from the average BMD of people of the same age and 
sex as the patient, which is equivalent to the T-score of an individual minus the average T-
score for that age and sex. The Z-score is assumed to follow standard Normal distribution: a 
person who is average has a Z-score of zero and is at the 50th percentile, and approximately a 
quarter of people have a Z-score of -0.68 or lower. In the model for this thesis, the Z-score was 
assumed to remain constant for an individual across time. It is noted that T-score would, 
however, change as the mean T-score differ by age.  
The average T-score at the femoral neck for females was calculated using values at the mid-
point of each age band derived from a linear relationship,  𝑇 − 𝑠𝑐𝑜𝑟𝑒 = 2.0251 − (0.0512 ×
𝐴𝑔𝑒 𝑖𝑛 𝑦𝑒𝑎𝑟𝑠), which was estimated from a UK population-based study by Holt et al. (2002).  
Although the average T-scores were reported only for people aged 50 and over, the value for 
the age band of 45-49 was calculated backwards using the same linear relationship. The 
average T-score for the age band 85-89 were used for those aged 85 years and over.   
The average UK T-scores were reported only for female population in Stevenson et al. (2009). 
The raw data from which the figures for female population were derived (Holt et al., 2002) 
could not be obtained for male population, hence the average difference between men and 
women in the population of the study by Holt et al. (2002) was applied to calculate the average 
T-scores for men (Table 7.1).  The difference was calculated using T-scores measured at the 
femoral neck.  A constant difference between men and women for all age groups was used.  
However, it is noted that this assumes that the same rates of deterioration in BMD for age 
groups and equal age distributions for men and women, an assumption that is uncertain.  
The T-score of an individual was derived from the sum of the average T-score for the age group 
and sex of the person and the sampled Z score. Gradual deterioration of T-score on a 
continuous time scale or at regular time intervals was not recorded in the model. Instead, T-
score was updated before every occasion where the current T-score could influence 
parameters of equations used to estimate time to next event, and consequently, costs and 
utility values. Prevalence of osteoporosis was determined when this T-score was lower than -
2.5 SDs.  
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Table 7.1. Average T score for men and women in the UK by age band 
Age in years 
(mid-point) 
Average UK T score for 
women 
Average UK T score for 
men* 
45-49 (47.5) -0.41 0.31 
50-54 (52.5) -0.66 0.06 
55-59 (57.5) -0.92 -0.20 
60-64 (62.5) -1.17 -0.45 
65-69 (67.5) -1.43 -0.71 
70-74 (72.5) -1.69 -0.97 
75-79 (77.5) -1.94 -1.22 
80-84 (82.5) -2.20 -1.48 
85-89 (87.5) -2.45 -1.73 
*T-scores for men were calculated as T-scores for women +0.72 (the men-women difference in 
Holt et al. (2002))  
 
 
7.3.4. History of previous osteoporotic fracture at model entry 
 
Previous osteoporotic fracture could affect the risk of subsequent fractures and utility values.  
Upon the entry to the model, a proportion of people with prevalent osteoporosis (T-score of -
2.5 or lower) were assigned to have a history of previous osteoporotic fractures at different 
sites. As in Stevenson et al. (2009), ‘severe osteoporosis’ was used to describe osteoporosis 
patients with a prior fracture. The proportion of people with severe osteoporosis in the UK 
female population reported in Stevenson et al. (2009) was split into groups of people with 
fracture history at four different sites, using the distribution of fractures by age and gender.   
The model for this thesis included fractures occurring to both osteoporotic and non-
osteoporotic populations. However, this section concerns people with severe osteoporosis 
who have a history of fracture at model initiation: only osteoporotic fractures were considered.  
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Table 7.2 shows the proportion of women with severe osteoporosis. Stevenson et al. (2009) 
calculated the percentage of people with severe osteoporosis at each age using data from 
Kanis et al. (2000) on the incidence of fractures in men and women by fracture site. The ratio 
of people with severe osteoporosis to the total osteoporotic population was calculated for 
each age group using data reported in Stevenson et al. (2009) (Table 40, Appendix 7).  As data 
on the proportion of people with severe osteoporosis was available only for the female 
population and the underlying calculations were not shown in Stevenson et al. (2009), it was 
assumed that the ratio of people with severe osteoporosis to people with osteoporosis is 
maintained for the male population and the ratio for the age band 75-79 was also used for 
people aged 80 years and over. Due to lack of data, it was also assumed that those aged 45-49 
years did not have severe osteoporosis.   
 
Table 7.2. Proportion of people with severe osteoporosis 
Age Proportion of 
women with 
osteoporosis 
(including severe) (A) 
Proportion of women 
with severe osteoporosis 
(among all female 
population) (B) 
Proportion of severe 
osteoporosis among 
osteoporotic 
population (B/A)* 
50-54 3.29% 0.49% 14.89% 
55-59 5.71% 2.4% 42.03% 
60-64 9.18% 5.28% 57.52% 
65-69 14.23% 9.46% 66.48% 
70-74 20.9% 15.6% 74.64% 
75-79 28.77% 22.4% 77.86% 
*B/A was assumed to maintain for male population.  
 
In order to assign a history of fracture at different sites to individuals with severe osteoporosis, 
distributions of four fracture sites were derived (Table 7.3).  The distribution of fracture sites 
by age and sex was calculated by summing the proportions of fractures at different sites 
reported in Kanis et al. (2007) (Table 15; reproduced from Table 3 in Kanis et al. (2001)). The 
four sites of fractures incorporated other relevant fracture sites as in Stevenson et al. (2009) 
(see Section 7.3.5). Hip fracture included pelvis and other femoral fractures; proximal humerus 
fracture included tibia and fibula, and humeral shaft fractures; and wrist fracture incorporated 
distal forearm, rib, clavicle, scapula, and sternum fractures. In the model for this thesis, only 
one previous fracture per person with severe osteoporosis was assigned according to the 
distribution of fractures with the location of their previous fracture occurred based on data in 
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Table 7.3. The fracture site was randomly sampled from the distribution of fractures 
(proportions of each fracture sites were calculated to match 100% using the proportion of 
fractures at different sites reported in Kanis et al. (Kanis et al., 2001, Kanis et al., 2007).  
 
Table 7.3. Distribution of fractures at model entry at different sites 
 Women Men 
Age Hip Vertebral 
Proximal 
humerus 
Wrist Hip Vertebral 
Proximal 
humerus 
Wrist 
50-54 5.6% 15.1% 21.0% 58.2% 7.7% 21.9% 9.8% 60.6% 
55-59 10.0% 12.7% 19.9% 57.4% 7.8% 9.1% 3.2% 79.9% 
60-64 15.5% 19.2% 16.3% 49.1% 16.0% 20.3% 7.2% 56.5% 
65-69 18.2% 16.4% 21.3% 44.0% 17.4% 12.1% 6.2% 64.3% 
70-74 26.6% 20.0% 15.9% 37.5% 23.5% 19.9% 11.0% 45.6% 
75-79 31.8% 17.3% 15.4% 35.6% 33.8% 19.5% 7.5% 39.2% 
 
 
   
7.3.5. Fracture risks  
 
The risks of fracture for the general population including people with and without osteoporosis 
were split into the baseline risks for a population with average BMD and no previous fracture 
and the risks for a more severe population. The risks for a population with high BMD were 
estimated assuming that risk reductions are made by the same factor as the risk increases, but 
in the opposite direction. This section first describes the risks for the general population, and 
moves onto how fracture risks were adjusted for low BMD, other relevant fracture sites, and 
previous fracture; and how the baseline risks for those with normal BMD and no previous 
fracture were calculated based on the population-level risks and the relative risks for high-risk 
populations.  
 
Population level risks of the four main fractures 
 
Both osteoporotic and non-osteoporotic populations are at risk of fracture. Hence, this section 
concerns total fracture risks. It is noted that, at model initiation, previous osteoporotic fracture 
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was assigned in order to incorporate the increased risk of future fracture for people with 
severe osteoporosis.  
Stevenson et al. (2009) estimated the risks of fractures at four different sites by fitting an 
exponential regression to smooth the data taken from a large Scottish study by Singer et al. 
(1998). The estimated exponential survival function was used to extrapolate the incidence to 
those aged 50 years and under for the model in this thesis.  The female population risks of 
fractures estimated from the study by Singer et al. (1998) are summarised in Table 7.4.  
 
Table 7.4. Annual female population risks of fractures  
Female population risk of fracture 
Age Hip 
fracture 
Vertebral 
fracture 
Proximal 
fracture 
Wrist 
fracture 
45-50 0.0003 0.0009 0.0007 0.0031 
50-55 0.0003 0.0009 0.0007 0.0031 
55-60 0.0006 0.0013 0.0009 0.0036 
60-65 0.0011 0.0019 0.0012 0.0043 
65-70 0.002 0.0028 0.0015 0.0051 
70-75 0.0038 0.004 0.002 0.0061 
75-80 0.0073 0.0059 0.0026 0.0072 
80-85 0.0138 0.0085 0.0035 0.0086 
85-90 0.0262 0.0123 0.0046 0.0102 
Adapted from Table 13 in Stevenson et al. (2009)
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Increased risks of fracture incorporating sites other than the four 
 
As in Stevenson et al. (2009), other fracture sites were incorporated into the four main 
fracture types. This was in order to use a meta-model that Stevenson et al. (2004) previously 
estimated. The meta-model was used to instantaneously calculate incremental costs and 
QALYs with a different parameter configuration in Stevenson et al. (2009). Hence, in order to 
use Stevenson et al. (2009) as the basis of the model in this thesis, the incidence of hip, 
vertebral, wrist and proximal humerus factures shown in Table 7.4 was adjusted to incorporate 
the incidence of fractures at other sites using multipliers reported in Table 7.5. The incidence 
of vertebral fractures was not increased as in Stevenson et al. (2009).  
 
Table 7.5. The multipliers used to incorporate fractures at other sites 
Age 
(years) 
Increase in hip 
fracture incidence to 
incorporate pelvis and 
other femoral 
fractures 
Increase in proximal 
humerus fracture 
incidence to 
incorporate tibia and 
fibula fractures 
Increase in wrist 
fracture incidence to 
incorporate rib, 
sternum, clavicle and 
scapula fractures 
45-50 1.26 1.87 1.63 
50-55 1.26 1.87 1.63 
55-60 1.25 1.75 1.33 
60-65 1.23 1.63 1.17 
65-70 1.22 1.51 1.14 
70-75 1.2 1.39 1.24 
75-80 1.19 1.27 1.48 
80-85 1.17 1.15 1.86 
85-90 1.17 1.15 1.86 
Adapted from Table 14 in Stevenson et al. (2009) 
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Increased risks due to low BMD 
 
The population risks of fracture were adjusted for BMD status. The increased probabilities of 
fracture associated with a Z score of -1 SD reported in Stevenson et al. (2009) were used (Table 
7.6-7.7). The risk of hip fracture was adjusted using the data reported by Johnell et al. (2005). 
In Table 7.6, the increase factor for hip fracture in people aged 45-50 years was assumed to be 
the same as that in 50-55 year olds.  For other fractures, a single factor was used for all ages 
and sexes based on the data reported by Marshall et al. (1996) (Table 7.7). 
 
Table 7.6. Increased risk of hip fracture associated with a Z-score of -1 SD 
Age 
Increased risk of hip 
fracture 
45-49 
3.68 
50-54 
3.68 
55-59 
3.35 
60-64 
3.07 
65-69 
2.89 
70-74 
2.78 
75-79 
2.58 
80-84 
2.28 
85-90 
1.92 
 
 
Table 7.7. Increased risk of fracture associated with a Z-score of -1 SD 
 Increased risk of fracture 
per -Z score 
Vertebral fracture 1.8 
Proximal humerus 
fracture 
1.6 
 
Wrist fracture 1.4 
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The increased risk of fracture factor was used as the base raised to the power of the minus Z-
score of the individual. For example, for a patient aged 67 years with a Z-score of -1.5 SDs, the 
risk of hip fracture is 4.91 times (=2.891.5) the general population risk. These values were used 
in the same way for those with positive Z-score. Hence, for those whose BMD is higher than 
the average of the same age and sex group, the fracture risks were reduced. For example, the 
risk of vertebral fracture for people with a Z score of +1.5 would be 41.4% (=1.8(-1.5)) of the 
general population risk.  
 
Increased risks after previous fracture 
 
Previous fractures increase the risk of subsequent fractures. The incidence rate of fractures 
was adjusted for previous fracture history.  Stevenson et al. (2009) used the results from 
Klotzbuecher et al. (2000) and the summary of the relative risks used in the model in this thesis 
is given in Table 7.8.  
 
Table 7.8. The relative risk of subsequent fracture following an initial fracture 
Previous fracture Subsequent fractures 
 Hip Vertebral Proximal humerus Wrist 
Hip 2.3 2.5 1.9 1.4 
Vertebral 2.3 4.4 1.8 1.4 
Proximal 
humerus 
2.0 1.9 1.9 1.8 
Wrist 1.9 1.7 2.4 3.3 
  
As in Stevenson et al. (2009), it was assumed that only the greatest risk adjustment would be 
applied for people who have history of fractures at two or more fractures. Hence, for example, 
if an individual had suffered a vertebral fracture previously, regardless of other fracture history, 
the RR adjustment for hip fracture and vertebral fracture would be 2.3 and 4.4, respectively.  
Adjustments for the relative risks associated with BMD status and previous fracture were 
made to the general population probability (risk) of fracture. As the model adopts the DES 
structure, the adjusted probabilities were converted to event rates (hazards).  
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Baseline risks for people with average BMD and without previous fractures 
 
Using the population-level risks of fracture including osteoporotic and non-osteoporotic 
populations and the relative risks associated with previous fracture and BMD, the baseline 
risks of fracture for people with average BMD and no previous fracture were estimated. The 
methodology reported in Stevenson et al. (2009) was followed to estimate the baseline risks of 
fracture for all age groups included in the model for this thesis (age 45 years and over). The 
assumptions and calculations were reported briefly in this section.  
The population risks reported in Table 7.4 was split into risks for three groups: women with a 
T-score of less than -2.5 SDs and a previous fracture (Group A); women with a T-score of -2.5 
SDs or less and without a previous fracture (Group B); and women with an average BMD (i.e. Z 
score of zero) and without a previous fracture (Group C). The risks in Group C were used as the 
baseline risks.  
Then, the average population risks (in Table 7.4) could be expressed as a linear combination of 
the risks for Groups A, B, and C with the weights of percentages of people in the three Groups: 
[Proportion of people in Group A (%) *Risk for Group A] +[Proportion of people in Group 
B (%) *Risk for Group B]+ [Proportion of people in Group C (%) *Risk for Group C] 
This can be expanded with respect to the baseline risk for Group C: 
[Proportion of people in Group A (%) *RR group A*Risk for Group C]+ [Proportion of 
people in Group B (%) *RR for Group B*Risk for Group C]+ [Proportion of people in 
Group C (%) *Risk for Group C] 
This will allow the estimation of Group C risks.  
Table 7.9 compares the T-score values of the average female population and of those with 
osteoporosis.  
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Table 7.9. T-score of the average female population and of those with osteoporosis 
Age Average T-
score for the 
UK female 
population 
Average T for 
patients with T-
score <-2.5 SDs 
Reduction in Z-
score between 
osteoporotic 
women and 
those with 
average BMD 
45-49 -0.41 -2.82* 2.41 
50-54 -0.66 -2.82 2.16 
55-59 -0.92 -2.72 1.80 
60-64 -1.17 -2.78 1.61 
65-69 -1.43 -2.84 1.41 
70-74 -1.69 -3.00 1.31 
75-79 -1.94 -2.97 1.03 
80-84 -2.20 -2.97 0.77 
85-89 -2.45 -2.97 0.52 
*Assumed to be the same as the value for age group 50-55.  
 
Using the data provided in Tables 7.6, 7.7 and 7.9, RRs associated with having low BMD with 
and without previous fracture were calculated (Table 7.10). It was assumed that the risk of 
fracture following a previous fracture is double that of a women without a previous fracture. 
Also, as data were available only for those aged 50 years and over in Stevenson et al. (2009), 
the model in this thesis assumed that the increased risk of fracture associated with a Z-score of 
-1 SD reported in Tables 7.6 and 7.7 are also applicable to the age group 45-50 years.  
Using the linear combination shown above, the baseline risks for Group C were calculated. The 
results in Table 7.11 do not incorporate fractures at other associated sites.  
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Table 7.10. The relative risks of fracture for women with low bone mineral density with and 
without previous fracture 
 Hip fracture Vertebral fracture Proximal fracture Wrist fracture 
Age 
(years) 
Group 
A 
Group B Group A Group B Group A Group B Group 
A 
Group 
B 
45-49 46.40 23.20 8.26 4.13 6.22 3.11 4.50 2.25 
50-54 33.24 16.62 7.11 3.55 5.51 2.76 4.13 2.07 
55-59 17.65 8.82 5.77 2.88 4.66 2.33 3.67 1.83 
60-64 12.10 6.05 5.14 2.57 4.25 2.13 3.43 1.72 
65-69 8.92 4.46 4.58 2.29 3.88 1.94 3.21 1.61 
70-74 7.66 3.83 4.33 2.16 3.71 1.85 3.11 1.56 
75-79 5.29 2.65 3.66 1.83 3.24 1.62 2.83 1.41 
80-84 3.78 1.89 3.15 1.57 2.87 1.44 2.59 1.30 
85-89 2.80 1.40 2.71 1.35 2.55 1.27 2.38 1.19 
 
 
Table 7.11. Baseline risks of fracture for Group C (not incorporating fractures at other fracture 
sites) 
Age (years) Hip fracture Vertebral 
fracture 
Proximal 
humerus 
fracture 
Wrist fracture 
45-49 0.019% 0.083% 0.066% 0.299% 
50-54 0.019% 0.082% 0.065% 0.297% 
55-59 0.036% 0.110% 0.080% 0.330% 
60-64 0.062% 0.148% 0.099% 0.372% 
65-69 0.104% 0.200% 0.114% 0.412% 
70-74 0.174% 0.253% 0.136% 0.449% 
75-79 0.353% 0.358% 0.169% 0.502% 
80-84 0.822% 0.560% 0.242% 0.625% 
85-89 1.834% 0.875% 0.337% 0.772% 
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The increased risk multipliers to incorporate the incidence of fracture at other sites reported in 
Table 7.5 were applied to the baseline risks in Table 7.11, and these risks were converted to 
rates. The converted baseline event rates for the female population are provided in Table 7.12. 
For example, the risk of hip fracture incorporating fracture at other sites for women aged 65-
70 years was calculated as 0.127%, by multiplying 0.104% (Table 7.11) by the increase factor of 
1.22 (Table 7.5). This equated to an annual rate of 0.0013 (=-ln(1-0.127%)).  
 
Table 7.12. Baseline incidence rates for female population with a Z-score of 0 SD and no 
previous fracture (annual incidence rates incorporating other fracture sites) 
Age (years) Hip fracture Vertebral 
fracture 
Proximal 
humerus 
fracture 
Wrist 
fracture 
45-49 0.0002 0.0008 0.0012 0.0049 
50-54 0.0002 0.0008 0.0012 0.0048 
55-59 0.0005 0.0011 0.0014 0.0044 
60-64 0.0008 0.0015 0.0016 0.0044 
65-69 0.0013 0.0020 0.0017 0.0047 
70-74 0.0021 0.0025 0.0019 0.0056 
75-79 0.0042 0.0036 0.0021 0.0075 
80-84 0.0097 0.0056 0.0028 0.0117 
85-89 0.0217 0.0088 0.0039 0.0145 
 
 
In order to estimate the baseline fracture risks for men, the baseline incidence for female 
population was adjusted using incidence ratio of men to female population (Table 7.13). The 
incidence ratios of males to females for fractures at different sites were obtained by dividing 
the incidence of each fracture for male population by that for female population using data 
from Kanis et al. (2000). It was assumed that distal forearm fractures represent wrist fracture, 
and that the incidence ratio for the 45-49 age group was the same as that for 50-54 group.  
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Table 7.13. Incidence ratios of males to females (men/women)†  
 Incidence Ratio (men/women) 
Age (years) 
Hip Vertebral Proximal humerus Wrist 
45-49 
1.43* 1.21* 0.52* 0.24* 
50-54 
1.43 1.21 0.52 0.24 
55-59 
1.55 0.75 0.24 0.33 
60-64 
0.37 0.75 0.47 0.25 
65-69 
0.65 0.55 0.26 0.41 
70-74 
0.54 0.64 0.54 0.10 
75-79 
0.48 0.56 0.28 0.17 
80-84 
0.70 0.80 0.40 0.21 
85-89 
0.46 0.73 0.45 0.23 
†Calculated from Kanis et al. (2000); *Assumed the same as the value for age 50-54 group. 
 
These incidence ratios were applied to the baseline fracture risks for the female population 
incorporating fracture at other sites to derive those for male population (Table 7.14). All other 
RR adjustments were applied in the same way as female population. For men aged 75-80 years, 
the baseline incidence of vertebral fracture was 0.0020 (=0.0036 (Table 7.12) × 0.5572 (Table 
7.13)). This is equal to the annual probability of 0.0020 (= 1 − 𝑒−0.0020). For men with a Z-
score of -1.5 SDs, the annual probability of vertebral fracture increases by 2.415 (=1.81.5) times, 
resulting in 0.00482, which is equivalent to an incidence rate of 0.00483.  
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Table 7.14. Baseline incidence rates for male population with average BMD and no previous 
fracture 
Age (years) 
Hip fracture 
Vertebral 
fracture 
Proximal 
humerus 
fracture 
Wrist fracture 
45-49 
0.0003 0.0010 0.0006 0.0012 
50-54 
0.0003 0.0010 0.0006 0.0012 
55-59 
0.0007 0.0008 0.0003 0.0015 
60-64 
0.0003 0.0011 0.0008 0.0011 
65-69 
0.0008 0.0011 0.0004 0.0019 
70-74 
0.0011 0.0016 0.0010 0.0005 
75-79 
0.0020 0.0020 0.0006 0.0013 
80-84 
0.0068 0.0045 0.0011 0.0025 
85-89 
0.0099 0.0064 0.0018 0.0034 
 
 
The age-group specific incidence rates after adjustments for previous fracture and T-score 
were used to sample time to fracture at each site. Time to fracture was sampled using the 
technique described in Chapter 4, that is, when time to next age band was reached before the 
sampled time to fracture, the incidence rate was replaced by the incidence rate for the new 
age band and the time to the next age-band was assumed fracture free. The age-specific 
adjustment for the risk of hip fracture associated with a Z-score of -1 SD (Table 7.6) was 
applied in the same way. Hence, the incidence rate was increased if the time points when a 
change in age band was reached before the sampled time to next event.  
The baseline fracture risks for the 45-49 age group were nearly identical to those for 50-54 
group, as some values for the age group 45-49 years were assumed to be the same as those of 
the adjacent 50-54 group when calculating the baseline risks. However, it is noted that the 
final fracture risks for this group will be generally lower than those for the 50-54 years group 
due to the adjustments for previous fracture and T-score. For example, no history of previous 
fracture was assigned to those aged 45-49 years at the start of the model due to the 
unavailability of data. 
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7.3.6. Nursing home entry following hip fracture 
 
It was assumed that only hip fracture (including pelvis or other femoral fractures) could result 
in entry into nursing home. The percentage of people who move from the community to a 
nursing home following a hip fracture calculated using data from the second East Anglian audit 
of hip fracture (Freeman et al., 2002) is shown in Table 7.15. As in the AD model, it was 
assumed that people who entered a nursing home will not return to community dwelling. The 
same percentages were applied to men.  
 
Table 7.15. Percentage of people who move to a nursing home following a hip fracture 
Age (years) Percentage 
50-59 0% 
60-69 4% 
70-79 4% 
80-89 12% 
90+ 17% 
 
 
7.3.7. Mortality 
 
Mortality following fracture 
 
Excess mortality after hip fracture was included in Stevenson et al. (2009). Mortality rates that 
were assumed attributable to hip fracture were estimated from data reported in the second 
East Anglian audit of hip fracture (Freeman et al., 2002). The percentage of hip fracture that 
was assumed to result directly in death reported in Stevenson et al. (2009) was used in the 
model for this thesis (Table 7.16). Although 90-day mortality rates were used for the 
estimation, it was assumed that these patients die immediately after hip fracture in the model. 
These values were assumed to be applicable for pelvis and other femoral fractures as in 
Stevenson et al. (2009).  
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Table 7.16. Percentage of hip fractures that result directly in mortality 
Age (years) Percentage of hip fractures that result directly in 
mortality by residential status 
 Community Nursing home 
<59 2% 0% 
60-69 6% 0% 
70-79 6% 13% 
80-89 11% 22% 
90+ 16% 23% 
  
The model for this thesis could not easily incorporate a hazard ratio (HR) for mortality 
following vertebral fracture as assumed in Stevenson et al. (2009) using a HR of 4.4 (95% CI 
1.85 to 10.6). This was due to time to death sampled directly from discrete probability 
distributions derived from annual mortality rates (see Chapter 4), rather than from a 
parametric distribution with a rate parameter to which a HR could be applied. Hence, for 
simplicity, the time to non-disease death values were reduced by a factor of the rate ratios for 
the mortality of people with and without prevalent vertebral fracture (Table 7.17) estimated 
using data from a UK study (Jalava et al., 2003) in order to reflect the increased mortality 
following vertebral fracture. It was further assumed that vertebral fractures affect mortality 
only for one year after the fracture, so the reduced time-to-death was not applied if it was 
greater than one year. For example, if the remaining time to non-disease death was 12 years 
when a 65-year-old person had a vertebral fracture, time to death following the fracture could 
become 3 years (=12/4) using the ratio for the 60-69 age group, but as this was longer than 1 
year, it was not used and the original time-to-death of 12 years was applied.  
 
Table 7.17. Ratio of mortality rates of people with prevalent vertebral fracture to those 
without vertebral fracture 
 Vertebral fracture Proximal humerus 
fracture 
Age (years) ≤59 60-69 ≥70  
Rate ratio 6.67 4.00 3.75 2.00* 
*Only 28% of time to deaths to which this factor was applied were used in the model; (Jalava 
et al., 2003, Kanis et al., 2004a);  
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In line with assumptions made by Stevenson et al. (2009), no increase in mortality from wrist 
fractures (incorporating rib, sternum, clavicle and scapula) was assumed.  For proximal 
humerus fractures, it was assumed that the fractures will double the mortality and that 28% of 
deaths associated with humeral fractures are causally related (Kanis et al., 2004a). The 
increase in mortality was applied in the same way as that for vertebral fracture, assuming that 
fractures at proximal humerus increase mortality risk only in the first year.  
 
Mortality due to other causes 
 
In Stevenson et al. (2009), mortality rates for the general female population taken from 1999 
interim life tables were adjusted to incorporate mortality associated with low BMD. A factor of 
1.22 per SD decrease was applied to the probability of death for the general population 
(Browner et al., 1991). The data provided in Stevenson et al. (2009) reported summary 
probabilities for different age bands and for women only. The model for this thesis used data 
from interim life tables based on 2009-2011 data (Office for National Statistics, 2013b) and the 
distributions for time to death were constructed based on the mortality rates adjusted for low 
BMD for each yearly age and sex.  
The same factor of 1.22 was used in the model for this thesis to adjust the mortality risks for 
low BMD assuming that the mortality for the general population is associated with the average 
T score for each age and sex group. The individual’s risk of mortality was then calculated from 
their Z-score (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑖𝑠𝑘 × 1.22(−𝑧−𝑠𝑐𝑜𝑟𝑒)).  
All-cause mortality obtained from interim life tables was adjusted according to an individual’s 
Z-score. To simplify the analyses, it was assumed that broad Z-score bands could be used 
rather than the exact Z-score of an individual.  These Z-score bands were combined with age 
and gender to estimate mortality. These data are shown in Table 7.18 with the rates calculated 
using the mid-points of the Z-score ranges and each yearly age. Table 7.19 summarises the 
mortality rates of the general female population and those of women with a T-score of -2.5 
SDs.  
In models considering osteoporosis and another of the chosen diseases, the mortality rates 
associated with BMD replaced the distributions for time to non-disease death used in the 
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other individual disease models. Therefore, time to non-disease death sampled in the all-
disease linked model reflected the BMD status of all modelled individuals. Further distributions 
removing the estimated rate of cardiac death were calculated when a model linking 
osteoporosis and heart disease was used (mortality rates reported in Appendix 7.1 Table 7.18’).  
It is noted that the use of the distributions based on the ranges of Z-score could cause average 
life years from the model in this chapter to be different from those from the other disease 
models due to the difference in distributions for time to non-disease death. Also, the adjusted 
mortality rates in Table 7.18 extrapolated beyond the evidence adopted in Stevenson et al. 
(2009): studies have suggested that low BMD is associated with increased mortality. As the 
model by Stevenson et al. (2009) included only postmenopausal women with low BMD, only 
this assumption on the association between low BMD and mortality was used (Browner et al., 
1991, Johansson et al., 1998). However, in order to maintain the total mortality across groups 
of population with different BMD levels, reduced mortality risk was assumed in the model for 
this thesis for those with BMD higher than average.   
Whilst Z-scores have a symmetrical distribution centred on zero, the risk of death is associated 
with the Z-score in a non-linear fashion, which may result in differences in the sample means 
of time to non-disease death between the distributions based on Z-score and those based on 
age and sex only.  
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Table 7.18. Mortality rates due to causes other than fractures in association with BMD 
 Z score = -2 SD 
(-2.5, -1.5) 
Z score = -1 SD 
(-1.5, -0.5) 
Z score = 0 SD 
(-0.5, 0.5)  
General population 
Z score = 1 SD 
(0.5, 1.5) 
Z score = 2 SD 
(1.5, 2.5) 
Age Women Men Women Men Women  Men  Women  Men Women Men 
45 0.21% 0.33% 0.17% 0.27% 0.14% 0.22% 0.11% 0.18% 0.09% 0.15% 
46 0.22% 0.35% 0.18% 0.29% 0.15% 0.23% 0.12% 0.19% 0.10% 0.16% 
47 0.23% 0.36% 0.19% 0.29% 0.16% 0.24% 0.13% 0.20% 0.11% 0.16% 
48 0.26% 0.40% 0.21% 0.33% 0.17% 0.27% 0.14% 0.22% 0.12% 0.18% 
49 0.29% 0.43% 0.24% 0.35% 0.20% 0.29% 0.16% 0.24% 0.13% 0.20% 
50 0.32% 0.46% 0.26% 0.38% 0.22% 0.31% 0.18% 0.25% 0.15% 0.21% 
51 0.34% 0.53% 0.28% 0.43% 0.23% 0.36% 0.19% 0.29% 0.16% 0.24% 
52 0.40% 0.60% 0.32% 0.49% 0.27% 0.40% 0.22% 0.33% 0.18% 0.27% 
53 0.43% 0.64% 0.35% 0.53% 0.29% 0.43% 0.23% 0.35% 0.19% 0.29% 
54 0.49% 0.69% 0.40% 0.56% 0.33% 0.46% 0.27% 0.38% 0.22% 0.31% 
55 0.51% 0.78% 0.42% 0.64% 0.34% 0.52% 0.28% 0.43% 0.23% 0.35% 
56 0.57% 0.88% 0.46% 0.72% 0.38% 0.59% 0.31% 0.48% 0.26% 0.40% 
57 0.62% 0.93% 0.51% 0.76% 0.41% 0.63% 0.34% 0.51% 0.28% 0.42% 
58 0.66% 1.04% 0.54% 0.85% 0.44% 0.70% 0.36% 0.57% 0.30% 0.47% 
59 0.73% 1.11% 0.60% 0.91% 0.49% 0.75% 0.40% 0.61% 0.33% 0.50% 
60 0.79% 1.24% 0.65% 1.01% 0.53% 0.83% 0.44% 0.68% 0.36% 0.56% 
61 0.86% 1.32% 0.70% 1.08% 0.58% 0.89% 0.47% 0.73% 0.39% 0.59% 
62 0.91% 1.41% 0.74% 1.16% 0.61% 0.95% 0.50% 0.78% 0.41% 0.64% 
63 1.01% 1.56% 0.83% 1.28% 0.68% 1.05% 0.56% 0.86% 0.46% 0.70% 
64 1.11% 1.71% 0.91% 1.40% 0.74% 1.15% 0.61% 0.94% 0.50% 0.77% 
65 1.22% 1.88% 1.00% 1.54% 0.82% 1.26% 0.67% 1.04% 0.55% 0.85% 
66 1.35% 2.11% 1.11% 1.73% 0.91% 1.42% 0.74% 1.16% 0.61% 0.95% 
67 1.44% 2.28% 1.18% 1.87% 0.97% 1.53% 0.79% 1.25% 0.65% 1.03% 
68 1.61% 2.56% 1.32% 2.10% 1.08% 1.72% 0.89% 1.41% 0.73% 1.16% 
69 1.81% 2.83% 1.48% 2.32% 1.21% 1.90% 0.99% 1.56% 0.82% 1.28% 
70 2.05% 3.13% 1.68% 2.56% 1.38% 2.10% 1.13% 1.72% 0.93% 1.41% 
71 2.19% 3.44% 1.80% 2.82% 1.47% 2.31% 1.21% 1.89% 0.99% 1.55% 
72 2.43% 3.80% 2.00% 3.11% 1.64% 2.55% 1.34% 2.09% 1.10% 1.71% 
73 2.65% 4.15% 2.17% 3.40% 1.78% 2.79% 1.46% 2.29% 1.20% 1.87% 
74 3.04% 4.60% 2.49% 3.77% 2.04% 3.09% 1.67% 2.53% 1.37% 2.08% 
75 3.34% 5.03% 2.73% 4.13% 2.24% 3.38% 1.84% 2.77% 1.51% 2.27% 
76 3.79% 5.71% 3.11% 4.68% 2.55% 3.83% 2.09% 3.14% 1.71% 2.58% 
77 4.28% 6.23% 3.51% 5.11% 2.87% 4.19% 2.36% 3.43% 1.93% 2.81% 
78 4.82% 6.99% 3.95% 5.73% 3.24% 4.69% 2.66% 3.85% 2.18% 3.15% 
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79 5.43% 7.78% 4.45% 6.38% 3.65% 5.23% 2.99% 4.29% 2.45% 3.51% 
80 6.18% 8.82% 5.06% 7.23% 4.15% 5.92% 3.40% 4.86% 2.79% 3.98% 
81 6.92% 9.85% 5.68% 8.08% 4.65% 6.62% 3.81% 5.43% 3.13% 4.45% 
82 7.89% 11.03% 6.47% 9.04% 5.30% 7.41% 4.35% 6.07% 3.56% 4.98% 
83 8.98% 12.16% 7.36% 9.97% 6.03% 8.17% 4.94% 6.70% 4.05% 5.49% 
84 10.06% 13.66% 8.24% 11.20% 6.76% 9.18% 5.54% 7.52% 4.54% 6.17% 
85 11.25% 15.24% 9.22% 12.49% 7.56% 10.24% 6.20% 8.39% 5.08% 6.88% 
86 12.74% 16.76% 10.45% 13.74% 8.56% 11.26% 7.02% 9.23% 5.75% 7.56% 
87 14.24% 18.87% 11.67% 15.47% 9.57% 12.68% 7.84% 10.39% 6.43% 8.52% 
88 16.00% 20.91% 13.12% 17.14% 10.75% 14.05% 8.81% 11.51% 7.22% 9.44% 
89 18.11% 23.85% 14.85% 19.55% 12.17% 16.02% 9.97% 13.14% 8.18% 10.77% 
90 20.12% 24.64% 16.49% 20.20% 13.52% 16.55% 11.08% 13.57% 9.08% 11.12% 
91 21.76% 26.47% 17.83% 21.70% 14.62% 17.79% 11.98% 14.58% 9.82% 11.95% 
92 23.81% 28.04% 19.52% 22.98% 16.00% 18.84% 13.11% 15.44% 10.75% 12.66% 
93 26.80% 31.84% 21.97% 26.10% 18.01% 21.39% 14.76% 17.53% 12.10% 14.37% 
94 30.19% 35.21% 24.75% 28.86% 20.28% 23.66% 16.63% 19.39% 13.63% 15.89% 
95 33.32% 38.28% 27.31% 31.38% 22.38% 25.72% 18.35% 21.08% 15.04% 17.28% 
96 35.83% 40.99% 29.37% 33.60% 24.07% 27.54% 19.73% 22.57% 16.18% 18.50% 
97 38.72% 44.23% 31.73% 36.26% 26.01% 29.72% 21.32% 24.36% 17.48% 19.97% 
98 41.42% 47.22% 33.95% 38.70% 27.83% 31.73% 22.81% 26.00% 18.70% 21.31% 
99 44.10% 48.83% 36.15% 40.03% 29.63% 32.81% 24.29% 26.89% 19.91% 22.04% 
100 47.48% 52.00% 38.91% 42.62% 31.90% 34.94% 26.15% 28.64% 21.43% 23.47% 
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Table 7.19. Mortality rates due to causes other than fractures in the general population and in 
people at the threshold for osteoporosis 
 General population Population with a T-score of -2.5 SDs  
Age 
(years) 
Women  Men Women Men 
45 
0.14% 0.22% 0.22% 0.40% 
46 
0.15% 0.23% 0.23% 0.42% 
47 
0.16% 0.24% 0.24% 0.42% 
48 
0.17% 0.27% 0.26% 0.47% 
49 
0.20% 0.29% 0.29% 0.50% 
50 
0.22% 0.31% 0.32% 0.53% 
51 
0.23% 0.36% 0.34% 0.60% 
52 
0.27% 0.40% 0.38% 0.67% 
53 
0.29% 0.43% 0.41% 0.71% 
54 
0.33% 0.46% 0.46% 0.75% 
55 
0.34% 0.52% 0.48% 0.84% 
56 
0.38% 0.59% 0.53% 0.94% 
57 
0.41% 0.63% 0.57% 0.99% 
58 
0.44% 0.70% 0.60% 1.09% 
59 
0.49% 0.75% 0.66% 1.15% 
60 
0.53% 0.83% 0.71% 1.27% 
61 
0.58% 0.89% 0.76% 1.34% 
62 
0.61% 0.95% 0.79% 1.42% 
63 
0.68% 1.05% 0.87% 1.56% 
64 
0.74% 1.15% 0.95% 1.69% 
65 
0.82% 1.26% 1.03% 1.84% 
66 
0.91% 1.42% 1.13% 2.04% 
67 
0.97% 1.53% 1.20% 2.18% 
68 
1.08% 1.72% 1.33% 2.43% 
69 
1.21% 1.90% 1.47% 2.66% 
70 
1.38% 2.10% 1.65% 2.91% 
71 
1.47% 2.31% 1.75% 3.16% 
72 
1.64% 2.55% 1.92% 3.46% 
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73 
1.78% 2.79% 2.07% 3.75% 
74 
2.04% 3.09% 2.35% 4.11% 
75 
2.24% 3.38% 2.55% 4.45% 
76 
2.55% 3.83% 2.88% 4.99% 
77 
2.87% 4.19% 3.21% 5.40% 
78 
3.24% 4.69% 3.58% 5.99% 
79 
3.65% 5.23% 3.99% 6.60% 
80 
4.15% 5.92% 4.50% 7.41% 
81 
4.65% 6.62% 4.99% 8.19% 
82 
5.30% 7.41% 5.63% 9.07% 
83 
6.03% 8.17% 6.34% 9.91% 
84 
6.76% 9.18% 7.03% 11.02% 
85 
7.56% 10.24% 7.78% 12.17% 
86 
8.56% 11.26% 8.73% 13.24% 
87 
9.57% 12.68% 9.65% 14.76% 
88 
10.75% 14.05% 10.74% 16.19% 
89 
12.17% 16.02% 12.03% 18.28% 
90 
13.52% 16.55% 13.23% 18.69% 
91 
14.62% 17.79% 14.16% 19.88% 
92 
16.00% 18.84% 15.34% 20.85% 
93 
18.01% 21.39% 17.09% 23.43% 
94 
20.28% 23.66% 19.06% 25.65% 
95 
22.38% 25.72% 20.82% 27.61% 
96 
24.07% 27.54% 22.16% 29.26% 
97 
26.01% 29.72% 23.71% 31.25% 
98 
27.83% 31.73% 25.11% 33.02% 
99 
29.63% 32.81% 26.46% 33.81% 
100 
31.90% 34.94% 28.19% 35.64% 
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The general population death rates (accounting for BMD level) have not been adjusted for 
fracture-related death, similar to Stevenson et al. (2009). Hence, the non-disease adjusted 
mortality rates could be slight overestimates.  In the model for this thesis, given that the rates 
of fracture-related death were applied only for one year after the fracture to a proportion 
whose death were assumed to be directly related to the fracture and a large proportion of the 
base-case population were low-risk people without osteoporosis, it was considered unlikely 
that using this non-disease adjusted mortality would change the model results significantly.  
 
 
7.3.8. Default treatment and the effect and duration of the treatment 
 
As in Stevenson et al. (2009), the default treatment assumed in this model was one of the 
second-generation bisphosphonates, 70mg alendronic acid taken once weekly.  
The NICE Technology Appraisal (TA) 161 recommends bisphosphonates (alendronate, 
etidronate and risedronate) for the secondary prevention of fragility fractures in 
postmenopausal women who have osteoporosis and have had an osteoporotic fracture.  NICE 
TA 160 relates to the primary prevention of osteoporotic fractures: alendronate is 
recommended as a first choice treatment for postmenopausal women who have had 
osteoporosis diagnosed but have not had a fracture. Both NICE TA 160 and 161 say that 
women aged 75 years and older may not need a BMD scan to have osteoporosis diagnosed. 
Since these TAs, the price of alendronate has drastically reduced (see Section 7.3.9), hence the 
decision on the use of alendronate may change upon review (ScHARR, 2015).  
In this model, the primary assumption was that any men and women at high risk of 
osteoporotic fracture would receive alendronate. The high risk of osteoporotic fracture in this 
model meant having low BMD (T-score of -2.5 SDs or less) regardless of whether or not the 
individual had sustained an osteoporotic fracture, or was a postmenopausal woman. However, 
it was considered implausible to assume everyone who is osteoporotic in the population gets 
diagnosed and receives treatment as soon as their T-score reaches the threshold for 
osteoporosis or they experience menopause. Also, although women aged 75 years and older 
are not required to have a BMD scan to receive treatment, it is not probable that every woman 
aged 75 years or older would receive the treatment. NICE guidance states that a BMD scan is 
not required when the responsible clinician considers the scan to be clinically inappropriate or 
269 
 
infeasible, and the woman aged 75 years and older has one or more independent clinical risk 
factors for fracture such as low body mass index and untreated premature menopause, but did 
not previously had a BMD test.  It is likely that only the women who have osteoporotic fracture 
or known risk factors would seek medical attention.  Hence, in this model, it was assumed that 
the treatment initiates when women and men have an osteoporotic fracture. It is noted that 
some individuals were assumed to be receiving treatment when entering the model due to 
history of previous osteoporotic fracture (severe osteoporosis) with varying time left until 
treatment discontinuation. Although NICE TAs did not cover the use of alendronate in men, it 
was assumed that men would also start receiving the treatment when they have an 
osteoporotic fracture.  
Reduction in fracture risks from the use of alendronate is shown in Table 7.20. The RRs were 
estimated from a random effects model detailed in Stevenson et al. (2009).  
 
Table 7.20. Relative risks of fracture for alendronate treatment 
Relative risks for the drug treatment (95% C.I) 
Hip fracture 0.72 (0.58-0.88) 
Vertebral fracture 0.58 (0.50-0.67) 
Other fractures 0.82 (0.74-0.90) 
 
 
The risk reduction due to the drug treatment was assumed applicable to both men and women.  
The RRs were applied to the baseline probabilities (not rates) of fractures, and the probabilities 
were converted to incidence rates. Table 7.21 shows the annual rates of fractures for those on 
drug treatment, and these can be compared with Tables 7.12 and 7.14 (Baseline incidence 
rates for female and male population with average BMD and no previous fracture).  
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Table 7.21. Incidence rates of fracture for individuals receiving the drug treatment (RRs* 
applied) 
 Female Male 
Age 
(years) 
Hip 
fracture 
Vertebral 
fracture 
Proximal 
Humerus 
fracture 
Wrist 
fracture 
Hip 
fracture 
Vertebral 
fracture 
Proximal 
Humerus 
fracture 
Wrist 
fracture 
45-50 0.0002 0.0005 0.0010 0.0040 0.0002 0.0006 0.0005 0.0010 
50-55 0.0002 0.0005 0.0010 0.0040 0.0002 0.0006 0.0005 0.0010 
55-60 0.0003 0.0006 0.0011 0.0036 0.0005 0.0005 0.0003 0.0012 
60-65 0.0005 0.0009 0.0013 0.0036 0.0002 0.0006 0.0006 0.0009 
65-70 0.0009 0.0012 0.0014 0.0039 0.0006 0.0006 0.0004 0.0016 
70-75 0.0015 0.0015 0.0016 0.0046 0.0008 0.0009 0.0008 0.0005 
75-80 0.0030 0.0021 0.0018 0.0061 0.0015 0.0012 0.0005 0.0010 
80-85 0.0070 0.0033 0.0023 0.0096 0.0049 0.0026 0.0009 0.0021 
85-90 0.0156 0.0051 0.0032 0.0118 0.0071 0.0037 0.0014 0.0028 
*RR=relative risk 
 
The duration of the drug treatment was assumed to be 5 years as in Stevenson et al. (2009).  It 
was assumed that once an individual had previously received and discontinued the drug 
treatment after five years, the treatment would not be given to the same person again.  
There were people who were already receiving the drug treatment at the entry to the model 
(i.e. either they were women aged 75 years and over or they were assigned a history of 
osteoporotic fracture at model time zero). Assuming this population had started receiving the 
drug treatment at a constant rate before model initiation, the duration of drug treatment left 
before discontinuation at the model entry was sampled from Uniform distribution with the 
lower bound of 0 and upper bound of 5 years.  
The efficacy of the drug treatment was assumed, in accordance with Stevenson et al. (2009), to 
wane over a 5-year period after treatment discontinuation in a linear fashion.  The relative 
risks of fracture for those on alendronate treatment in Table 7.20 increased in a linear manner 
since treatment cessation. Over the 5-year period, an RR was re-calculated in relation to time 
since treatment discontinuation at every yearly period from the time point where a new time 
to event is sampled.  
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When sampling time to a new fracture event, changes in fracture incidence rates due to 
changes in these RRs as efficacy waned and changes in age band were accounted for. The RR of 
fracture due to the efficacy of the drug waning was assumed to change annually.  Change in 5-
year age band and change in RR due to the waning of efficacy were acting as competing risks. 
Time to event was re-sampled when the rate of fracture changed.  
As Stevenson et al. (2009) focussed on assessing the cost-effectiveness of vitamin K treatment, 
a compliance rate applied for those receiving weekly alendronate was not mentioned in the 
description of their economic model. However, it was suggested that the compliance rate for 
bisphosphonates was generally higher than that for vitamin K. The data used in Stevenson et al. 
(2009) to identify the compliance to the vitamin K treatment also reported persistence rates 
for alendronate: Lloyd Jones and Wilkinson (2006) reported that the evidence identified from 
randomised trials suggested that the percentage of patients persisting with daily alendronate 
was 88%-100% at year 1, and decreased to 72%-89% and 70%-89% at year 2 and 3, 
respectively.  UK evidence from an un-randomised study (Biswas et al., 2003) reported the 
compliance rate of 75% with daily alendronate at one year. However, Lloyd Jones and 
Wilkinson (2006) suggested that the use of weekly rather than daily bisphosphonates regimens 
may improve persistence.   
Lloyd Jones and Wilkinson (2006) described the UK prescription-event monitoring (PEM) 
studies of alendronate and risedronate as the most relevant evidence for compliance with oral 
bisphosphonate treatment in the UK (Barrera et al., 2005, Biswas et al., 2003). Hence, the 
base-case model for this thesis assumed 75% compliance at the time of treatment initiation. 
Sensitivity analyses included the assumption of 50% compliance rate. In accordance with the 
assumption in Stevenson et al. (2009), non-compliant patients were assumed to incur three 
months’ cost of the drug treatment at the start of the treatment and receive no benefit.  
On initiation of treatment, 25% of people eligible for drug therapy were randomly selected to 
be non-compliant. Once non-compliant, it was assumed that the individual does not re-initiate 
drug treatment when a new fracture occurs.  
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7.3.9. Costs of fractures and drug treatment 
 
 
Table 7.22 summarises the cost of fracture events used in the model for this thesis. It was 
based on the calculation reported by Stevenson and Davis (2006). Healthcare Resource Groups 
(HRGs) data were used in the estimation of costs. Costs included: direct medical costs; home 
help; and nursing home costs. The costs were divided into first year costs and costs incurred in 
the subsequent years.  The cost values reported in Stevenson et al. (2009) were inflated to 
2012 price using the Hospital and Community Health Services (HCHS) inflation index (Curtis, 
2013). 
For hip fracture leading to nursing home admission, the monthly NHS cost of £2,293 as used in 
the AD model was applied in order to have consistency across individual disease models. This 
equates to the annual cost of £27,513, and was similar to the costs used in Stevenson et al. 
(2009) (£27,972-£28,777 when inflated to 2012 price).  
As a cheaper generic version of alendronate became available, the cost of drug used in 
Stevenson et al. (2009) was replaced by the most recent price. The annual cost of alendronate 
was taken from the British National Formulary (Joint Formulary Committee, 2014), and was 
£28.21. Stevenson et al. (2009) used £51 for their analysis in accordance with the drug price of 
that time. The results of applying a higher cost were examined in Section 7.4.  As previously 
mentioned, the cost of three months of drugs was applied for non-compliant population.  
  
273 
 
 
Table 7.22. Costs of fracture events by age and by first and subsequent years (£, 2012 price) 
  Cost of hip fracture 
(£) 
  
Cost of hip fracture 
leading to nursing 
home admission (£) 
Cost of death due to 
hip fracture (£) 
  
Cost of vertebral 
fracture (£) 
  
Cost of wrist 
fracture (£) 
  
Cost of proximal 
humerus fracture (£) 
Age 
(years) 
First 
year 
Subsequent 
years 
First 
year 
Subsequent 
years 
First 
year 
Subsequent 
years 
First 
year 
Subsequent 
years 
First 
year 
Subsequent 
years 
First 
year 
Subsequent 
years 
50-54 6,762 - 37,797 27,972 9,526 - 2,776 244 954 - 2,798 - 
55-59 6,762 - 37,797 27,972 9,526 - 2,776 244 1,078 - 2,656 - 
60-64 6,762 - 37,797 27,972 9,526 - 2,776 244 1,173 - 2,493 - 
65-69 7,629 - 38,674 28,374 9,526 - 2,776 244 1,193 - 2,305 - 
70-74 8,013 - 39,021 28,777 9,526 - 3,277 244 1,698 - 3,045 - 
75-80 8,013 - 39,021 28,777 9,526 - 3,277 244 1,487 - 2,678 - 
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7.3.10. Utilities 
 
The utilities used in Stevenson et al. (2009) were also used in this model (Table 7.23). Utilities 
associated with the fractures at other sites incorporated in the main four were reported to be 
combined and matched with those for the four fracture sites. The utility multipliers were 
combined multiplicatively with the baseline utilities for the general population reported in 
Chapter 4.  
 
Table 7.23. Utility multipliers used in the model 
Fracture site Utility multipliers in first 
year following fracture 
Utility multipliers in 
subsequent years following 
fracture 
Hip 0.792 0.813 
Vertebrae (Spine) 0.626 0.909 
Proximal humerus 0.794 Age Utility multipliers 
45-54 years 0.949 
55-59 years 0.952 
60-64 years 0.955 
65-69 years 0.958 
70-74 years 0.960 
75-79 years 0.963 
80+     years 0.966 
Wrist 0.977 1.000 
Source: Kanis et al. (2004c) 
 
Disutility associated with adverse events (AE) of bisphophnates was applied as in Stevenson et 
al. (2009). The model in Stevenson et al. (2009) adopted the same assumption used in 
Stevenson and Davis (2006). Bisphophonates were considered associated with an increased 
risk of upper gastro-intestinal (GI) problems, and the symptoms more likely to occur in the 
initial treatment month than in subsequent treatment months (Stevenson and Davis, 2006). 
The utility multiplier of 0.91 was applied for the first month since treatment initiation in order 
to incorporate the utility loss associated with GI problems (Groeneveld et al., 2001). As in 
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other events, this change caused the individual to move to the ‘transient utility state’. When 
an individual was allocated to drug treatment at model entry due to a previous fracture, it was 
assumed that the disutility associated with treatment had already occurred.  
It was assumed that the nursing home stay is associated with lower utility. For consistency, the 
utility weight used for institutionalised AD patients was also used. Stevenson et al. (2009) used 
a multiplier of 0.40, whilst the AD model used the absolute utility value of 0.33. As the utility of 
0.33 was used as the final utility weight, not as a multiplier, it is not expected to be 
significantly different from applying the utility multiplier of 0.40. 
 
 
7.4. Results from the osteoporosis only model 
 
 
7.4.1. First order uncertainty and comparison with existing model 
results 
 
First-order uncertainty was explored to identify the appropriate number of individuals to 
simulate (Figure 7.2). The mean results and uncertainty with varied number of simulated 
individuals ranging from 100 to 400,000 were examined. The error bars represent 95% 
confidence intervals around the mean.  Incremental costs and QALYs approached to values 
near zero as the number of simulated individuals increased. Due to the small incremental 
values, the cost per QALY could fluctuate with a small change in incremental cost or QALYs. 
Instead, incremental net monetary benefit (NMB) was calculated and reported in Figure 7.2 e).  
The drug treatment dominated no treatment when 150,000-400,000 individuals were 
simulated with the NMB of £111-£627 when the willingness to pay threshold of £20,000 per 
QALY was assumed. The results for the general public started to stabilise when 100,000 or 
more individuals were run. 
Although costs and QALYs stabilised quickly, considering the small values of incremental costs 
and QALYs, 400,000 individuals were simulated for the base case. With 400,000 individuals 
simulated and the threshold of £20,000, the NMB was £350 (undiscounted) and £252 
(discounted).  
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Figure 7.2. First order uncertainty in relation to the number of patients simulated (all 
population aged 45 years and older)  
a) Cost with drug treatment  
Undiscounted 
 
Discounted 
 
b) QALYs with drug treatment  
Undiscounted 
 
Discounted 
 
c) Incremental cost of drug treatment compared with no therapy 
Undiscounted 
 
Discounted 
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d) Incremental QALYs of drug therapy compared with no therapy 
Undiscounted 
 
Discounted 
 
e) Net monetary benefit (with the willingness-to-pay threshold of £20,000)  
Undiscounted 
 
Discounted 
 
 
 
The model results were compared to those reported for weekly alendronate treatment 
alongside the vitamin K treatment results in the HTA report by Stevenson et al. (2009). 
Stevenson et al. (2009) reported results for women only by age group, T-score, and the 
presence of previous fracture. Tables 7.24-7.27 compare the results with those from the HTA 
report.   
For comparison purposes, a narrower population was run with 100,000 individual patient 
simulations. The model population at entry was 75-year-old women with or without previous 
fracture. The cost of alendronate was increased to £51 to match with that used in Stevenson et 
al. (2009). 
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Results for women with no previous fracture 
 
The results for women aged 75 years without a previous fracture were compared in Tables 
7.24 and 7.25 for women with T-score of -3 SDs and -2.5 SDs, respectively, with those for 
alendronate treatment reported in Stevenson et al. (2009). Alendronate treatment dominated 
no treatment for women with a T-score of -3 SDs and -2.5 SDs. Compared the results where 
discount rates of 6% for costs and 1.5% with the HTA model results, alendronate treatment 
was more cost-saving with similar QALY gains for both T-score groups. Stevenson et al. (2009) 
adjusted the model outputs obtained using 6% annual discount rate for costs and 1.5% for 
utilities in retrospect to reflect interim changes in the NICE rates. The results using 6% and 1.5% 
discount rates with 50% compliance provided similar incremental costs and QALYs to those in 
the HTA report. The change in discount rates increased the incremental QALYs, but did not 
alter the results considerably. For women with a T-score of -2.5 SDs (Table 7.25), the drug 
treatment still dominated no treatment even when 50% compliance was assumed, whilst the 
results from Stevenson et al. (2009) showed a positive incremental cost. 
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Table 7.24. Comparison of cost-effectiveness results with those from Stevenson et al. (2009) for 75-year-old women with T-score of -3 SDs with no previous 
fracture assuming drug cost of £51 
 Base-case assuming compliance of 75% Base-case assuming compliance of 
50% 
Discount rates of 6% for cost and 
1.5% for utility, assuming compliance 
of 50% 
HTA 
Results† 
T score -3 With 
treatment 
No treatment Incremental With 
treatment 
No 
treatment 
Incremental With 
treatment 
No 
treatment 
Incremental Incremental 
Cost £ 12,429 £ 13,194 -£ 765 £ 12,486 £ 13,194 -£ 709 £ 12,486 £ 13,194 -£ 709  
Discounted Cost £ 7,887 £ 8,380 -£ 494 £ 7,945 £ 8,380 -£ 436 £ 5,939 £ 6,252 -£ 314 -£ 140 
QALYs 8.807 8.756 0.051 8.793 8.756 0.037 8.793 8.756 0.037  
Discounted 
QALYs 
6.847 6.815 0.031 6.838 6.815 0.022 7.852 7.823 0.030 0.0402 
Cost per QALY 
(£) 
  Dominating   Dominating   Dominating Dominating 
†Cost effectiveness of alendronate in women aged 75-79 years with a T-score of -3 SDs and no previous fracture from Stevenson et al. (2009) 
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Table 7.25. Comparison of cost-effectiveness results with those from Stevenson et al. (2009) for 75-year-old women with T-score of -2.5 SDs with no 
previous fracture assuming drug cost of £51 
 Base-case assuming compliance 
of 75% 
Base-case assuming compliance of 
50%  
Discount rates of 6% for cost and 1.5% for 
utility, assuming compliance of 50% 
HTA Results† 
T score -2.5 With 
treatment 
No 
treatment 
Incremental With 
treatment 
No 
treatment 
Incremental With treatment No treatment Incremental Incremental 
Cost £ 8,640 £ 9,265 -£ 625 £ 8,577 £ 9,265 -£ 688 £ 8,577 £ 9,265 -£ 688  
Discounted 
Cost 
£ 5,446 £ 5,840 -£ 394 £ 5,423 £ 5,840 -£ 416 £ 4,036 £ 4,335 -£ 299 £33.83 
QALYs 9.034 9.003 0.031 9.026 9.003 0.023 9.026 9.003 0.023  
Discounted 
QALYs 
6.987 6.968 0.019 6.983 6.968 0.014 8.042 8.023 0.019 0.0276 
Cost per 
QALY (£) 
  Dominating   Dominating   Dominating £ 1,226/QALY 
†Cost effectiveness of alendronate in women aged 75-79 years with a T-score of -2.5 SDs and no previous fracture from Stevenson et al. (2009) 
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Results for women with previous fracture 
 
The model results were compared with those reported in Stevenson et al. (2009) for women 
with previous fracture in Tables 7.26 and 7.27.  
For women with a T-score of -3 SDs, the model for this thesis produced results with similar cost 
savings but lower QALY gains in comparison with the HTA results. For women with a T-score of 
-2.5 SDs, alendronate treatment was associated with smaller QALY gains, but larger cost 
savings than the HTA results. All results showed that the treatment dominated no treatment in 
line with the HTA results. When 50% compliance was assumed, the cost-saving and QALY gains 
associated with the drug treatment decreased, but did not alter overall conclusions concerning 
the dominance of the treatment. 
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Table 7.26. Comparison of cost-effectiveness results with those from Stevenson et al. (2009) for 75-year-old women with T-score of -3 SDs with a previous 
fracture assuming drug cost of £51 
 Base-case assuming compliance of 
75% 
Results assuming compliance of 50% Discount rates of 6% for cost and 
1.5% for utility, assuming compliance 
of 50% 
HTA 
Results† 
T score -
3 
With 
treatment 
No 
treatment 
Incremental With 
treatment 
No 
treatment 
Incremental  With 
treatment 
No treatment Incremental  Incremental 
TC £ 19,721 £ 20,393 -£ 671 £ 19,953 £ 20,393 -£ 440 £ 19,953 £ 20,393 -£ 440  
TDC £ 12,818 £ 13,379 -£ 561 £ 13,005 £ 13,379 -£ 374 £ 9,886 £ 10,219 -£ 333 -£389 
TQ 7.799 7.754 0.044 7.770 7.754 0.016 7.770 7.754 0.016  
TDQ 6.115 6.079 0.036 6.092 6.079 0.013 6.965 6.951 0.015 0.0609 
Cost per 
QALY 
  Dominating   Dominating   Dominating Dominating 
†Cost effectiveness of alendronate in women aged 75-79 years with a T-score of -3 SDs and previous fracture from Stevenson et al. (2009) 
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Table 7.27. Comparison of cost-effectiveness results with those from Stevenson et al. (2009) for 75-year-old women with T-score of -2.5 SDs with a previous 
fracture assuming drug cost of £51 
 Base-case assuming compliance of 
75% 
Results assuming compliance of 
50% 
Discount rates of 6% for cost and 1.5% 
for utility, assuming compliance of 50% 
HTA 
Results† 
T score -
2.5 
With 
treatment 
No 
treatment 
Incremental With 
treatment 
No 
treatment 
Incremental With 
treatment 
No treatment Incremental Incremental 
Cost £ 14,440 £ 14,894 -£ 454 £ 14,552 £ 14,894 -£ 342 £ 14,552 £ 14,894 -£ 342  
Discounted 
Cost 
£ 9,356 £ 9,678 -£ 322 £ 9,422 £ 9,678 -£ 256 £ 7,133 £ 7,347 -£ 214 -£ 128 
QALYs 8.077 8.038 0.039 8.063 8.038 0.025 8.063 8.038 0.025  
Discounted 
QALYs 
6.292 6.259 0.033 6.280 6.259 0.020 7.206 7.183 0.023 0.0420 
Cost per 
QALY (£) 
  Dominating   Dominating   Dominating Dominating 
†Cost effectiveness of alendronate in women aged 75-79 years with a T-score of -2.5 SDs and previous fracture from Stevenson et al. (2009) 
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The difference in the modelling method, such as a patient-based transition-state model 
alongside the use of a meta-model in Stevenson et al. (2009) and a DES model in this thesis, 
could cause the results to differ. However, when a similar model population was used, the 
model results in Tables 7.24-7.27 were not different to a great extent from those reported in 
Stevenson et al. (2009).  
 
 
7.4.2. Base-case results for the general population 
 
The base-case model with the UK general population aged 45 and over resulted in the cost and 
life years outcomes reported in Table 7.28. For the base year population of men and women 
aged 45 years and over, the lifetime costs per person were £2,847 (£6,151 when the value was 
undiscounted) with QALYs of 11.191 (17.759 when undiscounted). For the incoming cohorts 
aged 45 years, the costs were considerably lower for men than women given the higher 
prevalence of osteoporosis and life expectancy among women (Table 7.29). Compared with no 
treatment, alendronate treatment was less costly and more effective (Table 7.30), and 
dominated no treatment.  
 
285 
 
Table 7.28. Base-case results based on 400,000 simulated individuals for the general UK 
population aged 45 years and over with the default alendronate treatment 
 Discounted Undiscounted 
Cost £ 2,847 £ 6,151 
QALYs 11.191 17.759 
Life years  23.530 
 
 
Table 7.29. Males and females aged 45 years at the start of the model (n=400,000) – with the 
default alendronate treatment 
 Men Women 
 Discounted Undiscounted Discounted Undiscounted 
Cost £ 1,002 £ 3,274 £ 2,432 £ 8,824 
QALYs 16.281 29.182 16.509 30.387 
Life years  36.065  39.144 
 
 
Table 7.30. Cost effectiveness of alendronate treatment following a fracture for population 
aged 45 years and older 
Base-case Discounted  Undiscounted 
 With 
treatment 
No 
treatment 
Incremental  With 
treatment 
No 
treatment 
Incremental  
Cost £ 2,847 £ 2,947 -£ 100 £ 6,151 £ 6,324 -£ 173 
QALYs 11.1913 11.1837 0.0076 17.7593 17.7505 0.0088 
Cost per 
QALY (£)   
Dominating   Dominating 
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7.4.3. Annual cost projections 
 
Total annual costs were projected to increase from £1.55 billion in 2012 to £4.91 billion in 
2037 (Figure 7.3). Cohort annual costs per person from the base year population and new 
cohorts of 45 year olds were also given in Figure 7.4. The cohort annual costs for those aged 45 
years showed stepped increases at 5-year intervals due to the increases in the estimates of 
fracture risks based on 5-year age bands. For those aged 45 years, most of the costs were 
incurred at the later stage of their life. As new 45-year-old cohorts enter the model every year, 
the total annual costs across all the yearly incoming cohorts will increase in the earlier years 
(the costs for 45-year olds at later years will come forward to earlier years after model 
initiation over time for the total population in Figure 7.4).  
 
 
Figure 7.3. Projected total annual costs by the year 2037 for the treatment and management 
of osteoporosis for the base-year and incoming populations aged 45 years and over 
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Figure 7.4. Cohort annual costs per person used to calculate the projected total annual costs 
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7.5. Discussion and Conclusion 
 
Alendronate drug treatment following a fracture for the prevention of osteoporotic fracture 
for the general population aged 45 years and over as well as women aged 75 years with T-
scores of -3 SDs and -2.5 SDs, dominated no treatment. As such, regardless of the willingness-
to-pay threshold per QALY, the drug treatment is likely to be a cost-effective option for 
fracture prevention.  
The total costs associated with treatment and management of osteoporosis was projected to 
increase over the projection horizon, reaching its peak at £4.9 billion in the farthest projection 
year of 2037. 
However, it is noted that the model results are based on numerous assumptions which 
increases uncertainty, in particular, the inclusion of the male population and people with BMD 
higher than average unlike the model by Stevenson et al. (2009). When data were not available, 
the estimation of parameters for these groups was often based on assumptions. Although 
efforts were made to make plausible assumptions based on available evidence, the estimates 
may not accurately reflect the true values. For example, the average difference between men 
and women obtained from Holt et al. (2002) was applied to calculate the average T-scores for 
men (see Section 7.3.3). However, this implicitly assumes that the same rates of deterioration 
in BMD for age groups and equal age distributions for men and women. Also, for those whose 
BMD is higher than average, the non-fracture related mortality was reduced by the same 
factor as that used to increase mortality for those with low BMD.  
Biases could be introduced in the process of estimating mortality rates based on mid-range 
values of Z-score. The same factor of 1.22 was used to adjust mortality for both people with 
low and high BMD in order to run a simulation for the general population as well as the 
diseased. Also, a standard Normal distribution was assumed for Z-score. If the model 
population aged 45 years and older does not have a symmetric distribution of Z-score as 
assumed, this can also introduce bias in the estimates. However, this was an extrapolation 
beyond available evidence, and was not considered to markedly influence the results.   
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CHAPTER 8   LINKING PAIRS OF DISEASES – 
CORRELATION BETWEEN DISEASES 
 
8.1. Background  
 
 
Individual disease models could be linked in two ways: one is where diseases were assumed 
independent and thus, the presence of one disease did not affect the risk of the others 
(denoted hereafter as ‘independently linked model’); and the other where correlations 
between diseases were incorporated, which can reflect changes in risks associated with the 
presence of other diseases (denoted hereafter as ‘correlated linked model’). A version of the 
linked model where all diseases were assumed independent was constructed in order to assess 
the reliability of results from the linked model. 
This chapter develops further the method of model linkage introduced in Chapter 4. It 
describes correlations between the diseases that were incorporated in the linked model and 
how these correlations were implemented. It reports results from linked models where only 
two of the diseases were considered in order to evaluate the effect of the pairwise 
correlations implemented.   
As described in Chapter 4, the order of the linkage was that the heart disease (HD) and 
Alzheimer’s disease (AD) models were linked first, and then the osteoporosis model was added 
onto the HD-AD linked model.  Hence, the results for the HD and AD pair will be reported from 
two models: the two-disease and three-disease linked models.  
In the linked models, costs were additive and utilities were multiplicative across diseases. It is 
noted that if a patient in the model with correlated diseases has AD, the utility weights 
associated with AD were used as baseline utilities instead of the age- and sex-specific utility for 
the general population. This was due to Bond et al. (2012) having used the MMSE-based 
utilities as final utilities without multiplying them by age and sex based baseline utilities. 
Targeted literature searches were conducted to identify data on correlations between the 
modelled diseases. Data were searched in the Medline and/or EMBASE databases using a 
combination of the disease names, the literature repository constructed for this thesis 
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(Chapter 3); and Google Scholar, and the method of snowballing was used to identify further 
literature from the papers identified from other sources. Where the impact of one disease (A) 
on another (B) was incorporated, the opposite direction of the correlation (the impact of B on 
A) was typically not included due to the potential risk of double-counting for a co-morbid 
population and the paucity of relevant data. In such cases, correlations regarding other disease 
events were prioritised for implementation in the model.  
There were correlations that could be embedded in the model other than those described in 
this chapter. However, it was considered sufficient to incorporate some key correlations 
deemed important for the purpose of this thesis, thus demonstrating a proof-of-concept 
model.  Researchers wishing to include further correlations may do so in their model using the 
method shown in this chapter.  The following sections summarise correlations identified from 
the literature searches and incorporated in the model for each of the three pairs of diseases. 
 
8.2. Correlation between Heart disease and Alzheimer’s disease 
 
 
Systematic searches for literature reporting the prevalence of AD and other co-existing 
conditions and the outcomes of treatment for patients with AD and other relevant conditions 
were conducted within the Medline and EMBASE databases. However, very few papers that 
could provide numerical data for populating the model were identified.  
A small number of studies that discussed empirical data on the effect of one disease on 
another were identified from the literature search. As Maslow (2004) noted, studies mainly 
listed common co-existing conditions that were present in their study population only, or 
intentionally excluded people with AD who have other co-morbidities as the effect of other 
diseases could confound the effect of AD. Studies focussing on heart disease reported similar 
results.  
The calculation methods described in this section were applied to other diseases.  
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8.2.1. Correlation of prevalence 
 
The prevalence of HD among AD patients was considered higher than that of HD randomly 
allocated according to the prevalence within the general population.  A number of studies 
have found that AD often co-exists with vascular conditions such as hypertension, hyper-
cholesterolaemia, and diabetes mellitus (Maslow, 2004, Muqtadar et al., 2012, Barnes and 
Yaffe, 2011, Polidori et al., 2012, Sparks et al., 2000).  
For instance, the US National Center for Health Statistics survey found that 82% of people in 
assisted living facilities where help is provided for daily activities such as bathing and dressing 
had one or more of dementia, hypertension, and heart disease (Figure 8.1) (The National 
Center for Health Statistics, 2010). 42% of the residents had Alzheimer’s disease or other forms 
of dementia and 34% had heart disease. 14% of people had both dementia and heart disease 
and 9% of them had all three of the diseases. However, this survey was conducted within a 
specific population living in assisted living centres and the survey respondents were likely to be 
older than other study population.  
 
Figure 8.1. Co-morbidities of residents in assisted living facilities 
 
292 
 
 
In order to incorporate the linkages between AD and HD with respect to the disease 
prevalence and incidence, the total prevalence of one disease was split into the prevalence of 
that disease for people with another disease and that for people without the disease, so that 
the total prevalence of people with a specific disease at model initiation match the sum of split 
prevalence values. For example, the total proportion of people who have AD at a specific point 
in time can be divided into the proportion of AD patients among people with heart disease and 
the proportion among people without HD.  
For each age and sex group, the total prevalence of AD at a specific point in time, 𝑃(𝐴𝐷 = 1), 
can be seen as a weighted average of two conditional probabilities 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) and 
𝑃(𝐴𝐷 = 1|𝐻𝐷 = 0) as follows;  
𝑃(𝐴𝐷 = 1) = 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) ∙ 𝑃(𝐻𝐷 = 1) + 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 0) ∙ 𝑃(𝐻𝐷 = 0)         
[Eq. 8.1] 
where AD and HD are binary variables taking the value of one when the disease is present and 
zero otherwise. Therefore,  𝑃(𝐴𝐷 = 1) and 𝑃(𝐻𝐷 = 1) are the prevalence of AD and HD, 
respectively. 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) denotes the probability of having AD conditional on the 
presence of HD, or the prevalence of AD among those with HD, and 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 1) the 
prevalence of HD among those with AD.  
In the same way, the total prevalence of heart disease can be shown as: 
𝑃(𝐻𝐷 = 1) = 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 1) ∙ 𝑃(𝐴𝐷 = 1) + 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 0) ∙ 𝑃(𝐴𝐷 = 0)        
[Eq. 8.2] 
Eq. 8.2 expresses the total prevalence of HD in terms of 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 1) and 𝑃(𝐻𝐷 =
1|𝐴𝐷 = 0) using the value of AD prevalence, 𝑃(𝐴𝐷 = 1). However, Eq. 8.2 could not be used 
as the total prevalence of heart disease had to be partitioned among the cardiac events 
included in the model and data required for using Eq. 8.2 were not available from the 
literature searches.  Hence, the prevalence of AD was split into the prevalence of AD for 
people with and without HD using Eq. 8.1. 
Using Bayes’ theorem, 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) in Eq. 8.1 was calculated as 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) =
[P(HD=1|AD=1)∙P(AD=1)] 
𝑃(𝐻𝐷=1)
  [Eq. 8.3]. The relationship in Eq. 8.1 was used to back-calculate 
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𝑃(𝐴𝐷 = 1|𝐻𝐷 = 0).  The following sections describe why these were calculated in this 
manner and report the calculation results.  
Regardless of which equation to use, the split should be the same as 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 1) and 
𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) represent the same coloured area in Figure 8.2 although the actual 
figures of the conditional probabilities differ depending on which disease status is assumed to 
be known.  
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Figure 8.2. Prevalence linkage between AD and heart disease 
 
 
Prevalence of Alzheimer’s disease among heart disease patients  
 
The prevalence of AD among HD patients, 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) in Eq. 8.1, was explored. The 
Cardiovascular Health Study (CHS) is an observational population-based, longitudinal study of 
coronary heart disease and stroke in adults aged 65 years and older, mainly aimed to identify 
factors related to the onset and course of coronary heart disease and stroke (Fitzpatrick et al., 
2004). However, AD prevalence was not reported in relation to the presence of heart disease 
or stroke.  
More data on the prevalence of HD in AD patients, 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 1), than for the 
prevalence of AD in HD patients, were identified. The US Medicare Alzheimer’s Disease 
Demonstration (MADD) study reported the prevalence of co-existing conditions in a large 
sample of people with dementia (Maslow, 2004). In the MADD study, conducted between 
1989 and 1994, a considerable proportion of people had cardiovascular and cerebrovascular 
diseases: 47% had hypertension; 33% coronary heart disease; 28% congestive heart failure; 
and 25% stroke.  A more recent study by the Alzheimer’s Association reported that 30% of 
people with AD or other dementias also had coronary heart disease, 22% congestive heart 
failure, and 14% stroke using data from the National 20% Sample Medicare Fee-for-Service 
Beneficiaries for 2009 (Alzheimer's Association, 2013).  
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However, no UK data were found on the prevalence of co-morbid conditions among the 
population aged 65 years and over, although there were papers reporting relative incidence of 
AD in association with the presence of heart disease.  Assuming that the prevalence of 
diseases that overlap in the older population is similar in the UK to the US population, the 
most recent data from the Alzheimer’s Association was used in the calculation. As age- and 
sex-specific probabilities were not available, 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 1)= 52% was used for people 
with a history of non-stroke cardiac conditions across all age and sex groups (Alzheimer's 
Association, 2013).  
 
Prevalence of non-stroke cardiac disease 
 
In the model for this thesis, the prevalence of stroke was not explicitly linked with the 
presence of AD. The existing literature has often focussed on non-stroke cardiovascular 
conditions in association with AD (Eriksson et al., 2010). It was considered that the association 
is unclear as studies often looked at vascular dementia, rather than AD, as the type of 
dementia that often occurs after stroke (Blom et al., 2014, Appel, 2007). Although vascular 
dementia often coexists with other types of dementia such as AD and the prevalence of stroke 
and other vascular risk factors is higher among people with AD as shown above (Alzheimer's 
Association, 2013, de la Torre, 2006), this linkage was not incorporated in the model in this 
thesis.  However, as previous cardiac events influence rates of other cardiac events including 
stroke in the model, implementing correlations between AD and non-stroke cardiac conditions 
does indirectly affect the rates of stroke.   
The prevalence of non-stroke cardiac events, denoted as 𝑃(𝐻𝐷 = 1) hereafter in this chapter, 
was obtained from simulated results from the heart disease model. This was due to the 
composite prevalence measure for only the non-stroke events included in the heart disease 
model – MI, angina, PAD, and revascularisation – being unavailable in the literature. In the HD 
model, these events were independently assigned according to the simulated prevalence of 
each HD event.  
Prevalence of non-stroke HD in the base year (at model entry) by age and sex is shown in Table 
8.1. As described earlier, the prevalence of AD for people aged 65 years and under was 
assumed to be zero, and thus the prevalence of HD was not split into people with and without 
AD for this age group. 
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Table 8.1. Prevalence of heart disease events included in the model by age and sex 
 Prevalence of all heart 
disease events 
Prevalence of non-
stroke heart disease 
events 
Age Men Women Men Women 
<65 years 0.12061 0.06452 0.10171 0.04953 
65-69 0.34052 0.15917 0.28695 0.12559 
70-74 0.36596 0.19145 0.31401 0.16154 
75-79 0.48773 0.37097 0.40906 0.29194 
80-84 0.48587 0.37356 0.39927 0.29204 
85 and 
over 
0.44709 0.36202 0.37302 0.28318 
 
 
Calculation and calibration of the prevalence of Alzheimer’s disease among heart 
disease patients 
 
The results on 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 1) and 𝑃(𝐻𝐷 = 1) were combined to calculate 
𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) using Eq. 8.3, and 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 0) was also estimated using Eq. 8.1. 
The resulting prevalence of AD split into 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) and 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 0) is 
shown in Table 8.2. These values were used in the linked model as the prevalence of AD in 
relation to the presence of heart disease. The ratio 
𝑃(𝐴𝐷=1|𝐻𝐷=1)
𝑃(𝐴𝐷=1|𝐻𝐷=0)
  varied with age group and 
sex as the prevalence of individual diseases, 𝑃(𝐻𝐷 = 1) and 𝑃(𝐴𝐷 = 1), differ between age 
and sex.  
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Table 8.2. Prevalence of AD divided into the prevalence for people with HD and that for people 
without HD (before calibration) 
 Prevalence of AD  
  People with HD ① People without HD ② Ratio (①/②) 
Age Men Women Men Women Men Women 
<65 0 0 0 0 NA NA 
65-69 0.018267 0.044718 0.006785 0.005929 2.69 7.54 
70-74 0.036962 0.05099 0.015618 0.009068 2.37 5.62 
75-79 0.051255 0.091056 0.032751 0.034654 1.57 2.63 
80-84 0.095646 0.180764 0.058681 0.068831 1.63 2.63 
85+ 0.196727 0.363585 0.108037 0.132586 1.82 2.74 
 
 
The prevalence of AD before and after applying the correlations were compared using the 
values sampled at the model entry in order to see whether the estimation method used for 
splitting prevalence produced similar results. The total prevalence of AD and the prevalence 
for people with and without HD are compared in Table 8.3. The prevalence values of AD with 
and without HD were combined for comparison with the total AD prevalence before splitting 
using 100,000 simulated individuals for each age group (in order to have enough numbers of 
simulated individuals in each age group). The absolute percentage differences ranged from 
0.23% to 5.09% between the total population values and the split values of prevalence.  The 
percentage difference was the largest for female population aged 70-74 years. The differences 
could be due to the use of the single estimate of 𝑃(𝐻𝐷 = 1|𝐴𝐷 = 1) in Eq. 8.3 for all age 
groups and sex, which fails to reflect variation among different populations in the estimation 
equation.   
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Table 8.3. Comparison of simulated proportions of people with Alzheimer’s disease (AD): 
between when the total prevalence of AD was used and when the prevalence of AD split into 
HD and non-HD groups was used  
 Total prevalence of 
AD (before splitting) 
Combined 
prevalence of AD 
using split 
prevalence values* 
% Difference  
(compared with the 
total prevalence AD) 
Age Men Women Men Women Men Women 
<65 0 0 0 0 0 0 
65-69 0.0101 0.0108 0.0098 0.0104 -3.01% -3.98% 
70-74 0.0223 0.0158 0.0232 0.0166 3.88% 5.09% 
75-79 0.0403 0.0511 0.0387 0.0503 -3.94% -1.52% 
80-84 0.0734 0.1015 0.0732 0.1020 -0.38% 0.44% 
85+ 0.1411 0.1980 0.1451 0.1985 2.79% 0.23% 
*Based on the results of 100,000 simulated individuals for each age group.  
 
Although the differences could be considered small, in order to start the model with the same 
population with respect to the total prevalence of AD, the prevalence of AD split for people 
with and without HD was calibrated to match the total prevalence. Based on the total 
prevalence values reported in Table 8.3, age- and sex-specific calibration multipliers were 
applied to the prevalence values for people with and without HD. These were calculated as the 
total prevalence divided by the combined prevalence using split values (Table 8.4). 
 
Table 8.4. Calibration multipliers for prevalence of AD 
Age Men Women 
<65 1 1 
65-69 1.031 1.041 
70-74 0.963 0.952 
75-79 1.041 1.015 
80-84 1.004 0.996 
85+ 0.973 0.998 
 
299 
 
The calibrated prevalence after these multipliers were applied is shown in Table 8.5. The 
prevalence of AD reported in Table 8.5 was used in all models for this thesis where AD and 
heart disease were correlated. The split ratios remained the same as in Table 8.2 as the same 
multiplier was used to calibrate both for those with and without HD.  Total prevalence 
obtained from running the model with the calibrated values in Table 8.5 was compared with 
that before splitting in Table 8.6. The percentage differences largely reduced after calibration, 
but were considered inconclusive as the differences increased for the age 75-79 and 80-84 
groups, and females aged 85 and over.  In order to examine the effect of the calibration at the 
population level, the numbers of people with AD across all age groups in the models before 
and after calibration were compared in Table 8.7 when 200,000 individuals aged 65 years and 
over were simulated for each model (the age distribution for people aged 65 and over was 
adapted from the ONS mid-2012 UK population estimates). The total numbers of people with 
AD among 200,000 simulated individuals from models with and without calibrated prevalence 
values were compared with that from the model where heart disease and AD were 
independently linked. The calibration reduced the difference between when the total AD 
prevalence was applied and when the split prevalence values were used from 0.50% to 0.24% 
for male population and from 1.89% to 1.18% for females.  
There still existed differences in the number of people with AD after calibration due to Monte 
Carlo sampling error. Perfect calibration would have been possible if the calibration factors 
were calculated using the model results with the infinite number of runs for each age and sex 
group. In addition, if the infinite number of individuals were simulated in the perfectly 
calibrated model and the independently linked model for figures in Table 8.7, the differences 
would have been eliminated.  
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Table 8.5. Prevalence of AD split into the prevalence for people with HD and that for people 
without HD (after calibration) used in the model 
 Prevalence of AD (after calibration)  
  People with HD ① People without HD ② Ratio (①/②) 
Age Men Women Men Women Men Women 
<65 0 0 0 0 NA NA 
65-69 0.018834 0.046570 0.006996 0.006174 2.69 7.54 
70-74 0.035583 0.048520 0.015035 0.008629 2.37 5.62 
75-79 0.053356 0.092461 0.034094 0.035189 1.57 2.63 
80-84 0.096015 0.179969 0.058907 0.068529 1.63 2.63 
85+ 0.191384 0.362735 0.105103 0.132276 1.82 2.74 
 
 
 
Table 8.6. Comparison of proportions of simulated people with Alzheimer’s disease (AD): 
between when the total prevalence of AD was used and when the prevalence of AD split into 
HD and non-HD groups was used  
 Total prevalence of 
AD (before splitting) 
Combined 
prevalence of AD 
using split 
prevalence values* 
% Difference  
(compared with the 
total prevalence AD) 
Age Men Women Men Women Men Women 
<65 0 0 0 0 0 0 
65-69 0.0101 0.0108 0.0103 0.0109 1.87% 0.91% 
70-74 0.0223 0.0158 0.0225 0.0160 0.94% 0.75% 
75-79 0.0403 0.0511 0.0420 0.0521 4.07% 2.01% 
80-84 0.0734 0.1015 0.0743 0.1007 1.18% -0.82% 
85+ 0.1411 0.1980 0.1414 0.1966 0.20% -0.69% 
*Based on the results of 100,000 simulated individuals for each age group.  
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Table 8.7. Number of individuals with Alzheimer’s disease (AD) before and after calibration 
compared with when total prevalence without correlations was applied 
Number with AD when 
Total AD prevalence was 
used** 
Number with AD when split prevalence values were used* 
(difference (n; %)) 
Men Women Men Women Men Women 
 Before calibration After calibration 
3378 6292 
3395 
(+17; +0.50%) 
6411 
(+119; 1.89%) 
3386 
(+8; 0.24%) 
6366 
(+74; +1.18%) 
*Among 200,000 simulated individuals aged 65 years and older; **Results from the model 
where heart disease and AD were linked with independence between diseases assumed.  
 
 
8.2.2. Correlation of incidence 
 
The incidence of AD for the total population was split into that for a population with heart 
disease and for a population without heart disease. Heart disease was considered as a 
forerunner of AD and the onset of AD was earlier on average for those who have a history of 
heart disease with a hazard ratio of 1.3 (Newman et al., 2005). 
In order to maintain the number of people with AD after the split, the incidence calculation 
was based on the prevalence of AD and HD. Eq. 8.1 was used as the basis of the calculation. 
However, it is noted that it could only approximate the incidence of AD as mortality rates and 
changes in mortality over time were ignored in the calculation.  
When 𝑟 is the baseline rate of AD incidence for people without HD per time unit 𝑡 and 𝐻𝑅 is 
the hazard ratio for people with HD (assumed to be constant across age groups and >1), the 
incidence rates for people with and without HD can be expressed as rHR and r, respectively.  
The conditional prevalences 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 1) and 𝑃(𝐴𝐷 = 1|𝐻𝐷 = 0) can be expressed 
with the incidence rate r and rHR using the relationship between probability and rate, 
𝑝 = 1 − 𝑒−𝑟𝑡.  
Eq. 8.1 reduces to: 
[𝑃(𝐴𝐷) − 1] = [𝑃(𝐻𝐷) − 1] ∙ 𝑒−𝑟𝑡 − 𝑃(𝐻𝐷) ∙ 𝑒−𝑟(𝐻𝑅)𝑡         [Eq. 8.4] 
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As the values of 𝑃(𝐴𝐷), 𝑃(𝐻𝐷), 𝑡 and 𝐻𝑅 could be obtained from the model or from the 
literature, Eq. 8.4. could be expressed in the the form of: 
𝑎 + 𝑏𝑐𝑟 = 𝑑 ∙ 𝑏𝑟 
, where 𝑟 is the rate parameter, 𝑟 ≠ 0, and known constants a, b, c, and d are 𝑎 =
1
𝑃(𝐻𝐷=1)
− 1, 
𝑏 = 𝑒𝑡, 𝑐 = 1 − 𝐻𝑅, and 𝑑 =
1−𝑃(𝐴𝐷=1)
𝑃(𝐻𝐷=1)
.  
However, there was no unique and exact (where no approximation was involved) solution for 
this exponential form: the rate was not a random variable but a fixed number in the equation, 
hence, differentiating both sides of any equation except an identity equation (an equation that 
is true for all values of the variables) would not make sense. Also, taking the natural logarithm 
of both sides does not solve the equation with respect to the parameter r as it would not 
remove the power of r due to the polynomial terms 𝑎 + 𝑏𝑐𝑟.  
In addition, the definition of time 𝑡 and prevalence in Eq. 8.4 made the incidence calculation 
intractable. Adopting the age bands used in Tables 8.5 and 8.6, 𝑃(𝐴𝐷 = 1) was the prevalence 
of AD newly developed since the previous age group (for all people with or without HD). As the 
prevalence of AD for people aged 65 years and under was zero, the time 𝑡 in Eq. 8.4 was 5 
years (or less than 5 years if mid-interval time points are used) for people in the 65-70 years 
age band. Equations for groups of higher age had to incorporate the prevalence for the 
population aged 65 years and under, and should be estimated sequentially from younger age 
groups to older.  
Alternatively, incidence rates were approximated such that the total incidence of AD would 
match with a simple linear combination of incidence of AD with and without HD with the 
proportion (prevalence) of HD taken as the weights as in Eq. 8.5, where r represented the 
baseline incidence rate for people without HD and the rate for those with HD was calculated as 
rHR. The incidence rates of AD for people with and without HD are shown in Table 8.8.  
 
[Eq. 8.5] 
𝑟 =
𝑇𝑜𝑡𝑎𝑙 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑜𝑓 𝐴𝐷
{𝑃(𝐻𝐷 = 1) ∙ 𝐻𝑅 + [1 − 𝑃(𝐻𝐷 = 1)]}
 
 
303 
 
Table 8.8. Incidence of Alzheimer’s disease (AD) for people with and without heart disease (HD) 
  a) Total incidence of 
AD 
b) Rate for people 
without HD 
c) Rate for HD 
patients 
Age Men Women Men Women Men Women 
<65 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
65-69 0.004968 0.004536 0.004508 0.004329 0.005860 0.005628 
70-74 0.010440 0.004392 0.009407 0.004153 0.012229 0.005399 
75-79 0.010224 0.010656 0.008919 0.009589 0.011595 0.012466 
80-84 0.012240 0.022464 0.010683 0.020200 0.013888 0.026260 
85+ 0.042048 0.051624 0.037075 0.046567 0.048198 0.060537 
 
 
The prevalence and incidence of AD before and after applying the correlations were compared 
using the values sampled at the model entry in order to see whether the estimation method 
used for splitting prevalence and incidence produced similar results to the totals assuming 
independence between the diseases.  
There were differences in the incidence rates with and without correlations applied as the 
method used was an approximation. When using the incidence rates for those with and 
without HD (Table 8.8), the average of time to AD onset sampled for individuals without AD at 
model initiation was approximately 1 year longer than that sampled from the independently 
linked model (39.8 years vs. 40.8 years, based on n=100,000), meaning that incorporating the 
correlation between AD and HD in the incidence of AD resulted in AD developing slightly more 
slowly compared with when no correlation was applied.  They could not be perfectly matched 
as Eq. 8.5 was an approximation and Eq. 8.4 could not be solved with available data. 
No numerical data were identified on the linkage between HD and AD in terms of the 
progression of the diseases. However, the correlations implemented with respect to 
prevalence and incidence indirectly influence the rate at which diseases progress.  
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8.2.3. Non-disease mortality 
 
In the linked models where HD was included, non-disease death was non-cardiac death with 
age specific cardiac death rates subtracted from all-cause mortality rates. When AD is included 
in the linked model, no such subtraction was performed as it was assumed that AD would not 
affect non-disease mortality in the base case. As described in Chapter 6, a risk equation for 
sampling time to AD-related death from the pre-institutionalisation event was implemented as 
a competing risk in the AD model (see Chapter 6).   
 
8.2.4. Costs 
 
Papers on the cost of treating people with both AD and HD were not found from a Medline 
search (using the MESH terms ‘Alzheimer’s disease’ AND ‘Heart diseases’, both with economics 
subheadings, limited to publications after 2000). However, there was some evidence showing 
that people with AD or other forms of dementia may incur higher cost for other co-existing 
diseases than people without dementia (Alzheimer’s Association 2013; Maslow 2004). The US 
2009 Medicare data showed that people with AD or dementia in addition to other co-existing 
conditions are more likely to be hospitalised than people with the same comorbid conditions 
but without AD or dementia (Alzheimer’s Association 2013). However, equivalent UK studies 
could not be found.  
In the model for this thesis, costs were assumed to be additive: if an individual has both AD 
and HD, it was assumed that the person incurs the cost for AD plus that for HD. 
 
8.2.5. Utilities 
 
Papers on the utility-based quality of life (QoL) values in relation to the co-existing AD and 
heart disease were not found from a Medline search (with search terms of ‘Alzheimer’s 
disease’ AND ‘Quality of Life’, or ‘Heart diseases’ AND ‘Quality of Life’). 
For those with both AD and HD, utility was assumed to be multiplicative. For patients with AD, 
the EQ-5D valuations of utilities based on cognitive function reported in Jönsson et al. (2006) 
were used as utility weights for patients with AD across all age and gender groups as used in 
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the model by Bond et al. (2012). If these patients were co-morbid with heart disease, the 
utilities associated with heart disease events were used as utility multipliers applied to the 
utility values for AD. If an individual had only heart disease, the utilities for heart disease were 
multiplied by the age and gender specific baseline utility values described in Chapter 4 (Ward 
et al., 2006, Ara and Brazier, 2010). 
 
 
8.3. Correlation between Heart disease and Osteoporosis  
 
Although there are a number of studies investigating possible correlations between 
osteoporosis and heart disease, the model in this thesis will focus specifically on correlations 
regarding hip fracture, and MI and stroke as these events are associated with the highest costs 
and utility effects.  Wherever possible, estimates of correlation controlled for other factors 
such as age, sex, drinking and smoking status were used in the model.  
 
8.3.1. Prevalent cardiovascular disease and fracture risks 
 
 
Fracture risks are influenced by the presence of CVD.  In a study that was a part of the 
Rochester Epidemiology Project, MI was associated with higher risk of all types of osteoporotic 
fracture (Gerber et al., 2011). Excess fracture risks after MI were found with the overall 
adjusted hazard ratio (HR) of 1.32 (95% CI 1.12-1.56) across all anatomic sites. Trends of the 
fracture incidence rates for three time-periods (1979-1989; 1990-1999; 2000-2006) were 
tested and an increase in fracture rates over time was found among MI patients. An HR of 1.66 
for both men and women for hip fracture was used in the model, which was for the most 
recent time period (2000-2006). Data reported in Gerber et al. (2011) was used in the model as 
this study was based on a large sample size and similar ethnic group to that of the UK, and 
provided relatively recent data in the format suitable to be applied to the time-to-event 
distributions used in the model.   
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However, only a transient increase of fracture risks after MI was identified in the study. In the 
Gerber et al. (2011) study, the mean follow-up time was only 4 years, and the association 
between and MI and 5-year risk of osteoporotic fracture was reported.  Also, in a large Danish 
case-control study including 124,655 fracture cases and 373,962 age and gender matched 
controls, a statistically significant increase in the risk of hip fracture was found only in the first 
3 years after MI (Vestergaard et al., 2009). Following the more recent data reported in Gerber 
et al. (2011), HR was applied for five years after MI.  
The incidence of hip fracture was split between that for those with MI and that for those 
without.  All other risk adjustments associated with hip fracture (e.g. drug use, previous 
fracture, etc.) were applied taking these split incidence rates as baseline.  
Using the prevalence of MI within the heart disease model, the total incidence of hip fracture 
was split between the incidence of hip fracture for patient who had an MI within 5 years and 
that for patients who did not have MI for the last 5 years. These were reported in Table 8.9 for 
those on no treatment (A) and on drug treatment for osteoporosis (B) where the RR of 72% for 
hip fracture was applied (see Chapter 7). Due to the low prevalence of MI among younger age 
groups, the baseline incidence for those without MI was similar to the total incidence including 
both groups with and without MI.  
 
 
Table 8.9. Hip fracture incidence split between rates for those with MI and without MI 
A. Hip fracture incidence with and without MI – No drug treatment 
  Total incidence of hip 
fracture 
Baseline rate r (without 
MI) 
Rate for patients with MI 
Age Men Women Men Women Men Women 
45-50 0.00030 0.00020 0.00030 0.00020 0.00049 0.00033 
50-55 0.00030 0.00020 0.00030 0.00020 0.00049 0.00033 
55-60 0.00070 0.00050 0.00067 0.00049 0.00112 0.00082 
60-65 0.00030 0.00080 0.00029 0.00079 0.00048 0.00131 
65-70 0.00080 0.00130 0.00073 0.00127 0.00121 0.00211 
70-75 0.00110 0.00210 0.00100 0.00206 0.00167 0.00341 
75-80 0.00200 0.00420 0.00180 0.00396 0.00299 0.00658 
80-85 0.0068 0.0097 0.00613 0.00915 0.01017 0.01519 
85+ 0.0099 0.0217 0.00892 0.02047 0.01481 0.03398 
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B. Hip fracture incidence with and without MI – For individuals on drug treatment for 
osteoporosis 
  Total incidence of hip 
fracture – on drug 
treatment 
Baseline rate r (without 
MI) 
Rate for patients with MI 
Age Men Women Men Women Men Women 
45-50 0.00025 0.00018 0.00025 0.00017 0.00041 0.00029 
50-55 0.00024 0.00017 0.00024 0.00017 0.00040 0.00028 
55-60 0.00050 0.00033 0.00048 0.00032 0.00080 0.00054 
60-65 0.00020 0.00055 0.00019 0.00054 0.00032 0.00090 
65-70 0.00060 0.00092 0.00054 0.00090 0.00090 0.00149 
70-75 0.00081 0.00150 0.00074 0.00147 0.00123 0.00244 
75-80 0.00145 0.00303 0.00131 0.00286 0.00217 0.00475 
80-85 0.00490 0.00695 0.00442 0.00656 0.00733 0.01088 
85+ 0.00713 0.01557 0.00643 0.01469 0.01067 0.02439 
 
 
The incidence rates of hip fracture with and without a recent MI reported in Table 8.9 were 
used as the baseline event rates for hip fracture for the first 5 year period after MI. The 
relative risks associated with factors that can influence the event rates, such as low BMD and 
previous fracture, were applied onto these baseline rates. When sampling time to next hip 
fracture, these baseline incidence rates of hip fracture were updated when the sampled time 
to event was longer than the time before a change in age band, or the time left to a change in 
the drug efficacy due to the treatment fall time after discontinuation. Hence, all three time 
intervals for which different event rates are applied – time to 5 years after MI, time to next age 
band, and time to next efficacy change due to the fall time of treatment effect – were 
continuously compared with the sampled TTE value. When the sampled TTE value is longer 
than any of the three, the baseline incidence rates were changed accordingly and TTE was 
resampled.  It was assumed that a previous MI at the initiation of the model does not affect 
the hip fracture risks (that is, it occurred more than 5 years ago).  
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8.3.2. Presence of osteoporosis and stroke risks 
 
Osteoporosis and stroke share several risk factors, including age, smoking, low physical activity, 
and hypertension. Thus, low BMD and high stroke risk can be correlated. Some studies showed 
that low BMD or a history of fracture has an association with the incidence of stroke (Lui et al., 
2003, Browner et al., 1993, Jørgensen et al., 2001). Jørgensen et al. (2001) examined the 
relationship, and found that women with BMD values in the lowest quartile had a higher risk of 
stroke than women with BMD values in the highest quartile (odds ratio= 4.8), and a linear 
trend over the quartiles was statistically significant. The OR for stroke increased 1.9 per SD 
(0.13 g/cm2) reduction in BMD, and the association between low BMD and stroke in women 
remained significant when the analysis was adjusted for potential confounders. In men, no 
statistically significant difference in BMD between the stroke patients and their controls was 
found.   
4024 American women aged 65 years or older were recruited in the Study of Osteoporotic 
Fractures, and found that low calcaneus BMD was associated with higher risk of stroke during 
a 2-year follow-up: per decrease of SD in calcaneus BMD (-0.09 g/cm2), the incidence of stroke 
was 1.31-fold higher (HR 1.31, 95% CI 1.03-1.65) (Browner et al., 1993). Also, in a cohort of 
Swedish elderly men and women, low femoral neck BMD was associated with higher risk of 
stroke during a follow-up of 5.5 years (Nordstrom et al., 2010). However, a study showed that 
the existence of stroke history was not significant for the association with quartiles of 
percentage changes in BMD (prevalence of low BMD) (Lui et al., 2003).  
Similarly, stroke risks were also often associated with a history of osteoporotic fracture.  In a 
case-control study conducted in 8,404 patients (of whom 2101 were with hip fracture 
identified from a Taiwanese healthcare database called ‘Longitudinal Health Insurance 
Database (LHID 2000)), a history of hip fracture was associated with a higher risk of having 
stroke during a 1-year follow up when adjusted for other cardiac diseases, diabetes, 
hypertension and hyperlipidemia (Kang et al., 2011). Using the same database, a more recent 
study covered a larger population (n=29,815 with 6013 hip fracture cases) and a longer data 
time frame (from 1996 to 2011) (Tsai et al., 2015). Although the effect of hip fracture over 5 
year follow-up period was reported with an adjusted HR of 1.54 (95% CI 1.42-1.67), the highest 
effect was observed during the first year after hip fracture (HR 1.96, 95% 1.67-2.28). The first-
year HR of 1.96 from the most recent data analysis was used in the model for one year after 
hip fracture.   
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For the first year of hip fracture, the total incidence of stroke was split into the incidence of 
stroke for those with a history of hip fracture and that without (Eq.8.6). The baseline incidence 
rate 𝑟 was multiplied by hazard ratio (HR) associated with the presence of hip fracture history.  
𝑇𝑜𝑡𝑎𝑙 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑜𝑓 𝑠𝑡𝑟𝑜𝑘𝑒 = 𝑃(𝐻𝑖𝑝 = 1) × (𝑟 ∙ 𝐻𝑅) + [1 − 𝑃(𝐻𝑖𝑝 = 1)] × 𝑟     [Eq.8.6] 
, where 𝑃(𝐻𝑖𝑝 = 1) is the prevalence of a recent (1 year) history of hip fracture, 𝑟 denotes the 
baseline rate of event without hip fracture, and 𝐻𝑅 the hazard ratio associated with the 
presence of the history of hip fracture in the preceding year.  
Due to the complex ways in which the total incidence of stroke was applied in the model 
where the rates were dependent on prior cardiac events (see Section 5.4.1), instead of directly 
calculating rates for people with and without previous hip fracture, a scale factor was 
calculated to be applied to all stroke incidence rates used in the first year after hip.  
When Eq. 8.6 is rearranged with respect to 𝑟,  
𝑟 = 𝑇 ∙ [1 𝑃(𝐻𝑖𝑝 = 1) ∙ 𝐻𝑅 + [1 − 𝑃(𝐻𝑖𝑝 = 1)]⁄ ] = 𝑇 ∙ 𝐴     [Eq.8.7] 
, where 𝑇 denotes the total incidence of stroke and 𝐴 is 
[1 𝑃(𝐻𝑖𝑝 = 1) ∙ 𝐻𝑅 + [1 − 𝑃(𝐻𝑖𝑝 = 1)]⁄ ], the scale factor by which the total stroke incidence 
is adjusted.  
Assuming the HR and the prevalence of hip fracture are constants, the baseline rate of stroke 
is the total incidence of stroke (without the split between people with and without hip fracture) 
multiplied by a constant 𝐴.  Likewise, the scale factor for the incidence rate of stroke for 
people with a previous hip fracture within 1 year is 𝐴 ∙ 𝐻𝑅, as 𝑟 ∙ 𝐻𝑅 = 𝑇 ∙ 𝐴 ∙ 𝐻𝑅 from Eq.8.7.  
The application of this scale factor does not affect the order of the maximum event rates 
applied in the heart disease model when comorbidities are found (see Section 5.3.2).  
Due to the stochastic allocation of BMD and relationship between BMD and hip fracture 
prevalence,  the simulated prevalence of hip fracture that was obtained directly from the 
model (as a result of running 100,000 individuals)were used to calculate the scale factors.  The 
prevalence of hip fracture used for this calculation and the scale factor applied to the 
incidence of stroke whenever time to stroke was sampled are presented in Tables 8.10-8.11.  
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Table 8.10. Prevalence of hip fracture obtained from the simulation model (based on 
n=100,000 simulated individuals) 
Prevalence of Hip fracture by age 
and sex 
Age Men Women 
<55 0.0001 0.0001 
55-59 0.0002 0.0018 
60-64 0.0020 0.0090 
65-69 0.0048 0.0194 
70-74 0.0097 0.0423 
75-79 0.0268 0.0784 
80-84 0.0327 0.1292 
85+ 0.0664 0.1620 
 
 
Table 8.11. Scale factors to be applied to the total incidence of stroke for the incorporation of 
correlation between hip fracture and stroke incidence 
 Scale factor A for baseline 
rates 
(individuals without 
previous hip fracture) 
Scale factor A*HR: 
(individuals with previous 
hip fracture)  
Age MEN WOMEN MEN WOMEN 
<55 0.99995 0.99989 1.95990 1.95979 
55-59 0.99985 0.99829 1.95971 1.95664 
60-64 0.99804 0.99145 1.95616 1.94324 
65-69 0.99540 0.98173 1.95099 1.92418 
70-74 0.99081 0.96096 1.94199 1.88349 
75-79 0.97494 0.92998 1.91089 1.82277 
80-84 0.96957 0.88968 1.90036 1.74377 
85+ 0.94010 0.86541 1.84261 1.69621 
 
 
The stroke event rates were adjusted using these scale factors for the first year after hip 
fracture in all cases where time to stroke is sampled by age at the time of sampling and sex (for 
individuals with and without hip fracture history). Once hip fracture occurs, a new time to 
stroke was sampled based on the updated rates at the hip fracture event in the osteoporosis 
model, which was compared with the time to next event values from the heart disease model. 
If the new time to stroke is shorter than other cardiac event times, then it replaced the earliest 
time to next heart disease event.   
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There were other studies that showed higher incident CVD events among those with 
osteoporosis or low BMD, or a history of osteoporotic fracture.  In the placebo branch of the 
Multiple Outcomes of Raloxifene Evaluation (MORE) study, osteoporosis (T -score < − 2.5 at 
the spine or the femoral neck) was associated with a fivefold higher risk of cardiovascular 
events such as stroke and myocardial infarction (Tankó et al., 2005).  In a group of 6,800 men 
and women (Multinational Monitoring of Trends and Determinants for Cardiovascular Diseases 
(MONICA) and Västerbotten Intervention Programme databases), low hip BMD was associated 
with higher risk of myocardial infarction (Wiklund et al., 2012). In men, this association 
remained significant after adjustment for confounders including cardiovascular risk factors. In 
the Framingham cohort, lower cortical mass of the second metacarpal was associated with a 
higher incidence of coronary heart disease in postmenopausal women but not in older men 
(Samelson et al., 2004). In the Health ABC (Health, Aging, and Body Composition) cohort, 
incident CVD was defined as the onset of coronary heart disease, cerebrovascular disease, PAD 
or carotid artery disease (Farhat et al., 2007). In this cohort, low hip BMD was associated with 
higher incidence of the above CVD in black, but not white, women. Contrastingly, low lumbar 
spine volumetric BMD was associated with higher CVD incidence in white, but not black, men. 
However, the higher incidence of other CVD events among population with osteoporosis or 
low BMD was not incorporated in the model for this thesis due to the various – hence, not 
comparable – modes of measurements by which correlations were shown, and the risk of 
double counting with the correlation between the prevalent CVD and the risk of fracture 
applied in the model.  
 
 
8.3.3. Non-disease death in osteoporosis-linked model 
 
In any linked models where osteoporosis was included, time to non-disease death was 
sampled as described in Chapters 4 and 7: the age- and sex-specific time-to-death distributions 
were further adjusted based on the Z-score of the individual. When the model includes both 
osteoporosis and heart disease, the mortality from cardiac causes were subtracted from the 
rates used to establish the time to non-disease death distributions in the osteoporosis-linked 
model (see Table 7.18’ in Appendix 7.1 and Chapter 5, Section ‘Non-disease mortality’ section).  
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When osteoporosis is included in the model, multiple sets of non-disease death rates were 
established for ranges of Z-score (Table 7.18 in Chapter 7). In the model where HD and 
osteoporosis are linked, cardiac death rates were subtracted from these non-disease mortality 
rates based on Z-score (Table 7.18’ in Appendix 7.1).  
 
8.4. Correlation between Alzheimer’s disease and Osteoporosis 
 
 
8.4.1 Prevalent osteoporosis and the risk of Alzheimer’s disease 
 
A number of studies have demonstrated correlations between low BMD and the risk of AD 
(Chang et al., 2014b, Duthie et al., 2011, Tan et al., 2005).  Tan et al. (Tan et al., 2005) 
examined whether low BMD in elderly individuals is associated with an increased incidence of 
AD. The relative risks for the relationship between age and sex-specific quartiles of BMD and 
the incidence of AD  were reported for women and men adjusted for age, sex and other 
covariates such as smoking status, education, and apolipoprotein E ε4 status. The values for 
the lowest BMD quartile and the remaining quartiles of BMD measured at femoral neck 
adjusted for all covariates were used in the model in this thesis. The ‘relative risks’ reported in 
Tan et al. (2005) were considered to be hazard ratios given that Cox proportional hazard 
models were used within their statistical analyses and the paper discussed incidences of AD. 
The hazard ratios used were 2.04 (95% CI 1.11-3.75) for women and 1.33 (95% CI 0.46-3.86) for 
men. Although the value for men was not statistically significant, the central value was still 
used in the model. As all modelled individuals are assigned a Z-score which is an age and sex 
specific T-score, the lowest quartile of BMD was the 25th percentile of standard normal, that is, 
-0.67. Those whose Z-score is below -0.67 were assigned a higher incidence of AD than the 
remaining people.  
The incidence rates split by BMD level were calculated using the same method as in Section 8.2 
and are shown in Table 8.12.  
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Table 8.12. Splitting incidence of Alzheimer’s disease into two groups: people with low BMD vs. 
people without low BMD 
  Total incidence of AD Baseline rate without low 
BMD (Quartiles 2-4) 
  
Rate for patients with low 
BMD (Quartile 1) 
Age Men Women Men Women Men Women 
<65 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
65-69 0.004968 0.004536 0.004589 0.003600 0.006104 0.007344 
70-74 0.010440 0.004392 0.009644 0.003486 0.012827 0.007111 
75-79 0.010224 0.010656 0.009445 0.008457 0.012562 0.017253 
80-84 0.012240 0.022464 0.011307 0.017829 0.015039 0.036370 
85+ 0.042048 0.051624 0.038843 0.040971 0.051662 0.083582 
 
 
Incidence of Alzheimer’s disease based on the prevalence of heart disease and 
osteoporosis 
 
In order to fully account for correlations between the three diseases, the values in Table 8.12 
were further divided between people with prevalent HD and with no prevalent HD using the 
incidence rates reported in Table 8.8 in Section 8.2.2 (incidence of AD split between people 
with HD and without HD). These can be compared with the total incidence of AD shown in 
Table 8.12 which was used in the individual AD model.   
 
Table 8.13. Incidence of AD into four groups (with or without HD & with or without low BMD) 
 Without heart disease With heart disease 
  Incidence without 
low BMD (Quartiles 
2-4) 
Incidence with low 
BMD (Quartile 1) 
Incidence without 
low BMD (Quartiles 
2-4) 
Incidence with low 
BMD (Quartile 1) 
Age Men Women Men Women Men Women Men Women 
<65 0 0 0 0 0 0 0 0 
65-69 0.00416 0.00344 0.00554 0.00701 0.00541 0.00447 0.00720 0.00911 
70-74 0.00869 0.00330 0.01156 0.00672 0.01130 0.00428 0.01503 0.00874 
75-79 0.00824 0.00761 0.01096 0.01553 0.01071 0.00989 0.01425 0.02018 
80-84 0.00987 0.01603 0.01313 0.03270 0.01283 0.02084 0.01706 0.04252 
85+ 0.03425 0.03696 0.04555 0.07539 0.04452 0.04805 0.05922 0.09801 
 
In the other direction, AD patients were more prone to osteoporosis and osteoporotic 
fractures. Weller and Schatzker (2004) found that osteoporosis was more prevalent among 
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nursing home residents with AD as opposed to those without AD. However, this was not 
incorporated in the model.  
 
8.4.2. Costs, utilities and non-disease mortality 
 
As in previous sections, costs were additive and utilities were multiplicative. Non-disease 
mortality rates were adjusted for Z-score. 
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8.5. Results from two-disease linked models 
 
8.5.1. Single-disease results from the independently linked model 
  
 
For the validation of the linked model results, results from the individual disease models were 
compared with those from the independently linked model where diseases outside of the 
comparison were assumed to have zero incidence.   
All results in this section were obtained from the models for general UK population aged 45 
years and older, and simulated individuals were assumed to receive default treatments (statin 
for HD; donepezil for mild-to-moderately severe AD and memantine for severe AD; and 
alendronate for osteoporosis) upon the onset of each disease. The same non-disease death 
distributions as those used in the individual disease model were applied in the linked model for 
this comparison. The HD and AD were linked first with osteoporosis subsequently added to the 
two-disease linked model, and thus results related to osteoporosis were obtained from a 
three-disease linked model. 
Table 8.14 compares per-person results from each of the individual disease models with those 
from the independently linked models in which only the relevant diseases were considered.  
For all diseases, the results from the independently linked model were similar to those from 
individual disease models with differences of less than 1% in most reported outcomes. These 
showed that the creation of linked models did not alter the results significantly, which 
indicated that this did not introduce coding errors.  
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Table 8.14. Comparison between independently linked models and individual disease models (% 
in brackets represents percentage differences from the individual disease model results)  
1. Heart disease (HD)  only (n=200,000) 
 Individual heart disease 
only model 
HD-AD linked model 
where only HD was 
considered 
Three disease linked model 
where only HD was 
considered 
 Discounted Undiscounted Discounted Undiscounted Discounted Undiscounted 
Cost £ 8,091 £ 14,224 £ 8,123 
(+0.39%) 
£ 14,281 
(+0.40%) 
£ 8,108      
(-0.21%) 
£ 14,227 
(-0.02%) 
QALYs 9.249 13.843 9.218         
(-0.33%) 
13.791 
(-0.37%) 
9.241      
(-0.09%) 
13.833 
(-0.07%) 
Life 
years 
lived 
 21.319  21.256     
(-0.30%) 
 21.313  
(-0.03%) 
2. Alzheimer’s disease (AD) only (n=200,000) 
 Individual AD only model HD-AD linked model 
where only AD was 
considered 
Three disease linked model 
where only AD was 
considered 
 Discounted Undiscounted Discounted Undiscounted Discounted Undiscounted 
Cost £ 4,582 £ 8,845 £ 4,599 
(+0.38%) 
£ 8,889 
(+0.49%) 
£ 4,586      
(+0.09%) 
£ 8,888 
(+0.48%) 
QALYs 10.642 16.548 10.650     
(+0.07%) 
16.548 
(0.00%) 
10.648      
(+0.05%) 
16.553 
(+0.03%) 
Life 
years 
lived 
 21.653  21.650  
(-0.01%) 
 21.662  
(+0.04%) 
3. Osteoporosis only (n=400,000) 
 Individual osteoporosis 
only model 
 
HD-AD linked model 
where only osteoporosis 
was considered 
Three disease linked model 
where only osteoporosis 
was considered 
 Discounted Undiscounted Discounted Undiscounted Discounted Undiscounted 
Cost £ 2,847 £ 6,151 NA NA £ 2,811      
(-1.28%) 
£ 6,075 
(-1.23%) 
QALYs 11.191 17.759 NA NA  11.195     
(+0.03%) 
17.770 
(+0.06%) 
Life 
years 
lived 
 23.530  NA   23.541 
(+0.05%) 
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8.5.2. Two-disease model results with and without correlations 
 
 
This section reports lifetime per-capita results from the linked models in which only pairs of 
diseases were considered in order to see the results of incorporating the correlations 
described in this chapter.  The three-disease linked model results will follow in Chapter 9 to 
fully examine the effect of model linkage and correlations in the larger model.  For any pair of 
diseases which included osteoporosis, results were obtained from the three-disease linked 
model with the irrelevant disease not considered.  
Table 8.15 shows costs and QALYs results for three pairs of diseases from the linked models 
with and without correlations with percentage changes compared with the results from the 
independently linked model.  Across all pairwise results, 500,000 individuals aged 45 years and 
older were simulated.  
Incorporating correlations between diseases did not alter results for the general population to 
a great degree in this model with the difference in costs and QALYs below 4% and 2%, 
respectively, compared with assuming independence between diseases. When only HD and AD 
are considered, the costs obtained from the independently linked model were smaller than the 
sum of costs from individual disease models, whilst QALYs and the average number of years 
lived were lower than the minimum of the individual disease model results (Table 8.16 (1)). In 
the model with correlations, the costs were lower compared with the results from the 
independently linked model when HD-AD and AD-osteoporosis pairs were considered, whilst 
the HD-osteoporosis only model produced slightly higher costs.  
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Table 8.15. Base-case results from the linked model where only two diseases were activated 
(n=500,000) 
 Independently linked model Correlated linked model 
 Discounted Undiscounted Discounted Undiscounted 
1. When Heart disease and Alzheimer’s disease are considered 
Cost £ 11,935 
(£ 11,904)* 
£ 21,229 
(£ 21,185)* 
£ 11,802  
(-1.11%) 
(£11,909;  
+0.04%)* 
£ 20,869  
(-1.70%) 
(£21,067; -
0.55%)* 
QALYs 8.918 
(8.910)* 
13.144 
(13.135)* 
8.918 (0.00%) 
(8.914; +0.04%)* 
13.154 (+0.07%) 
(13.141; 
+0.05%)* 
Life years lived  20.301 
(20.281)* 
 20.302 (+0.01%) 
(20.279; -
0.01%)* 
2. With Heart disease and Osteoporosis are considered 
Cost £ 11,311 £ 21,080 £ 11,372 
(+0.54%) 
£ 21,235 
(+0.74%) 
QALYs 9.300 13.963  9.291 (-0.10%)  13.946 (-0.12%) 
Life years lived  22.009   21.987 (-0.10%) 
3. When Alzheimer’s disease and osteoporosis are considered 
Cost £ 7,183 £ 14,328 £ 6,989 (-2.71%) £13,755 (-4.00%) 
QALYs 10.751 16.741 10.755 (+0.04%) 16.767 (+0.15%) 
Life years lived  22.341  22.359 (+0.08%) 
%percentage in the brackets show the percentage difference compared with the 
independently linked model results.  
*Numbers in brackets: results from the two-disease HD-AD linked model. Otherwise, results 
are from the three-disease linked models where only two of the diseases were activated.  
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Table 8.16. Summary of base-case results from individual disease models described in 
Chapters 5-7 
 Sum of costs from individual disease models 
 (1) HD only 
and AD only  
models* 
(2) HD only and 
osteoporosis 
only models* 
 
(3) AD only and 
osteoporosis 
only models* 
(4) Three 
individual 
disease models 
(HD, AD, and 
osteoporosis) 
Cost - 
Discounted 
£ 12,673 £ 10,938 £ 7,429 £ 15,520 
Cost £ 23,069 £ 20,374 £ 14,996 £ 29,220 
 Minimum of QALYs/LYs from individual disease models 
QALYs - 
Discounted 
9.249 9.249 10.642 9.249 
QALYs 13.843 13.843 16.548 13.843 
Life years lived 21.319 21.319 21.653 21.319 
*Results from treatment arm; HD=heart disease, AD=Alzheimer’s disease 
 
 
The effect of correlations in models where patients were assumed to already have the diseases 
at model initiation was also explored.  At model entry, individuals were assumed to have one 
of: a T-score of -2.5; Alzheimer’s disease; or receiving statins for the secondary prevention of 
heart disease events. Results for those who already have a relevant disease are shown in Table 
8.17. For comparison with the base-case results, the base-case population aged 45 years and 
over was simulated with one of the above disease status added as patient characteristics at 
model entry.    
For patients assumed to be receiving statins for secondary prevention of heart disease events, 
the previous event history was assigned in the same manner as the secondary prevention 
population in Chapter 5. All individuals had only one previous heart disease event on a pro rata 
basis according to the ratio of prevalence of each event at the patient’s age.  
Compared with the base-case, the differences between the results from the independently 
linked model and the correlated linked model were generally larger when 100% prevalence 
was assumed for one of the diseases at model initiation. Costs were higher in the correlated 
linked model than in the independently linked model, when individuals enter the model with 
HD or osteoporosis. 
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Table 8.17. Two-disease model results for those already with the diseases at model initiation 
(n=500,000)  
 Independently linked model Correlated linked model* 
 Discounted Undiscounted Discounted Undiscounted 
1. Heart disease and Alzheimer’s disease 
1-1) When all individuals have heart disease at model entry 
Cost £ 20,388 £ 33,845 £ 21,111 
(+3.54%) 
£ 34,857 (+2.99%) 
QALYs 7.768 11.451 7.697 (-0.90%) 11.326 (-1.10%) 
Life years lived  20.109   19.905 (-1.01%) 
1-2) When all individuals have Alzheimer’s disease at model entry 
Cost £ 95,015 £ 128,511 £ 94,886  
(-0.14%) 
£ 128,282 (-0.18%) 
QALYs 2.545 3.106 2.545 (-0.03%) 3.105 (-0.04%) 
Life years lived  7.687  7.683 (-0.06%) 
2. Heart disease and Osteoporosis 
2-1) When all individuals have heart disease at model entry 
Cost £ 20,178 £ 34,624 £ 20,183 
(+0.02%) 
£ 34,631 (+0.02%) 
QALYs 8.119 12.204 8.102 (-0.21%)  12.168 (-0.29%) 
Life years lived  21.843   21.783 (-0.28%) 
2-2) When all individuals have osteoporosis at model entry 
Cost £ 17,286 £ 35,390 £ 17,580 
(+1.70%) 
£ 36,001 (+1.73%) 
QALYs 8.926 13.204 8.922 (-0.05%) 13.180 (-0.18%) 
Life years lived  21.842  21.801 (-0.18%) 
3. Alzheimer’s disease and osteoporosis 
3-1) When all individuals have Alzheimer’s disease at model entry 
Cost £ 96,568 £ 132,279 £ 96,586 
(+0.02%) 
£ 132,286 (+0.01%) 
QALYs 2.841 3.542 2.838 (-0.10%) 3.538 (-0.12%) 
Life years lived  8.028  8.019 (-0.12%) 
3-2) When all individuals have osteoporosis at model entry 
Cost £ 12,502 £ 26,624 £ 13,067 
(+4.53%) 
£ 27,405 (+2.93%) 
QALYs 10.310 15.747 10.206 (-1.01%) 15.508 (-1.52%) 
Life years lived  22.161  21.844 (-1.43%) 
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Table 8.18 presents the projected annual costs of treating only two of the diseases considered 
in the model.  The changes in the annual costs from incorporating correlations are given in 
Figure 8.3. Negative values meant the annual costs projected from the correlated linked model 
being lower than those from the independently linked model.  
 
Table 8.18. Annual costs projected from the models where pairs of diseases were considered 
(£, millions) 
 HD-AD only model HD-osteoporosis only 
model 
AD-osteoporosis only 
model 
Year Model with 
independent 
diseases 
Model with 
correlated 
diseases 
Model with 
independent 
diseases 
Model 
with 
correlated 
diseases 
Model with 
independent 
diseases 
Model 
with 
correlated 
diseases 
2012  £14,136   £ 14,367   £11,218   £11,234   £6,417   £6,301  
2013  £14,298   £ 14,313   £12,050   £12,132   £6,372   £6,229  
2014  £15,045   £ 15,005   £12,773   £12,840   £6,661   £6,657  
2015  £15,779   £ 15,616   £13,517   £13,514   £7,045   £7,108  
2016  £16,356   £ 16,131   £14,180   £14,125   £7,420   £7,505  
2017  £16,867   £ 16,813   £14,962   £14,961   £7,750   £7,836  
2018  £17,385   £ 17,372   £15,681   £15,626   £7,911   £8,005  
2019  £17,853   £ 17,717   £16,326   £16,283   £8,154   £8,254  
2020  £18,296   £ 18,264   £16,806   £16,807   £8,427   £8,475  
2021  £18,622   £ 18,807   £17,528   £17,420   £8,445   £8,631  
2022  £18,821   £ 19,160   £18,170   £17,984   £8,677   £8,854  
2023  £19,394   £ 19,542   £18,629   £18,471   £8,851   £8,869  
2024  £19,953   £ 19,763   £19,081   £19,081   £8,985   £8,990  
2025  £20,182   £ 20,054   £19,577   £19,624   £9,095   £9,071  
2026  £20,473   £ 20,359   £19,960   £20,003   £9,291   £9,192  
2027  £20,770   £ 20,512   £20,488   £20,453   £9,564   £9,424  
2028  £21,072   £ 20,837   £20,803   £20,905   £9,659   £9,530  
2029  £21,397   £ 21,019   £21,172   £21,254   £9,854   £9,714  
2030  £21,627   £ 21,393   £21,566   £21,647   £10,214   £9,915  
2031  £22,110   £ 21,743   £21,908   £22,051   £10,337   £9,960  
2032  £22,352   £ 21,961   £22,379   £22,396   £10,383   £10,050  
2033  £22,607   £ 22,167   £22,638   £22,751   £10,615   £10,162  
2034  £22,899   £ 22,593   £22,850   £23,153   £11,098   £10,378  
2035  £23,110   £ 22,891   £23,143   £23,427   £11,355   £10,579  
2036  £23,360   £ 23,083   £23,456   £23,721   £11,390   £10,751  
2037  £23,524   £ 23,322   £23,763   £23,996   £11,454   £10,931  
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The differences in annual costs were projected to widen over time with the costs from the 
correlated disease model results being lower. This may be due to the correlations associated 
with AD making individuals with AD more likely to develop the other diseases that increase 
mortality, and hence decreasing the number of people who get the costly institutional care in 
later stages of life.  
Without such cost savings due to the correlation between AD and the other diseases, the 
model where only HD and osteoporosis were considered produced higher projected annual 
costs in later years with correlations incorporated than when using the results from the 
independently linked model. Also, as the presence of HD increases the incidence of fracture 
and vice versa, correlations between HD and osteoporosis would only increase the number of 
people with both HD and osteoporosis over time among those who survived the diseases in 
earlier years, which causes higher costs in later years.  
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Figure 8.3. Difference in projected annual costs after incorporating correlations in the model 
(Negative values mean the costs from the correlated linked model are lower than those from 
the independently linked model) 
1) Heart disease and Alzheimer’s disease only 
 
2) Heart disease and osteoporosis only 
 
3) Alzheimer’s disease and osteoporosis only 
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8.6. Discussion 
 
 
The linked models where one disease was considered at a time showed similar results to those 
from individual disease models, indicating that the model linkage does not introduce 
significant inaccuracy compared with the single-disease model. Incorporating correlations 
between diseases into the linked model produced different costs and QALY results from those 
from the independently linked model, although the differences were small. The differences 
when running the model for people already with any of the diseases were larger. 
It is noted that only some of the possible correlations between the included diseases were 
incorporated in the model as a proof-of-concept. Correlations were not incorporated for both 
directions of influence; for instance, the linked model reflects that individuals with low BMD 
have higher incidence of AD, but does not consider that prevalent or incident AD can 
accelerate the deterioration of BMD.  Researchers wishing to explore further the impact of 
implementing correlations in the linked model may incorporate more correlations as 
exemplified in this chapter.  
Chapter 9 will report results in more detail from the all-disease linked model including the 
cost-effectiveness of each intervention.  
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CHAPTER 9   RESULTS FROM THE ALL-DISEASE LINKED 
MODEL & SCENARIO ANALYSES 
 
9.1. Base case results from the three disease linked model 
 
This chapter presents the simulation results from the models where all the three diseases were 
linked. In the ‘linked’ model, an individual can experience events from any of the three 
diseases (HD, AD, and osteoporosis) within a single model (Chapter 4). There were two 
versions of the linked model: the model where the diseases were linked with correlations 
(‘correlated linked model’) and the model where the diseases were linked but assumed to be 
independent (‘independently linked model’).  The correlated linked model assigns disease 
history and event probabilities based on the status of the other diseases included in the model 
and patient characteristics such as age and sex (Chapter 8). The independently linked model 
does so, based only upon patient characteristics that are not necessarily related to the other 
diseases.  
A set of scenario analyses to answer the main questions shown in Box 4.1 in Chapter 4 are also 
presented. All comparisons of results made in this chapter focussed more on costs rather than 
QALYs, with the projected annual costs taken as one of the main outcomes. 
 
9.1.1. First-order uncertainty analyses 
 
The first-order uncertainty associated with random variability around the mean incremental 
cost and QALYs, incremental net monetary benefit (NMB) and cost per QALY gained (CPQ) was 
examined using the results from the correlated linked model for the population aged 45 years 
and older. Incremental values were computed in comparison with no treatments for all three 
of the diseases. The standard errors of the mean results were estimated having varied the 
numbers of simulated individuals from 1,000 to 700,000.  The jackknife 95% confidence 
interval for the mean CPQ and the NMB results with more than 400,000 simulated individuals 
were derived using R programming language (R version 3.2.1, © The R Foundation) due to 
limited capacity of the spreadsheet software. Jackknifing execution time for the data from 
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700,000 simulated individuals was 4.69 hours on an Intel ® Core ™ i5 CPU 2.30 GHz processor 
with 4.00 GB of RAM (3.54 hours for 600,000 data points).  
As shown in Figure 9.1, incremental cost and QALYs stabilised when more than 200,000 
individuals were simulated. The standard errors of the mean NMB and CPQ started to stabilise 
after running more than 500,000 simulated individuals. The chosen number of individuals to 
simulate was 700,000 for the base-case all-disease linked models (with and without 
correlations) in order to further reduce the variability of the results.  
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Figure 9.1. First order uncertainty in relation to the number of patients simulated in the all-
disease linked model with correlations (base-year population aged 45 years and over) 
1) Incremental cost (compared with none of the three treatments) 
Undiscounted 
 
Discounted 
 
2) Incremental QALYs (compared with none of the treatments for the three diseases) 
Undiscounted 
 
Discounted 
 
3) Cost per QALYs (95% jackknife confidence interval) 
Undiscounted 
 
Discounted 
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4) Net monetary benefit (£20,000 threshold) 
Undiscounted 
 
Discounted 
 
 
 
In the next sections, the base-case results from models with independent and correlated 
diseases will be compared in order to see the effect of incorporating correlations in the all-
disease linked model. Also, the results from the independently linked model will be compared 
to examine the effect of multi-disease linkage on the per-capita cost, QALYs, life years and 
projected annual costs.  
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9.1.2. Base-case results from the linked model where diseases were 
assumed independent – Effect of linking the individual disease models  
 
The base-case results from the independently linked model are given in Table 9.1. For the 
treatment arm results, the default treatments described in Chapters 5 - 7 were assumed to be 
used.  For comparison, the results from the three individual disease models used to calculate 
the sum of the incremental cost and QALYs across the three disease models in Table 9.1 (see in 
Chapters 5 - 7) are presented in Table 9.2. Comparison of the results from the linked model 
with the sum of the results from the three individual disease models would indicate the effect 
of the model linkage on model outcomes. It is noted that the individual disease model results 
came from runs with different sized patient groups (700,000 for three disease model, 200,000 
for HD; 200,000 for AD, and 400,000 for osteoporosis). However, this was not expected to 
influence the results which are reported per person. 
The cost per QALY of the combined treatments for heart disease (HD), Alzheimer’s disease (AD) 
and osteoporosis was £3,582 (£3,854 when undiscounted). The absolute costs from the 
independently linked model (Table 9.1) were slightly lower than the sum of the absolute costs 
from the three individual disease models (Table 9.2 – the sum of three treatment arm results 
being £15,520 when discounted and £29,220 when undiscounted; and the sum of no 
treatment results £15,112 when discounted and £28,389 when undiscounted). The absolute 
QALYs (Table 9.1 – 8.956 when discounted and 13.233 undiscounted) were lower than the 
minimum of the equivalent values from the three individual disease models, which were 9.249 
(discounted) and 13.843 (undiscounted) from the HD only model (Table 9.2), as the population 
in the model including multiple diseases are sicker on average than those in single disease 
models.   
The ICER of the combined treatments for the three diseases calculated as the sum of 
incremental costs divided by the sum of incremental QALYs in Table 9.2 (£1,458/QALY) was 
lower than the ICER estimated using the linked model results in Table 9.1 (£3,582/QALY) due 
to the higher incremental cost (£840) and lower incremental QALYs (0.234) from the linked 
model compared with the sum of the three individual disease model results (£408, 0.280). This 
shows that the estimates of the cost effectiveness of combined interventions derived from 
individual disease models can be substantially different from estimates derived from a model 
where multiple diseases are linked. This may be significant from a policy perspective as it can 
influence the ultimate adoption decisions relating to treatments.  
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Table 9.1. Per-capita results from the independently linked model based on n=700,000 
 All disease linked model results Individual disease 
models 
With all 
treatments*  
 
None of the 
three 
treatments 
Incremental 
values 
Sum of incremental 
values across three 
individual models† 
Cost - 
Discounted 
£ 14,776 £ 13,936 £ 840 £ 408 
QALYs - 
Discounted 
8.956 8.722 0.234 0.280 
Cost £ 27,093 £ 25,179 £ 1,914 £ 831 
QALYs 13.233 12.736 0.497 0.597 
Life years 
lived 
20.867 19.947 0.919 1.007 
ICER – 
Discounted 
(£/QALY) 
    £ 3,582 £ 1,458 
ICER (£/QALY)   £ 3,854 £ 1,391 
*All the default treatments described in Chapter 5 - 7 were assumed to be available;  
†See Table 9.2 for calculation.
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Table 9.2. Summary of the results from the individual disease models from Chapters 5, 6, and 7 for comparison 
 1)  
Heart disease only model 
2)  
Alzheimer’s disease only model 
3)  
Osteoporosis only model 
4)  
Sum of 
incremental values 
across 1)-3) 
Treatment  No 
treatment 
Incremental 
values (A) 
Treatment  No 
treatment 
Incremental 
values (B) 
Treatment  No 
treatment 
Incremental 
values (C) 
(A)+(B)+(C) 
Cost - 
Discounted 
£ 8,091 £ 7,569 £ 522 £4,582 £4,596 -£ 14 £ 2,847 £ 2,947 -£ 100 £ 408 
 
QALYs - 
Discounted 
9.249 8.978 0.271 10.642 10.641 0.001 11.191 11.184 0.008 0.280 
Cost £ 14,224 £ 13,197 £ 1,027 £8,845 £8,869 -£ 23 £ 6,151 £ 6,324 -£ 173 £ 831 
QALYs 13.843 13.257 0.586 16.548 16.545 0.003 17.759 17.751 0.009 0.597 
Life years 
lived 
21.319 20.319 1.000 21.653 21.650 0.003 23.530 23.525 0.004 1.007 
ICER – 
Discounted  
  £ 1,926 
/QALY 
  Dominating   Dominating £ 1,458 /QALY 
ICER   £ 1,754 / 
QALY 
  Dominating   Dominating £ 1,391 / QALY 
HD: based on n=200,000; AD n=200,000; Osteoporosis n=400,000
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As part of the base-case results from the independently linked model, the male and female 
cohorts of 45-year-olds that enter the population every year were simulated to incur £ 31,141 
and £37,640, respectively, over their lifetime with 21.772 and 22.593 QALYs gained (Table 9.3). 
The equivalent figures when discounted were £13,057 and £14,308 and 13.335 and 13.557 
QALYs.  As in the other model results, the female population was estimated to incur a higher 
cost with longer life years. These figures were used to project future population-level costs of 
treating the three included diseases.  
 
Table 9.3. Per-capita results from the linked model where diseases were assumed to be 
independent for the incoming cohorts of 45 year olds 
 
Male Female 
Cost – Discounted  £ 13,057 £ 14,308 
QALYs - 
Discounted 13.335 13.557 
Cost £ 31,141 £ 37,640 
QALYs 21.772 22.593 
LY 32.660 35.079 
Based on n=700,000 simulated individuals; All default treatments were assumed available. 
 
 
Figure 9.2 shows graphically the cohort annual costs per person of the population aged 45 
years and older in the base year and the new incoming cohorts of males and females aged 45 
years in their entry year, and the total annual costs projected using the per-capita costs and 
the ONS population projection data (Office for National Statistics, 2013c). Per-capita cohort 
costs for 45-year-old males peaked earlier than those for females. The total annual costs were 
projected to increase from £15.90 billion in 2012 to £28.57 billion in 2037. Per-capita annual 
costs of the future incoming cohorts of male and female populations aged 45 years at model 
initiation (Figure 9.2a) did not change smoothly over time due to the stepped increase in 
cardiac death rates that were subtracted from the all-cause mortality in order to calculate non-
disease death rates (see Chapter 5 Section 5.4.1). This was more prominent for female cohort 
due to their lower rates of disease-related mortality in HD and thus, a higher probability of the 
time to non-disease death (sampled from the distributions based on these stepped non-
disease death rates) becoming their total life years.   
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Table 9.4 compares the projected annual cost results from the independently linked model 
with the sum of the three individual disease model results. The annual costs from the 
independently linked model were lower than the summed results with the cumulative 
difference estimated to amount to £16 billion (£7.8 billion when using discounted costs) over 
the period 2012-2037. This shows that the use of multi-disease models may have significant 
policy implications, impacting funding decisions about potential treatment interventions or 
influencing policy decisions about the prevention and treatment of relevant diseases. The 
difference in projected annual costs was estimated to be generally larger into the future years, 
whilst in earlier years of the projection horizon the differences showed irregular changes 
(Figure 9.3). Linked models do not double-count items such as the cost of institutionalisation. 
Hence, as individuals in the linked disease model age and more of them reach the age of 65 
where AD prevalence becomes positive, those in the linked model can save more in later years 
on such costs overlapping between the three diseases.  In earlier years, there is less potential 
for such savings, but more uncertainty due to different rates of cost accrual each year in the 
three individual disease models which result in an uneven increase in the sum of costs over 
time. Also, smaller differences are subject to more uncertainty in terms of the direction of 
savings as per-capita costs were scaled up to the population level. 
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Figure 9.2. Total population-level annual cost projections from the independently linked model 
a) Per capita annual costs – total annual costs divided by the number of people at model 
initiation 
 
 
b) Total population level costs projected to the year 2037 
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Table 9.4. Projected annual costs from the linked model where diseases were assumed 
independent in comparison with the sum of the individual disease model results 
 Undiscounted costs Discounted costs 
Year Annual 
costs (£, 
millions)  
(1)  
Sum of annual 
costs from 
three 
individual 
disease 
models  
(£, millions) 
(2)  
Difference 
(£, 
millions) 
(1)-(2)  
Annual costs 
(£, millions)  
 (1)’ 
Sum of annual 
costs from 
three 
individual 
disease 
models  
(£, millions) 
(2)’ 
Difference (£, 
millions) 
(1)’-(2)’ 
 
2012  £ 15,905   £ 15,840   £ 65   £ 15,637   £ 15,574   £ 63  
2013  £ 16,481   £ 16,323   £ 158   £ 15,652   £ 15,502   £ 150  
2014  £ 17,365   £ 17,260   £ 104   £ 15,933   £ 15,837   £ 96  
2015  £ 18,085   £ 18,147  - £ 62   £ 16,032   £ 16,088  -£ 56  
2016  £ 18,973   £ 19,014  -£ 41   £ 16,250   £ 16,287  -£ 37  
2017  £ 19,904   £ 19,583   £ 321   £ 16,472   £ 16,207   £ 265  
2018  £ 20,616   £ 20,431   £ 186   £ 16,486   £ 16,336   £ 149  
2019  £ 21,160   £ 20,968   £ 192   £ 16,348   £ 16,199   £ 149  
2020  £ 21,746   £ 21,577   £ 170   £ 16,233   £ 16,106   £ 127  
2021  £ 22,187   £ 22,224  -£ 37   £ 16,002   £ 16,028  -£ 26  
2022  £ 22,619   £ 22,828  -£ 209   £ 15,762   £ 15,907  -£ 146  
2023  £ 23,168   £ 23,453  -£ 285   £ 15,598   £ 15,791  -£ 192  
2024  £ 23,689   £ 24,113  -£ 424   £ 15,410   £ 15,686  -£ 275  
2025  £ 24,076   £ 24,763  -£ 687   £ 15,132   £ 15,564  -£ 431  
2026  £ 24,398   £ 24,990  -£ 592   £ 14,816   £ 15,176  -£ 359  
2027  £ 24,790   £ 25,743  -£ 953   £ 14,544   £ 15,104  -£ 559  
2028  £ 25,168   £ 26,350  -£ 1,181   £ 14,268   £ 14,937  -£ 669  
2029  £ 25,489   £ 26,732  -£ 1,243   £ 13,961   £ 14,642  -£ 682  
2030  £ 25,933   £ 27,112  -£ 1,179   £ 13,724   £ 14,348  -£ 624  
2031  £ 26,218   £ 27,645  -£ 1,427   £ 13,405   £ 14,134  -£ 730  
2032  £ 26,790   £ 27,902  -£ 1,111   £ 13,235   £ 13,784  -£ 549  
2033  £ 27,058   £ 28,464  -£ 1,406   £ 12,915   £ 13,586  -£ 671  
2034  £ 27,308   £ 29,060  -£ 1,751   £ 12,594   £ 13,402  -£ 808  
2035  £ 27,804   £ 29,377  -£ 1,573   £ 12,388   £ 13,090  -£ 701  
2036  £ 28,276   £ 29,714  -£ 1,439   £ 12,173   £ 12,792  -£ 619  
2037  £ 28,568   £ 30,176  -£ 1,608   £ 11,883   £ 12,552  -£ 669  
Total 
(2012-
2037)  
£ 603,775 £ 619,788 -£ 16,013 £ 382,854 £390,659 -£7,805 
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Figure 9.3. Difference [(1)-(2)] between annual costs projected from the linked model with 
independent diseases (1) and the sum of annual costs from three individual disease models 
(2)* 
 
*Negative values denote lower costs from using the linked model with independent 
diseases. 
 
 
Table 9.5 presents cost per QALY estimates of each intervention based on 700,000 simulated 
individuals when the other two interventions are available. The results differ from the results 
from the models where only one disease was considered which are reproduced in Table 9.2. 
AD treatment produced lower QALYs with lower costs than no treatment whilst it was 
dominating no treatment in the individual AD model, although the absolute change in 
incremental QALYs between the two model results were very small and the results in Table 9.5 
did not show face validity as it was considered implausible to have negative incremental QALYs 
for AD treatment. The results produced using a higher number of simulated individuals (n= 
2,000,000) are shown in Table 9.6. With the 2 million individuals simulated, the AD treatment 
now dominated no treatment with a very small QALY gain.  
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Table 9.5. Cost-effectiveness of individual treatments from the all-disease linked model where 
diseases were assumed independent based on 700,000 simulated individuals 
All disease 
linked 
model 
results 
HD treatment AD treatment Osteoporosis treatment 
No HD 
treatment*  
Incremental 
values 
No AD 
treatment* 
Incremental 
values 
No Osteo-
porosis 
treatment* 
Incremental 
values 
Cost - 
Discounted 
£ 13,815 £ 960 £ 14,800 -£ 24 £ 14,942 -£ 166 
QALYs - 
Discounted 
8.720 0.236 8.957 -0.001 8.954 0.002 
Cost £ 24,945 £ 2,148 £ 27,140 -£ 47 £ 27,391 -£ 298 
QALYs 12.731 0.502 13.235 -0.003 13.230 0.003 
Life years 
lived 
19.939 0.928 20.870 -0.004 20.869 -0.003 
ICER  £ 4,277  £ 18,740†  Dominating 
ICER - 
Discounted 
 £ 4,068  £ 32,549†  
HD=heart disease; AD=Alzheimer’s disease; *the other two treatments were assumed to be 
available; †Treatment with lower costs and lower QALYs. 
 
Table 9.6. Cost-effectiveness of individual treatments from all-disease linked model where 
diseases were assumed independent based on 2,000,000 simulated individuals  
 HD treatment AD treatment Osteoporosis treatment 
No HD 
treatment*  
Incremental 
values 
No AD 
treatment* 
Incremental 
values 
No Osteo-
porosis 
treatment* 
Incremental 
values 
Cost - 
Discounted 
£ 13,798 £ 1,004 £ 14,819 -£ 18 £ 14,914 -£ 112 
QALYs - 
Discounted 
8.717 0.240 8.958 0.000 8.952 0.005 
Cost £ 24,918 £ 2,212 £ 27,168 -£ 38 £ 27,359 -£ 228 
QALYs 12.727 0.508 13.235 0.000 13.227 0.008 
Life years 
lived 
19.933 0.938 20.869 0.002 20.861 0.009 
ICER  £ 4,355  Dominating  Dominating 
ICER - 
Discounted 
 £ 4,175   
HD=heart disease; AD=Alzheimer’s disease;*the other two treatments were assumed to be 
available. 
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Further investigation of the model suggested that despite stability having been shown for the 
AD model in isolation, and in the linked model where all the diseases and relevant treatments 
were considered, this was not the case in the three-disease linked model when individual 
treatments were assessed. In the individual disease models, stability was defined as an 
adoption decision being robust. This allows the potential changes in costs and QALYs due to 
sampling error in a single disease model to remain considerably large in relation to other 
diseases, although the conclusions regarding adoption decision to be robust.  
The size of incremental QALYs and costs per person from the three individual disease models 
presented in Chapters 5-7 are summarised in Table 9.7: it is seen that the effect of HD 
treatment is much larger than treatments for AD and osteoporosis. Hence, even though the 
results have been shown to be stable within individual disease models, the cost-effectiveness 
outcomes for individual treatments from the linked model where all three diseases were 
incorporated could be significantly altered should a change in the order of random numbers 
influence the simulated numbers of HD events.  
 
Table 9.7. Incremental costs and QALYs of individual treatments from the individual disease 
models 
 Individual heart 
disease model 
Individual 
Alzheimer’s disease 
model 
Individual 
osteoporosis model 
Incremental Cost - 
Discounted 
£ 522 -£ 14 -£ 100 
Incremental QALYs - 
Discounted 
0.271 0.001 0.008 
 
 
In the individual HD model (Chapter 5), the margin of error, defined as half-width of a 
confidence interval, around the mean incremental QALYs at 95% confidence level with 200,000 
simulated individuals was 0.0288. In order to estimate the predicted margin of error of the 
mean incremental QALYs with the higher number of simulated individuals, the power 
regression model was used to fit a non-linear curve that decreases proportionally to 1
√𝑁
⁄ .  
The fitting results and the estimated errors using the fitted equation, which has an R2 of 0.9999, 
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with varying numbers of simulated individuals are shown in Figure 9.4 and Table 9.8. The 
predicted margin of error in incremental QALYs for HD treatment with 700,000 individuals was 
0.0155. With 10 million individuals simulated, this value (0.0042) was still large compared with 
the incremental QALYs associated with AD (0.001) and osteoporosis (0.008) treatments.  As 
such, it is believed that the allocation of random numbers to simulate HD events is the 
probable cause of the lack of face validity in the results for the AD treatment. This shows that, 
in the case where the treatment of one disease has a much larger absolute impact on cost and 
QALYs than the impact of treatments for other diseases in a model where multiple diseases are 
linked, a very large number of individuals may need to be simulated for stable results for each 
of the three disease treatments.  
Linked models incorporating interactions between diseases can produce more accurate results 
than individual disease models if sufficient individual patients are modelled. Whether this is 
feasible within the time scales of projects is likely to be dependent on the characteristics of the 
decision problem. 
 
Figure 9.4. Power regression results for the margin of error (95% confidence level) in 
incremental discounted QALYs from the individual heart disease model  
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Table 9.8. Predicted margin of error for incremental discounted QALYs of heart disease 
treatment with increased number of simulated individuals 
Number of simulated individuals Margin of error of mean incremental 
QALYs (95% confidence level) 
700,000 0.0155 
2,000,000 0.0092 
5,000,000 0.0059 
10,000,000 0.0042 
20,000,000 0.0030 
 
 
In order to examine the effect of sampling error when all three treatments have a similar level 
of QALY gains, the scenarios in Table 9.9 were assumed: these are not meant to provide 
accurate evaluations of current treatments but to indicate that the results would be intuitive 
when QALY gains are comparable. For all three individual diseases, populations aged 65 years 
and older were simulated. Scenarios for larger QALY gains for AD and osteoporosis and 
reduced QALY gain for HD were explored. Table 9.9 shows the scenario assumptions applied to 
each of the three disease models in comparison with the base-case assumptions.  
 
Table 9.9. Comparison of scenario assumptions and base-case assumptions 
Base-case assumptions Scenario assumptions 
1. Heart disease model 
Relative risks were assumed to be 0.656, 
0.754, 0.876, 0.59, 0.74, and 0.656 for MI, 
non-fatal stroke, fatal stroke, stable 
angina, fatal CHD, and non-cardiac death, 
respectively.  
Relative risks of 0.98 for statin treatment 
were assumed for all events.  
Utility values for MI, stroke and 
revascularisation were set to 0.76, 0.629, 
and 0.78, respectively. 
Utility values for MI, stroke, and 
revascularisation were reduced to 0.5. 
2. Alzheimer’s disease model  
4% of monthly treatment discontinuation 
rate was assumed.  
Lifetime treatment: No treatment 
discontinuation was assumed 
6 months duration of treatment effect 
was assumed. 
Lifetime treatment effect was assumed. 
Utility value for institutionalised Utility value for those institutionalised 
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individuals was 0.33. was reduced to 0.1 
The average annual improvements in 
MMSE score were 2.48 for donepezil and 
1.4 for memantine per year.  
Double treatment effect on MMSE score: 
the average improvements in MMSE 
score were set to 4.96 for donepezil and 
2.8 for memantine per year.  
Some individuals are institutionalised at 
model entry, and some patients are 
institutionalised immediately after 
diagnosis. 
No individuals start at the 
institutionalisation state at model entry, 
nor get institutionalised immediately 
after the diagnosis (i.e. No individuals 
move to the institutionalisation event 
from the diagnosis event with zero time 
passed.) 
3. Osteoporosis model 
Relative risks of fracture for alendronate 
treatment were set to 0.72, 0.58, and 0.82 
for hip, vertebral, and other fractures, 
respectively.  
Relative risks were assumed to be 0.33 
for all fracture types.  
5 years of treatment duration was 
assumed.  
Lifetime treatment duration was 
assumed.  
 
 
Table 9.10 compares incremental outcomes from the three individual disease models with 
those for each of the individual treatments from the linked model where the diseases were 
assumed independent. Under the hypothetical scenarios, a comparable magnitude of QALY 
gains across all three individual disease models (Table 9.10 Column a) was achieved.  The 
margins of error around incremental costs and QALYs at 95% confidence level are shown in 
brackets.  
Table 9.10 also repeats the analyses in Table 9.5, but under the scenarios in Table 9.9, 
assuming the diseases were independent. When none of the treatments have much larger 
impact on QALYs gained the linked model produced similar results to those from the individual 
disease models. This shows the robustness of the adoption decision within the linked model 
for individual treatments.   
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Table 9.10. Cost-effectiveness results under larger QALY gain scenarios for individual 
treatments from the individual disease models and the independently linked model 
1. Heart disease 
 a. Individual heart 
disease model† 
b. Independently linked model (n=700,000) 
 Incremental values 
(Margin of error) ‡ 
All 
treatments 
No HD 
treatment* 
Incremental 
values 
DCost £ 683 (£ 66) £ 11,001 £ 10,201 £ 800 
DQALYs 0.0539 (0.0179) 4.9232 4.8784 0.0448 
TCost £ 913 (£ 94) £ 15,499 £ 14,380 £ 1,119 
TQALYs 0.0875 (0.0267) 6.2589 6.1861 0.0728 
ICER (disc.) £ 12,665   £ 17,878 
ICER £ 10,433   £ 15,360 
2. Alzheimer’s disease (AD) 
 a. Individual AD 
model† 
b. Independently linked model (n=700,000) 
 Incremental values 
(Margin of error) ‡ 
All 
treatments 
No AD 
treatment* 
Incremental 
values 
DCost -£ 4,551 (£ 93) £ 11,001 £ 15,413 -£ 4,412 
DQALYs 0.0508 (0.0020) 4.9232 4.8855 0.0377 
TCost -£ 6,319 (£ 130) £ 15,499 £ 21,582 -£ 6,083 
TQALYs 0.0688 (0.0028) 6.2589 6.2089 0.0500 
ICER (disc.) Dominating    Dominating 
ICER Dominating   Dominating 
3. Osteoporosis 
 a. Individual 
osteoporosis 
model† 
b. Independently linked model (n=700,000) 
 Incremental values 
(Margin of error) ‡ 
All 
treatments 
No osteoporosis 
treatment* 
Incremental 
values 
DCost -£ 1,186 (£ 74) £ 11,001 £ 11,983 -£ 982 
DQALYs 0.0545 (0.0128) 4.9232 4.8918 0.0314 
TCost -£ 1,856 (£ 123) £ 15,499 £ 16,970 -£ 1,471 
TQALYs 0.0900 (0.0204) 6.2589 6.2090 0.0499 
ICER (disc.) Dominating    Dominating  
ICER Dominating   Dominating 
† Based on n=200,000 for HD and AD models; and n=400,000 for osteoporosis model, as in the base-case; ‡ Margin 
of error at 95% confidence level; *The other two default treatments were assumed to be available; D=discounted. 
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When all the individual disease models produce similar QALY gains (without any disease with a 
significantly larger impact) the impact of a change in the order of random numbers sampled 
for one disease on the incremental outcomes and cost-effectiveness of the other diseases can 
be much less influential. None of the margin of error estimates in Table 9.10 (0.0179, 0.0020, 
and 0.0128 for HD, AD, and osteoporosis models, respectively) will have a significant effect 
that changes the +/- signs of the values on the incremental QALY results from the linked model 
(0.0448, 0.0377, and 0.0314 for HD, AD, and osteoporosis treatments, respectively).  Hence, 
when QALY gains are similar across all diseases, the results are less susceptible to sampling 
error from the other diseases. The base-case estimated very small QALY gains for AD and 
osteoporosis treatments which could fluctuate between positive and non-positive values due 
to the sampling error associated with the treatment for HD. In cases where QALY gains are 
similar, however, the proposed methods of linking individual disease models are likely to 
produce more accurate cost-effectiveness estimates for individual treatments.  
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9.1.3. Base-case results from the all-disease model with correlated 
diseases – Effect of correlations on the model outcomes 
 
 
The base-case results from the model where the all diseases were linked with correlations are 
shown in Table 9.11. By incorporating correlations, disease status and event rates are 
influenced by the presence of the other diseases, which was deemed to better reflect 
population characteristics, rather than assuming independence between diseases. The general 
population per-person lifetime costs associated with the treatment of the three diseases were 
estimated to be £26,921 and £14,741 in undiscounted and discounted values, respectively. 
QALYs of 13.253 (undiscounted) and 8.962 (discounted) were estimated.  
In comparison with no treatment for all three diseases, the combination of the three 
treatments was considered cost-effective with the discounted cost per QALY of £3,583 
(£3,899/QALY when undiscounted).  These were similar to the results from the independently 
linked model where the ICER of £3,854 (undiscounted) and £3,582 (discounted) per QALY were 
obtained.  
Table 9.12 gives the results for male and female populations aged 45 years from the correlated 
linked model. As before, all default treatments were assumed to be used. In comparison to 
when diseases were assumed independent (Table 9.3), the costs are lower whilst the QALYs 
and life years were higher.  This was due to positive correlations between diseases resulting in 
a greater number of disease-free people. 
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Table 9.11. Base-case results from the all-disease model with correlations based on n=700,000 
All disease linked 
model (linked with 
correlations) 
With all three 
treatments 
assumed  
None of the three 
treatments 
 
Incremental values  
Cost - Discounted  £        14,741  £        13,894  £           847 
QALYs - Discounted 8.962 8.725 0.236 
Cost  £        26,921 £        24,968   £        1,953 
QALYs 13.253 12.752 0.501 
Life years lived 
20.890 19.963 0.927 
ICER - Discounted    £3,583/QALY 
ICER   £ 3,899/QALY  
 
 
Table 9.12. Simulation results from the correlated disease model for the incoming cohorts of 
45 year olds (with all default treatments on) 
All disease linked 
model (linked with 
correlations) 
Males aged 45 years 
with all treatments 
assumed  
Females aged 45 years 
with all treatments 
assumed  
Cost - Discounted £12,967 £14,207 
QALYs - Discounted 13.333 QALYs 13.568 QALYs 
Cost £30,806 £37,223 
QALYs 21.785 QALYs 22.640 QALYs  
Life years lived 32.690 35.157 
 
 
Figure 9.5 shows the total annual costs projected using the results from the correlated linked 
model and per-capita annual costs obtained from the model results. For the male and female 
populations aged 45 years at entry, per-capita costs peaked at later stages of life: around 30 
years after model initiation for male population and 40 years for female population, which 
equate to ages of 75 and 85 years, respectively.  
Table 9.13 gives the estimates of the projected annual costs. The undiscounted annual costs 
were projected to increase from £15.97 billion in 2012 to £28.30 billion in 2037. When 
compared with the results from the independently linked model, the differences in annual 
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costs varied over the projection horizon as costs were accrued at different rates in the two 
linked models. In general, the results from the correlated disease model suggested higher 
costs in the next 20 years, whilst the annual costs were estimated to be lower than those 
estimated from the independent disease model when projected further into the future (Table 
9.14). This was believed to be caused by the higher prevalence of co-morbidities in the model 
with correlations between diseases resulting in high-cost populations with multiple diseases 
dying faster as the base-year population grow older, leading to lower costs in later time 
periods. It was considered that incorporating correlations between diseases would provide 
more realistic estimates of future expenditure than assuming independence between diseases. 
However, in this case study, simplifications were made in the estimation of correlated 
parameters, and thus the full effect of including correlations might not be captured.   
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Figure 9.5. Per-capita annual costs obtained from the correlated linked model 
a) Per-capita (cohort) annual costs for base year population (age 45 and over, all gender) 
 
b) Per-capita (cohort) annual costs for male and female population aged 45 years at entry 
  
c) Total annual costs projected from the correlated linked model 
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Table 9.13. Annual costs of treating the three diseases included projected using the results 
from the model with correlated diseases 
Year Annual costs  
– Undiscounted  
(£, millions) 
Annual costs–
Discounted  
(£, millions) 
2012  £             15,971   £             15,701  
2013  £             16,689   £             15,849  
2014  £             17,505   £             16,062  
2015  £             18,263   £             16,191  
2016  £             19,076   £             16,338  
2017  £             19,891   £             16,461  
2018  £             20,336   £             16,262  
2019  £             21,097   £             16,299  
2020  £             21,723   £             16,215  
2021  £             22,359   £             16,126  
2022  £             22,928   £             15,977  
2023  £             23,219   £             15,633  
2024  £             23,622   £             15,366  
2025  £             24,049   £             15,116  
2026  £             24,509   £             14,883  
2027  £             24,895   £             14,607  
2028  £             25,241   £             14,309  
2029  £             25,650   £             14,049  
2030  £             25,997   £             13,757  
2031  £             26,283   £             13,438  
2032  £             26,566   £             13,124  
2033  £             27,032   £             12,903  
2034  £             27,420   £             12,645  
2035  £             27,721   £             12,352  
2036  £             28,013   £             12,060  
2037  £             28,297   £             11,770  
Total 
(2012-
2037) 
£ 604,349 £ 383,493 
 
 
Table 9.14. Cumulative difference in annual costs between the results from the linked model 
with correlations and with independent diseases 
Year Difference from the 
independently linked model 
-Undiscounted* 
(£, millions) 
Difference from the 
independently linked model 
-Discounted* 
(£, millions) 
2012-2021  £     487   £     459  
2022-2031  £     842   £     515  
2032-2037 -£     756  -£     334  
Sum over the 
projection horizon 
 £     574   £     639  
*A positive number means that the costs were higher in the correlated model. 
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As in Section 9.1.2, the costs per QALYs for each of the three treatments are reported in Table 
9.15. With correlations incorporated in the model, costs were lower by small magnitude 
although the QALYs and life years lived were higher compared with assuming independence 
between diseases. This was considered due to the co-morbidities being more concentrated on 
a narrower population when correlations were applied. This results in a wider population to be 
‘disease-free’.  
However, there is still lack of face validity, when 700,000 individuals are simulated, as 
discussed in Section 9.1.2. The level of error in the mean incremental values of HD treatment 
could make a critical difference in the ICER of the AD and osteoporosis treatments when 
assessing the cost-effectiveness of individual treatments within the linked model. As such 2 
million simulated individuals were run with the results shown in Table 9.16.  
 
 
 
Table 9.15. Cost effectiveness of individual treatments using results from the all-disease model 
with correlations based on n=700,000 simulated individuals 
 No HD 
treatment 
Incremental 
values for 
HD 
treatment 
No AD 
treatment 
Incremental 
values for 
AD 
treatment 
No 
Osteoporosis 
treatment 
Incremental 
values for 
osteoporosis 
treatment 
Cost - 
Discounted 
£ 13,758 £ 983 £ 14,714 £ 27 £ 14,854 -£ 113 
QALYs - 
Discounted 8.733 0.229 8.961 0.001 8.960 0.002 
Cost £ 24,743 £ 2,178 £ 26,869 £ 51 £ 27,144 -£ 223 
QALYs 12.767 0.486 13.253 0.000 13.250 0.003 
Life years 
lived 19.988 0.902 20.889 0.001 20.884 0.006 
ICER - 
Discounted 
(£/QALY) 
 £ 4,297  £ 43,897  Treatment 
dominates 
ICER 
(£/QALY) 
 £ 4,481  Dominated  Treatment 
dominates 
HD=heart disease; AD=Alzheimer’s disease. 
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Table 9.16. Cost effectiveness of individual treatments using results from the all-disease model 
with correlations based on n=2,000,000 simulated individuals 
 No HD 
treatment 
Incremental 
values for 
HD 
treatment 
No AD 
treatment 
Incremental 
values for 
AD 
treatment 
No 
Osteoporosis 
treatment 
Incremental 
values for 
osteoporosis 
treatment 
Cost - 
Discounted 
£ 13,791 £ 936 £ 14,742 -£ 15 £ 14,869 -£ 142 
QALYs - 
Discounted 8.730 0.235 8.963 0.002 8.961 0.004 
Cost £ 24,803 £ 2,098 £ 26,927 -£ 26 £ 27,158 -£ 257 
QALYs 12.761 0.498 13.254 0.004 13.251 0.008 
Life years 
lived 19.982 0.914 20.891 0.005 20.887 0.009 
ICER – 
Discounted 
(£/QALY) 
 £ 3,978  Treatment 
dominates 
 Treatment 
dominates 
ICER 
(£/QALY) 
 £ 4,216  Treatment 
dominates 
 Treatment 
dominates 
HD=heart disease; AD=Alzheimer’s disease.
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9.2. Population projection variants 
 
 
In order to examine the effect of future population scenarios on the population-level costs, 
adjustments were made to the base-case projected population estimates. The base-case 
annual cost projections were carried out using the simulation model results and the Principal 
projection estimates for the UK from the 2012-based National Population Projections data 
published by ONS for the projection horizon of 2012-2037 (Office for National Statistics, 2013c). 
The ONS ‘Principal projections’ were performed under a pre-defined set of assumptions on 
fertility, mortality (life expectancy), and migration rates. Variant projections were produced 
based on a combination of assumptions on high or low levels of fertility, life expectancy and 
migration by the ONS. This section reports annual costs using these variant population 
projections. 
The ONS ‘High population projection’ assumes high levels of increase in fertility, mortality and 
migration rates. This projection result would provide an indication of the upper bound of the 
population size, and thus of the total cost given the historic population trends.  
The ONS ‘Principal projection’ assumed that completed family size for the UK would stabilise at 
1.89 children per woman in the long-term.  The high fertility variant assumes the long-term 
family sizes of 0.2 children per woman higher than the principal assumptions, which is 2.09 for 
the UK. Also, the principal projections assumed that rates of mortality improvement would 
converge to 1.2 % for most ages in mid-2037 and remain at 1.2 % each year thereafter. The 
high life expectancy variant assumed 2.4% improvement in annual rates of mortality in mid-
2037 for most ages, which meant life expectancy at birth in mid-2037 to be 2.1 and 1.8 years 
higher for males and females, respectively.  The principal assumption for net migration to the 
four countries of the UK combined was +165,000 each year. The high migration variant 
assumed long-term annual net migration to the UK to be 60,000 people higher, that is, 
+225,000.  
In order to reflect the future time trends in birth, mortality, and migration rates assumed in 
the high population projection, annual costs using variant population projections were 
calculated differently from the base-case where it was assumed that the number of people in 
each cohort in the beginning of the entry year remained constant throughout the projection 
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horizon. Instead, yearly estimates of the projected number of people at each single year of age 
were combined in every projection year.   
In the calculation described in Chapter 4, the total projected cost for a calendar year j was the 
sum of the costs for that year across all relevant cohorts, and the annual cost for cohort i and 
year j was the per-capita cost multiplied by the projected number of people in year j as below.  
𝑇𝑜𝑡𝑎𝑙 𝑎𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑓𝑜𝑟 𝑦𝑒𝑎𝑟 𝑗 = ∑[ 𝑃𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 𝑐𝑜𝑠𝑡𝑖𝑗 × 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒𝑖𝑗]
𝑖∈𝐼
 
, where 𝐼 denotes the set of all cohorts assumed to have entered the model by year j. 
The base-case assumed the constant numbers of people in cohorts with per-capita costs 
decreasing over time to take mortality into consideration. In contrast, the variant method 
explicitly allowed the population size, Number of people ij, to decrease over time, so that the 
Number of people reflects the trends in mortality, migration, and fertility assumed in the 
variant population projections. The Per capita cost was calculated as the total annual cost from 
the model results divided by the number of people who are ‘alive’, or able to incur costs, 
within the model in year j. Without incorporating mortality and other population changes, per-
capita cost increased over time as each cohort of population is likely to utilise more health 
services as they age.   
Table 9.17 present the total annual costs projected under the higher population scenario from 
the correlated linked model. Under the high population scenario, the total population-level 
annual costs were projected to increase to £36.57 billion in 2037. The annual difference 
between the base-case and the high population estimate increased from £152 million in 2013 
to £8.27 billion in 2037 with the cumulative difference estimated to near £80 billion over the 
26-year horizon.   
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Table 9.17. Total annual costs - High population scenario 
Year Annual costs  
(£, millions) 
Difference from 
base-case  
(£, millions) 
Year Annual costs  
(£, millions) 
Difference from 
base-case 
(£, millions) 
2012  £   15,971   £            -    2025  £   26,634   £     2,585  
2013  £   16,840   £       152  2026  £   27,441   £     2,932  
2014  £   17,762   £       257  2027  £   28,179   £     3,285  
2015  £   18,637   £       374  2028  £   28,900   £     3,659  
2016  £   19,582   £       506  2029  £   29,726   £     4,076  
2017  £   20,549   £       658  2030  £   30,502   £     4,505  
2018  £   21,145   £       809  2031  £   31,233   £     4,950  
2019  £   22,105   £     1,009  2032  £   31,996   £     5,430  
2020  £   22,936   £     1,213  2033  £   33,008   £     5,976  
2021  £   23,812   £     1,452  2034  £   33,938   £     6,518  
2022  £   24,639   £     1,712  2035  £   34,795   £     7,074  
2023  £   25,195   £     1,976  2036  £   35,672   £     7,659  
2024  £   25,890   £     2,269  2037  £   36,567   £     8,270  
  
 
Total  
2012-2037 
£   683,655 £   79,306 
 
 
The low population scenario assumed that the current life expectancy level is maintained over 
the projection horizon and the number of the incoming cohorts of 45 year olds after the base 
year would follow the figures estimated from the ONS projections assuming low life 
expectancy, birth rate, and migration.  
As the base-case results were obtained assuming no changes in the mortality level at the base 
year over the projection period, the projected low population estimates were applied only to 
the new incoming cohorts of 45 year olds. Since the base-year population of 45 years or over 
at time zero forms the largest share of the model population, the results under the low 
population scenario showed relatively small differences from the base-case annual costs 
compared with the high population scenario results.  
Table 9.18 shows the effect of assuming low population scenario for the new incoming cohorts 
of 45 year olds from year 1.  As the new cohorts enter the model population on a yearly basis, 
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the difference between the base case and the low population results widens gradually over 
time. The assumed changes in the number of future cohorts of 45-year-olds were estimated to 
save £121 million in 2037 with the cumulative savings of £923 million over the projection 
period.  
 
Table 9.18. Total annual costs - Low population scenario (£, millions) 
Year Annual costs  
(£, millions) 
Difference from 
base-case  
(£, millions) 
Year Annual costs  
(£, millions) 
Difference from 
base-case (£, 
millions) 
2012 £   15,971   £     -  2025 £  24,025   -£  24.8  
2013 £   16,689   -£   0.0  2026 £  24,481   -£  28.5  
2014 £   17,505   -£   0.1  2027 £  24,862   -£  32.8  
2015 £   18,263   -£   0.2  2028 £  25,202   -£  38.4  
2016 £   19,076   -£   0.4  2029 £  25,606  -£  43.9  
2017 £   19,890   -£   0.7  2030 £  25,947   -£  50.1  
2018 £   20,328  -£   8.1  2031 £  26,226   -£  57.1  
2019 £   21,087   -£ 10.0  2032 £  26,501   -£  64.9  
2020 £   21,711   -£ 11.7  2033 £  26,958   -£  74.1  
2021 £   22,346   -£ 13.7  2034 £  27,336   -£  84.2  
2022 £   22,912   -£ 15.9  2035 £  27,626   -£  95.2  
2023 £   23,201   -£ 18.5  2036 £  27,905  -£ 107.5  
2024 £   23,600   -£ 21.4  2037 £  28,176   -£ 121.2  
   Total  
2012-2037 
£  603,425 -£ 923 
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9.3. Scenario analyses 
 
9.3.1. Hypothetical eradication of diseases 
 
 
Box 4.1 in Chapter 4 summarises the key outcomes that were aimed to be derived from the 
linked disease model.  Although unachievable, it is possible to ask how much could be saved by 
eradicating further events from one of the diseases; and also how many QALYs or life years 
could be produced. These questions were examined by comparing the results from the all-
disease linked model and the results from models where only two diseases were set to be 
available. This was equivalent to zero incidence for eradication of further disease events with 
the current level of prevalence.  
Adding osteoporosis into the linked model involved adjustments of probability distributions for 
time to non-disease death for the Z-score of individuals: these changes may introduce bias in 
the difference between the all-disease and all-but-osteoporosis model results, confounding 
the effect of eradicating osteoporosis. All results for the scenario of disease eradication were 
obtained from the model where the non-disease mortality based on the ranges of Z-score with 
CVD mortality subtracted was applied as used in the all-disease linked model, and 700,000 
individuals were simulated in this section.   
Table 9.19 shows the difference between the all-disease model results and the two-disease 
results with further events from one of the diseases eradicated. Eradicating further HD events 
included in the model was associated with an increase of 3.289 years of life, and was 
estimated to save a discounted cost of £ 4,382 and provide 2.053 more QALYs over a lifetime 
of an average individual from the population aged 45 and over in the base year (based on the 
results from models with correlations). Based on comparison between the results of the life 
time per-capita costs, eradicating further HD events was most cost-saving. The cost savings 
and the increase in QALYs when eradicating osteoporosis were the least among the three 
diseases.  
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Table 9.19. Hypothetical eradication of diseases – Comparison between the all-disease and the 
two-disease model results* 
Difference between the all-disease model results and all-but-one disease model 
results  
I. Linked model with independent diseases assumed 
 1) Eradicating Heart 
Disease 
2) Eradicating 
Alzheimer’s Disease  
3) Eradicating 
osteoporosis   
Cost - 
Discounted 
-£ 4,187 -£ 3,497 -£ 2,185 
QALYs - 
Discounted 
2.040  0.338 0.106 
Cost -£ 6,517 -£ 6,067 -£ 4,380 
QALYs 4.288 0.722 0.239 
Life years lived 3.246 years 1.130 years 0.147 years 
II. Model linked with correlations 
 1) Eradicating Heart 
Disease 
2) Eradicating 
Alzheimer’s Disease  
3) Eradicating 
osteoporosis   
Cost - 
Discounted 
-£ 4,382 -£ 3,380 -£ 2,199 
QALYs - 
Discounted 
2.053  0.330 0.112 
Cost -£ 6,965 -£ 5,713 -£ 4,389 
QALYs 4.332 0.695 0.251  
Life years lived 3.289 years 1.100 years 0.172 years 
*Non-disease mortality distributions based on z-score with CVD mortality subtracted 
as in the all-disease model were used (see Chapter 7); Based on n=700,000 individuals 
 
 
Table 9.20 presents population-level cost savings from eradicating each of the diseases. The 
projected annual costs over the 26-year horizon were compared with and without each of the 
diseases. Eradicating HD would save the most amongst the three diseases, with the cumulative 
savings over the projection horizon estimated to amount to £251 billion, compared with £119 
billion and £77 billion from eradicating AD and osteoporosis, respectively. This shows the 
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burden of the three individual diseases within the linked model: heart disease is not only 
associated with the highest per-capita cost, but also the largest population-level spending.  
 
 
Table 9.20. Projected cost savings from the hypothetical eradication of a disease (£, millions)* 
 Projected cost savings from the eradication of: 
 Heart Disease Alzheimer’s Disease Osteoporosis  
2012 Base year  4,680   4,760   1,596  
2013-2017  31,224   23,786   10,702  
2018-2022  41,694   24,252   13,910  
2023-2027  50,974   22,634   15,521  
2028-2032  58,819   21,670   16,839  
2033-2037  63,791   21,881   18,297  
Cumulative 
savings in 2012-
2037 
 251,183   118,982   76,865  
*based on results from models with correlations between diseases incorporated 
(undiscounted results) 
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9.3.2. Increase in treatment efficacy 
 
 
This section tests which disease would benefit most from an improved intervention. This will 
give an indication of how much a healthcare system can expect to gain from focussing on the 
treatment of certain diseases.  This section presents how much savings could be made when 
the efficacy of treatment for each one of the three diseases increases by 20%.  
The results from the 20% efficacy increase scenario are compared with the base-case with the 
default treatment efficacy assumed. As this comparison involves changes in the efficacy of 
individual disease treatments within the three-disease model, the problem associated with the 
dominance of the HD treatment effect within the linked model and its impact on the 
effectiveness estimates of the other treatments applies as discussed in Section 9.1.2. Due to 
the large number of simulated patients required to achieve stable AD and osteoporosis 
outcomes in the linked model, the results for this scenario analysis were obtained from 
individual disease models reported in Chapters 5-7.  
As the mechanism in which the drug treatment influences the progression of each of the three 
diseases differs, the application of the same 20% improvement in drug efficacy could mean a 
different impact on the incidence of associated events in individual diseases. For example, in 
the AD model (Chapter 6), donepezil and memantine can delay institutionalisation by helping 
slow the deterioration of, or improve cognitive function and functional ability of patients, 
whilst the statin treatment in the heart disease model (Chapter 5) directly reduces the 
incidence of disease events.   
In order to avoid this inconsistency, 20% fewer events were uniformly assumed for all diseases. 
The following three hypotheses were tested: 
a) An improved treatment for Heart disease reduces 20% of previously simulated heart 
disease events. 
b) An improved treatment for Alzheimer’s disease reduces 20% of previously simulated 
institutionalisations due to Alzheimer’s disease. 
c) An improved treatment for Osteoporosis reduces 20% of previously simulated 
fractures.  
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As an example, if the RR was 0.7 initially, the RR with 20% increase in efficacy was adjusted to 
0.56 (=0.7 x (1-0.2)), which will subsequently reduce the incidence of the event by 20% 
compared with the base-case.   
This scenario of improved treatment efficacy illustrates how the model can be used to inform 
policy on potential interventions. The model can be used in various ways to explore the impact 
of potential changes in treatments and care delivery – for example, more people receiving 
home help resulting in less people needing institutional care, all people paying their own costs 
of institutional care and subsequent demand changes, or widely implementing tele-monitoring 
equipment and services – on the cost-effectiveness of interventions and on expenditure at the 
population level. 
For the comparison of the increased efficacy scenario with the base-case, the number of 
simulated individuals required for stable cost-effectiveness estimates would be larger than in 
the base-case as both populations are on treatment with and without the adjustment for 
treatment efficacy and thus, are subject to the same sequence of random numbers. Individuals 
who do not experience disease events associated with the reduction in event rates would yield 
zero incremental costs and QALYs. In order to determine the number of individuals to simulate 
for each of the individual disease models, the mean incremental NMB of individual treatments 
with increased efficacy and the 95% confidence interval with varying numbers of simulated 
individuals are shown in Figure 9.6. Due to treatment dominance and associated negative 
incremental cost and QALYs values, results are shown for incremental NMB instead of cost per 
QALY.  
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Figure 9.6. First-order uncertainty for the comparison of the 20% increase in treatment 
efficacy scenario vs. base-case treatment efficacy (based on individual disease model results) 
20% increase in treatment efficacy vs. base-case without efficacy increase 
1) Individual heart disease model 
Undiscounted 
 
Discounted  
 
2) Individual Alzheimer’s disease model 
Undiscounted 
 
Discounted 
 
3) Individual osteoporosis model 
Undiscounted 
 
Discounted 
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For the comparison of HD treatment with and without the efficacy adjustment, 500,000 
individuals were chosen to be simulated in the heart disease model as incremental NMB 
(undiscounted) appeared stable for all values greater than 500,000 individuals. For AD, the 
number of individuals chosen to simulate was 700,000.  
However, for osteoporosis model results, the level of error around NMB showed that the NMB 
outcomes did not stabilise with 900,000 simulated individuals. Due to the software limitation 
associated with the maximum size of individual patient data that could be saved, the margin of 
error with higher number of simulated individuals was estimated by fitting a power regression 
model. Based on the margin of error values calculated for up to 900,000 simulated individuals, 
the regression equation was estimated (Table 9.21 a), and the estimated equations were used 
to extrapolate the estimates for the margin of error with 1 million to 9 million simulated 
individuals (Table 9.21 b).  For osteoporosis model, 5 million individuals were chosen to be 
simulated to ensure the 95% confidence interval of incremental NMB (discounted) falls in the 
positive range.  
 
 
Table 9.21. Power regression results for the estimation of the margin of error for incremental 
net monetary benefit (incre. NMB) of osteoporosis treatment 
a) Power regression results for discounted incre. NMB 
of osteoporosis treatment 
b) Estimated margin of error 
 
Number of 
individuals 
Estimated 
margin of error 
(£) 
             900,000             202  
         1,000,000             194  
         2,000,000             148  
         3,000,000             127  
         4,000,000             113  
         5,000,000             104  
         6,000,000               97  
         7,000,000               91  
         8,000,000               87  
 
 
Table 9.22 presents the lifetime costs and QALYs obtained from individual disease models 
when assuming 20% reduction in disease events due to an increase in the efficacy of the three 
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treatments in comparison with the base-case where no efficacy adjustment was assumed. 
With 20% reduction in the occurrence of heart disease events (Table 9.22 (1)), individuals aged 
45 years and over were estimated to live 0.4 years longer on average. With the efficacy 
increase, individuals gained 0.225 (undiscounted) and 0.107 (discounted) QALYs with lower 
lifetime costs by £199 (undiscounted) and £154 (discounted), compared with the base-case 
model results without the efficacy adjustment.  Male population aged 45 years at model entry 
gained more life years and QALYs than females, whilst cost savings were larger for female 
population. The differences in incremental costs and QALYs between undiscounted and 
discounted values were larger for female population given the higher life expectancy. As heart 
disease generally develops at an earlier stage of life than Alzheimer’s disease and osteoporosis, 
the effect of the increase in treatment efficacy could be reaped for a longer period of time 
than in the other diseases.  
When assuming 20% reduction in institutionalisation events due to increase in the efficacy of 
the drug therapy for the treatment and management of AD (Table 9.22 (2)), per-capita cost 
saving was the largest among the three disease treatments with costs estimated to be lower 
than the base-case by £957 (undiscounted) and £520 (discounted). However, fewer 
institutionalisation events did not have much impact on life years and QALYs with incremental 
life years and QALYs estimated to be close to zero, as it was assumed that institutionalisation 
would not impact mortality and per-capita reduction in time in institutional care due to the 
improvement in treatment efficacy was not long enough to achieve noticeable QALY gain. 
Considering the monthly cost of institutionalisation, £2,293, the per-capita saving of £957 
indicates that the duration for which QALY gain is generated due to avoided institutionalisation 
was less than 1 month on average for the base-case population. Table 9.22 (3) shows that the 
increase in the efficacy of alendronate would save £108 over a lifetime of an average individual 
from the population aged 45 years and over. The saving was larger for female population with 
the undiscounted lifetime saving of £224 per person. Life years lived and QALYs were also 
higher than the base-case without the efficacy adjustment.  
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Table 9.22. Effect of 20% reduction in disease events due to an increase in the efficacy of 
default treatments (based on results from individual disease models)  
 Base-year population aged 
45 years and over 
Male aged 45 years at 
entry 
Female aged 45 years at 
entry 
 20% 
reduction in 
disease 
events*  
Increments 
compared 
with the 
base-case 
without 
efficacy 
adjustments 
20% 
reduction 
in disease 
events* 
Increments 
compared 
with the 
base-case 
without 
efficacy 
adjustments 
20% 
reduction 
in disease 
events* 
Increments 
compared 
with the 
base-case 
without 
efficacy 
adjustments 
(1) Heart disease events reduction by 20% due to an increase in the efficacy of statin 
therapy 
Cost 
 £ 14,002  -£ 199   £ 20,629  -£ 478   £ 22,324   -£ 502  
DCost 
 £ 7,934  -£ 154   £ 9,658  -£ 293   £ 9,675  -£ 300  
QALYs 
14.049 0.225 22.310 0.372 23.468 0.321 
DQALYs 
9.347 0.107 13.491 0.135 13.775 0.109 
Life 
years 21.698 0.405 33.130 0.629 36.053 0.601 
(2) Alzheimer’s disease events (institutionalisation) reduction by 20% due to an increase in 
the efficacy of donepezil and memantine therapy 
Cost 
 £ 8,000  -£ 957   £ 6,856  -£ 1,050   £ 8,534   -£ 1239  
DCost 
 £ 4,116  -£ 520   £ 2,067   -£ 319   £ 2,356  -£ 345  
QALYs 
16.553 0.000 27.889 0.000 29.380 0.002 
DQALYs 
10.650 0.000 15.938 0.000 16.218 0.000 
Life 
years 21.660 -0.002 34.131 0.000 37.183 0.002 
(3) Osteoporosis events (fracture) reduction by 20% due to an increase in the efficacy of 
alendronate therapy 
Cost 
 £ 5,957  -£ 108   £ 3,239  -£ 61   £ 8,705  -£ 224  
DCost 
 £ 2,760  -£ 57   £ 995  -£ 17   £ 2,405  -£ 59  
QALYs 
17.753 0.009 29.199 0.003 30.388 0.011 
DQALYs 
11.189 0.004 16.288 0.001 16.509 0.003 
Life 
years 23.517 0.008 36.083 0.002 39.140 0.007 
*With all treatments assumed available; DCost=discounted cost; DQALYs=discounted QALYs. 
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Using the results in Table 9.22, the additional expenditures per person of the 20% 
improvement that would be permitted whilst maintaining an ICER of £20,000 per QALY – the 
incremental NMB per person compared with the base-case without the efficacy improvement 
– were calculated in Table 9.23. The highest expenditure could be additionally spent on the 
treatment of heart disease: at a willingness-to-pay threshold of £20,000 per QALY gained due 
to the additional treatment that would reduce 20% of the disease events, the incremental 
NMBs of the treatments for heart disease, AD and osteoporosis were £2,292, £517, and £143, 
respectively, on average over an individual’s lifetime.  
Assuming the other two treatment costs remain constant, these figures can be interpreted as 
the amount of resources that could be invested in an intervention reducing disease events by 
20% for an average individual from the base-case population of men and women aged 45 years 
and over in the base year, while still achieving a cost per QALY of £20,000 when compared 
with the current treatment.  The time on treatment was considered to calculate the additional 
cost per treatment year per person that could be charged (Table 9.24). 
 
Table 9.23. Additional expenditure per person to maintain an ICER of £20,000 per QALY for the 
treatments with improved efficacy* 
 a) Heart disease  – 
20% treatment 
efficacy increase 
b) Alzheimer’s disease 
– 20% treatment 
efficacy increase 
c) Osteoporosis – 20% 
treatment efficacy 
increase 
Undiscounted incremental values 
Cost** -£199  -£ 957  -£ 108  
QALYs gained 0.225 0.000 0.009 
Incre. NMB† £ 4,696  £ 951 £ 280 
Discounted incremental values 
Disc. Cost** -£154   -£ 520   -£ 57  
Discounted. 
QALYs gained 
0.107 0.000 0.004 
Discounted 
incre. NMB† 
£ 2,292 £ 517  £ 143 
*Compared with the base-case results without efficacy improvement from individual disease 
models 
**Negative values mean cost savings 
†Incremental net monetary benefit (incre. NMB): the willingness-to-pay threshold of £20,000 
per QALY gained due to additional treatments was assumed. 
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At the population level, if a government programme can guarantee a 20% reduction in heart 
disease events, £62 billion (discounted costs) can be spent on top of the default treatment for 
heart disease over the lifetime of the model population.  The equivalent amounts that can be 
spent on the treatment and prevention of AD and osteoporosis are £14 billion and £4 billion 
over the lifetime of the base-year population.  
For the annual treatment cost, the highest extra costs could be spent on the treatment of AD 
assuming the same estimated treatment duration as the base-case. If 20% fewer 
institutionalisation events can be guaranteed from an improved treatment, £7,631 per person 
per year can be additionally spent on treating an average individual from the population with 
AD.  If a new heart disease treatment can guarantee the 20% reduction effect with the same 
average duration of treatment, this means an additional (discounted) cost of £293 per person 
per year can be spent on the treatment to have the ICER of £20,000 compared with the base-
case treatment. For the treatment of osteoporosis, annual per-capita cost of £276 could be 
spent in addition to the default treatment cost.  
 
 
Table 9.24. Cost savings made by the 20% reduction in event occurrence for the base-year 
population 
 a) Heart disease  – 
20% treatment 
efficacy increase 
b) Alzheimer’s 
disease – 20% 
treatment efficacy 
increase 
c) Osteoporosis – 
20% treatment 
efficacy increase 
Discounted values 
Cost to spend on 
population-level 
intervention over 
lifetime  
£62.04 billion £14.00 billion £3.87 billion 
Duration of 
treatment for the 
base-year 
population* 
7.82 years  0.07 years 0.52 years 
Additional cost per 
person per annum 
on treatment 
£293 £7,631 £276 
*Per person who entered the model, not per person who received the treatment. 
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For the total population including male and female populations aged 45 years at model entry, 
the efficacy change meant reduced yearly projected costs. With 20% reduction in heart disease 
events due to the increased treatment efficacy, the annual costs were lower with £17.82 
billion in 2037 (Table 9.25). Yearly projected savings (undiscounted) due to the efficacy 
increase could exceed £500 million as shown in Figure 9.7a).  Cost savings from 20% reduction 
in institutionalisation due to the increased efficacy of the treatment for AD were estimated to 
be larger than those from heart disease treatment, with the projected annual cost of £6.28 
billion in 2037 (Table 9.25 and Figure 9.7b)).  The annual cost savings were estimated to 
decrease over time as the entry population include people with diagnosed and undiagnosed 
AD, thus the larger population in earlier years is affected by the improved efficacy of AD 
treatment. The savings were generally larger in the next 10 years than in the rest of the 
projection horizon although there were savings in later years due to the ageing of the 45-year-
old incoming cohorts (Figure 9.7b)). Compared with the base-case, the annual costs with 20% 
reduction in fracture events due to the increased efficacy of osteoporosis treatment were 
lower with £1.48 billion in 2012 and £4.71 billion in 2037 (Table 9.25).  Figure 9.7c) shows that 
undiscounted yearly savings from improved osteoporosis treatment were lower than those 
from HD and AD treatments.  
Cost savings projected in Figure 9.7 were shown as cost savings by 5-year band and cumulative 
savings over the projection horizon in Table 9.26. The largest cost savings compared with base 
case were projected to be obtained from the increased efficacy of treatment for AD, with a 
cumulative saving of over £16 billion over the 26-year horizon, followed by savings from the 
HD treatment (£10 billion) and the osteoporosis treatment (£1.7 billion). These results with 20% 
reduction in disease events assumed were not necessarily proportional to the population-level 
savings associated with the eradication of further disease events, as the 20% reduction in 
event probabilities due to improved treatment efficacy affects only the population on 
treatment, which depends on the duration of the treatment effect and the size of the 
population receiving the treatment in the three disease models.  Also, unlike per-capita cost 
savings, annual cost savings could be affected by a difference in the rate at which costs accrue 
between the base-case model and the improved efficacy scenario model, as the yearly cost 
was multiplied by the projected number of people in the corresponding year. 
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Table 9.25. Comparison of annual costs projected under increased efficacy scenarios with the 
base-case 
Annual costs 
Year 
Heart Disease Alzheimer’s Disease Osteoporosis 
Base-case 
(£, 
millions) 
20% 
increase in 
HD 
treatment 
efficacy 
(£, 
millions) 
Base-case 
(£, millions) 
 
20% 
increase in 
AD 
treatment 
efficacy 
(£, 
millions) 
Base-case  
(£, millions) 
20% increase 
in 
Osteoporosis  
treatment 
efficacy 
(£, millions) 
2012  9,489   9,119   4,879   3,946   1,564   1,476  
2013  9,991   9,710   4,545   3,699   1,741   1,654  
2014  10,461   10,234   4,668   3,850   1,956   1,854  
2015  10,982   10,679   4,950   4,082   2,153   2,052  
2016  11,409   11,161   5,103   4,303   2,370   2,272  
2017  11,907   11,592   5,257   4,545   2,584   2,489  
2018  12,526   12,090   5,335   4,651   2,780   2,695  
2019  12,867   12,514   5,445   4,708   2,976   2,895  
2020  13,211   12,907   5,430   4,818   3,151   3,054  
2021  13,597   13,278   5,478   4,977   3,289   3,221  
2022  14,094   13,646   5,603   5,131   3,423   3,350  
2023  14,419   14,041   5,780   5,314   3,541   3,493  
2024  14,685   14,384   5,874   5,380   3,633   3,614  
2025  15,145   14,732   5,927   5,380   3,739   3,727  
2026  15,485   15,101   5,883   5,402   3,839   3,828  
2027  15,789   15,413   6,014   5,560   3,912   3,896  
2028  16,100   15,666   6,071   5,658   4,005   3,987  
2029  16,376   16,042   6,110   5,711   4,117   4,071  
2030  16,668   16,225   6,287   5,700   4,224   4,158  
2031  16,924   16,440   6,397   5,778   4,298   4,253  
2032  17,145   16,766   6,437   5,889   4,413   4,347  
2033  17,449   16,987   6,504   5,955   4,508   4,440  
2034  17,677   17,148   6,663   6,049   4,603   4,544  
2035  17,936   17,363   6,748   6,104   4,688   4,605  
2036  18,113   17,611   6,904   6,158   4,740   4,644  
2037  18,238   17,822   7,039   6,276   4,805   4,712  
Total 
(2012-
2037) 
378,680 368,672 151,329 135,026 91,051 89,333 
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Figure 9.7. Projected annual cost savings from the increased efficacy of interventions in 
comparison with the base-case (£, millions) 
a) Annual cost savings from 20% reduction in heart disease events due to an increase in 
heart disease treatment efficacy  
 
b) Annual cost savings from 20% reduction in Alzheimer’s disease event 
(institutionalisation) due to an increase in treatment efficacy  
 
c) Annual cost savings from  20% reduction in osteoporosis events(fracture) increase in 
Osteoporosis treatment efficacy  
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Table 9.26. Projected 5-year cost savings from the increase efficacy of interventions in 
comparison with the base-case, using results from individual disease models (£, millions) 
 Projected cost savings from 20% reduction in events of: 
 Heart Disease Alzheimer’s Disease Osteoporosis  
2012 Base year 370 932 88 
2013-2017 1,373 4,044 482 
2018-2022 1,860 3,005 404 
2023-2027 1,851 2,442 105 
2028-2032 2,074 2,565 241 
2033-2037 2,482 3,315 398 
Cumulative 
savings in 2012-
2037 
10,009 16,303 1,718 
 
 
 
9.4. Findings and Conclusion from the all-disease linked model 
 
 
This chapter presented results obtained from the models where HD, AD and osteoporosis were 
linked with and without correlations.  
The results showed that including multiple diseases with competing risks can alter the model 
outcomes such as the cost-effectiveness of interventions and future expenditure estimates 
compared with using results from multiple single-disease models. In the model for this thesis, 
when the results from the independently linked model were compared with the individual 
disease model results, the costs from the linked disease model were lower than the sum of the 
individual model results. Absolute QALYs from the linked model were also lower than the 
minimum of QALYs from the individual disease models. This indicates that different decisions 
on technology adoption could be reached when a model with multiple diseases linked is used. 
Also, the lower projected population-level costs when using the linked model compared with 
using individual disease models suggest that the estimation of future costs by summing costs 
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at the individual disease level may not be accurate, and thus funding decisions based on such 
estimates may not represent efficient allocation of resources.  
However, although the linked model could produce stable ICERs for the three treatments 
combined, it was shown that when one disease has a much larger impact on costs and QALYs 
than the others, the sampling error around the treatment with larger impact could make a 
significant difference in the cost-effectiveness of the other individual treatments, which could 
lead to lack of face validity for the more minor diseases. The number of simulated patients 
sufficient to make the conclusions on adoption decisions stable within individual disease 
models may not be sufficient to make such claims in the model where multiple diseases are 
linked. In this case study, if the random numbers get misaligned between model runs due to 
different sequences of events, random error in HD events could markedly alter the ICERs for 
AD and osteoporosis treatments.   
Including correlations could potentially change the cost-effectiveness of interventions. When 
correlations were implemented, absolute QALYs were higher than when the diseases were 
assumed independent due to the concentration of co-morbidities onto an already diseased 
population, resulting in lower QALY loss from an additional disease than the random allocation 
of diseases to the general population. When comparing all treatments with none of the three 
treatments in this case study, however, the ICERs for all three treatments combined were 
similar with and without incorporating correlations (£3,582/QALY when assuming 
independence between diseases; and £3,583/QALY when incorporating correlations). The 
projected annual costs were generally lower with correlated diseases in later time periods on 
the projection time horizon. Adding correlations was considered to have better reflected the 
relationship between multi-morbidities and mortality. However, it is noted that in this case 
study simplifications were made in terms of the estimation of correlated parameters, and thus 
the results may not capture the full effect of incorporating correlations.  
In the scenario analyses, eradicating further HD events would provide the highest cost-saving 
and QALY gain amongst the three diseases, with the discounted cost-saving of £4,382 and 
2.053 QALY gain based on the comparison between the lifetime per-capita costs. At the 
population level, the cost savings from eradicating HD amounted to £251 billion over the 26-
year projection horizon.  
The 20% reduction in event occurrence due to increased efficacy of treatments for the three 
diseases provided cost savings.  These results were obtained from runs within individual 
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disease models due to the dominant size of the HD treatment effect within the linked model 
when assessing individual treatments. When considering the projected number of population 
over the 26-year projection horizon, the increase in efficacy of the AD treatment in reducing 
institutionalisation events could save the most among the three treatments with a cumulative 
saving of over £16 billion. Assuming the effect of 20% event reduction can be guaranteed and 
incorporating the results with the prevalence of the diseases and the average treatment 
duration, additional costs that could be spent on drug treatments per person were £293, 
£7,631, and £276 per annum for HD, AD, and osteoporosis, respectively. A population-level 
government programme that can guarantee the 20% event reduction can spend £62 billion, 
£14 billion and £4 billion on the treatment of HD, AD and osteoporosis, respectively, to obtain 
an ICER of £20,000 per QALY. The highest amount can be spent at the individual level on the 
AD treatment that can reduce institutionalisation by 20%. At the population level, however, 
the programme targeting HD is associated with the greatest gain in net monetary terms.  
Potentially, the model provides flexibility that enables policymakers to examine the impact of 
possible changes in the efficacy of interventions, delivery of care and funding methods on the 
projected costs and cost-effectiveness of interventions. However, the reader should note the 
caveat below.  
Incorporating multiple diseases and correlations between them in a model can lead to 
different costs and health outcomes associated with the disease and estimates of future 
healthcare expenditure. In this case study, the cost-effectiveness of individual interventions 
could not be obtained from the linked model due to HD having a much larger impact on the 
model outcomes than the others. This may be mitigated by selecting a balanced set of diseases 
with similar cost and QALY outcomes for model linkage and using the model only to assess 
combined treatments that aim to tackle all diseases included in the model. Further research on 
better approaches to minimising this problem, in particular when incremental costs and QALYs 
are small in magnitude, would be beneficial.  
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CHAPTER 10   DISCUSSION 
 
10. 1. Thesis summary and key implications 
 
This final chapter comprises a summary of the key findings and implications of this thesis, a 
discussion of its limitations, an outline of the contributions to current knowledge made by this 
thesis as well as recommendations for future research priorities.   
This thesis presented a methodology for modelling health and healthcare for an ageing 
population and estimating future healthcare expenditure at the disease level. It demonstrated 
a proof-of-concept model using three diseases of the older population: heart disease (HD); 
Alzheimer’s disease (AD); and osteoporosis.  
This PhD study included the following elements:  
 A pragmatic method for searching literature in diffuse topic areas was developed.  
 A freely-accessible literature repository containing papers on population ageing and 
healthcare expenditure was established. 
 Multiple DES models for three diseases (HD, AD, and osteoporosis) were extended 
from existing HTA models, incorporating a range of methodological amendments 
necessary to model the general population, as opposed to only the prevalent cohorts 
of individuals.  
 The individual disease models were linked in a single model by implementing a set of 
simple central routing logic in the model.  
 Correlations between the diseases were incorporated in the linked model in order to 
fully examine the effect of linking correlated diseases on the model outcomes. 
 Using the individual DES and linked models, the methods for projecting future 
healthcare expenditures were demonstrated. Population ageing and potential 
demographic changes were incorporated in the projection using external population 
projection data.  
 An unanticipated finding related to the relative sizes of QALY gain between diseases 
that could affect the robustness of linked model results was identified. 
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Chapter 2 presented a pragmatic literature search method to identify relevant literature in the 
diffuse topic area of population ageing and healthcare demand. This approach identified 7,745 
hits from 12 seed papers compared with over 29,000 hits from a broad search in Medline and 
over 21,000 hits in EMBASE. Moreover, the broad searches had lower sensitivity than the 
proposed approach identifying only 9 of 11 (10) seed papers available in Medline (EMBASE). 
The literature review in Chapter 3 reported the categorisation of the identified literature and a 
review of projection models. It also presented a literature repository containing 2,263 papers 
screened from the 7,745 papers with the categorisation results. Given the broad and diffuse 
nature of the literature on the topic, the repository is expected to provide a valuable resource 
for researchers wishing to quickly identify papers relevant to specific topics in this area. The 
review of models projecting future health and social care expenditure showed that the 
majority of the existing models adopt a macro-simulation approach in which aggregate levels 
of population and cost data are combined to estimate the total healthcare expenditure. Based 
on the examination of the existing models, Chapter 4 provided a rationale for the modelling 
approach chosen for this thesis.  
The individual disease models described in Chapters 5 – 7 were based on existing models used 
within published health technology assessment (HTA) monographs identified from a brief 
review undertaken for each disease. New data were used if more up-to-date data equivalent 
to those used in HTA models are available and the models were modified if deemed 
appropriate to model different events from those included in the HTA models for the scope of 
the model or the implementation of a DES format. Instead of modelling diseased populations 
only, the model simulated individuals representative of the entire UK general population aged 
45 years and over. A DES model structure was used throughout all individual disease models: 
time and patient characteristics updates were performed in the same order within the models 
to facilitate the linkage of the models. In all of the individual disease models, drug treatments 
were cost-effective assuming a £20,000 per QALY gained threshold used which was in line with 
the outcomes from the existing models. In all three diseases, the costs were projected to 
increase during the period of 2012 – 2037. When individual disease models are used, the 
highest annual costs among the three diseases were estimated to come from heart disease. 
The greatest proportional increase was for osteoporosis with the annual cost for treating and 
preventing osteoporosis projected to triple over the projection period 2012-2037 (from £1.55 
billion in 2012 to £4.91 billion in 2037). For comparison, the annual costs for HD were expected 
to nearly double over the same period (£9.4 billion to £18.3 billion) and those for Alzheimer’s 
disease to increase by 42% (£4.87 billion to £6.92 billion). 
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Chapter 8 described correlations between the diseases incorporated in this model reporting 
the results from models in which pairs of the three diseases were linked with and without the 
correlations subsumed. Chapter 9 reported the results from the all-disease linked model.  
The key implication of the findings from the linked model is that the estimates of costs and 
(quality-adjusted) life years differ when multiple diseases are modelled within a single model 
in comparison with the summed results from single disease models. Consequently, the 
projected expenditure for healthcare services for the modelled diseases will also differ. In the 
case study presented in this thesis, the total annual costs of treating and managing HD, AD and 
osteoporosis from the independently linked model were lower than the sum of the costs from 
the three individual disease models. It implies that the use of the linked model can influence 
decisions on funding interventions for the prevention and treatment of diseases. When 
correlations between diseases were incorporated, the absolute costs were lower whilst the 
absolute QALYs and life years were higher due to a greater number of disease-free individuals 
due to the positive correlations identified. This indicates that the inclusion of correlations 
could alter the cost-effectiveness of interventions depending on the strength and direction of 
the correlations (positive or negative). Hence, policy decisions on the allocation and planning 
of healthcare resources based on the results from individual disease models can be different 
from those based on linked models with correlations incorporated.  
It was found that when one disease has a much larger impact on costs and QALYs than the 
others included in the linked model despite all having clear adoption decisions, the sampling 
error around the effect of the treatment with higher impact could significantly influence the 
effect of the other individual treatments and create unintuitive results. In the model for this 
thesis, sampling error in HD events due to the misalignment of random numbers between 
model runs could make a considerable impact on the cost-effectiveness of AD and 
osteoporosis treatments which had small incremental costs and QALYs. However, in 
circumstances where QALY gains are similar across individual treatments, it is likely that the 
proposed methods of linking individual disease models produce more accurate cost-
effectiveness estimates for the individual treatments. 
Variants of population projections were also examined for their impact on the future 
healthcare expenditure. Population changes could significantly alter the future healthcare 
expenditure: in the higher population scenario with high levels of mortality improvement, 
fertility, and migration, the annual cost increase compared with the base-case was from £152 
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million in 2013 to £8.27 billion in 2037. The impact of the variants on Gross Domestic Product 
was not considered.  
In exploring the impact of advances in treatment, the hypothetical eradication of further HD 
events (zero incidence rates) would save the most with the cumulative projected savings over 
the 2012-2037 period projected to amount to £251 billion, compared with £119 billion and £77 
billion from eradicating AD and osteoporosis, respectively. The 20% reduction in 
institutionalisation due to the increase in the efficacy of the AD treatment would result in the 
highest cumulative saving of over £16 billion over the 26-year projection horizon, followed by 
savings from the treatment of HD (£10 billion) and osteoporosis (£1.7 billion). Combining the 
cost results with QALY gains, it was estimated that the highest amount of resources (£62 billion) 
can be spent on a population-level government programme that can guarantee a 20% 
reduction in HD event occurrence over the lifetime of the base-year population to achieve a 
value of £20,000 per QALY gained, followed by AD (£14 billion) and osteoporosis (£3.9 billion).  
The existing cost projection models reviewed in Chapter 3 explored the implications of 
potential policy changes in their scenario analyses. For example, Hancock et al. (2003) 
reported projected costs of long-term care under a policy of free personal care, as well as 
under the current funding arrangements. The context of the analysis was that the Royal 
Commission on Long Term Care recommended a change to ‘free’ personal and nursing care 
whilst individuals in care homes continue to meet their accommodation and living costs 
according to their means test results (Royal Commission on Long Term Care, 1999). The 
government in England accepted many of the Royal Commission’s recommendations including 
free nursing care, but not free personal care. However, as the Scottish government 
implemented a policy of free personal and nursing care, Hancock et al. (2003) examined the 
financial consequences of introducing free personal care in the entire UK. Also, analysts have 
used Future Elderly Model (FEM) to investigate the value of preventing expensive diseases 
among the elderly. For example, Goldman et al. (2009) examined the cost and health effects of 
reducing the key risk factors associated with heart disease, such as hypertension, smoking, 
obesity and diabetes.  POHEM (Population Health Model) developed by Statistics Canada has 
also been extensively used to evaluate the effects of alternative health programmes, mainly 
with respect to the cost-effectiveness of interventions. For example, Berthelot et al. (2000) 
evaluated the cost-effectiveness of different chemotherapeutic therapies on patients with 
non-small-cell lung cancer, and Will et al. (2001) analysed the impact of reduced length of 
hospital stay following breast cancer surgery.  
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In addition to the scenarios explored in this thesis, it is believed that the model can be used 
flexibly and modified to examine the impact of potential changes in treatments, care delivery 
and funding methods for healthcare. For example, the impact of a reduced NHS contribution 
to institutional care (from the current 72%; see Chapter 6) for AD patients on the cost-
effectiveness of AD treatment and future costs can be estimated. The use of the linked model 
can also help prioritise potential government programmes targeting the prevention and 
treatment of the diseases included in the model and can also be applied to other diseases. The 
modelling approach presented in this thesis makes possible various applications to explore the 
impact of such policy and intervention options, with some modifications such as linking 
additional risk factors to diseases, if needed. 
The outcomes from the model in this thesis permit rigorous analyses in exploring the impact of 
potential changes in policy and treatments. Although not fully investigated in this thesis, the 
model can record the characteristics of all modelled individuals throughout the course of 
simulated events, and thus the distributional effect of policy changes can be examined. For 
example, groups of individuals affected by a policy change more than others can be identified, 
along with individual attributes strongly associated with reduction in healthcare utilisation 
after the implementation of a prevention programme. The model can incorporate more 
specific outcomes rather than only total costs and QALYs. For example, it can explore the 
average number of strokes over a lifetime in a population with previous hip fracture, and the 
proportion of individuals with low bone mineral density amongst those receiving institutional 
care.  
 
10.2. Limitations 
 
An unanticipated finding was that despite each disease having a clear adoption decision, this 
could be reversed in a linked model where the simulated number of patients is held at similar 
levels. When assessing the cost-effectiveness of individual disease treatments within the linked 
model, the size of treatment effect for HD dominated that for AD and osteoporosis.  This thesis 
found that if random samples of variables associated with HD events are misaligned between 
treatment and no treatment arms, random error in incremental cost and QALYs of HD 
treatment could make a crucial difference in relatively small incremental outcomes of the 
other treatments included in the linked model. 
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The proof-of-concept model reported in this thesis was constructed to demonstrate the 
methodology of linking multiple single-disease models and incorporating correlations between 
the included diseases when estimating future healthcare expenditure. Future research based 
on this thesis could focus on the role of extensive probabilistic sensitivity analyses in linked 
models. 
The diseases modelled in this PhD study were not exhaustive, however, the three diseases 
included were carefully chosen. There remains uncertainty in that the outcomes for the 
modelled diseases may not reflect the trends in future healthcare expenditure for other 
diseases of an ageing population, and the default treatments assumed currently may not be 
used in the future. However, this proof-of-concept model can be expanded and modified to 
include further diseases or/and other potential interventions.  
In addition, given the large number of parameters included in the models, not all possible 
correlations between the parameters required for the three diseases could be addressed. Only 
a few selected correlations regarding the prevalence and incidence of the diseases that were 
deemed to influence utility and cost outcomes were considered, although the methods for 
estimating the correlated parameters were illustrated. Other correlations, such as the 
presence of AD possibly delaying the initiation of the preventative treatment for osteoporotic 
fractures, presumably due to barriers in seeking healthcare owing to a decline in cognitive 
function could exist (Chang et al., 2014a, Yaffe et al., 2012, Haasum et al., 2012). Furthermore, 
some of the correlations embedded in the model were approximations based on assumptions. 
This was due to the absence of appropriate estimation methods given the data available, and 
may have caused biases in the final model outcomes.  
With respect to the modelling method, the use of the DES framework enabled the seamless 
linkage of the three disease models. There may be challenges in applying the method of model 
linkage presented in this thesis to other model forms, especially those with fixed time cycles. 
The application of the linkage method in other model structures has not been explored in this 
thesis.  
In the model developed for this thesis, ‘status quo’ assumptions were applied including current 
treatment regimes and prices of healthcare. Moreover, epidemiological characteristics of the 
population regarding the prevalence and incidence of disease events were assumed 
throughout the projection horizon. The estimation of trend parameters using statistical models 
or via the examination of the existing literature for making informed assumptions could not be 
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performed within the time scale of this PhD given the large number of potential parameters 
that could influence the expenditure.   
However, the existing literature suggests that there are many time trends that can potentially 
affect future healthcare expenditure. In addition to the changes in age composition over time, 
the prices of health and social care relative to other goods and services may increase over time. 
This would mean increases in unit costs of health and social care may exceed real GDP growth 
or average earning growth (Hancock et al., 2007a, Wittenberg et al., 2006). Healthcare is a 
labour-intensive sector and it is often considered that labour productivity does not grow as 
fast as productivity in other sectors of the economy. Nonetheless, in order to attract a highly-
skilled workforce, wages in the healthcare sector may have to increase in line with the other 
sectors, which then makes healthcare relatively more expensive in the long term (van Elk et al., 
2010). This problem of rising relative prices in the healthcare sector has been theoretically 
advocated (Baumol et al., 2012, Baumol and Bowen, 1966), and empirical evidence has shown 
that NHS pay inflation has been rising in line with that in the other sectors of the UK economy 
without a noticeable increase in labour productivity (Appleby, 2013). Nonetheless, the 
strength of the trend in the relative price of healthcare or whether it will continue is not clear.  
The model reported in this thesis does not incorporate possible future trends in the prices of 
health and social care, but assumes that the current level of care costs are maintained in the 
future.  The cost of drug interventions generally decreases over time due to patent expiry and 
availability of wider treatment options. This has not been incorporated in the model for this 
thesis and the intensity of treatments provided may change over time.  
Technological progress can also contribute to growth in real spending on healthcare (Astolfi et 
al., 2012, Appleby, 2013). The availability of new health technologies and surgical methods can 
impose cost pressures, and a number of studies have identified technological changes as one 
of the dominant factors in the expenditure growth, which is estimated to account for 27-65% 
of health spending growth (Cutler, 1995, Smith et al., 2009, Newhouse, 1992, OECD, 2006). 
Increased life expectancy due to effective treatments could also add to future healthcare 
needs (Astolfi et al., 2012). As all individuals with a disease were assumed to receive the 
default treatment in 2015, the model results do not reflect the variety of treatment regimes 
that are adopted in real clinical practice. Technological breakthroughs that may significantly 
increase the cost of treatment but also increase life years or QALYs were not explored in the 
model, although this could be performed.  
379 
 
In relation to the availability of new technologies and emergence of surgical methods, patterns 
of healthcare utilisation may also change in the future.  Schulz (2005: alternative scenarios) 
attempted to estimate trends in healthcare utilisation. However, due to the short period of 
data collection, trend analyses could not be undertaken. The country-specific data used by 
Schulz (2005) showed that increasing life expectancies are associated with higher utilisation of 
inpatient care. It is possible that life expectancy arising from the development of new 
technologies and treatment methods may lead to more hospital admissions. In this thesis, 
however, the current treatment regime was assumed throughout the projection period.  
The structure of consumption may change in the long term towards a larger share of income 
spent on healthcare. Historical trends in the US and OECD countries have shown that as people 
get richer, the percentage of their income on healthcare increase more than that on food, 
clothing and shelter. This may drive the expenditure spent on healthcare over time (Fogel, 
2008).  
However, as parameter values were considered constant in this thesis, the impact of the 
potential trends in non-demographic factors mentioned above including those associated with 
the wider economy such as possible changes in consumption patterns and healthcare system 
reforms have not been examined.   
As the existing HTA models and their data were used, some of the data used to populate the 
model were not up-to-date. Given the time scale of this PhD and the breadth of the data 
sources that could potentially be searched, new literature searches for all required data were 
not considered feasible.  
Although the model results include variability among individual observations, probabilistic 
analyses which involve specifying probabilistic distributions for model parameters and 
sampling from these distributions using Monte Carlo simulation (Claxton et al., 2005) to handle 
uncertainty were not performed in the proof-of-concept model reported in this thesis.  Also, 
uncertainty around the structure of the model was not examined.  In the model for this thesis, 
time-to-event distributions and random numbers were used to represent variability across 
different individuals. However, parameters used to define the distributions were constants 
that do not vary, and parameter changes were made only when there are changes in: age band; 
disease status of the individual; or any other events that can affect the point estimates of 
these parameters. Hence, it is not known whether the uncertainty of some parameters might 
have had a significant impact on the model outcomes. This is an area for future research. 
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In order to conduct probabilistic sensitivity analyses (PSA) for this model, relevant evidence 
needs to be identified and synthesised to define probabilistic distributions to appropriately 
represent uncertainty around selected parameters. Also, significant model running time is 
expected: for example, the base-case model involving the three diseases required 
approximately one hour of running time, so 100 PSA runs would take five days. However, it is 
possible to reduce total run time by spreading the PSA runs across multiple computers. 
 
10.3. Future research and recommendations 
 
Future research 
 
Due to the nature of this study incorporating the modelling of multiple diseases and the 
associated need for large amounts of data, a thorough review for each parameter could not be 
performed. Instead, secondary data used in published literature on the models of the diseases 
included in this PhD were sought and updated wherever possible.  More up-to-date and 
detailed data (including data on the probabilistic distributions of parameters) and the inclusion 
of more relevant diseases and correlations between them need to be explored. Preferably, the 
use of individual patient data and corresponding appropriate statistical analyses of data 
collected in the relevant setting or country is recommended for a more accurate estimation of 
parameters to populate the model and thus, provide more reliable outcomes.  
Also, further research on treatment costs and utility estimates for comorbid populations would 
improve the accuracy of estimates from multi-disease models. As shown in this thesis, total 
and incremental costs may differ when incorporating diseases incurring overlapping costs such 
as the cost of institutional care from Alzheimer’s disease and fracture. Hence, linking multiple 
diseases can result in changes in the cost-effectiveness estimate of an intervention. Utilities 
were assumed to be multiplicative in the model for this thesis, which may over- or under-
estimate the actual utilities of people with comorbidities. No agreement has been reached 
regarding the best approach to estimate utility values for people with comorbid conditions. 
However, there have been a growing number of studies estimating EQ-5D utility values for 
comorbid populations such as Ara and Brazier (2012) using the Health Survey for England data; 
and Sullivan and Ghushchyan (2016) for diabetes-related comorbidities. 
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A valuable extension of the model reported in this thesis would be the linkage of DES models 
for further diseases additional to those incorporated in this thesis. Using this model, it would 
be possible to assess a broader range of potential policies and interventions and examine the 
impact of the correlations between the diseases on the healthcare expenditure at the 
population level.  However, care must be taken to ensure such diseases have the central 
estimate of incremental QALYs greater than the standard error in other diseases, or if this is 
the case, that a sufficient number of individuals are simulated. It is also noted that adding any 
new disease would require an amendment in non-disease mortality by subtracting mortality 
rates associated with the additional disease. 
In order to inform realistic options for policies and interventions, future research is 
recommended to define specific sets of scenarios that may be implemented in real settings. In 
addition to this, further applications are possible, such as diverse sub-group analyses using the 
individual attributes assigned, and the examination of the impact of hypothetical changes in 
the population composition, strength of correlations between diseases, availability of 
improved technologies and policy options on future health and healthcare. In the current 
political context where it is often suggested that radical policy shifts are necessary in order to 
contain future health and social care costs, the model could be used to explore the potential 
impact of such changes on public expenditure (Committee of Public Accounts, 2015).  
Further research on projecting long term trends in parameters that influence the outcomes of 
interest, such as those regarding health status, treatment efficacy, and population changes are 
expected to greatly improve the findings reported in this thesis. Identifying more detailed and 
up-to-date data sources should precede and will facilitate the projection.  
Last but not least, uncertainty around the model results can be explored in future research by 
undertaking an extensive probabilistic sensitivity analysis. This will aid handling uncertainty 
when making decisions on alternative treatments and policy options.  
 
Recommendations for modellers 
 
Practical recommendations for modellers include:  
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 In the linked model, at all events, the values of time to all other events that can occur 
next should be specified in order to prevent potential errors that may arise when 
changes are made to the model.  For example, although it was modelled that fatal 
stroke cannot occur immediately after the PAD event, time to fatal stroke should be 
specified at the PAD event. Otherwise, in the linked model where all the most recent 
time-to-event values are compared, fatal stroke may be simulated at an incorrect time 
point.   
 Variables that can be updated after time to earliest disease event across all included 
diseases should be updated only once at a central routing point for efficiency.  
For example, time points where utility weights change due to the split between the 
first and subsequent years of events and where adverse events associated with 
treatment initiation are processed may be updated at the central routing point, 
without the need for including them at every event.  
 Correlations between diseases can be implemented in various ways within the model. 
Care should be taken to apply correlations in intended directions (event A influencing 
event B or event B influencing event A).   
 Especially at model entry, individual characteristics should be carefully ordered, due to 
the included correlations. If variable A depends on the status of variable B, then 
variable B should be specified first. When multiple diseases are linked, this may 
require careful consideration as a large number of variables representing individual 
characteristics can be involved.  
 Individual disease models should be constructed to have a similar order in which time 
variables are updated to make model linkage easier. For example, if all variables 
regarding time to change in treatment efficacy (such as time to treatment 
discontinuation, and time since treatment discontinuation for the calculation of 
efficacy fall time) are updated immediately after the time to next event is determined 
in one model, all the other models should have the same time update structure as this.  
 
The proposed method of linking diseases can be communicated to healthcare decision-makers 
and stakeholders by focussing on its intuitive logic of event occurrences rather than its 
background calculations. Decision makers may have neither the technical expertise nor 
motivation for understanding the underlying calculations and coding methods. Hence, the 
method can be explained as a mechanism through which the existing single-disease models 
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are expanded to incorporate other disease events where the central routing point serves as a 
bridge connecting the wider range of the included disease events. Graphical representation of 
the outputs of the model would be desirable, rather than trying to communicate the 
technicalities that are behind the method. Most bespoke DES software provides an intuitive 
interface with static or animated graphics showing patient movements. Within other generic 
software, similar graphics can be created manually. It is also possible to show a sequence of 
events occurring to a particular individual with comorbidities as an example, with the patient 
characteristics and disease history displayed alongside cost and QALY outcomes.  
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10.4. Conclusions 
 
This thesis estimated future healthcare expenditure at the individual disease level. The 
patient-level models linked with correlations can provide more detailed and potentially more 
accurate results than a crude summation of costs projected from multiple individual disease 
models.  
In summary, the key contributions of this PhD include the following: 
 This study provided a modelling framework that has the potential to be flexibly 
modified or expanded to incorporate other disease areas and examine further 
outcomes of analysts’ interest for the assessment of policy and intervention options 
and the estimation of future healthcare expenditure.  
 The proof-of-concept model developed for this thesis illustrated that model linkage is 
feasible by implementing a simple routing logic. 
 The analysis of hypothetical scenarios such as which disease would save the most if an 
additional treatment reduces disease events by 20% illustrated that this model could 
be used to inform decisions on healthcare resource allocations and the assessment of 
potential policy or interventions.   
 The analysis of the linked model identified an unanticipated problem in combining 
multiple diseases in a single model. In the model for this thesis, the sampling error 
around incremental QALYs for HD treatment could make a significant impact on the 
cost-effectiveness of AD and osteoporosis treatments.  
 Using the model, the impact of policy changes, for example, switching delivery of 
services to alternative sectors or increasing private co-payments, on total population 
health and care costs over time, can potentially be explored.  
 A pragmatic literature search method which can be used for literature within diffuse 
topic areas was developed. 
 A literature repository for future researchers to explore the existing literature in the 
diffuse topic area of ageing and healthcare expenditure was created.  
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APPENDICES 
Appendix 2.1: Exploratory Searches 
 
MEDLINE search statements 
(Ovid MEDLINE(R) <1948 to November Week 3 2011>) (Accessed on 01Dec.2011) 
Medline search 1  
1     Health Care Costs/ (22464) 
2     *Aged/ (19896) 
3     *Aging/ (105913) 
4     Health Expenditures/ (12037) 
5     "Costs and Cost Analysis"/ or "Cost of Illness"/ or "Delivery of Health Care"/ (108834) 
6     1 or 4 or 5 (135093) 
7     2 or 3 (125271) 
8     6 and 7 (729) 
 
Medline search 2 
1     Aging/ (174887) 
2     Aged/ (2073048) 
3     1 or 2 (2186829) 
4     *Health Expenditures/ or *"Costs and Cost Analysis"/ or *"Cost of Illness"/ or *"Delivery of 
Health Care"/ (50948) 
5     *Health Care Costs/ (9550) 
6     4 or 5 (58918) 
7     3 and 6 (7578) 
 
Medline search 3  
1     Health Care Costs/ (22464) 
2     Health Expenditures/ (12037) 
3     Aging/ (174887) 
4     Aged/ (2073048) 
5     limit 4 to ("all aged (65 and over)" or "aged (80 and over)") (2073048) 
6     limit 3 to ("all aged (65 and over)" or "aged (80 and over)") (61588) 
7     Population Dynamics/ (37800) 
8     5 or 6 or 7 (2108924) 
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9     "Delivery of Health Care"/ (56747) 
10     "Health Services Needs and Demand"/ (36772) 
11     Health Services for the Aged/ (13998) 
12     1 or 2 or 9 or 10 or 11 (132873) 
13     8 and 12 (29673) 
 
Medline search 4   
1     Health Care Costs/ (22464) 
2     *"Health Services Needs and Demand"/ (13743) 
3     "proximity to death".mp. (62) 
4     older.ab,ti. (206812) 
5     elder$.ab,ti. (151750) 
6     *Aged/ (19896) 
7     Population Dynamics/sn, td [Statistics & Numerical Data, Trends] (6) 
8     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Supply & Distribution, Trends, Utilization] (30876) 
9     Health Expenditures/ec, lj, sn, sd, td [Economics, Legislation & Jurisprudence, Statistics & 
Numerical Data, Supply & Distribution, Trends] (5538) 
10     ag?ing.ab,ti. (110062) 
11     3 or 4 or 5 or 6 or 7 or 10 (421010) 
12     1 or 2 or 8 or 9 (69587) 
13     11 and 12 (4442) 
 
Medline search 5  
1     ag?ing.ab,ti. (110062) 
2     Aged/ (2073048) 
3     "proximity to death".mp. (62) 
4     older.ab,ti. (206812) 
5     *Aging/ (105913) 
6     *Population Dynamics/ (7246) 
7     Health Care Costs/ (22464) 
8     Health Policy/ (44086) 
9     Health Expenditures/ (12037) 
10     "Health Services Needs and Demand"/ (36772) 
11     "Delivery of Health Care"/ (56747) 
12     Hospitals/ut [Utilization] (2819) 
13     Long-Term Care/ut [Utilization] (325) 
14     7 or 8 or 9 or 10 or 11 or 12 or 13 (161216) 
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15     1 or 2 or 3 or 4 or 5 or 6 (2268361) 
16     14 and 15 (22771) 
 
Medline search 6  
1     ag?ing.ab,ti. (110062) 
2     "proximity to death".mp. (62) 
3     older.ab,ti. (206812) 
4     *Aging/ (105913) 
5     *Population Dynamics/ (7246) 
6     Health Care Costs/ (22464) 
7     Health Policy/ (44086) 
8     Health Expenditures/ (12037) 
9     "Health Services Needs and Demand"/ (36772) 
10     "Delivery of Health Care"/ (56747) 
11     Hospitals/ut [Utilization] (2819) 
12     Long-Term Care/ut [Utilization] (325) 
13     6 or 7 or 8 or 9 or 10 or 11 or 12 (161216) 
14     1 or 2 or 3 or 4 or 5 (353046) 
15     13 and 14 (6408) 
 
Medline search 7  
1     ag?ing.ab,ti. (110062) 
2     "proximity to death".mp. (62) 
3     older.ab,ti. (206812) 
4     *Aging/ (105913) 
5     *Population Dynamics/ (7246) 
6     Health Care Costs/ (22464) 
7     Health Policy/ (44086) 
8     Health Expenditures/ (12037) 
9     Hospitals/ut [Utilization] (2819) 
10     Long-Term Care/ut [Utilization] (325) 
11     1 or 2 or 3 or 4 or 5 (353046) 
12     *"Health Services Needs and Demand"/ (13743) 
13     "Delivery of Health Care"/ec, lj, ma, mt, og, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Statistics & Numerical Data, 
Supply & Distribution, Trends, Utilization] (26948) 
14     6 or 7 or 8 or 9 or 10 or 12 or 13 (113344) 
15     11 and 14 (4361) 
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Medline search 8  
1     ag?ing.ab,ti. (110062) 
2     "proximity to death".mp. (62) 
3     older.ab,ti. (206812) 
4     *Aging/ (105913) 
5     *Population Dynamics/ (7246) 
6     Health Care Costs/ (22464) 
7     Health Policy/ (44086) 
8     Health Expenditures/ (12037) 
9     Hospitals/ut [Utilization] (2819) 
10     Long-Term Care/ut [Utilization] (325) 
11     *"Health Services Needs and Demand"/ (13743) 
12     "Delivery of Health Care"/ec, lj, ma, mt, og, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Statistics & Numerical Data, 
Supply & Distribution, Trends, Utilization] (26948) 
13     6 or 7 or 8 or 9 or 10 or 11 or 12 (113344) 
14     *Longevity/ (6638) 
15     1 or 2 or 3 or 4 or 5 or 14 (357004) 
16     13 and 15 (4391) 
 
Medline search 9  
1     ag?ing.ab,ti. (110062) 
2     "proximity to death".mp. (62) 
3     older.ab,ti. (206812) 
4     *Aging/ (105913) 
5     *Population Dynamics/ (7246) 
6     Health Care Costs/ (22464) 
7     Health Policy/ (44086) 
8     Health Expenditures/ (12037) 
9     Hospitals/ut [Utilization] (2819) 
10     Long-Term Care/ut [Utilization] (325) 
11     *"Health Services Needs and Demand"/ (13743) 
12     "Delivery of Health Care"/ec, lj, ma, mt, og, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Statistics & Numerical Data, 
Supply & Distribution, Trends, Utilization] (26948) 
13     6 or 7 or 8 or 9 or 10 or 11 or 12 (113344) 
14     *Longevity/ (6638) 
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15     1 or 2 or 3 or 4 or 5 or 14 (357004) 
16     *Aged/ or *Health Services for the Aged/ (30660) 
17     15 or 16 (378103) 
18     13 and 17 (5585) 
 
Medline search 10  
1     "proximity to death".mp. (62) 
2     older.ab,ti. (206812) 
3     *Aging/ (105913) 
4     *Population Dynamics/ (7246) 
5     Health Care Costs/ (22464) 
6     Health Expenditures/ (12037) 
7     "Health Services Needs and Demand"/ (36772) 
8     "Delivery of Health Care"/ (56747) 
9     Hospitals/ut [Utilization] (2819) 
10     Long-Term Care/ut [Utilization] (325) 
11     Life Expectancy/ (12612) 
12     *Longevity/ (6638) 
13     *"Health Services Needs and Demand"/ (13743) 
14     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Supply & Distribution, Trends, Utilization] (30876) 
15     ag?ing.ab,ti. (110062) 
16     1 or 2 or 3 or 4 or 11 or 12 or 15 (366616) 
17     5 or 6 or 9 or 10 or 13 or 14 (77808) 
18     16 and 17 (4188) 
 
Medline search 11  
1     "proximity to death".mp. (62) 
2     older.ab,ti. (206812) 
3     *Aging/ (105913) 
4     *Population Dynamics/ (7246) 
5     Health Care Costs/ (22464) 
6     Health Expenditures/ (12037) 
7     "Health Services Needs and Demand"/ (36772) 
8     "Delivery of Health Care"/ (56747) 
9     Hospitals/ut [Utilization] (2819) 
10     Long-Term Care/ut [Utilization] (325) 
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11     Life Expectancy/ (12612) 
12     *Longevity/ (6638) 
15     ag?ing.ab,ti. (110062) 
16     1 or 2 or 3 or 4 or 11 or 12 or 15 (366616) 
20     5 or 6 or 7 or 8 or 9 or 10 (123795) 
21     16 and 20 (6445) 
 
Medline search 12  
1     "proximity to death".mp. (62) 
2     Health Care Costs/ (22464) 
3     Hospitals/ut [Utilization] (2819) 
4     Long-Term Care/ut [Utilization] (325) 
5     *"Health Services Needs and Demand"/ (13743) 
6     older.ab,ti. (206812) 
7     elder$.ab,ti. (151750) 
8     *Aged/ (19896) 
9     Population Dynamics/sn, td [Statistics & Numerical Data, Trends] (6) 
10     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Supply & Distribution, Trends, Utilization] (30876) 
11     Health Expenditures/ec, lj, sn, sd, td [Economics, Legislation & Jurisprudence, Statistics & 
Numerical Data, Supply & Distribution, Trends] (5538) 
12     *Aging/ (105913) 
13     ag?ing.ab,ti. (110062) 
14     1 or 6 or 7 or 8 or 9 or 12 or 13 (462108) 
15     2 or 3 or 4 or 5 or 10 or 11 (72478) 
16     14 and 15 (4804) 
 
Medline search 13  
1     "proximity to death".mp. (62) 
2     Health Care Costs/ (22464) 
3     Hospitals/ut [Utilization] (2819) 
4     Long-Term Care/ut [Utilization] (325) 
5     *"Health Services Needs and Demand"/ (13743) 
6     older.ab,ti. (206812) 
7     elder$.ab,ti. (151750) 
8     *Aged/ (19896) 
9     Population Dynamics/sn, td [Statistics & Numerical Data, Trends] (6) 
411 
 
10     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Supply & Distribution, Trends, Utilization] (30876) 
11     Health Expenditures/ec, lj, sn, sd, td [Economics, Legislation & Jurisprudence, Statistics & 
Numerical Data, Supply & Distribution, Trends] (5538) 
12     *Aging/ (105913) 
13     ag?ing.ab,ti. (110062) 
14     Life Expectancy/ (12612) 
15     *Longevity/ (6638) 
16     1 or 6 or 7 or 8 or 9 or 12 or 13 or 14 or 15 (475218) 
17     2 or 3 or 4 or 5 or 10 or 11 (72478) 
18     16 and 17 (5330) 
 
Medline search 14  
1     "proximity to death".mp. (62) 
2     older.ab,ti. (206812) 
3     elder$.ab,ti. (151750) 
4     *Aged/ (19896) 
5     Population Dynamics/sn, td [Statistics & Numerical Data, Trends] (6) 
6     *Aging/ (105913) 
7     ag?ing.ab,ti. (110062) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (462108) 
9     Health Care Costs/ (22464) 
10     Health Expenditures/ (12037) 
11     "Health Services Needs and Demand"/ (36772) 
12     "Delivery of Health Care"/ (56747) 
13     Hospitals/ut [Utilization] (2819) 
14     Long-Term Care/ut [Utilization] (325) 
15     Life Expectancy/ (12612) 
16     *Longevity/ (6638) 
17     9 or 10 or 11 or 12 or 13 or 14 (123795) 
18     8 or 15 or 16 (475218) 
19     17 and 18 (8873) 
 
Medline search 15  
1     "proximity to death".mp. (62) 
2     older.ab,ti. (206812) 
3     elder$.ab,ti. (151750) 
412 
 
4     *Aged/ (19896) 
5     Population Dynamics/sn, td [Statistics & Numerical Data, Trends] (6) 
6     *Aging/ (105913) 
7     ag?ing.ab,ti. (110062) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (462108) 
9     Health Care Costs/ (22464) 
10     Health Expenditures/ (12037) 
11     Hospitals/ut [Utilization] (2819) 
12     Long-Term Care/ut [Utilization] (325) 
13     Life Expectancy/ (12612) 
14     *Longevity/ (6638) 
15     *"Health Services Needs and Demand"/ (13743) 
16     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Supply & Distribution, Trends, Utilization] (30876) 
17     9 or 10 or 11 or 12 or 15 or 16 (77808) 
18     8 or 13 or 14 (475218) 
19     17 and 18 (5770) 
 
Medline search 16  
1     "proximity to death".mp. (62) 
2     older.ab,ti. (206812) 
3     *Aging/ (105913) 
4     *Population Dynamics/ (7246) 
5     Life Expectancy/ (12612) 
6     *Longevity/ (6638) 
7     ag?ing.ab,ti. (110062) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (366616) 
9     Health Care Costs/ (22464) 
10     Hospitals/ut [Utilization] (2819) 
11     Long-Term Care/ut [Utilization] (325) 
12     *"Health Services Needs and Demand"/ (13743) 
13     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Supply & Distribution, Trends, Utilization] (30876) 
14     Health Expenditures/ec, lj, sn, sd, td [Economics, Legislation & Jurisprudence, Statistics & 
Numerical Data, Supply & Distribution, Trends] (5538) 
15     9 or 10 or 11 or 12 or 13 or 14 (72478) 
16     8 and 15 (3860) 
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Medline search 17  
1     "proximity to death".mp. (62) 
2     older.ab,ti. (206812) 
3     elder$.ab,ti. (151750) 
4     *Aged/ (19896) 
5     *Aging/ (105913) 
6     ag?ing.ab,ti. (110062) 
7     Life Expectancy/ (12612) 
8     *Longevity/ (6638) 
9     Health Care Costs/ (22464) 
10     Hospitals/ut [Utilization] (2819) 
11     Long-Term Care/ut [Utilization] (325) 
12     *"Health Services Needs and Demand"/ (13743) 
13     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Supply & Distribution, Trends, Utilization] (30876) 
14     *Population Dynamics/ (7246) 
15     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 14 (480888) 
16     Health Expenditures/ec, lj, sn, sd, td [Economics, Legislation & Jurisprudence, Statistics & 
Numerical Data, Supply & Distribution, Trends] (5538) 
17     9 or 10 or 11 or 12 or 13 or 16 (72478) 
18     15 and 17 (5442) 
 
Complementary MEDLINE search 
1     Health Expenditures/ (12037) 
2     Forecasting/ (65850) 
3     1 and 2 (613) 
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EMBASE search results 
Table 1. EMBASE search results (Access Date: 01 Dec. 2011; Database: Embase <1980 to 2011 Week 47>) 
No
. 
Search 
details 
Sample papers 
Numb
er of 
hits 
Number  of 
sample 
papers 
included 
(sensitivity) 
Percentage 
of the 
sample 
paper 
among the 
papers 
retrieved 
(precision) 
Zweifel 
et al. 
1999 
Lloyd-
Sherlock 
2000 
Spillman 
and 
Lubitz 
2000 
Reinhardt 
2003 
Schulz 
et al. 
2004 
Seshamani 
and Gray 
2004 
Borge
r et al. 
2006 
Payne 
et al. 
2007 
Werblow 
et al. 
2007 
Hakkinen 
et al. 
2008 
Palankaraya 
and Yong 
2009 
Caley 
and 
Sidhu 
2011 
Availability: √ √ √ √ √ √ √ √ √ √ NA NA Max. = 10 
1 Broad 
ageing 
term 
search 
 
√ √ √ √ √ √ x √ √ √ NA NA 
2108
7 
9 
(90%) 
0.04% 
 
2 Combine 
Search 1  
with 
“health 
care cost” 
using AND 
√ x √ √ x √ x √ √ √ NA NA 
1182
4 
7 
(70%) 
0.06% 
 
3 Title and 
abstract 
search 
with 
limiters 
applied 
√ x √ √ x √ x √ √ √ NA NA 5248 
7 
(70%) 
0.13% 
 
4 As Search 3 
but with 
narrower 
HC terms 
√ x √ √ x √ x √ √ √ NA NA 6031 
7 
(70%) 
0.12% 
 
5 Broader 
ageing 
terms & 
focused 
√ x √ x x √ x √ √ √ NA NA 1343 
6 
(60%) 
0.45% 
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No
. 
Search 
details 
Sample papers 
Numb
er of 
hits 
Number  of 
sample 
papers 
included 
(sensitivity) 
Percentage 
of the 
sample 
paper 
among the 
papers 
retrieved 
(precision) 
Zweifel 
et al. 
1999 
Lloyd-
Sherlock 
2000 
Spillman 
and 
Lubitz 
2000 
Reinhardt 
2003 
Schulz 
et al. 
2004 
Seshamani 
and Gray 
2004 
Borge
r et al. 
2006 
Payne 
et al. 
2007 
Werblow 
et al. 
2007 
Hakkinen 
et al. 
2008 
Palankaraya 
and Yong 
2009 
Caley 
and 
Sidhu 
2011 
Availability: √ √ √ √ √ √ √ √ √ √ NA NA Max. = 10 
“*health 
care cost” 
only for HC 
terms 
6 Ageing  
terms from 
Search 5 
combined 
with much 
broader HC 
terms 
√ x √ √ √ √ x √ √ √ NA NA 
1021
3 
8 
(80%) 
0.08% 
 
7 As Search 6 
but with 
broader HC 
terms 
added 
(including 
*health 
care policy) 
√ √ √ x √ √ x √ √ √ NA NA 
1288
1 
8 
(80%) 
0.06% 
 
8 As Search 
6, but no 
‘Elder’ 
term & 
with 
‘health 
policy’ 
term 
added 
√ √ x √ √ √ x √ √ √ NA NA 9739 
8 
(80%) 
0.08% 
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No
. 
Search 
details 
Sample papers 
Numb
er of 
hits 
Number  of 
sample 
papers 
included 
(sensitivity) 
Percentage 
of the 
sample 
paper 
among the 
papers 
retrieved 
(precision) 
Zweifel 
et al. 
1999 
Lloyd-
Sherlock 
2000 
Spillman 
and 
Lubitz 
2000 
Reinhardt 
2003 
Schulz 
et al. 
2004 
Seshamani 
and Gray 
2004 
Borge
r et al. 
2006 
Payne 
et al. 
2007 
Werblow 
et al. 
2007 
Hakkinen 
et al. 
2008 
Palankaraya 
and Yong 
2009 
Caley 
and 
Sidhu 
2011 
Availability: √ √ √ √ √ √ √ √ √ √ NA NA Max. = 10 
9 As Search 
6, but no 
‘health 
policy and 
health 
service’ 
term and 
with  
‘Longevity’ 
added  
√ √ √ x √ √ x √ √ √ NA NA 8587 
8 
(80%) 
0.09% 
 
10 The same 
age terms 
as Search 9 
but no 
‘health 
policy’ 
broader 
cost terms 
√ √ √ √ √ √ x √ √ √ NA NA 
1135
1 
9 
(90%) 
0.08% 
 
11 As Search 
10, but no 
‘older’ 
term & 
with 
narrower 
HC terms 
added 
√ √ √ √ √ √ x √ √ √ NA NA 3584 
9 
(90%) 
0.25% 
 
√: Included; X: Not included; NA: Not available in the database.
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EMBASE search statements 
EMBASE <1980 to 2011 Week 47> (Accessed on 01 Dec 2011) 
EMBASE search 1 
1     aged/ (1894973) 
2     *aging/ (80604) 
3     1 or 2 (1939177) 
4     "health care cost"/ (103416) 
5     health care delivery/ (109691) 
6     health care financing/ (10624) 
7     health care need/ (15425) 
8     4 or 5 or 6 or 7 (220998) 
9     3 and 8 (21087) 
 
EMBASE search 2 
1     aged/ (1894973) 
2     *aging/ (80604) 
3     1 or 2 (1939177) 
4     "health care cost"/ (103416) 
5     3 and 4 (11824) 
 
EMBASE search 3 
1     "health care cost"/ (103416) 
2     health care delivery/ (109691) 
3     health care financing/ (10624) 
4     health care need/ (15425) 
5     1 or 2 or 3 or 4 (220998) 
6     ag?ing.ti,ab,kw. (131566) 
7     older.ti,ab,kw. (241970) 
8     elder$.ti,ab,kw. (190237) 
9     6 or 7 or 8 (493848) 
10     5 and 9 (11346) 
11     limit 10 to (human and english language and aged <65+ years>) (5248) 
 
EMBASE search 4 
1     "health care cost"/ (103416) 
2     ag?ing.ti,ab,kw. (131566) 
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3     older.ti,ab,kw. (241970) 
4     elder$.ti,ab,kw. (190237) 
5     2 or 3 or 4 (493848) 
6     1 and 5 (6031) 
 
EMBASE search 5 
1     *"health care cost"/ (23189) 
2     *aging/ (80604) 
3     ag?ing.ti,ab,kw. (131566) 
4     older.ti,ab,kw. (241970) 
5     elder$.ti,ab,kw. (190237) 
6     2 or 3 or 4 or 5 (517676) 
7     1 and 6 (1343) 
 
EMBASE search 6 
1     "health care cost"/ (103416) 
2     health care need/ (15425) 
3     *aging/ (80604) 
4     ag?ing.ti,ab,kw. (131566) 
5     older.ti,ab,kw. (241970) 
6     elder$.ti,ab,kw. (190237) 
7     health care utilization/ (30309) 
8     3 or 4 or 5 or 6 (517676) 
9     1 or 2 or 7 (139384) 
10     8 and 9 (10213) 
 
EMBASE search 7 
1     "health care financing"/ (10624) 
2     *"health care cost"/ (23189) 
3     health care need/ (15425) 
4     "health care facilities and services"/ (365) 
5     *aging/ (80604) 
6     health care utilization/ (30309) 
7     long term care/ (75092) 
8     ag?ing.ti,ab. (127541) 
9     older.ti,ab. (241697) 
10     elder$.ti,ab,kw. (190237) 
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11     5 or 8 or 9 or 10 (515846) 
12     1 or 2 or 3 or 4 or 6 or 7 (148361) 
13     11 and 12 (12881) 
 
EMBASE search 8 
1     "health care cost"/ (103416) 
2     health care policy/ (119016) 
3     health care need/ (15425) 
4     *aging/ (80604) 
5     health care utilization/ (30309) 
6     ag?ing.ti,ab. (127541) 
7     older.ti,ab. (241697) 
8     *population dynamics/ (9052) 
9     4 or 6 or 7 or 8 (387246) 
10     1 or 2 or 3 or 5 (242328) 
11     9 and 10 (9739) 
 
EMBASE search 9 
1     "health care financing"/ (10624) 
2     *"health care cost"/ (23189) 
3     health care need/ (15425) 
4     "health care facilities and services"/ (365) 
5     *aging/ (80604) 
6     health care utilization/ (30309) 
7     long term care/ (75092) 
8     1 or 2 or 3 or 4 or 6 or 7 (148361) 
9     ag?ing.ti,ab. (127541) 
10     older.ti,ab. (241697) 
11     *population dynamics/ (9052) 
12     longevity/ (13859) 
13     5 or 9 or 10 or 11 or 12 (396390) 
14     8 and 13 (8587) 
 
EMBASE search 10 
1     "health care financing"/ (10624) 
2     "health care cost"/ (103416) 
3     health care need/ (15425) 
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4     *aging/ (80604) 
5     health care utilization/ (30309) 
6     long term care/ (75092) 
7     ag?ing.ti,ab. (127541) 
8     older.ti,ab. (241697) 
9     *population dynamics/ (9052) 
10     longevity/ (13859) 
11     4 or 7 or 8 or 9 or 10 (396390) 
12     1 or 2 or 3 or 5 or 6 (218366) 
13     11 and 12 (11351) 
 
EMBASE search 11 
1     "health care financing"/ (10624) 
2     "health care cost"/ (103416) 
3     health care need/ (15425) 
4     *aging/ (80604) 
5     health care utilization/ (30309) 
6     long term care/ (75092) 
7     ag?ing.ti,ab. (127541) 
8     *population dynamics/ (9052) 
9     longevity/ (13859) 
10     4 or 7 or 8 or 9 (182117) 
11     1 or 2 or 3 or 5 or 6 (218366) 
12     10 and 11 (3584) 
 
Complementary EMBASE search 
1     *"health care cost"/ (23189) 
2     forecasting/ (35943) 
3     1 and 2 (566) 
 
EconLit <1961 to October 2011> searches 
Search 1  
Broad search 
3     older.ti,ab. (4628) 
4     elder$.ti,ab. (2797) 
5     long term care.mp. [mp=heading words, abstract, title, country as subject] (603) 
10     "health?care expenditure".mp. [mp=heading words, abstract, title, country as subject] (29) 
11     "health?care demand".mp. [mp=heading words, abstract, title, country as subject] (2) 
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12     "health?care utili?ation".mp. [mp=heading words, abstract, title, country as subject] (38) 
22     ag?ing.ti,ab,kw. (3309) 
23     health?care.ti,ab,kw. (4891) 
30     health.ti,ab,kw. (26182) 
31     hospital$.ti,ab,kw. (4295) 
32     3 or 4 or 22 (9621) 
33     5 or 10 or 11 or 12 or 23 or 30 or 31 (29769) 
34     32 and 33 (2248) 
 
Search 2 
Narrow search 
19     ag?ing.ti,ab,kw. (3309) 
20     health?care.ti,ab,kw. (4891) 
35     19 and 20 (159) 
 
Search 3 
19     ag?ing.ti,ab,kw. (3309) 
37     demography.ti,ab,kw. (973) 
38     population.ti,ab,kw. (25187) 
20     health?care.ti,ab,kw. (4891) 
27     health.ti,ab,kw. (26182) 
28     hospital$.ti,ab,kw. (4295) 
39     19 or 37 or 38 (27416) 
40     20 or 27 or 28 (29395) 
41     39 and 40 (3471) 
 
Search 4 (Accessed on 13 Dec. 2011) 
1     ag?ing.ti,ab,kw. (3320) 
2     health?care.ti,ab,kw. (4908) 
3     hospital$.ti,ab,kw. (4303) 
4     demograph$.ti,ab,kw. (10948) 
5     "long term care".mp. [mp=heading words, abstract, title, country as subject] (603) 
6     longevity.mp. [mp=heading words, abstract, title, country as subject] (911) 
7     1 or 4 or 6 (14120) 
8     2 or 3 or 5 (9004) 
9     7 and 8 (542) 
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ASSIA (1987-) searches (accessed on 30/11/2011) 
 
Search 1: Narrow search 
su.EXACT("Health costs" OR "Health services" OR "Long term care" OR "Health policy" OR 
"Expenditure") AND su.EXACT("Ageing" OR "Elderly people" OR "Demographic change" OR 
"Population") 752 results 
 
Search 2: Broader search 
 (su.EXACT("Ageing" OR "Elderly people" OR "Demographic change" OR "Population") OR 
AB,TI(ag?ing)) AND su.Exact("health care utilization" OR "health care costs" OR "health care 
needs" OR "Health costs" OR "Health services" OR "Long term care" OR "Health policy" OR 
"Expenditure") 764 results 
 
 
 
 
423 
 
Table 2. EconLit <1961 to October 2011>, ASSIA(1987-current), and CINAHL (1982-) search results 
No
. 
Search details 
Seed Papers 
Number 
of hits 
Number 
of seed 
papers 
identified 
(coverage) 
Access 
Date 
Zw
e
if
e
l e
t 
al
.  
1
9
9
9
 
Ll
o
yd
-
Sh
e
rl
o
ck
  
2
0
0
0
 
Sp
ill
m
an
 
an
d
 L
u
b
it
z 
 
2
0
0
0
 
R
e
in
h
ar
d
t 
 
2
0
0
3
 
Sc
h
u
lz
 e
t 
al
.  
2
0
0
4
 
Se
sh
am
an
i a
n
d
 G
ra
y 
2
0
0
4
 
B
o
rg
e
r 
e
t 
al
.  
2
0
0
6
 
P
ay
n
e
 e
t 
al
.  
2
0
0
7
 
W
e
rb
lo
w
 
e
t 
al
.  
2
0
0
7
 
H
ak
ki
n
e
n
 
e
t 
al
.  
2
0
0
8
 
P
al
an
gk
ar
ay
a 
an
d
 
Y
o
n
g 
 
2
0
0
9
 
C
al
e
y 
an
d
 
Si
d
h
u
  
2
0
1
1
 
EconLit availability: Yes No No No No Yes No No Yes Yes Yes No Max.=5 
1 Broad title, 
abstract, 
keyword  search 
√ NA NA NA NA √ NA NA √ √ √ NA 2248 
5/5 
(100%) 
21/11/11 
2 Narrow search 
√ NA NA NA NA √ NA NA √ √ √ NA 159 
5/5 
(100%) 
21/11/11 
3 Population & 
demography 
added to ageing 
terms  
√ NA NA NA NA √ NA NA √ √ √ NA 3471 
5/5 
(100%) 
21/11/11 
4 Refined from 
Search 3 
including ‘long-
term care’ and 
‘longevity’ 
√ NA NA NA NA √ NA NA √ √ √ NA 542 
5/5 
(100%) 
13/12/11 
ASSIA availability:  Yes Yes No No No Yes No Yes Yes No No Yes Max.=6 
1 Narrow search 
√ √ NA NA NA √ NA √ √ NA NA √ 752 
6/6 
(100%) 
30/11/11 
2 Broad search 
√ √ NA NA NA √ NA √ √ NA NA √ 764 
6/6 
(100%) 
30/11/11 
CINAHL availability:  No No No No Yes No No No Yes No No Yes Max.=3 
1 Complementary 
search similar 
to Medline 
Search 16 
NA NA NA NA √ NA NA NA √ NA NA √ 1334 
3/3 
(100%) 
30/11/11 
√: Included; X: Not included; NA: Not available in the database
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Appendix 2.2: Final search results 
 
MEDLINE (accessed on: 19 January 2012) 
Database: Ovid MEDLINE(R) <1946 to January Week 2 2012> 
1     "proximity to death".mp. (64) 
2     older.ab,ti. (200935) 
3     *Aging/ (101582) 
4     *Population Dynamics/ (7148) 
5     Life Expectancy/ (12347) 
6     *Longevity/ (6274) 
7     ag?ing.ab,ti. (105283) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (354785) 
9     Health Care Costs/ (22138) 
10     Hospitals/ut [Utilization] (2816) 
11     Long-Term Care/ut [Utilization] (323) 
12     *"Health Services Needs and Demand"/ (13692) 
13     "Delivery of Health Care"/ec, lj, ma, mt, og, st, sn, sd, td, ut [Economics, Legislation & 
Jurisprudence, Manpower, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Supply & Distribution, Trends, Utilization] (30683) 
14     Health Expenditures/ec, lj, sn, sd, td [Economics, Legislation & Jurisprudence, Statistics & 
Numerical Data, Supply & Distribution, Trends] (5469) 
15     9 or 10 or 11 or 12 or 13 or 14 (71870) 
16     8 and 15 (3814) 
17     Health Expenditures/ (11889) 
18     Forecasting/ (64816) 
19     17 and 18 (603) 
20     16 or 19 (4353) 
21     limit 20 to (english language and humans) (3731) 
 
EMBASE (accessed on 19 Jan 2012) 
Database: Embase <1980 to 2012 Week 02> 
1     "health care financing"/ (10664) 
2     "health care cost"/ (104506) 
3     health care need/ (15605) 
4     *aging/ (81282) 
5     health care utilization/ (30700) 
6     long term care/ (75858) 
7     ag?ing.ti,ab. (129066) 
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8     *population dynamics/ (9077) 
9     longevity/ (14032) 
10     4 or 7 or 8 or 9 (184007) 
11     1 or 2 or 3 or 5 or 6 (220647) 
12     10 and 11 (3624) 
13     *"health care cost"/ (23366) 
14     forecasting/ (36029) 
15     13 and 14 (567) 
16     12 or 15 (4153) 
17     limit 16 to (human and english language) (3052) 
 
EconLit (accessed on 19 January 2012) 
Database: Econlit <1961 to December 2011> 
1     ag?ing.ti,ab,kw. (3354) 
2     health?care.ti,ab,kw. (4953) 
3     hospital$.ti,ab,kw. (4347) 
4     demograph$.ti,ab,kw. (11067) 
5     "long term care".mp. [mp=heading words, abstract, title, country as subject] (608) 
6     longevity.mp. [mp=heading words, abstract, title, country as subject] (932) 
7     1 or 4 or 6 (14285) 
8     2 or 3 or 5 (9086) 
9     7 and 8 (549) 
 
ASSIA (1987-) (accessed on 19 January 2012) 
(su.EXACT("Ageing" OR "Elderly people" OR "Demographic change" OR "Population") OR 
AB,TI(ag?ing)) AND su.Exact("health care utilization" OR "health care costs" OR "health care 
needs" OR "Health costs" OR "Health services" OR "Long term care" OR "Health policy" OR 
"Expenditure") 
757* results (*Represents the approximate result count without duplicates) 
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Appendix 3.1. Review of Projection Models 
 
Table 1. Summary of Statistical/Econometric models  
Name/develo
per of the 
model 
Main objective  
Projection 
outcomes  
Time 
horizo
n 
Method 
Cou
ntry 
Key 
factors 
included 
Key 
assumptions  
Key datasets 
Main 
scenarios 
Conclusions 
Bhattacharya 
et al. (2004): 
NBER 
(National 
Bureau of 
Economic 
Research) and 
RAND model 
To project the 
future 
Medicare costs 
Future per-
capita 
Medicare cost 
2000-
2030 
Stat modelling 
(regression-based 
forecasting model); 
However, cost 
projections are based 
on cell-based method 
combining the age-
gender-disability 
profiles of Medicare 
costs from the 
previous section with 
our forecasts of 
population in each 
age-gender-disability 
cell to produce 
forecasts of Medicare 
costs. 
US     
Medicare Current 
Beneficiary Survey 
(MCBS) and National 
Health Interview Study 
(NHIS) 
1. Base: Age-
prevalence 
profile 
changes 
based on 
trends in the 
MCBS; 2. 
Constant: 
Age-
prevalence 
profile fixed 
based on 
initial year; 3. 
Manton et al 
(1997): Age-
prevalence 
profile 
changes 
based on 
trends in 
NLTCS from 
1989-1994; 4. 
Manton and 
Gu (2001): 
Age-
prevalence 
proffle 
changes 
based on 
trends in 
NLTCS from 
Per-capita Medicare costs will decline 
for the next 15-20 years; this finding is 
in accordance with recent declines in 
disability among the elderly. By 2020, 
however, percapita costs begin to rise as 
a result of growth in disability among 
the young old. As these young-old 
cohorts age, per-capita costs will 
continue to grow. Total costs may well 
remain relatively flat until 2010 and 
then begin to rise as per-capita costs will 
cease to decline rapidly enough to offset 
the influx of new elderly people. As a 
result of growth in per-capita costs, 
total costs will then begin to grow at an 
accelerating rate. 
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1994-1999 
Breyer and 
Felder (2006) 
To estimate 
the impact of 
both age and 
time-to-death 
on health care 
expenditures; 
To estimate 
what the 
expenditures 
in 2002 would 
have been if 
the 
demographic 
composition 
corresponded 
to the 
predictions for 
certain future 
dates; 
Per-capita 
health 
expenditures 
of Social 
Health 
Insurance 
2002-
2050 
Regression analysis 
(two-part model), age–
expenditure profiles 
for men and women, 
each separated by 
survival status, are 
estimated.  
Ger
man
y 
Age, 
gender, 
survival 
status. 
Everything but 
the age 
structure 
remains 
constant at 
year 2002 
levels 
Swiss sickness fund 
1999 claims data 
1. Only age 
structure 
changes; 2. 
Age structure 
and medical 
technology 
changes;  
Explicitly accounting for costs in the last 
years of life leads to a downward 
correction of the demographic impact 
on per-capita expenditures as compared 
to a calculation on the basis of crude 
age-specific health expenditures; the 
impact of medical progress on health 
care expenditures is much larger than 
the impact of ageing so that taking this 
factor into account diminishes the 
relative importance of the error in the 
calculation of the demographic effect 
even further; Given the tremendous 
increase in expenditures over the next 
decades, the transition to uniform per-
capita premiums may be a necessary 
step to at least partially uncouple health 
care financing from demography. 
Centers for 
Medicare and 
Medicaid 
(CMS)/Office 
of Actuary 
model CMS 
(2001, 2009, 
2011) - Heffler 
et al. 2002, 
2003; Smith et 
al. 1999 
To project US 
healthcare 
spending on 
personal care, 
Medicare and 
Medicaid 
Total national 
health 
expenditures 
10 
years 
Statistical/Actuarial 
models (NHE 
projection model is an 
econometric model 
that is estimated 
based on the historical 
National Health 
Expenditures; Actuarial 
projections for 
Medicare and 
Medicaid spending and 
projections for 
macroeconomic 
variables are included 
as exogenous 
variables) 
US 
Macroeco
nomic 
variables 
(economic 
growth 
and 
inflation), 
disposable 
personal 
income, 
relative 
medical 
price 
inflation, 
etc. 
Based on 
historical data; 
Set of 
macroeconomi
c assumptions 
Board of Trustees 
report; National 
Health Interview 
Survey (NHIS); Current 
Population Survey 
(CPS);  
  Depends on the application; 
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ENEPRI/AHEA
D - 
Christiansen 
et al. (2006) 
To investigate 
the 
relationship 
between 
ageing and the 
development 
in the 
aggregate 
healthcare 
expenditure in 
EU countries 
on a 
macroeconomi
c level. 
More of a 
paper 
examining 
factors that 
may influence 
healthcare 
spending; 
Total HCE per 
capita for the 
next 10 years;  
10 
years 
Statistical modelling 
(regression and time-
series analysis) 
EU 
Various 
demand, 
supply, 
and 
institution
al factors 
  
OECD/WHO, 
EUROSTAT 
  
The 10-year expenditure forecast show 
varying speeds during the 2004-2014 
period. Expenditure is expected to 
increase but to a varying extent. 
ENEPRI/AHEA
D project - 
Khoman and 
Weale – 
Builds on 
Christiansen 
et. al (2006) 
To project 
health care 
expenditure in 
order to assess 
the impact of 
ageing on 
future 
spending levels 
and to re-
estimate it in a 
form which is 
convenient for 
incorporation 
into a 
spreadsheet 
model. 
Total health 
care 
expenditure 
per capita 
  
Stat modelling (fixed 
effects panel 
regression estimated 
by Generalised Least 
Squares) 
EU 
Economic 
variables; 
Demograp
hic 
variables; 
Health 
care 
system 
variables;  
  
Panel dataset that 
covers 13 of the old 
EU member states 
(1980 - 2003) 
  
A variety of variables seems to influence 
health spending- and the influence of 
factors such as the share of the public 
sector in the total could easily be 
omitted from more mechanical 
calculations.Institutional variables are of 
great importance. (e.g. Finland having 
limited its health spending over the last 
ten years or so by means of institutional 
change); Total spending on health is 
significantly and positively related to the 
share of health spending paid for by the 
public sector. 
Hashimoto et 
al. (2010) 
To examine the 
impact of 
aging, time to 
death, 
survivorship, 
and use of LTC 
on medical 
care 
expenditure 
for people 
aged 65 and 
above in Japan 
Probability of 
service use; 
the amount of 
expenditure 
conditional on 
the use of the 
service;  
  
Stat modelling (two 
part model); Individual 
model (related to 
Polder et al. (2006), 
but still the model is 
different);  
Japa
n 
Survival 
status and 
age 
  
Japanese public 
medical insurance 
data covering 
outpatient and 
inpatient medical 
services that cover the 
cost of physicians, 
hospitals, drugs, 
laboratory 
examinations, dental 
care, and surgical 
equipment 
  
Findings are similar to those of Polder, 
et al. (2006); Elderly survivors require 
less spending on medical care compared 
to decedents, and survivors‘ medical 
costs did not differ across age 
categories. 
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Lowthian et 
al. 2011 
To measure 
the growth in 
emergency 
ambulance use 
across 
metropolitan 
Melbourne 
since 1995, to 
measure the 
impact of 
population 
growth and 
ageing on 
these services, 
and to forecast 
demand for 
these services 
in 2015 
Emergency 
ambulance use 
1995–
2015 
Stat modelling: Log-
linear regression 
modelled the main 
effects and 
interactions of sex and 
age, and of age and 
time on the logarithm 
of the transportation 
rate while controlling 
for the introduction of 
a referral service (The 
future numbers of 
transportations were 
calculated by 
multiplying predicted 
rates by projected 
population estimates). 
AUS 
Age and 
gender 
  
Emergency 
transportation data by 
Ambulance Victoria 
Projections 
based on 
conservative 
assumptions 
of fertility, 
life 
expectancy 
and migration 
Transportation rate increases were only 
partly accounted for by changes in 
population size and age and sex 
distribution. The rate of transportation 
for all ages increased by 75% over the 
14 years studied (95% CI, 62%–89%). 
Patients aged  85 years were eight times 
(incident rate ratio, 7.9 [95% CI, 7.6–
8.3]) as likely to be transported as those 
aged 45– 69 years. Demand by people 
aged  85 years will continue to 
accelerate in the future. The study 
showed that introduction of a referral 
service reduced the rate of 
transportations but did not slow the 
steady increase over time. 
OECD 
econometric 
analysis 
(Antioch et al. 
model) - Not a 
projection 
study Antioch 
(1997, 1999); 
Gerdtham et 
al. (1993); 
Oxley and 
MacFarlan 
(1994); 
Hagemann 
and Nicoletti 
(1989) 
To estimate 
total and 
components of 
hospital 
expenditure in 
OECD 
countries; To 
discuss the 
various policy 
options for 
better 
achievement 
of 
health policy 
goals within 
the context of 
strained 
budgets 
Overall 
Expenditure; 
Ambulatory 
Care; In-
patient Care 
Expenditure; 
Pharmaceutica
l; Factors 
underlying 
past and 
future 
spending 
pressures;  
  
Statistical modelling 
(regression and time-
series analysis) 
OEC
D 
cou
ntrie
s 
 Efficiency 
and 
Effectiven
ess of 
Health-
care 
Supply 
  
OECD Health Data 
(1993) 
    
Powers et al. 
(2005) 
To evaluate 
several 
statistical 
modelling 
approaches in 
predicting 
Total annual 
health costs; 
Pharmacy 
costs; 
2001-
2003 
(retros
pectiv
e 
validat
Stat modelling (linear 
models) Two-year 
longitudinal analysis; 
Individual Stat model: 
several multivariate 
econometric 
US 
Age/gende
r/pharmac
y 
cost/PHD 
category 
Assumptions 
required to 
run the 
specified 
statistical 
models. 
Integrated medical 
and pharmacy 
insurance claims data 
from a >600,000 
participant state 
employer 
  
The Pharmacy Health Dimensions (a 
pharmacy-based risk index) derived 
solely from pharmacy claims data can be 
used to predict future total health costs. 
Using PHD with a simple OLS model may 
provide similar predictive accuracy in 
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prospective 
total annual 
health costs 
(medical plus 
pharmacy) of 
health plan 
participants 
using 
Pharmacy 
Health 
Dimensions 
(PHD). 
ion) approaches were 
explored. OLS, log-
transformed 
regression, two-part 
models 
comparison to more advanced 
econometric models. 
van Elk et al. 
(2009) – 
ENEPRI/AHEA
D 
To give an up 
to date 
overview of 
the literature 
on health care 
expenditures & 
to contribute 
to the existing 
literature by 
investigating 
the in an 
empirical 
analysis using 
an error-
correction 
model 
Health care 
expenditure 
per capita; 
total 
healthcare 
expenditure;  
  
Stat modelling (panel 
time-series, seemingly 
unrelated regression 
(SUR) model) 
EU       
 Impact of 
several 
factors on 
health care 
expenditures 
was 
investigated 
the increasing price of health care helps 
to explain the increase in real health 
care expenditures. However, the use of 
health care in volume terms is 
negatively affected by the increasing 
price. This effect seems to be stronger in 
periods of cost containment policy. the 
increasing price of health care helps to 
explain the increase in real health care 
expenditures. However, the use of 
health care in volume terms is 
negatively affected by the increasing 
price. This effect seems to be stronger in 
periods of cost containment policy. 
Wang (2009) 
To forecast 
short-term 
growth of 
health 
expenditure; 
To investigate 
whether the 
current equity 
market 
captures useful 
information on 
the growth of 
future health 
care 
Total 
healthcare 
expenditure 
Short 
term 
(1 
year) 
predic
tabilit
y  
Stat modelling 
(random walk, AR(1), 
AR(2); Stock returns 
model) 
US 
Stock 
returns, 
asset 
prices, 
GDP 
growth;  
(Not many 
factors 
included) 
  
US annual 
observations of real 
personal health care 
expenditure (HEALTH) 
and its three major 
components: hospital 
care (HPCARE), 
durable medical 
equipment (MEDEQ) 
and prescription drugs 
(DRUG). 
The market 
performances 
of three 
health care 
related 
industry 
portfolios, 
the aggregate 
health sector, 
health 
services and 
durable 
medical 
equipment, 
The random walk model performs quite 
well in forecasting all four expenditure 
variables; Model incorporating 
HCEGRTH and one-period lagged 
RETURN performs best for HEALTH 
among the six competitors, implying 
that the one-period lagged stock returns 
contain useful information for 
forecasting current period total personal 
health care expenditure;  
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expenditure have some 
predictive 
power for 
their 
correspondin
g health 
expenditure 
components 
at a one-year 
horizon. 
Zhao et al. 
(2001, 2005) 
T o examine 
and evaluate 
models that 
use inpatient 
encounter data 
and outpatient 
pharmacy 
claims data to 
predict future 
health care 
expenditures. 
Individual 
model;  
  
Stat modelling 
(regression) 
US 
Historical 
drug 
expenditur
e of 
enrollees 
and 
diagnostic
s data;  
  
1997 and 1998 
MEDSTAT Market Scan 
® Research Database 
NA 
Models using both drug and diagnostic 
data best predicted subsequent-year 
total health care costs (highest R2 = 
0.168 versus 0.116 and 0.146 for models 
based on drug or diagnostic data alone, 
respectively); Drug costs were far more 
predictable than total or non-pharmacy 
cost.  
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Table 2. Summary of macro-simulation models  
Name/develo
per of the 
model 
Main objective  
Projection 
outcomes  
Time 
horizon 
Method Country 
Key factors 
included 
Key 
assumptions 
Key 
datasets 
Main 
scenarios 
Conclusions 
Alberta 
diabetes 
model (Lau et 
al. 2011) 
To predict the 
prevalence and 
costs of diabetes 
from 2008 to 
2035 in Alberta 
Diabetes 
prevalence, 
total 
physician 
costs, 
emergency 
department 
costs and 
hospital costs 
2008-
2035 
Macro modelling (Life 
table method); Life table 
model similar to dynamic 
multi-state approach (new 
incident cases are added 
and deaths are subtracted; 
to estimate prevalence 
and cost of care, etc.  
Canada 
Disease 
incidence, 
prevalence, 
mortality; 
Migration; 
incidence will 
continue to 
increase for 
an additional 
8 years (2008 
to 2015) and 
mortality 
rates will 
continue to 
decrease for 
the same 
period, based 
on trends in 
the preceding 
decade (1995 
to 2007). 
Alberta 
Diabetes 
Surveillance 
System 
(ADSS) 
  
Total healthcare costs for 
diabetes in Alberta in 2035 
were predicted to be $2.27 
billion, a 237% increase 
from 2007. The category 
with the greatest 
increase in costs is 
predicted to be total 
physician costs, with a rise 
of 253% 
Batljan and 
Lagergren 
(2004) 
To make 
projections of 
future 
inpatient/outpati
ent health care 
demand showing 
how 
demographic 
development 
may influence 
health care 
demand in 
Sweden  
Inpatient and 
outpatient 
costs in terms 
of remaining 
years of life 
2000 - 
2030 
Macro modelling (the 
number of people given 
age group and gender with 
0, 1, 2, 3, 4, 5, 6+ years left 
to live * previous cost 
estimates—given age 
group, gender and 
remaining years = total 
inpatient/outpatient cost 
per gender, age and 
remaining years of life) 
Sweden 
Age, gender, 
remaining years 
of life 
postponemen
t of morbidity 
hypothesis 
(i.e. 
connection 
between the 
decline in 
mortality and 
the 
improvement 
in health) 
Data from 
Skane region 
(The 
National 
Board of 
Health and 
Welfare 
2002) 
NA 
The high per capita cost of 
those with few years left to 
live; the less than 1% of 
population with zero 
remaining years of life 
account for circa 11% ofthe 
total annual expenditure 
for inpatient care; The 
increase in health care 
demand in the period 
2000–2030 arrived at, by 
means ofour method, is 
circa 37% lower than 
estimates done with a 
simple demographical 
extrapolation; 
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Begg et al. 
(2008) 
To introduce a 
large body of 
work that 
explores the 
modelling of 
expenditure on 
health services 
per person living 
with major 
causes of disease 
or injury as a 
valid basis for 
conclusions 
regarding future 
health 
expenditure in 
Australia; 
Total health 
expenditure 
2002-
2032 
Macro-simulation 
(Separate projections 
were calculated for 
important health 
conditions by type of 
expenditure (hospital care, 
medical services, 
pharmaceuticals, aged 
care homes and other 
health services)) 
US 
Expected 
changes in the 
number of 
affected cases, 
the proportion 
of cases treated, 
the volume of 
health services 
per treated case 
and excess 
health price 
inflation  
Background 
paper for the 
UN World 
Economic 
Social Survey 
(2007) 
    
Total health expenditure in 
Australia will grow by 0.5% 
greater than growth in the 
economy, to 10.8% of GDP 
in 2032–33. Population 
ageing will account for 
32.3% of this growth; and 
non-demographic factors 
(excess price inflation, 
treatment proportion and 
volume per case) a further 
36.5%. 
Boyle et al. 
(2010): Burden 
of diabetes 
To provide 
contemporary, 
realistic 
estimates of the 
growth of the 
national diabetes 
burden; a formal 
projection of 
costs is beyond 
the scope of this 
analysis;  
National 
burden of 
diabetes  
2010-
2050 
Individual model; 
Currently Macro-modelling 
with Hare et al.; Disease-
specific (diabetes); a series 
of dynamic models that 
consisted; of systems of 
difference equations in 
time; (three-, four-, and 
five-state models); GAUSS 
software; More of a health 
projection model;  
US 
The time-varying 
transition matrix 
that 
differentially 
allotted 
population into 
states of normal 
glucose 
tolerance, 
prediabetes, and 
undiagnosed 
diabetes/diagno
sed diabetes;  
1. people 
cannot move 
from diabetes 
to 
nondiabetes; 
2. the relative 
risks of death 
for the two 
diabetes 
states versus 
the no 
diabetes state 
are constant 
over time, i.e. 
no time 
variation; 3. 
the transition 
rates to 
diagnosed or 
undiagnosed 
diabetes for 
nondiabetics 
are constant 
multiples of 
US Census 
Bureau and 
the Centers 
for Disease 
Control and 
Prevention 
(CDC) 
  
All four model scenarios 
indicate at least a doubling, 
and in some cases an even 
greater increase, in the 
number of people with 
diagnosed diabetes from 
2010 through 2050. 
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the transition 
rate to 
diagnosed 
diabetes for 
undiagnosed 
diabetics. 
Caley and 
Sidhu (2011) 
To describe a 
methodology 
that can be easily 
applied to 
estimating future 
healthcare costs 
using routinely 
available data 
that takes into 
account both 
increases in costs 
in the years 
before death and 
morbidity 
compression 
Global 
healthcare 
demand 
2006-
2031 
Macro model (indiv) UK Time to death 
Compression 
or expansion 
of morbidity 
Department 
of Health 
data; Office 
for National 
Statistics 
data;  
i) 
Compression
/Expansion of 
morbidity, 
and ii) 
Proximity to 
death taken 
into account,  
Models with different 
assumptions resulted in 
markedly different 
estimates of future costs. 
The increases in healthcare 
costs in the final years of 
life and morbidity 
compression/expansion are 
fundamental and have a 
large effect on costs.  
CBO - the 
Congressional 
Budget 
Office’s 
(CBO’s) long-
term model, 
CBOLT 
The model 
developed over 
2001-2009 is 
used to analyse 
the budgetary 
and distributional 
effects of the 
Social Security 
programme and 
other federal 
policies and 
programmes, to 
evaluate 
potential reforms 
to federal 
entitlement 
programmes, and 
to quantify the 
nation's long-
term fiscal 
challenges. 
National long 
term care 
expenditures 
(Medicare, 
Medicaid, 
Private Long-
Term Care 
Insurance, 
Out of 
Pocket, Other 
Payer) 
Long 
term 75 
year 
projectio
ns 
CBOLT itself is a 
microsimulation model 
which can generate 
distributional outcomes, 
however, projections of 
health-care spending were 
made at an aggregated 
level in its actuarial section 
(macro-simulation) 
US 
Excess health 
cost growth; 
economic 
growth; age 
composition of 
the population 
   
Various scenario analyses 
are available using the 
micro-simulation model; 
Distribution effects can be 
examined 
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Colombier and 
Weber (2011) 
To examine the 
impact of 
population 
ageing on 
healthcare 
expenditure 
Health and 
long-term 
care 
expenditure 
2004-
2050 
HC expenditures are 
decomposed by age 
groups, gender and 
services, i.e. LTC and HC. 
The decomposition of HC 
expenditures results in 
four different expenditure 
profiles. These profiles 
encompass the per capita 
expenditure of men and 
women by age group for 
HC and LTC.  
Switzerlan
d 
Age; Proximity 
to death; 
Medical 
progress;  
No policy 
change is 
taken into 
account; real 
wage growth 
corresponds 
to labour 
productivity 
growth of the 
economy; 
productivity 
growth (v) to 
be equal to 
1% 
      
COMPACCS 
model (Angus 
et al. 2000) 
To estimate the 
future demand 
for critical care 
and pulmonary 
services 
Demand and 
supply of 
intensivists 
(demand as 
physician-
per-
population 
ratios) 
  
The three major 
components of the model 
are 
• Population projections 
by age,42 sex, and 
metropolitan/non-
metropolitan location; 
• Projected insurance 
distribution by insurance 
type, age, sex, 
metropolitan/nonmetropo
litan location; and 
• Detailed physician-to-
population ratios. 
US   
The 
COMPACCS 
study starts 
with the 
assumption 
that in the 
base year 
(1997) 
intensivist 
supply and 
demand are 
in 
equilibrium. 
    
COMPACCS estimated a 
shortage in the number of 
available intensivist hours 
of care equal to 22 percent 
of demand by 2020 and 35 
percent by 2030.16 In their 
analysis, the shortage 
became more severe if the 
demand for intensivist care 
was extended to a greater 
proportion of ICU patients. 
Alternative scenarios 
modeling changes in the 
variables affecting demand 
for critical care services, 
including greater managed 
care penetration, had little 
impact on this shortage. 
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Desai et al. 
(2008) 
To project the 
demand for older 
people’s services 
over the next 5 
years, and 
calculate the 
impact this would 
have on the 
service provision 
required; to test 
the effectiveness 
of different 
interventions 
Future 
demand for 
older 
people's 
services 
(numbers of 
initial 
contacts, 
numbers of 
service 
recipients, 
numbers of 
care 
packages, 
etc.) 
2006-
2011 
Macro-modelling (System 
Dynamics (SD) simulation 
model (NOT a micro-
modelling)); Individual 
model;  
UK 
Age of clients; 
whether client's 
initial referral is 
from an acute 
NHS setting or 
elsewhere; 
Whether the 
client was 
initially assessed 
as having a 
critical or 
substandtial 
level of need;  
Due to the 
frequent 
movements 
of clients, 
age-group 
changing was 
not 
incorporated 
in the 
demand side 
model;  
  
Influences' 
were 
changed to 
test different 
scenarios; 
Changes in 
rate of client 
inflow; 
Population 
increases/dec
reases;  
As anticipated the numbers 
requiring care will increase 
over the next 5 years, 
particularly among clients 
aged over 85. The effects 
of two possible 
interventions were 
explored and demonstrate 
that providing care to 
critical clients only will 
reduce the numbers 
receiving care. However, a 
decrease in the number of 
substantial clients does not 
lead to the same 
percentage decrease in the 
number of care packages. 
DG-ECFIN 
Ageing Reports 
- European 
Commission 
(EC) 
To provide 
objective, reliable 
and comparable 
information on 
possible 
challenges to 
fiscal 
sustainability of 
EU countries in 
relation to 
population 
ageing. 
Aggregate 
health and 
long term 
care 
expenditure, 
and other 
public 
expenditures. 
up to 
2060 
Macro-simulation EU 
Macro-
economic: 
labour 
productivity and 
potential 
economic 
growth; new 
technologies and 
medical 
progress; 
institutional 
features of the 
health system;  
  EUROPOP 
Scenarios 
added to the 
2009 report: 
Non-
demographic 
determinants 
scenario: 
using 
econometric 
estimates; ii) 
Decomposed 
indexation 
scenario: 
input specific 
indexation 
(unit cost) 
Limited growth in total 
population size together 
with a growing proportion 
of elderly will lead to ever 
higher demand for 
healthcare; Developments 
in medical technology will 
require further investment, 
but may pay off over the 
medium and long term; 
Persisting high 
discrepancies in healthcare 
provision across EU states 
will exert additional 
pressure on public 
expenditure in countries 
offering the narrowest and 
incomplete coverage to 
their citizens.  
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ENEPRI - AIM 
(semi-
aggregate 
model) - 
Ferraresi & 
Monticone 
(2009 - ENEPRI 
No. 62); Soede 
et al. (2004) 
To project public 
expenditure on 
pensions and 
other social 
benefits, and 
produce a 
sustainability 
indicator (Not 
necessarily 
project 
healthcare 
expenditure, but 
may inform the 
projection 
methods) 
Aggregate 
projections of 
social 
protection 
expenditures; 
Semi-
aggregate 
projections of 
income 
sources by 
age class and 
gender; an 
indicator of 
the pension 
system 
sustainability 
up to 
2050 
Semi-aggregate approach 
(some features of the 
multistate approach as 
well as the aggregate 
models); Social projection 
expenditures were 
computed as the project 
of the number of 
recipients times the 
average amoung of each 
benefit.  
EU 
Stylised 
parameterisatio
n of national 
economic and 
institutional 
features;  
Conservative 
assumptions 
regarding 
future 
migration 
flows; Interest 
rate (short 
term real ) 2% 
for all 
countries and 
all periods; 
Debt to GDP 
ratio Constant 
for the whole 
projection 
period; All 
income 
sources/avera
ge benefit in 
each category 
are assumed 
to grow for 
each 
age/gender 
class 
according to 
labour 
productivity;  
ECHP and 
SHARE; 
Europop 
2004 
i.  Lisbon 
scenario 
(unrealistic): 
70% for total 
employment, 
60% for 
female 
employment; 
50% for 
middle-aged 
(55-64) 
employment; 
Sensitivity 
analysis on 
demographic 
projections; 
Sensitivity 
analysis on 
old-age 
benefits 
level;  
the increase in social 
spending is evident in 
many countries. The 
increase in employment 
and the recent reforms are 
at least partially able to 
offset the rise in public 
pensions expenditure. 
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ENEPRI AGIR 
project 
(Westerhout 
and Pellikaan 
2005) 
To assess the 
implications of 
population 
ageing for acute 
healthcare, LTC, 
and public 
pension 
expenditure for 
15 EU countries; 
Age-specific 
prevalence 
rates, 
average 
length of 
hospital stay, 
average 
number of 
contacts with 
a doctor;  
  Macro-simulation EU 
Time trend of 
age profile of 
health 
expenditure 
included;  
  
Main 
projection 
by DIW 
(German 
Institute for 
Economic 
Research); 
EU- EPC 
Eurostat 
datasets for 
population 
figures; 
Utilisation 
data from 
ECHP 
(European 
Community 
Household 
Panel); 
    
ESRI’s HERMES 
model of the 
Irish economy 
(Layte et al. 
2009) 
To apply the 
demographics 
projections from 
HERMES to the 
patterns of 
healthcare 
utilisation and 
growth trends; 
Overall 
population 
changes; 
Acute public 
hospital 
services; GP 
utilisation; 
Outpatient 
services; 
Long-term 
health and 
social care 
services; 
2006-
2021 
Macro-simulation; 
HERMES - population 
projection model;  
Ireland 
Population 
health status; 
Technological 
change in health 
care; Changing 
demand; the 
availability and 
supply of care; 
Health care 
policy;  
The rate of 
improvement 
in mortality 
will slow 
down to a 
long-run 
average rate 
of 1.5 per 
cent; Age-
specific 
fertility rates 
change at an 
equal rate for 
each age 
group, which 
preserves this 
pattern.Patter
ns of referral 
between 
hospital 
networks do 
not change;  
Hospital In-
Patient 
Enquiry 
System data;  
  
While there are 
undoubtedly benefits to an 
integrated model of health 
care provision as proposed 
by the HSE, reducing the 
over-reliance on hospitals 
inherent in the Irish health 
care system will be a 
challenge not only for the 
acute public hospital sector 
but for the health care 
system as a whole. 
439 
 
Feenstra/ 
Struijs (multi-
state life table 
method) 
(earlier model: 
Feenstra et al.) 
to estimate 
expected 
increase in 
stroke/COPD 
patients in the 
Netherlands;  
The future 
burden of 
stroke in the 
Netherlands 
in terms of 
the 
incidence, 
prevalence, 
and potential 
years of life 
lost (PYLLs); 
1995-
2015 
(COPD); 
2000-
2020 
(Stroke) 
Macro-modelling (dynamic 
multi-state life table 
method); prevalence 
projections were 
combined with age-
specific information on the 
use of health care in 
physical units and the unit 
costs of care; Transition 
probabilities, Markov 
property;  
The 
Netherlan
ds 
trends in 2 major 
risk factors for 
stroke, ie, 
hypertension 
and smoking;  
Cost 
projections 
assumed 
constant 
prices and 
constant 
treatment 
patterns; 
Markov 
property: 
conditional on 
sex, age, and 
risk factor 
class, the 
model states 
1 year ahead 
are 
independent 
of the past 
model states; 
Conditional 
independence
: Conditional 
on the risk 
factor class, 
disease 
incidence and 
mortality 
rates are 
assumed to 
be mutually 
independent;  
GP 
registration 
data; Data 
provided by 
the 
Foundation 
for Smoking 
and Health; 
The Dutch 
1993 cost of 
illness study; 
The Dutch 
Ministry of 
Health data; 
Struijs et al. 
(2005): i) A 
demographic 
scenario, in 
which the 
future 
prevalence 
depends only 
on 
demographic 
changes. ii) A 
hypertension 
scenario, in 
which the 
incidence 
rates depend 
on past 
trends in the 
prevalence of 
hypertension. 
iii) A smoking 
scenario, in 
which 
incidence 
rates depend 
on the trend 
in smoking 
prevalence. 
iii) A 
combined 
hypertension 
and smoking 
scenario 
For the medium term, the 
increase in prevalence is 
marginally explained by 
expected changes in 
smoking behavior and 
changes in the prevalence 
of hypertension. Despite 
the conclusion that a large 
part of the increase in 
stroke/COPD patients is 
inevitable, the authors 
believe more attention 
should be paid to primary 
prevention and successful 
efforts to reduce smoking 
in society as a whole can 
reduce prevalence 
substantially in the long 
run. 
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Fox et al. 
(2001) 
To estimate the 
current and 
projected 
economic burden 
of caring for 
community 
resident and 
institutionalised 
people with 
Alzheimer 
disease in 
California 
Disease-
specific 
(Alzheimers 
disease) 
2000-
2040 
Macro model US 
Per capita costs 
of care and the 
number of 
people with AD 
only 
10% AD 
prevalence 
rate for 
people aged 
65+;  
  None 
With projected increases in 
the number of persons at 
risk of developing AD in 
California, the economic 
impact of the disease in the 
future will be substantial. 
The amount of informal 
care provided is not 
significantly affected by the 
level of formal care 
received 
Gerdtham 
(1993) 
To estimate the 
impact of 
population 
ageing in Sweden 
Healthcare 
expenditure 
1985-
2005 
Macro modelling (+other 
statistical analyses); 
Individual model (not 
related to the OECD 
statistical analysis); 
Sweden Age structure       
The impact of changing 
population age structure 
on health spending has 
been 
modest. 
Hare et al. 
2009 model 
1. the number 
and age 
distribution of 
potential clients 
and Age 
dependent entry 
rates are then 
applied to 
determine the 
number of 
potential clients 
at each state; 2. 
Transitions 
between client 
groups and exits 
from the model 
are computed.  
The number 
of clients of 
each age 
group for 
eight 
different 
home care 
and 
community 
care services  
  
Macro modelling 
(deterministic multi-state 
model: between macro 
and micro?)  
Canada   
British 
Columbia 
model 
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IIASA social 
security model 
(MacKellar et 
al. 2004) 
To investigate 
economic 
impacts of 
demographic 
trends and 
structures, and 
associated 
uncertainties, in a 
globally 
consistent 
macroeconomic 
framework; To 
study linkages 
between 
population 
dynamics, the 
macro-economy, 
the pension and 
healthcare 
systems and 
intergenerational 
distribution; 
HCE is not 
the main 
projection 
outcome;  
  
Stat modelling (Economic 
demographic growth 
model (stock-flow 
model)): The model is built 
within the macro-
economic framework 
using production function, 
etc. It tracks income, 
expenditure, and assets of 
each single-year cohort as 
it ages. (HC module & LTC 
module); Uses the partial 
equilibrium approach to 
obtain the model 
estimates.  
Japan 
Capital, 
production, 
labour force and 
employment,  
HC/LTC as 
part of social 
expenditure 
    
 The relative robustness to 
changes in demographic 
assumptions indicates that 
among the many sources of 
uncertainty regarding the 
impact of population aging 
on Japan, uncertain 
demography probably 
ranks rather low. 
Iwamoto & 
Fukui (2009) 
To provide long-
term outlook of 
social security 
financing 
problem in Japan; 
To examine the 
effect of social 
security system 
reforms; 
Future social 
security costs 
(including 
pension, 
healthcare, 
welfare, and 
long term 
care) 
2005-
2105 
First, per capita health 
care costs by age group 
were proportionally 
adjusted so that the 
national aggregate of the 
costs matches the figure 
reported in the Medical 
Information Analysis 
System (MEDIAS). The 
national aggregate of the 
health care costs was 
calculated as the product 
of population and per 
capita costs by age group. 
Similarly, the rescaled age-
cost profile was used to 
project future health care 
costs.  
Japan Age only 
LTC: Per 
capita long-
term care 
costs by age 
group would 
increase 1.2% 
faster than 
wages; 
Medical 
Information 
Analysis 
System 
(MEDIAS); 
FY2004 
National 
Medical 
Expenditure 
(MHLW); 
Monthly 
Reports of 
Long-Term 
Care 
Benefits 
provided by 
MHLW;  
Policy 
simulations: a 
balanced 
budget 
scheme (pay-
as-you-go 
scheme) & 
prefunding 
scheme to 
equalise the 
intergenerati
onal burden; 
The introduction of a 
'funded' insurance system 
may be worth discussing to 
correct the 
intergenerational 
inequality in burdens; 
Simulations using updated 
population projections 
show that the insurance 
premium would raise the 
peak premium. However, 
the premium increase 
during the transition to the 
pre-funded system would 
be small, indicating the 
system change would 
absorb some of the risks 
from demographic 
fluctuations. 
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Joyce et al. 
(2003) 
  
GP services 
only 
  
Macro-simulation 
(Method used in Denton 
et al. 2000) 
AUS 
Trends in service 
use 
  
Health 
Insurance 
Commission 
on GP 
services; 
Australian 
Bureau of 
Statistics 
(ABS 2000, 
2001, 2002) 
    
Karlsson et al. 
2006; 
Rickayzen and 
Walsh 2002; 
To estimate 
future costs for 
long term care 
for older people 
in the UK 
Long term 
care costs 
2000-
2050 
Macro-simulation (Based 
on multi-state disability 
projection model) 
UK LTC 
model 
Prevalence of 
disability;  
Current 
patterns of 
informal care 
provision do 
not change in 
the future; 
Prices of LTC 
services 
increase in 
line with 
general 
earnings; 
Trends in 
dependency 
and 
demography 
are the main 
drivers of LTC 
expenditure;  
  
Various sets 
of 
assumptions 
on trends in 
healthy life 
expectancy 
data 
(mortality, 
disability 
rate, etc.) 
The demand for long-term 
care will start to increase 
considerably about 10 
years from now, and reach 
a peak somewhere after 
2040. The most important 
increase will be in informal 
care, since the number of 
older recipients is 
projected to increase from 
2.2 million today to 3.0 
million in 2050. 
Kildemoes et 
al. (2010) 
To develop a 
method for 
projecting the 
impact of ageing 
and changing 
drug utilization 
patterns on 
future drug 
expenditure 
Drug 
expenditure 
only 
2006-
2015 
Macro modelling (semi-
Markov model); Similar to 
multi-state model; 
Individual model;  
Denmark 
Age and gender, 
changing drug 
utilisation 
patterns 
    
1. 
Extrapolation 
of the 
historical 
trends 
observed 
during 2000-
2005; 2. 
Parameters 
fixed at 2005 
values. 
Increasing treatment 
prevalences with three 
cardiovascular drug 
categories are likely to 
pose substantial burden on 
future healthcare 
resources. Yet, treatment 
incidence is likely to 
depend upon decisions 
internal to the healthcare 
system (e.g. guidelines).  
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VHA LTC 
Planning 
Model 
(Version 2.2); 
LTC Policy 
Model 
(Version 3.1) – 
Kinosian et al. 
(2007) 
To describe the 
projected use for 
long-term-care 
services through 
2012 
Long term 
care service 
use 2002-
2013, Nursing 
home use for 
enrolled 
veterans, 
Medicaid 
home and 
community 
based (HCBS) 
use; 
2012 
The projection took the 
cell-specific rate and 
applied it to the 
age/gender/marital 
status/disability class–
specific enrolled veteran 
population projected for 
that year to produce the 
ADC for nursing home and 
HCBS use; 
US 
age/gender/mari
tal 
status/disability 
class 
the decline in 
disability from 
the 2002 level 
is at the same 
rate as the 
observed 
mortality 
decline—
approximatel
y 0.6% per 
year. 
Veterans 
Health 
Administrati
on (VHA); 
For service 
use rates 
from the 
1999 
National 
Long-Term 
Care Survey 
and the 
2000 
National 
Health 
Interview 
Survey 
  
Projected use for long-
term-care services will 
grow substantially over the 
next decade, by 22% and 
24% for nursing home and 
HCBS services, respectively. 
Lagergren 
(2005) - ASIM 
III-model  
To provide 
estimates on the 
amount of public 
long term care 
services provided 
per age group, 
gender, marital 
status and degree 
of disability both 
retrospectively 
for the period 
1985-2000 and 
prospectively 
according to the 
same terms for 
the period 2000-
2030. 
Total annual 
long term 
care costs; 
Number of 
persons per 
level of 
services. 
2000–
2030 
Macro modelling; (the 
ASIM III-model consists of 
two parts: a retrospective 
part and a prospective 
part. The model involves a 
sub-division of the 
Swedish population 65 
years and above into 
subgroups according to 
age, gender, civil status 
and degree of illness. The 
number of persons that 
receive public LTC services 
for each subgroup. Then, 
multiply the estimated 
number of persons each 
year with the respective 
proportion of persons 
receiving services on the 
respective levels in the 
year 2000 as calculated in 
the retrospective part of 
the model. 
Sweden 
age, gender, civil 
status (with or 
without spouse, 
and degree of ill-
health 
Health trends 
will remain up 
to the year 
2030; the 
proportion of 
persons, per 
age group, 
gender, civil 
status and 
degree of ill-
health, 
receiving 
services on 
the respective 
levels remains 
unchanged at 
the year 2000 
level. 
SNAC 
(Swedish 
National 
Study on 
Ageing and 
Care); 
Swedish 
National 
Survey of 
Living 
Conditions 
(ULF) - for 
prevalence 
of ill-health;  
continued 
positive ill-
health trends 
until 
2010/2020; 
constant 
prevalence of 
ill-health 
The wide range of results 
produced by alternative 
assumptions show that an 
effective preventive health 
policy aimed at the older 
persons is crucial. (In the 
most pessimistic scenario D 
the projected cost increase 
in fixed prices during the 
period amounts to 69%—in 
the most optimistic 
scenario 0 the cost increase 
stays at 25%.) 
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Lee and Miller 
(2002) 
To quantify 
uncertainty in 
forecasts of 
health 
expenditures 
    
Macro-simulation (simple 
accounting model: the 
sum of the number of 
people in a given health 
status times the annual 
spending associated with 
that status) 
US 
Age, time to 
death 
Assume that 
the schedule 
of spending 
by time until 
death has a 
fixed shape, 
and that the 
level of 
spending by 
time until 
death is 
determined 
by multiplying 
this fixed 
schedule by a 
shifting index 
of spending 
    
Medicare expenditures are 
currently 2.2 percent 
ofGDPin the United States. 
We project them to rise to 
8 percent of GDP by 2075. 
There is substantial 
uncertainty about the 
future course of mortality 
decline. Demographic 
uncertainty has very little 
effect on the probability 
bounds for the forecast for 
the first forty years or so; 
only uncertainty about 
spending-per-beneficiary 
matters over this period. 
Madsen, 
Serup-Hansen 
Danish model 
– Serup-
Hansen et al 
(2002); 
Madsen et al 
(2002); Polder 
et al (2006) 
To project future 
costs of hospital 
in-patient care 
and primary 
healthcare 
services in 
Denmark. 
Future costs 
of hospital in-
patient care 
and primary 
healthcare 
services 
1995-
2020 
Macro modelling (cohort 
components method to 
project demographic 
changes); Total costs for a 
given age-group  = averate 
cost per person per year 
for this group multiplied 
by the number of persons 
within the group (macro-
method); 
Denmark/ 
The 
Netherlan
ds 
  
Constant 
average costs 
of use of 
primary 
health care 
services 
during the 
period 1995–
2020;  
    
Madsen et al. (2002): 
Ageing as well as costs in 
the last year of life appear 
to have almost no effect on 
future costs of primary 
health care services. 
Hence, the future costs of 
primary care providers (but 
excluding drugs, nursing 
homes, etc.) appear to be 
determined largely by 
population size and not by 
ageing. A rather different 
conclusion in Serup-Hansen 
et al. (2002) is that: The 
high costs in the last year 
of life does matter in 
projections of future costs 
of hospital in-patient care 
and primary care services. 
Furthermore, ageing per se 
seems to have 
considerable impact.  
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Martini and 
Garrett (2007) 
model 
HC demand 
projection 
  
2000-
2050 
Macro-simulation (Cell-
based: MPC-specific age 
and gender per capita cost 
rates using 
cross-sectional data for 
2002–2003 and projects 
U.S. changes by MPC due 
to aging) *Major Practice 
Categories 
US Age and sex   MEPS   
total U.S. per capita costs 
due to aging from 2000 to 
2050 are projected to 
increase 18 percent (0.3 
percent annually), the 
impact by MPC ranges 
from a 55 percent increase 
in kidney disorders to a 12 
percent decrease in 
pregnancy and infertility 
care. Over 80 percent of 
the increase in total per 
capita cost will result from 
just seven of the 22 total 
MPCs. 
Mendelson 
and Schwartz 
(1993) 
To estimate the 
effect of 
demographic 
changes on past 
and future costs 
using existing 
secondary data 
and a series of 
models; 
Annual % 
contribution 
of ageing and 
population 
growth to the 
rise in costs 
1990-
2005 
Simple macro model   
Macro model by 
age group only 
The relative 
expense of 
treating each 
age group, 
observed in 
1987, will 
remain 
constant over 
time. 
Health Care 
Financing 
Administrati
on (HCFA) 
  
In the acute care sector, 
aging and population 
growth accounted for 
roughly 20 percent of the 
real rise in costs; in long-
term care, roughly 35 
percent. There has been a 
steady reduction in the 
contribution of aging and 
population growth (taken 
together) to the rise in 
costs in both the acute care 
and long-term care sectors 
between 1975 and 1990.  
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New Zealand 
MoH model – 
Frizelle (2005); 
Ministry of 
Health, New 
Zealand 
(2004); 
To develop 
projections of 
health 
expenditure over 
the next 50 years; 
To examine 
whether 
improvements in 
health status can 
offset the impact 
of population 
ageing;  
Total 
healthcare 
expenditure 
2002-
2051 
Macro-simulation (cell-
based): the model 
simulates the NZ 
population (disaggregated 
by age and sex) over 2002-
2051. The model consists 
of 'population' component 
and 'cost' component; 
Individual model 
New 
Zealand 
Age, gender, 
health status, 
mortality, 
disability, 
growth in 
coverage and 
prices, growth in 
GDP per worker;  
Central 
assumptions: 
Government 
expenditure 
as a 
proportion of 
GDP increases 
by 50% from 
6.2% to 9.2%;  
    
Under ‘central’ 
assumptions 
· % GDP spent on health 
will increase from 6% to 
9%. 
· Older people’s share of 
health expenditure will 
increase from 40% to 63%, 
yet the ratio of spending 
on the average older 
versus younger person will 
decrease (by approximately 
25%). 
· Growth in coverage and 
prices, not population 
ageing, will continue to be 
the key driver of health 
expenditure. 
· However, ageing will 
increase upward pressure 
on spending (especially 
from about 2026). 
· Yet relative compression 
of morbidity (if it can be 
achieved) will reduce 
lifetime healthcare costs 
and so ease ageing 
pressure on health 
spending, constraining 
total health expenditure 
growth (by up to 30% of 
what it would otherwise 
have been). 
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OECD & EU-
EPC (Dang et 
al. 2001) Dang 
et al. 2001; 
Economic 
Policy 
Committee of 
the EU (2000); 
EU EPC (2001, 
2003); Bains 
and Oxley 
(2004); 
To project age-
related public 
spending; To run 
projections of 
public 
expenditure on 
health and long 
term care in 
order to assess 
the impact of 
ageing 
populations on 
future 
expenditure 
levels; 
International 
comparison of 
future 
expenditures;  
Aggregate 
health and 
long term 
care 
expenditure, 
and future 
burden for 
public 
finances. 
2000-
2050 
Macro-simulation (EPC 
(2001): Age- and sex-
related expenditure 
profiles were matched to 
demographic projections 
for future years); Most 
recent estimates of per-
capita health costs by age 
group were multiplied by 
the number of individuals 
in each age group in 2000 
(base year)) 
EU, OECD 
countries 
Age and sex; 
(Not modelled 
are diffusion of 
medical 
technology, 
relative prices 
for medical 
inputs, the 
intensity of care 
and 
concentration of 
health 
expenditures at 
the end of life) 
No detailed 
account of 
modelling 
methods; 
(EPC 2001) 
Cost 
assumptions - 
1. per-capita 
expenditures 
grow at the 
same rate as 
GDP per 
capita, 2. per-
capita 
expenditures 
grow at the 
same rate as 
GDP per 
worker.  
Member 
states' own. 
  
(EPC 2001) Total HC & LTC 
increase in expenditure 
in % of GDP: +1.8-+2.5 
(UK), +2.2-+2.7 (EU); Main 
conclusion: the impact of 
ageing on public 
expenditure onm health 
and long term care is likely 
to be significant. The 
consequences of 
demographic changes in 
terms of increase public 
expenditure would range 
from 1.7 to 3.9 % points of 
GDP. The largest part of 
this increase would come 
from expenditures on LTC.  
Polder et al. 
(2002): Dutch 
projections 
To describe the 
age pattern of 
health care costs, 
to analyse the 
age-specific cost 
changes and to 
project future 
healthcare costs 
in an ageing 
population 
National 
healthcare 
costs 
projections 
(acute care, 
long-term 
care) 
2015 Macro modelling 
EU (The 
Netherlan
ds) 
Age and sex only 
Age-specific 
1988-1994 
trends in 
acute and 
long term 
care costs 
persist in 
future 
decades. 
Cost of 
illness data 
from the 
Ministry of 
Health, 
Netherlands
; Probability 
distributions 
of key 
variables 
were 
derived 
from sector-
specific 
registries 
and sample 
surveys 
No scenario 
analyses 
The share of the elderly in 
total healthcare costs will 
increase. Ageing as well as 
technological and 
epidemiological changes 
reinforce the age pattern in 
HCE. The influence of HC 
policy seems to be 
relatively large, larger in 
LTC than in acute care. 
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Polder et al. 
(2006) - 
Cohort 
component 
model 
(1) To estimate 
health care costs 
in the last year of 
life in the 
Netherlands; (2) 
to describe age 
patterns and 
differences 
between causes 
of death for men 
and women; (3) 
To compare cost 
profiles of 
decedents and 
survivors; and (4) 
to use these 
figures in 
projections of 
future health 
expenditure. 
Healthcare 
costs in the 
last year of 
life 
1999-
2020 
Macro modelling (cohort 
components method): We 
used life tables (Siegel & 
Swanson, 2004) for 
the Dutch population 
(Statistics Netherlands, 
2005) to estimate 
expected lifetime health 
care costs from birth until 
death according to 
mortality rates in 1999 
and 2020. Using 
population forecasts of 
Statistics Netherlands (de 
Jong, 2003) in a simple 
cohort-component 
method  
The 
Netherlan
ds 
Time to death; 
Population 
growth; 
Changing size of 
birth cohorts, 
mainly the 
ageing baby-
boom 
generation; 
Changing 
mortality 
resulting in 
higher life 
expectancy and 
higher health 
expenditure for 
survivors;  
  
Health 
insurance 
data 
representing 
13.4% of the 
whole Dutch 
population. 
  
11.1% of total expenditure 
of the included health 
services is estimated to be 
assigned to people in their 
last year of life. In a model 
in which lifetime expected 
costs comprised different 
estimates for the last year 
of life and all other years, 
the estimated growth rate 
of health expenditure is 
substantially lower 
compared to standard 
projection methods (9.3% 
for total expenditure,  
13.0% for per capita 
expenditure and  25.8% if 
only the effect of increased 
longevity and 
postponement of death 
were taken into account). 
Future expenditures are 
affected by a lot of other 
factors.  
PSSRU Long 
Term Care 
model for 
older people 
(Wittenberg 
2006, other 
PSSRU papers) 
Comas-
Herrera et al 
(2001, 2003, 
2006, 2007, 
2011); 
(PSSRU1) 
To make 
projections of the 
future numbers 
of disabled older 
people, the likely 
level of demand 
for LTC services 
and disability 
benefits for older 
people, the costs 
associated with 
meeting this 
demand and the 
social care 
workforce 
required. To 
study long term 
care finance 
Numbers of 
disabled 
older people, 
likely level of 
demand and 
disability 
benefits, 
costs of 
meeting 
demand. 
Up to 
2040 or 
2050 
Macro-simulation (the 
model divides the 
population into 1000 cells) 
UK Disability level;  
Constant ratio 
of 
single/marrie
d people 
living alone to 
single/marrie
d people 
living with 
their children 
or others; 
Prevalence 
rates of 
disability by 
age and 
gender 
remain 
unchanged; 
the 
2001/2 
General 
Household 
Survey; 
PSSRU 
surveys of 
residential 
care;  
Trends in 
functional 
disability; 
Availability of 
informal 
care; Future 
patterns of 
care; Unit 
costs 
development 
The numbers of disabled 
older people requiring LTC 
will rise significantly; 
Projections are sensitive to 
assumptions; Policy makers 
need to plan for 
uncertainty in future 
demand for LTC; Need to 
promote measures likely to 
reduce disability in old age; 
A substantial expansion of 
non-residential services will 
be required. 
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(funded by the 
UK Department 
of Health) 
proportions 
of people 
receiving 
informal care, 
formal 
services, 
residential 
care, and 
disability 
benefits 
remain 
constant; 
Health and 
social care 
unit costs rise 
by 2% per 
year in real 
terms;  
450 
 
PSSRU Social 
care projection 
model for 
younger adults 
Wittenberg et 
al (2008); Snell 
et al.(2011) 
To make 
projections of the 
future numbers 
of disabled 
younger adults 
and the likely 
level of demand 
for LTC services 
and disability 
benefits for 
younger adults; 
Numbers of 
disabled 
younger 
adults; 
Numbers of 
service 
recipients; 
Public 
expenditure 
on social 
services for 
younger 
adults; 
Numbers of 
staff 
providing 
social care for 
younger 
adults; 
2005-
2041 
Macro-simulation (an 
adapted version of PSSRU 
LTC model for older 
people) 
UK 
Disability; Unit 
cost of care;  
Similar to the 
model used in 
Wittenberg et 
al (2006) for 
older adults; 
Marital status 
rates for 
physically 
disabled 
younger 
adults change 
in line with 
ONS 2008- 
based marital 
status and 
cohabitation 
projections 
(ONS, 2010), 
while those 
for learning 
disabled 
people 
remain 
constant; The 
supply of 
formal care 
will adjust to 
match 
demand; The 
real unit costs 
of social 
services and 
of ILF 
payments 
remain 
unchanged to 
2015 and rise 
by 2% per 
year in real 
terms 
thereafter; 
Family 
Resource 
Survey 
(1996/7); 
Emerson et 
al. (2005) for 
disability 
prevalence; 
Tribal Secta 
data 
provided by 
Department 
of Health, 
UK; PSS 
Expenditure 
data 
(2005/6) for 
unit costs; 
(Updated 
data were 
used for 
Snell et al. 
(2011) 
study); 
Changes in 
assumptions 
on overall 
number of 
people aged 
18-64, 
prevalence of 
disability, 
unit costs of 
services, and 
funding 
scenarios 
The updated study by Snell 
et al. (2011) showed that 
the number of learning 
disabled youner people 
would rise by 32.2% and 
the number of physically 
and sonsorily impaired 
younger people would risd 
by 7.5% between 2010-
2030 ; Net expenditure on 
social care (net of user 
contributions) is projected 
to rise by 66.6% from £6.8 
bn. to £11.3 bn between 
2010-2030; The sensitivity 
analysis demonstrated the 
projections are sensitive to 
changes in those 
assumptions. This meant 
that the projections should 
not be regarded as 
forecasts of the future. The 
projections are not the 
total costs to society of 
long-term care for younger 
adults. That would require 
inclusion of the costs of a 
wider range of services to a 
wider range of public 
agencies and service users 
and the opportunity costs 
of informal care. Also, no 
allowance has been made 
for changes in public 
expectations about the 
quality, range or level of 
care. 
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Reuben et al. 
(1993) 
To estimate the 
number of full-
time-equivalent 
(FTE) physicians 
and geriatricians 
needed to 
provide medical 
care 
Physician 
supply based 
on service 
utilisation 
estimates (in 
terms of 
ambulatory 
care, nursing 
home visits, 
and hospital 
visits per 
year) 
2000-
2030 
Macro modelling 
(Individual model): The 
model stratifies the 
population into two 
subgroups: 
institutionalised and non-
institutionalised, and 
these were sub-divided by 
age and functional status. 
US   
Economic 
growth;  
1985 
National 
Ambulatory 
Care Survey 
(NAMCS), 
1986 
Medicare 
Data Tapes, 
1984 
National 
Health 
Interview 
Supplement 
on Aging 
(NHIS-SOA), 
AND 1985 
National 
Nursing 
Home Study 
(NNHS). 
Scenario 1: 
Moderate 
economic 
growth 
similar to the 
1970s; 
Scenario 2: 
hard times, 
Scenario 3: 
steady 
growth 5% 
per year. 
Assuming moderate 
growth similar to the 
1970s, a 39% increase in 
the total number of 
physician FTEs was 
projected by 2000. The 
total FTE geriatricians 
needed for year 2000 
ranged from 1577 
(Scenario 2) to 4176 
(Scenario 3). The range of 
the estimates suggest that 
economic forces play a 
substantial (but not 
dominant) role in the 
adquacy of physician 
supply. Population changes 
may be the major factor 
determining the manpower 
requirements for medical 
care of the aged 
Rice et al. 
1983 (U.S. 
Department of 
Health and 
Human 
Services) 
To examine the 
range of possible 
consequences for 
the health sector 
of an increasingly 
older American 
population 
Projected 
number of 
persons with 
limitation of 
activity; 
Projections of 
physician 
visits, 
hospital days 
of care, and 
nursing home 
residents;  
1983-
2003 
Macro modelling (cohort 
components method): The 
projection method used 
was the standard cohort-
component approach in 
which separate 
assumptions are made for 
future levels of the 
demographic 
components—births, 
migration, and deaths. For 
this projection method, 
each age group, or cohort, 
is followed through 
successive calendar years. 
Each age group is survived 
from one calendar year to 
the next by applying 
survival probabilities. 
US   
Age-specific 
rates of 
health 
services 
utilization are 
assumed 
to be 
constant 
throughout 
the projection 
period 
US 
Government 
data 
Mortality 
assumptions 
The aging of the population 
has a much greater impact 
on nursing home residents 
than on days of hospital 
care or physician visits. The 
amount spent on 
physicians’ services is 
projected to increase 30 to 
37 percent, from $36 
billion in 1978 to between 
$47 and $50 billion in 2003. 
However, little change will 
occur in the age 
distribution of 
expenditures, with people 
between 20 and 64 years 
of age accounting for more 
than 60 percent of the 
total. The implications of 
the aging of the population 
in the years ahead for 
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social institutions, including 
the health care delivery 
system, should be 
considered in policy 
planning. The U.S. 
population will grow more 
elderly and the need for 
health care facilities may 
well increase. 
Roos et al. 
(1998) 
To examine 
changes in the 
physician supply 
and assess the 
availability of 
physicians 
relative to 
population 
growth and 
ageing 
Physician 
supply based 
on service 
utilisation 
estimates 
  
Macro modelling 
(Individual model) 
Canada     
Canadian 
Institute for 
Health 
Information 
(CIHI) 
    
Russell 1981 
To project the 
use of medical 
care forward and 
backward (1950-
2050), to show 
the importance 
of the chang- ing 
age structure of 
the population 
for medical 
sector. 
  
1950 - 
2050 
Macro-simulation (Use 
rates for each age-sex 
group were multiplied by 
the population-actual or 
projected-in that group for 
each year, and summed to 
estimate total use.) 
US   
A slow but 
steady decline 
in mortality 
rates was 
assumed; 
Current 
differences in 
use by age 
and sex 
continue 
(fixed rates of 
use by age 
and sex);  
National 
Center for 
Health 
Statistics 
(NCHS) 
survey; 
  
Age structure is more 
important for nursing 
home care than for 
hospital care; Changes in 
the age structure of the 
population have been and 
will continue to be 
important for institutional 
care, but not for outpatient 
visits to physicians or 
dentists. 
Schneider and 
Guralnik 
(1990) 
To project future 
costs for 
Medicare, 
nursing homes, 
dementia, and 
hip fractures. 
Medicare 
expenses; 
Nursing 
home costs; 
Dementia 
and hip 
fracture costs 
1987-
2040 
Simple macro model US           
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Schofield and 
Earnest (2006) 
To develop 
models of future 
demand for 
hospital care and 
examine the 
sensitivity of the 
results to model 
assumptions 
Demand for 
public 
hospital bed-
days 
2005-
2050 
Macro-simulation (CELL-
BASED) 
AUS 
Age and 
population 
growth; Non-
demographic 
factors (policy 
changes, new 
treatment 
approaches, and 
new 
technologies) 
  
Australisan 
Institute of 
Health and 
Welfare 
(AIHW); 
Australian 
Bureau of 
Statistics 
(ABS);  
Future 
population 
growth at the 
rate 
projected by 
ABS;  
Between 2005 and 2050, 
the demand for hospital 
bed-days was projected to 
almost double, to about 30 
million bed-days in 2050. 
There will be a need for 
additional staff. It seems 
the majority of the 
efficiency gains to be made 
from policies such as early 
discharge and same-day 
treatment have already 
been obtained. Plans to 
ensure future hospital 
needs of the ageing 
population are met are 
needed now. 
Schulz, Leidl, 
Konig (2004) - 
the example of 
Germany 
To show the 
impact of the 
isolated ageing 
effect on the use 
of hospital and 
long term care in 
Germany 
Total number 
of hospital 
days; Number 
of long term 
care 
recipients;  
1998-
2050 
Macro modelling Germany 
Time to death; 
Functional 
disability; 
Informal care 
availability; 
Socio-economic 
characteristics;  
Utilisation 
rates were 
held constant 
over time;  
German 
Institute for 
Economic 
Research; 
Diagnosis 
statistics 
from Federal 
Statistical 
Office; 
Utilisation 
data from 
Busse et al. 
2002 (a 
German 
sickness 
fund) 
Constant/incr
easing life 
expectancy; 
With/Withou
t split 
between 
survivors and 
decedents;  
Although demographic 
impact on the healthcare 
system is often discussed in 
terms of cost and financial 
consdquences, the study 
shows that significant 
policy issues may emerge 
on the side of care itself. 
The impact of demographic 
chage on LTC is likely to be 
much stronger and more 
difficult to cope with, and it 
is difficult to increase the 
supply. Health policy must 
consider strategies in the 
care sectors themselves, 
and measures to reduce 
actual demand. 
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SIMPOP model 
(part of 
MAP2030 
project) Jagger 
et al. (2011) 
To examine how 
trends and 
treatments in 
multiple chronic 
conditions might 
impact on 
disability and the 
future demand 
for LTC 
The number 
of older 
people with 
disability; 
age-specific 
disability and 
disease 
prevalence;  
2010 - 
2030 
Macro-simulation: SIMPOP 
projects the number of 
older people with 
disability from two-year 
transition probabilities to 
and from disability and to 
death derived from the 
MRC Cognitive Function 
and Ageing Study (MRC 
CFAS) and then applied to 
the 1992 mid-year England 
and Wales revised 
population estimates;  
UK 
Changing 
patterns of 
chronic 
disability;  
Given the 
paucity of 
data on the 
impact of 
interventions 
on morbidity, 
a 5% change 
in the 
transition 
probabilities 
to onset of 
disability and 
to death was 
assumed;  
MRC CFAS 
1. Central 
health 
('status quo') 
scenario: 
Age-specific 
prevalence/in
cidence 
remain at 
2006 levels, 
2. Improving 
population 
health 
scenario: 
decline in risk 
factors (10% 
decrease in 
disability 
onset for 
arthritis, 
stroke, CHD 
and mild CI 
from 2012; 3. 
Continuation 
of current 
trends 
scenario: 
Current 
obesity 
trends of 1–
2% increase 
annually. 
Population ageing will 
result in an increasing 
trend in disability 
prevalence and a 
substantial increase of 
almost one million in the 
numbers of older people 
needing LTC, many of these 
being the very old with 
multiple diseases; More 
effective treatments and 
greater use of assistive 
technology are allowing 
older people to remain 
independent; Efforts 
should be made on 
prevention and slowing 
down the progression to 
disability; 
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Strunk et al. 
(2006) 
To predict how 
changes in the 
age distribution 
of the U.S. 
population will 
affect the future 
use of hospital 
inpatient 
services; Hospital 
care demand 
Hospital 
inpatient 
services 
2005-
2015 
Macro-simulation US   
Utilisation 
rate helt 
constant over 
time;  
National 
Center for 
Health 
Statistics 
(NCHS), 
National 
Hospital 
Ambulatory 
Medical 
Care Survey 
(NHAMCS) 
and National 
Survey of 
Ambulatory 
Surgery 
(NSAS). 
  
Between 2005-2015, per 
person inpatient resource 
use will increase by 7.6 
percent because of aging, 
or 0.74 percent per year. 
However, aging still 
accounts for a relatively 
small portion of the growth 
in hospital spending 
projected for the next 
decade: only 11.8 % of the 
total increase. Changing 
technology is a much larger 
factor in changes in 
treatment than population 
aging. The effect of aging 
effect on use of inpatient 
serviceswill be small, but it 
will have a larger impact on 
use by patients with certain 
types of medical conditions 
that are more 
concentrated among the 
elderly. 
The Whole 
Systems 
Partnership 
(2011) End of 
life care cohort 
model 
To provide 
simulations of 
the likely end of 
life care needs 
for a selected 
population; To 
frame discussions 
between 
strategic partners 
about the 
implications and 
alternatives in 
implementing the 
National Strategy 
for End of Life 
Care;  
the number 
of people 
whose end of 
life care 
needs will 
follow one of 
five 
trajectories 
of illness; 
Numbers of 
hospital 
admissions 
that will be 
saved from 
the 
implementati
on of the 
National EoLC 
  
Dynamic systems model 
(using iThink) Stock and 
flow approach;  
UK         
 Depends on the 
application 
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Strategy 
Tuulonen et al. 
(2009) 
(i) to create a 
structural 
simulation model 
capable of 
predicting the 
future need and 
cost of eyecare 
services in 
Finland; and 
(ii) to test and 
rank different 
policy 
alternatives for 
access to care 
and the required 
physician 
workforce 
the number 
of cataract 
operations, 
glaucoma 
visits, 
screening of 
diabeties, 
AMD visits 
and PDT 
(photodynam
ic therapy) 
treatments; 
2005-
2040 
Macro-modelling (System 
Dynamics (SD) simulation 
model (NOT a micro-
modelling)); Individual 
model;  
Finland Five age groups;      
The 
estimated 
demand for 
cataract 
surgery 
without and 
with the 
implementati
on of the 
national 
criteria of 
cataract 
surgery; 
different 
numbers of 
glaucoma 
visits in 
public sector; 
Different 
frequencies 
of diabetes 
screening;  
The results of this 
modelling study indicate 
that policy initiatives, such 
as defining criteria for 
access to care, can have 
substantial implications on 
the demand for care and 
waiting times whereas the 
effect of ageing alone was 
relatively small. Measures 
to control several other 
factors – such as the 
adoption and price level of 
new technologies, 
treatments and practice 
patterns – will be at least 
equally important in order 
to restrain healthcare costs 
effectively. 
US CBO Long 
term budget 
outlook 
Manchester 
and Schwabish 
(2010); CBO 
(1999, 2005, 
2007, 2008, 
2012) 
To examine the 
implications of a 
continuation of 
current federal 
law, rather than 
to make a 
prediction of the 
future. 
PROJECTIONS 
OF NATIONAL 
LONG-TERM 
CARE 
EXPENDITURE
S 
FOR THE 
ELDERLY 
(Medicare, 
Medicaid, 
Private Long-
Term Care 
Insurance, 
Out of 
Pocket, Other 
Payer) 
Long 
term 75 
year 
projectio
ns 
Macro-simulation 
(combine estimates of the 
elderly population 
with per capita 
expenditures for long-
term care, classified by 
disability category and 
type of payer); CBO 
combines an assumption 
about excess cost growth 
in the spending on health 
care with projections of 
the growth and aging of 
the population and of the 
growth in per capita GDP. 
US   
The 
population 
projections 
assume that 
current 
trends in 
disability 
among the 
elderly will 
continue until 
2040, with 
the 
prevalence of 
disability 
declining, on 
average, by 
1.1 percent a 
year (CBO 
1999); private 
Congression
al Budget 
Office 
calculations 
based on 
data from 
the Lewin 
Group and 
the Center 
for 
Demographi
c Studies at 
Duke 
University. 
CBO's 
(2007)baselin
e budget 
projections 
for 2008 to 
2017 assume 
no change in 
current 
federal law; 
an alternative 
scenario that 
assumes a 
change in 
federal law to 
prevent the 
reductions 
that 
would 
otherwise 
The ageing of the US 
population would account 
for a modest fraction of the 
growth that CBO projects.  
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insurance 
spending for 
long-term 
care will rise 
during the 
2000-2020 
period; 
(CBO2008) 
CBO assumed 
that even in 
the absence 
of changes in 
federal law, 
rates of 
spending 
growth in the 
Medicare and 
Medicaid 
programs 
would 
probably 
moderate to 
some degree. 
Historical 
excess cost 
growth rate 
will continue 
in the future.  
occur in the 
fees that 
Medicare 
allows for 
physicians’ 
services 
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Warshawsky 
(1994) 
To answer the 
question of 'Can 
the steady 
increases in 
health care 
expenditures as a 
share of GDP 
projected by 
widely cited 
actuarial models 
be rationalized by 
a macroeconomic 
model with 
sensible 
parameters and 
specification?' 
Health care 
expenditures 
as a share of 
gross 
domestic 
product 
(GDP) 
1990 - 
2065 
Actuarial and 
macroeconomic 
approaches 
US 
Actuarial 
analysis: 
demographic 
forecast, GDP 
projection 
(implicitly 
employing 
numerous other 
forecasts, 
including those 
of the labour 
force 
participation 
rate, the 
unemployment 
rate, the 
inflation rate, 
the rate of 
productivity 
growth; 
Forecasts of 
Healthcare 
inflation: i) 
from simple 
regression 
analysis & ii) 
"structural" 
forecast 
based on 
HCFA 
assumptions 
(based on 
earnings of 
health care 
providers and 
non-labour 
inputs of 
hospital) 
  
The most 
conservative 
assumptions: 
robust 
economic 
growth, 
improved 
demographic 
trends, or a 
significant 
moderation 
in the rate of 
health care 
price 
inflation; 
Both models unanimously 
project a continued 
increase in the ratio of 
health care expenditures to 
GDP. The model projects 
the health care sector will 
consume 25%-50% of 
national output by 2065. In 
the macroeconomic model, 
the increasing use of 
capital goods in the health 
care sector explains the 
observed rise in relative 
prices. Moreover, this 
"capital deepening" implies 
that a relatively modest 
fraction of the labour force 
is employed in health care 
and that the rest of the 
economy is increasingly 
starved for capital, 
resulting in a declining 
standard of living. 
Projected expenditures 
show questionable 
sustainability of HC 
funding; serious and 
immediate structural 
reform is critical; 
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Weinberg 
(1995) 
To examine the 
impact of 
demographic 
change upon the 
need for acute 
medical beds to 
the year 2000 in 
a district hospital 
using a Monte 
Carlo simulation; 
Individual 
model; 
Hospital care 
only; Change 
in bed 
numbers 
needed in the 
year 2000;  
1993 - 
2000 
Macro modelling (Monte 
Carlo simulation): Cell-
based method, while the 
Monte Carlo technique 
has been used; computer-
generated 'patients' were 
admitted to 'beds' for the 
period of their age-specific 
length of stay before being 
'discharged'; Service 
utilisation variables were 
sampled from probability 
distributions, apart from 
that, the population has 
been stratefied by age.  
UK 
Daily number of 
admissions, the 
age of the 
admission and 
the age-specific 
length of stay 
Current 
admission 
rates and 
length of stay 
will be 
maintained in 
the year 2000 
Minimum 
Data Set 
(District 
Health 
Authority) 
Two different 
population 
projections 
used: 
Regional 
Health 
Authority 
(1989) and 
County 
Council 
projections 
based on 
1991 Census 
No significant differences 
between the bed 
requirements under the 
current starting conditions 
and the modelled starting 
conditions for the year 
2000; Reducing all lengths 
of stay by one day reduced 
the mean bed requirement 
by more than the critical 
number (significant at 
Scheffe's test). 
WHO Long 
term care 
future tool-kit 
(2002) 
to give policy 
makers and 
stakeholders a 
tool to help 
investigate the 
future of LTC in 
their country and 
find new 
directions for 
effective health 
policy 
Demand & 
supply: the 
number of 
disabled 
across 
demographic 
categories, 
the numbers 
of Informal 
and Formal 
LTC workers.  
Disability 
Prevalence, 
Dependency 
Ratio.  
  
No detailed account of the 
method used; As in other 
WHO models, would be 
macro modelling 
Worldwide 
Supply Factors: 
Family Structure, 
Social Capital, 
Economic 
Factors, Informal 
Caregiver Supply 
and Support; 
Demand factors: 
Technologies, 
Environment, 
Social Risks, 
Personal 
Lifestyles.  
The toolkit is 
not designed 
to make 
specific future 
forecasts for 
LTC; rather it 
uses 
quantitative 
forecasts as 
the starting 
off point for 
further 
investigation 
of LTC.  
UN 
Population 
projections. 
1. The 
stabilization 
and gradual 
improvement 
of the 
economic 
system, 2. 
Hostile 
climate 
events, poor 
economic 
growth, and 
internal 
conflict, 3. a 
strong 
compression 
of morbidity 
(scenarios 
adjustable 
within the 
tool) 
Depends on the 
application.  
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Table 3. Summary of micro-simulation models 
Name/developer 
of the model 
Main objective  
Projection 
outcomes  
Time 
horizon 
Method Country 
Key factors 
included 
Key 
assumptions 
(Important) 
Key datasets Main scenarios Conclusions 
Basu and Gupta 
Basu and Gupta 
(2008) 
To explore the 
future utilisation 
of physicians in 
terms of full-
time equivalent 
in Nova Scotia 
to the year of 
2025 by 4 
general types of 
medical 
disciplines. 
Physician service 
use; Effect of 
population 
ageing on future 
demand for 
physicians 
2000-
2025 
Micro-simulation 
(estimating future 
demand for 
physicians); 
Individual model;  
Canada           
Cahow (2004) - 
PhD thesis 
 To estimate the 
demand for long 
term care 
Nursing home 
care only 
2005-
2025 
Use of statistical 
analyses to 
estimate 
transition 
probabilities, then 
micro-simulation) 
US           
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Davis et al. 
(2010) New 
Zealand model 
To assess micro-
simulation for 
testing policy 
options under 
demographic 
ageing 
Patients visits to 
GP; 
2002-
2021 
Micro-simulation NZ 
Morbidity and 
disability 
trajectories, 
availability of 
family and 
community 
support, 
intensity of 
practitioner 
behaviour; 
Various sets 
of 
assumptions 
on 
utilisation 
rates, GP 
behaviour, 
health 
status, etc. 
New Zealand 
Health 
Survey 
(1996/7 and 
2002/3), a 
national 
survey of 
ambulatory 
care in New 
Zealand 
(2001/2), 
and the 
Australian 
National 
Health 
Survey 
(1995) 
(a) profile of 
morbidity and 
disability 
associated with 
demographic 
ageing, as 
reflected in 
contrasting 
predictions of 
expansion and 
compression; 
(b) “healthy 
ageing”, as 
reflected in the 
potential of 
family and 
community 
capacity to assist 
in coping 
(autonomy, 
dependency, 
intermediate); 
(c) the impact of 
changes in health 
service delivery, 
such as, 
technology and 
changes in 
practitioner 
repertoires. 
Limited change in system demand 
on a 'pure' demographic model, 
although substantially more on 
scenario analysis of projections of 
morbidity burden and tractitioner 
behaviour; Micro-simulation models 
can contribute to addressing ‘what 
if?’ scenarios and realistic 
extrapolation into the future. 
Dormont et al. 
(2006) French 
model 
To estimate the 
future 
healthcare 
expenditure 
    
Micro-simulation 
model 
(statistically 
expressed in the 
paper, but 
individuals were 
stochastically 
modelled, hence 
micro-modelling); 
Econometric/ 
Statistical 
analyses;  
France     
a survey 
(Sante´ 
Protection 
Sociale) 
conducted 
by IRDES 
(Institute for 
Research 
and 
Information 
in Health 
Economics, 
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Paris) 
DYNASIM 
(Dynamic 
Simulation of 
Income Model) 
Zedlewski & 
McBride (1992); 
Zedlewski et al. 
(1990) (book); 
To serve as a 
framework for 
integrating 
economic and 
sociological 
research on 
micro entities, 
forecasting, 
policy analysis, 
investigation of 
the implications 
of 
socioeconomic 
change, and 
generation of 
individual and 
family histories 
Demographic 
Events, 
Education, 
Location, Labour 
force events, 
Social security 
eligibility and 
benefits, Health 
status/disabilitie
s;  
1990-
2030 
Micro-simulation US 
Individual 
characteristics
;  
  
1973 
Current 
Population 
Survey (CPS) 
  
Demographics, health, and income 
trends will interact to increase the 
demand for nursing-home care 
faster than many now realize. 
Whereas the number of elderly will 
increase by 100 to 125 percent by 
2030, the number requiring nursing-
home care will triple during the 
same period. The need to find 
alternative long-term care financing 
arrangements will be acute 
Gallagher et al. 
(2010) Monte 
Carlo simulation 
& Linear 
programming – 
Harper et al. 
(2012); 
to explore the 
required skill-
mix of the 
dental team to 
meet future 
need and 
demand of older 
people in 
England to 2028 
utilising 
operational 
research 
methods, and 
examine a range 
of future 
scenarios. 
NHS clinical 
supply hours 
to 2028 
MC simulation & 
linear 
programming 
together with 
Powell’s 
Intermediate Care 
workforce model; 
Added 
optimisation 
functionality (i.e. 
Linear program to 
optimise skill-mix 
and predict 
workforce 
requirements); 
Demand and 
supply data were 
fed into an 
optimisation 
model to provide 
recommendations 
on the 
composition of 
the optimal 
UK 
the 
contribution of 
clinical dental 
technicians  
 Department 
of Health 
(2004). 
Report of 
the primary 
care dental 
workforce 
review; NHS 
Education 
for Scotland, 
ISD Scotland 
(2004). 
Workforce 
planning for 
dentistry in 
Scotland; 
NHS 
Scotland 
(2006). 
  
5 different 
scenarios on 
varying staff 
competencies and 
skill-mix ('a gental 
evolution', 'no 
skill-mix', 'skill-
mix revolution', 
etc.) 
For the whole population, the 
current shortfall is estimated at 
3,812 NHS WTE dental staff in 2005 
and the shortfall is expected to peak 
in 2008, with a shortage of 4,018 
NHS WTE dental staff forecast. By 
2018 the shortfall is expected to 
reduce to 1,781 dental staff and by 
2028 the shortfall is expected to 
have disappeared altogether with a 
surplus of 2,354 dental staff 
projected (due to the planned 
expansion of dentist and 
hygienist/therapist training places 
and the increase in the percentage 
of time that dental staff devote to 
treating older people). The model 
suggests that with widening skill-
mix, dental care professionals can 
play a major role in building dental 
care capacity for older people in 
future. Policy makers need to 
explore the challenges and benefi ts 
of implementing the optimal skill-
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workforce.  mix workforce against the 
feasibility. 
Lubitz et al. 
(2003) 
 To estimate the 
expenditure for 
healthcare 
Expected 
Expenditures for 
Health Care 
from 70 Years of 
Age until Death 
According to 
Self-Reported 
Health at the 
Age of 70 
  
Compound 
method 
(multistate life-
table methods 
and micro-
simulation. Then, 
linked annual 
health care 
expenditures with 
transitions 
between health 
states; Age-
specific, first-
order Markov 
transition 
probabilities were 
estimated with 
the use of a 
multivariate 
hazard model, 
and Health-
expenditure 
matrixes were 
structured in a 
similar manner to 
the transition 
matrixes.  
US     
Medicare 
Current 
Beneficiary 
Survey 
    
POHEM, 
Statistics Canada 
To model 
diseases and risk 
factors in which 
the basic unit of 
analysis is the 
individual 
person; to 
estimate 
lifetime costs of 
diseases or 
assess health 
technologies 
Life-time costs 
of healthcare; 
  Micro-simulation Canada           
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PSSRU CARESIM-
LTC model 
(linked) (PSSRU3) 
Hancock et al 
(2003, 2007); 
Malley et al. 
(2006); Wanless 
social care 
review (2006); 
Leung et al. 
(2007) - macro 
model only 
To examine the 
effect of a range 
of options for 
paying for long 
term care. 
Future long term 
care costs by 
sources of 
finance 
2005-
2051 
Linkage between 
micro- and 
macro-simulation 
models 
UK 
Net income; 
household 
type; Disability 
level; 
Health and 
social care 
unit costs 
rise by 2% 
per year in 
real terms; 
the supply 
of formal 
care will 
adjust to 
match 
demand and 
demand will 
be no more 
constrained 
by supply in 
the future  
ELSA 
(English 
Longitudinal 
Survey 
Ageing); 
Department 
of Health 
GHS 
(General 
Household 
Survey); 
alternative long-
term care funding 
regimes (e.g. free 
personal care,  
The results show that even without 
any possible demand effects, a 
policy of free personal care would 
lead to a substantial increase in the 
number of older people receiving 
some publicly-funded home care.  
The complexity of long-term care 
funding in the UK makes it difficult 
to gauge the current 
and projected future costs and 
distributional effects of such 
reforms without the kind of analysis 
presented here. An important 
conclusion of the present paper is 
that analysis of this kind is essential 
if informed judgements about policy 
options are to be made. 
PSSRU dynamic 
micro-simulation 
(DMS) model 
(PSSRU4) Forder 
and Fernandez 
(2009, 2011 (Age 
UK doc.), 2012); 
Fernandez and 
Forder (2011); 
Fernandez and 
Forder (2010) 
To explore the 
consequences of 
alternative 
policy reforms, 
the effect of 
funding systems 
on the possible 
draw-down of 
assets by service 
users. 
Uptake rates of 
social security 
benefits; Assets 
and income; 
Amount of 
service and 
support any 
individual 
person uses in 
the care system; 
Levels of need;  
2009-
2025 
Micro-simulation UK   
Developed 
from an 
earlier static 
model for 
Wanless 
review 
(2006) 
BHPS (British 
Household 
Panel 
Survey); 
ELSA;  
  
The current funding system is unfair 
on people that save, it is 
stigmatising and open to fraud. It is 
in stark contrast with universal 
access philosophy of the NHS. 
People above the asset ceiling – i.e. 
who have savings but would not be 
regarded as particularly wealthy by 
many – are more likely to 
experience disproportionately high 
levels of unmet need and more 
rapid draw-down of assets, 
according to the model. 
RAND COMPARE 
model - Eibner 
(2009); Eibner et 
al. (2010, 2011) 
To predict the 
effect of a range 
of 
policy/reforms; 
To project 
potential 
behavioural 
changes of 
individuals and 
firms in the US 
Behaviour 
changes; 
Distributional 
impact of policy 
  Micro-simulation US           
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RAND Future 
Elderly Model 
(FEM) Goldman 
et al. (2004, 
2008) 
To project the 
future Medicare 
costs under the 
current and 
alternative 
health status 
and healthcare 
environment 
Per capita and 
total medical 
expenditures; 
Health status of 
the future 
elderly; 
2000-
2030 
Micro-simulation 
(three models are 
integrated: cost 
model, transition 
model, and 
rejuvenation 
model) 
US 
Age, gender, 
ethnicity, 
education, 
geographical 
area of 
residence, 
smoking 
status, etc.  
i) Future 
individuals 
with a given 
set of health 
conditions 
receive the 
same 
medical care 
as 
individuals 
in the MCBS: 
Costs 
assume a 
level of 
treatment 
and 
technology 
as it existed 
in the 
1990s; ii) 
1998 unit 
prices 
continue 
throughout 
our forecast 
period; iii) 
the elderly 
do not 
migrate 
across 
Census 
region 
borders as 
they age;  
Medicare 
Current 
Beneficiary 
Survey 
(MCBS) 
Potential 
breakthrough 
technologies (e.g. 
cancer vaccines, 
anti-ageing 
compounds); 
changes in 
lifestyle and the 
health care 
system 
Under the baseline scenario, the 
Medicare expenditures are $176 
billion in 2000, $192 billion in 2005, 
$212 billion in 2010, $240 billion in 
2015, $279 billion in 2020, $321 
billion in 2025, and $360 billion in 
2030. Breakthroughs in medical 
technologies or changes in risk 
factors  change the health status 
transitions and the cost projections. 
The simulation shows that it makes 
sense for Medicare to provide 
services to people who are younger 
than 65 years old and who are not 
yet in the Medicare program, 
because they will be healthier later 
when they do enroll in Medicare, 
which will reduce the total 
expenditures for Medicare. The 
health and expenditures of the 
future elderly could be dramatically 
affected by better 
detection of subclinical disease or 
early clinical disease. Primary 
prevention may be effective in 
reducing the future expenditures. 
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Swedish SESIM III 
model - 
Klevmarken and 
Lindgren (2008) 
To evaluate 
Swedish system 
for financing of 
pension, 
healthcare, etc. 
Life time events 
including 
income, 
retirement, 
health events, 
etc. 
1999-  
Micro-simulation 
model  
Sweden 
Demography, 
inter-
generational 
transfer, 
education, 
housing, 
labour 
market/status, 
tax and 
pension 
system, etc. 
  
LINDA panel 
data; 
HINK/HEK; 
GEOSWEDE;  
  Depends on the application; 
van Meijgaard et 
al. (2009) 
www.health-
forecasting.org; 
To primarily 
simulate 
individuals' 
lifetime 
histories and 
future health 
status of the 
population, and 
personal 
medical 
expenditure 
alongside. 
Health status of 
the future 
population; 
Future lifetime 
medical 
expenditures 
By 
2025 
Micro-simulation 
(comprehensive 
population 
health-forecasting 
model: The 
California Health 
Forecasting 
Model) 
US 
Obesity (Body 
Mass Index); 
Ethnicity; 
Exercise level;  
  
Medical 
Expenditures 
Panel 
Survey. 
  
The health forecasting model 
provides a strong rationale for 
current action, and support many 
specific interventions, policies, and 
programmes that can improve 
health of population in the long 
term.  
467 
 
Appendix 7.1 
 
Table 7.18’. Mortality rates due to causes other than fractures in association with BMD not 
incorporating cardiac deaths 
 Z score = -2  
(-2.5, -1.5) 
Z score = -1  
(-1.5, -0.5) 
Z score  
(-0.5, 0.5)  
General 
population 
Z score = 1  
(0.5, 1.5) 
Z score = 2  
(1.5, 2.5) 
Age Women Men Women Men Women  Men  Women  Men Women Men 
45 
0.19% 0.27% 0.15% 0.21% 0.12% 0.16% 0.10% 0.12% 0.08% 0.09% 
46 
0.21% 0.29% 0.17% 0.22% 0.13% 0.17% 0.11% 0.13% 0.08% 0.09% 
47 
0.22% 0.29% 0.17% 0.23% 0.14% 0.18% 0.11% 0.13% 0.09% 0.10% 
48 
0.24% 0.34% 0.20% 0.27% 0.16% 0.21% 0.13% 0.16% 0.10% 0.12% 
49 
0.28% 0.37% 0.22% 0.29% 0.18% 0.23% 0.14% 0.17% 0.11% 0.13% 
50 
0.30% 0.40% 0.25% 0.32% 0.20% 0.25% 0.16% 0.19% 0.13% 0.14% 
51 
0.33% 0.47% 0.26% 0.37% 0.21% 0.29% 0.17% 0.23% 0.14% 0.18% 
52 
0.38% 0.53% 0.31% 0.42% 0.25% 0.34% 0.20% 0.26% 0.16% 0.21% 
53 
0.41% 0.58% 0.33% 0.46% 0.27% 0.37% 0.22% 0.29% 0.17% 0.23% 
54 
0.47% 0.62% 0.38% 0.50% 0.31% 0.40% 0.25% 0.31% 0.20% 0.25% 
55 
0.45% 0.61% 0.36% 0.47% 0.28% 0.35% 0.22% 0.26% 0.17% 0.18% 
56 
0.51% 0.71% 0.41% 0.55% 0.32% 0.42% 0.25% 0.31% 0.20% 0.22% 
57 
0.56% 0.76% 0.45% 0.59% 0.36% 0.45% 0.28% 0.34% 0.22% 0.25% 
58 
0.60% 0.87% 0.48% 0.68% 0.38% 0.53% 0.30% 0.40% 0.24% 0.30% 
59 
0.67% 0.94% 0.54% 0.74% 0.43% 0.57% 0.35% 0.44% 0.27% 0.33% 
60 
0.74% 1.07% 0.59% 0.84% 0.48% 0.66% 0.38% 0.51% 0.30% 0.39% 
61 
0.80% 1.15% 0.65% 0.91% 0.52% 0.71% 0.41% 0.55% 0.33% 0.42% 
62 
0.85% 1.24% 0.69% 0.98% 0.55% 0.78% 0.44% 0.60% 0.35% 0.47% 
63 
0.95% 1.39% 0.77% 1.11% 0.62% 0.88% 0.50% 0.69% 0.40% 0.53% 
64 
1.05% 1.54% 0.85% 1.23% 0.69% 0.98% 0.55% 0.77% 0.44% 0.60% 
65 
1.02% 1.45% 0.80% 1.12% 0.62% 0.84% 0.47% 0.61% 0.35% 0.42% 
66 
1.15% 1.68% 0.91% 1.30% 0.71% 0.99% 0.54% 0.73% 0.41% 0.52% 
67 
1.24% 1.85% 0.98% 1.44% 0.77% 1.10% 0.59% 0.83% 0.45% 0.60% 
68 
1.41% 2.13% 1.12% 1.67% 0.89% 1.29% 0.69% 0.98% 0.53% 0.73% 
69 
1.61% 2.40% 1.28% 1.89% 1.01% 1.47% 0.80% 1.13% 0.62% 0.85% 
70 
1.85% 2.70% 1.48% 2.14% 1.18% 1.67% 0.93% 1.29% 0.73% 0.98% 
71 
1.99% 3.01% 1.60% 2.39% 1.27% 1.88% 1.01% 1.46% 0.79% 1.12% 
72 
2.23% 3.37% 1.80% 2.69% 1.44% 2.12% 1.14% 1.66% 0.90% 1.29% 
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73 
2.45% 3.72% 1.97% 2.98% 1.58% 2.36% 1.26% 1.86% 1.00% 1.45% 
74 
2.84% 4.17% 2.29% 3.34% 1.84% 2.66% 1.47% 2.11% 1.17% 1.65% 
75 
2.47% 3.71% 1.87% 2.81% 1.38% 2.06% 0.97% 1.45% 0.64% 0.95% 
76 
2.93% 4.39% 2.25% 3.36% 1.69% 2.52% 1.23% 1.82% 0.85% 1.26% 
77 
3.41% 4.92% 2.64% 3.79% 2.01% 2.87% 1.49% 2.11% 1.07% 1.50% 
78 
3.96% 5.67% 3.09% 4.41% 2.38% 3.38% 1.79% 2.53% 1.32% 1.84% 
79 
4.57% 6.46% 3.59% 5.06% 2.79% 3.91% 2.13% 2.97% 1.59% 2.19% 
80 
5.31% 7.50% 4.20% 5.91% 3.29% 4.60% 2.54% 3.54% 1.93% 2.66% 
81 
6.06% 8.54% 4.81% 6.76% 3.79% 5.30% 2.95% 4.11% 2.26% 3.13% 
82 
7.03% 9.71% 5.61% 7.72% 4.44% 6.09% 3.49% 4.75% 2.70% 3.66% 
83 
8.11% 10.84% 6.50% 8.65% 5.17% 6.85% 4.08% 5.38% 3.19% 4.17% 
84 
9.20% 12.34% 7.38% 9.88% 5.90% 7.86% 4.68% 6.20% 3.68% 4.85% 
85 
7.69% 11.15% 5.66% 8.40% 4.00% 6.15% 2.64% 4.30% 1.52% 2.79% 
86 
9.19% 12.66% 6.89% 9.64% 5.00% 7.16% 3.46% 5.13% 2.19% 3.47% 
87 
10.68% 14.77% 8.11% 11.37% 6.01% 8.58% 4.28% 6.30% 2.87% 4.42% 
88 
12.44% 16.81% 9.56% 13.04% 7.19% 9.95% 5.25% 7.42% 3.67% 5.34% 
89 
14.55% 19.76% 11.29% 15.46% 8.61% 11.93% 6.42% 9.04% 4.62% 6.67% 
90 
16.56% 20.54% 12.93% 16.10% 9.96% 12.46% 7.52% 9.47% 5.52% 7.03% 
91 
18.20% 22.38% 14.28% 17.61% 11.06% 13.69% 8.42% 10.48% 6.26% 7.86% 
92 
20.26% 23.94% 15.96% 18.89% 12.44% 14.74% 9.56% 11.35% 7.19% 8.56% 
93 
23.25% 27.75% 18.41% 22.00% 14.45% 17.30% 11.20% 13.44% 8.54% 10.28% 
94 
26.63% 31.12% 21.19% 24.77% 16.73% 19.56% 13.07% 15.30% 10.07% 11.80% 
95 
29.76% 34.19% 23.75% 27.29% 18.83% 21.63% 14.79% 16.99% 11.48% 13.19% 
96 
32.28% 36.89% 25.81% 29.50% 20.52% 23.44% 16.18% 18.48% 12.62% 14.41% 
97 
35.16% 40.14% 28.18% 32.16% 22.45% 25.62% 17.76% 20.26% 13.92% 15.87% 
98 
37.87% 43.12% 30.40% 34.61% 24.27% 27.63% 19.25% 21.91% 15.14% 17.22% 
99 
40.55% 44.74% 32.59% 35.93% 26.07% 28.71% 20.73% 22.80% 16.35% 17.95% 
100 
43.92% 47.91% 35.36% 38.53% 28.34% 30.84% 22.59% 24.54% 17.87% 19.38% 
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